[
  {
    "text": "![](images/a06cb3d7ab8edf2fb4fadd68cc81950edd3e421beeaa36bcf611f3d69be0a1ca.jpg) # 1.1 Global cervical cancer burden # 1.1.1 Incidence Cervical cancer (International Statistical Classification of Diseases and Related Health Problems, 10th revision [ICD-10] code, C53 – Malignant neoplasm of cervix uteri) is the fourth most commonly diagnosed cancer type in women of all ages worldwide (Sung et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2021).In women of reproductive age (15–44 years), it is the second most common cancer type; cervical cancer is the most common cancer in 23 countries, most of which are in sub-Saharan Africa (Ferlay et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).In 2020, there were an estimated $6 0 4 0 0 0$ new cases worldwide, and cervical cancer repre­ sented about $6 .5 \\%$ of the global cancer burden in women; the proportions were higher for only breast cancer $( 2 4 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2 \\% )$ , colorectal cancer $( 9 .4 \\% )$ , and lung cancer $( 8 .4 \\% )$ .The highest proportion of new cases occurred in Asia $( 5 8 .2 \\% )$ , followed by Africa $( 1 9 .4 \\% )$ , Latin America and the Caribbean $( 9 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8 \\% )$ , Europe $( 9 .6 \\% )$ , Northern America $( 2 .5 \\% )$ , and Oceania $( 0 .4 \\% )$ (Ferlay et al., 2020; Sung et al., 2021).In 2020, the global age-standardized inci­ dence rate (ASIR) of cervical cancer was 13.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3 per 100 000 women worldwide (Ferlay et al., 2020).The incidence rates of cervical cancer vary markedly across the world, with a 10-fold variation between the highest and lowest rates (Fig.1.1 and Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.2).The estimated incidence rates (ASIR, per 100 000 women) are highest in Eastern Africa (40.1), Southern Africa (36.4), Middle Africa (31.6), Melanesia (28.3), and Western Africa (22.9), followed by the Federated States of Micronesia (18.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "7), South-Eastern Asia (17.8), South America (15.4), and South-Central Asia (15.3), and lowest in Western Asia (4.1) and Australia and New Zealand (5.6) (Ferlay et al., 2020; Sung et al., 2021).The incidence rates of cervical cancer are higher in countries that have a high prevalence of HIV infection and/or lack sustained cervical cancer screening programmes (Rohner et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).# 1.1.2 Mortality Cervical cancer is the fourth most common cause of cancer death in women of all ages, after breast cancer, lung cancer, and colorectal cancer.In women of reproductive age (15–44 years), it is the second most common cause of cancer death (Arbyn et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).In 2020, there were an estimated 342 000 deaths worldwide due to cervical cancer; the proportion of deaths was highest in Asia $( 5 8 .5 \\% )$ and Africa $( 2 2 .5 \\% )$ , followed by Latin America and the Caribbean $( 9 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2 \\% )$ and Europe $( 7 .6 \\% )$ , and lowest in Northern America $( 1 .9 \\% )$ and Oceania $( 0 .4 \\% )$ (Ferlay et al., 2020; Sung et al., 2021).![](images/55cf4dd478b7915bafc1ff9df83f5713bd3aa61e727c9db99ccabac9793c63f9.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "jpg) Fig.1.1 Global distribution of estimated age-standardized (World) incidence rates (A) and ![](images/6652b304eeec91d4146a4749b606befca033c44c19469d11f67c2ab3c7a47751.jpg) Fig.1.2 Estimated age-standardized (World) incidence and mortality rates per 100 000 for cervical cancer, by large world regions, 2020 Adapted from Ferlay et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2020).Courtesy of Jérôme Vignat.In 2020, the age-standardized mortality rate (ASMR) for cervical cancer was 7.3 per 100 000 in women worldwide (Ferlay et al., 2020; Sung et al., 2021).The mortality rates of cervical cancer have a global pattern similar to that for the incidence rates, with a more than 15-fold variation between the highest and lowest rates (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.1 and Fig.1.2).The estimated mortality rates (ASMR, per 100 000 women) are highest in Eastern Africa (28.6), Middle Africa (22.7), Southern Africa (20.6), Melanesia (18.6), Western Africa (16.6), South-Eastern Asia (10.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0), and South-Central Asia (9.6), and lowest in Australia and New Zealand (1.6) and Western Europe (2.0) (Ferlay et al., 2020; Sung et al., 2021).The highest cervical cancer incidence and mortality rates are generally observed in countries with the lowest levels of the Human Development Index (HDI) (Ginsburg et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2017) (Fig.1.3).In countries with lower HDI, the inci­ dence and mortality rates span a wider range, suggesting that other factors besides HDI may account for the variability, such as exposure to human papillomavirus (HPV) or other cofactors or the coverage and type of screening (opportu­ nistic vs organized).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In those countries with the highest HDI, both incidence rates and mortality rates are in a narrow range despite similar prev­ alences of HPV infection or other cofactors.The age-specific incidence rates of cervical cancer are presented in Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.4.Cervical cancer incidence rates start rising after age 25 years worldwide, but in countries with high and very high HDI, the peak of incidence is reached at about age 40 years, whereas in countries with medium and low HDI, the rate continues to rise until age 55–69 years (Arbyn et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).![](images/0f0155dc49eb541a94e10bc2b714736971b3b8c862e4d61c559ca84f4149ac92.jpg) Fig.1.3 Correlation between estimated age-standardized (World) cervical cancer incidence rates (A) and mortality rates (B) per 100 000 and Human Development Index (HDI), 2020 The four tiers of HDI are: low $( < 0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5 5 )$ , medium $( \\geq 0 .5 5$ to $< 0 .7$ ), high $( \\geq 0 .7$ to $< 0 .8 \\dot { }$ ), and very high $( \\ge 0 .8 )$ .Created using data from Ferlay et al.(2020) and UNDP (2020).Courtesy of Jérôme Vignat.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "![](images/a7e153d7954d5b2fe85c3ddaef6a7c0edab438c510b6ab65b48860c2655d56ee.jpg) Fig.1.4 Age-specific incidence of cervical cancer worldwide and in terms of the four-tier Human Development Index (HDI), 2018 The four tiers of HDI are: low $( < 0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5 5 )$ , medium $\\geq 0 .5 5$ to $< 0 .7$ ), high $( \\geq 0 .7$ to $< 0 .8 \\dot { }$ ), and very high $( \\ge 0 .8 )$ .Reproduced from Arbyn et al.(2020).# 1.1.3 Trends in incidence An analysis of trends in age-standardized cervical cancer incidence rates over time using the Cancer Incidence in Five Continents database (Ferlay et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2018) revealed variability in trends across countries and showed how these trends are influenced by a country’s context of policy, programmes, practice, and culture.Fig.1.5 shows overall trends and trends in women younger than 40 years by country in all registries that provided data for the longest period.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Trends for women older than 40 years are not presented, because they tend to be very similar to the overall trends.Also, trends in the registries that provided data for the longest period may not represent trends in the whole country.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Three patterns emerge from these trends: (i) a decrease in rates over the years, (ii) an increase in overall rates, and (iii) an increase in rates in the younger age groups.![](images/c9d92b54b64467c786561bf8af2068f02e034d8d7be3caf6bd5f7f5a16b82301.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "jpg) Fig.1.5 Trends in age-standardized (World) incidence rates for cervical cancer by country ![](images/d330c4244f741a4e23d88a532729f937a71ac8e33d543e8e5f6ac39f965b558d.jpg) Fig.1.5 (continued) In most countries, cervical cancer incidence rates have been decreasing over the past decades, although the magnitude of the decrease may vary.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In many of these countries, the decrease can be attributed to sustained population-based screeningprogrammes;forexample,inDenmark, Finland, Norway, and Sweden, the introduction of screening programmes in the 1960s and 1970s resulted in an almost $5 0 \\%$ reduction in cervical cancer incidence.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In countries where there is no population-based screening, as for example in India, the decrease in cervical cancer incidence may reflect improved conditions, such as better education for girls and women, which lead to reduced exposure to HPV, among other factors (Dhillon et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2011).The second emerging pattern is a continued increase in incidence rates.In some countries (e.g.Belarus, Estonia, and Lithuania), incidence rates are increasing despite the introduction of screening programmes; this trend reflects weak opportunistic screening, poor coverage of screening, and poor quality (Vaccarella et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2016; Ojamaa et al., 2018).In Uganda, which has one of the longest-standing high-quality registries, there has been a continued increase in cervical cancer incidence rates.In a recent analysis of 10 African registries with 10–25 years of data, a similar pattern was seen and was attri­ buted to a high prevalence of HPV infection, a high prevalence of HIV infection, and a lack of well-attended population-based screening programmes (Jedy-Agba et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).In the third pattern, the overall trend is decreasing but incidence rates in women younger than 40 years are increasing.Such a pattern has been observed in China, most likely reflecting increased exposure to HPV in the youngest cohort of women (Li et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2017).Trends by histology cannot be provided at a global level, given the lack of histology data in many cancer registries.However, in selected countries the examination of incidence rates by histology provides insights into the impact of prevention strategies.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "For example, the reduc­ tion in the incidence of cervical cancer seen in the USA from the introduction of the Pap test in the 1960s until the early 2000s has been driven by reductions in the incidence rates of squamous cell carcinoma (SCC) of the cervix (Wang et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2004).In the past two decades, incidence rates of cervical SCC have stabilized in the USA (Islami et al., 2019), whereas incidence rates of cervical adenocarcinoma have increased both in the USA (especially in White women aged 40–60 years) (Islami et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019) and in Europe (Bray et al., 2005).This trend may reflect changing sexual behaviours over time (Ryser et al., 2017), as well as an inability to detect cervical adenocarcinoma through cytology-based screening programmes (Castle et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2017).# 1.1.4 Lifetime risk of cervical cancer The lifetime cumulative risk of cervical cancer for women aged 0–74 years is presented by region in Fig.1.6.In Africa, the lifetime risk varies from $8 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "6 \\%$ in Eswatini to $0 .3 \\%$ in Egypt.In Latin America and the Caribbean, women in the Plurinational State of Bolivia and in Guyana have a lifetime risk of $3 .7 \\%$ , whereas those in Martinique, France, have a lifetime risk of $0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "6 \\%$ .In Asia, the lifetime risk is highest in Maldives, Indonesia, and Mongolia and lowest in Iraq.Women in eastern Europe have consistently higher lifetime risk than those in western Europe (Ferlay et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020; Sung et al., 2021).# 1.1.5 Survival At the end of 2020, there were an estimated 1.5 million women alive who had been diagnosed with cervical cancer during the previous 5 years, representing about $5 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8 \\%$ of all people who were diagnosed with cancer within the previous 5 years (Ferlay et al., 2020).![](images/cc7ca6a5c9b82f48e5a562628924b45441ddd0bb5cb0a862f74ea5428f5e9ca9.jpg) Fig.1.6 Estimated cumulative risk (ages 0–74 years) of cervical cancer incidence by world region and country or territory, 2020 The third cycle of the CONCORD pro­ gramme for global surveillance of cancer survival trends (CONCORD-3) included data for 660 744 women diagnosed with cervical cancer in 2000–2014 from 295 population-based cancer registries in 64 countries or territories.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Population-based survival is estimated from data provided by population-based cancer regis­ tries that record all diagnoses of malignancy in the population of the country or region that they cover.It is a key measure of the overall effective­ ness of the health system in managing cancer in a given country or region (Allemani, 2017; Allemani et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2018).Population-based survival is a measure of the average survival of all patients with cancer.Population-based survival is usually presented as net survival (Perme et al., 2012), which is the probability of patients with cancer surviving until a given time since diagnosis, typically 5 years, after controlling for competing causes of death (background mortality).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The global range in 5-year age-standard­ ized net survival for cervical cancer was wide $( 5 0 - 7 0 \\% )$ in all three calendar periods $( 2 0 0 0 -$ 2004, 2005–2009, 2010–2014), reflecting ineq­ uity in access to diagnostic facilities and optimal treatment (Allemani et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2018).For women diagnosed in 2010–2014, 5-year age-standard­ ized net survival was $7 0 \\%$ or higher in seven countries or territories (Cuba; Denmark; Japan; Norway; the Republic of Korea; Switzerland; and Taiwan, China), most of which have high HDI.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Survival was in the range $6 0 - 6 9 \\%$ in 29 coun­ tries or territories: Canada and the USA; Brazil and Puerto Rico; 5 countries or territories in Asia (China, Hong Kong Special Administrative Region, Israel, Singapore, and Turkey); 18 coun­ tries in Europe; and Australia and New Zealand.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Survival was in the range $5 0 \\text{‰}$ in 5 countries or territories in Central and South America (Argentina; Ecuador; Martinique, France; Peru; and Uruguay) and in 6 countries in Europe (Bulgaria, Latvia, Lithuania, Malta, Poland, and the Russian Federation), most of which have low or medium HDI.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Between 2000 and 2014, 5-year survival increased by $4 \\mathrm { - } 6 \\%$ in Japan and in 11 European countries and by $10 \\%$ in India.In China, it increased from $5 3 \\%$ for women diagnosed in 2000–2004 to $6 8 \\%$ for those diag­ nosed in 2010–2014.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Survival trends could not be systematically assessed in Africa, because the data were incomplete (Allemani et al., 2018).# 1.1.6 Prevalence of HPV infection in women Cervical cancer incidence often reflects expo­ sure to HPV, which is the central cause of cervical cancer (see Sections 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2.1 and 1.2.2).A metaanalysis evaluated more than 500 studies that tested for HPV infection in 2.4 million women aged 15 years and older with normal cytology (Bruni et al., 2016), including population-based studies, screening studies, and representative control series in case–control studies.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The global pooled prevalence was $1 5 .3 \\%$ for any HPV infec­ tion, $70 \\%$ of which were with carcinogenic types.The age-standardized overall prevalence of HPV infection by world region is presented in Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.7.The Caribbean has the highest prevalence $( 5 0 .7 \\% )$ , and Southern Asia has the lowest $( 8 .5 \\% )$ .[Some estimates may be unstable for regions with few studies or with studies in subpopula­ tions.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "] The age-specific analysis (Fig.1.8) shows that the prevalence of HPV infection is highest in younger women and lower in older women, and that the pattern appears flatter for Asia than for other regions.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "For some regions, such as Northern and Western Africa and Central America, there is a modest second peak of HPV prevalence in women older than 40 years.In studies with specific information on HPV type distribution, HPV16 was the most common type in all regions (standardized prevalence, $3 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5 \\%$ ; HPV18 $( 1 .3 \\% )$ , HPV52 $( 1 .3 \\% )$ , HPV58 $( 1 .0 \\% )$ , and HPV31 $( 0 .9 \\% )$ ![](images/2f9b63ea19da81e10d0a6567f6e7b901943a3ff87b9cec4a04083e79a25111a3.jpg) Fig.1.7 Standardized prevalence of human papillomavirus (HPV) infection by world region Squares represent the estimated adjusted HPV prevalence from the random-effects models for each corresponding region Courtesy of Laia Bruni, Bruni et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2016).were the other most common carcinogenic HPV types (Bruni et al., 2016).Most HPV prevalence surveys have been conducted in women, and very few popula tion-based data exist for men.number of new cases and a $4 0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8 \\%$ increase in the number of deaths are projected by 2040.Numbers of deaths are projected to increase more rapidly in countries with lower HDI, and relatively large increases are projected in coun­ tries with medium and high HDI.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "These projec tions take into account only global demographic changes in population structure and growth according to United Nations estimates.The risk of developing or dying from cervical cancer is assumed to remain constant, and no allowance # 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.7 Projections of global burden Table 1.1 shows the estimated global burden of cervical cancer incidence and mortality in 2020 and projected to 2040, overall and by HDI cate­ gory.Overall, a $3 2 .0 \\%$ increase in the estimated !",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "[](images/66bca2ff1e6b2c76f91813206444cf33e04077d648c2f821bd474b9a4161438d.jpg) Fig.1.8 Age-specific standardized prevalence of human papillomavirus (HPV) infection by world region The shaded area represents the $9 5 \\%$ confidence interval for the global HPV prevalence.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Courtesy of Laia Bruni, Bruni et al.(2016).is made for changes in increased detection or improvements in survival.Modelling studies have also projected that the number of new cases per year will increase from 600 000 in 2020 to 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3 million in 2069; these projections also take into account changes in underlying demo­ graphics and exposure to risk factors (Simms et al., 2019).Widespread coverage of both HPV vaccination and screening has the potential to decrease the incidence of cervical cancer in the future (Brisson et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).# 1.2 Cervical neoplasia # 1.2.1 Biology of HPV and of the cervix relevant to carcinogenesis and screening HPVs are a group of circular, double-stranded DNA viruses of about 8000 base pairs that infect human skin and mucosal epithelia.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The group includes more than 200 different geno­ types, which are numbered in order of discovery and characterization.The small genomes of the HPV types that cause cervical cancer consist of an upstream regulatory region and six early (E) Table 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1 Global burden of cervical cancer: estimated annual numbers of incident cases and deaths, by HDI category and overall, in 2020 and projected to 2040 <html><body><table><tr><td>HDI categorya</td><td colspan=\"2\">Population in 2020</td><td colspan=\"2\">Number of new cases (thousands)</td><td>Increase</td><td colspan=\"2\">Number of deaths (thousands)</td><td>Increase</td></tr><tr><td></td><td>(millions)</td><td>(%)</td><td>2020</td><td>2040</td><td>(%)</td><td>2020</td><td>2040</td><td>(%)</td></tr><tr><td>Low HDI</td><td>494</td><td>12.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>82</td><td>162</td><td>97.3</td><td>56</td><td>112</td><td>99.9</td></tr><tr><td>Medium HDI</td><td>1136</td><td>29.4</td><td>183</td><td>292</td><td>59.6</td><td>113</td><td>189</td><td>66.8</td></tr><tr><td>High HDI</td><td>1442</td><td>37.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3</td><td>240</td><td>297</td><td>23.5</td><td>129</td><td>182</td><td>40.6</td></tr><tr><td>Very high HDI</td><td>791</td><td>20.5</td><td>99</td><td>105</td><td>6.1</td><td>43</td><td>51</td><td>18.0</td></tr><tr><td>World</td><td>3863</td><td>100</td><td>604</td><td>798</td><td>32.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0</td><td>342</td><td>481</td><td>40.8</td></tr></table></body></html> HDI, Human Development Index.a The four tiers of HDI are: low $( < 0 .5 5 )$ , medium $( \\geq 0 .5 5$ to $< 0 .7$ ), high $( \\geq 0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "7$ to $\\phantom { 0 } { < 0 .8 \\ ' }$ ), and very high $( \\geq 0 .8 )$ .Created using data from Ferlay et al.(2020) and UNDP (2020).Courtesy of Jérôme Vignat.and two late (L) genes on the positive coding strand.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The early genes are involved in viral repli­ cation and maintenance within the host cell; L1 and L2 encode the self-assembling major and minor capsid proteins, respectively (Schiffman et al., 2016).Evolutionary taxonomy predicts the cells that specific HPV types infect and their carcinogen­ icity (Schiffman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2005).The stable HPV genome has evolved very slowly in parallel with human evolution.The alpha genus contains 14 species, including more than 50 mucocutaneous types (Bzhalava et al., 2015); a single evolutionary branch includes the four species that contain the dozen or so HPV types that cause almost all cervical cancers (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.9).The 12 types classified by IARC as carcinogenic to humans (Group 1) are HPV16, HPV31, HPV33, HPV35, HPV52, and HPV58 in alpha-9; HPV18, HPV39, HPV45, and HPV59 in alpha-7; HPV51 in alpha-5; and HPV56 in alpha-6 (Bouvard et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2009).In addi­ tion, HPV68 in alpha-7 is classified as probably carcinogenic to humans (Group 2A).The IARC classification refers to the carcinogenic poten­ tial based on prevalence in cervical cancers, not potency.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Rarely, cervical cancers are found that contain only HPV types that are classified as possibly carcinogenic to humans (Group 2B), such as HPV73, but the attributable fraction and absolute risk are very low (Schiffman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2009; de Sanjose et al., 2010) (Fig.1.10).There is great variation in cervical carcinogenicity between the 12 HPV types that are classified by IARC in Group 1, and the impor­ tance of specific carcinogenic types may differ, depending upon the specific geographical popu­ lation (Guan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2012; de Martel et al., 2017; de Sanjosé et al., 2018; Demarco et al., 2020).The etiological fractions of the types can best be determined by analysing cervical cancer case series, which now include tens of thousands of cases of (mainly squamous) invasive cancer (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.10) (Combes et al., 2015).Five categories can be distinguished on the basis of cancer risk: HPV16 (in the alpha-9 species) is singularly carcinogenic and causes about $6 0 \\%$ of cases of SCC.HPV18 and HPV45 (in the alpha-7 species) cause $1 5 \\%$ and $5 \\%$ of SCC cases, respectively.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Other closely related alpha-9 types (HPV31, HPV33, HPV35, HPV52, and HPV58) together account, with some regional variation, for $1 5 \\%$ of SCC cases.The remaining carcinogenic types (HPV39 and HPV59 in alpha-7, HPV51 in alpha-5, and HPV56 in alpha-6) are much less carcinogenic and together cause about $5 \\%$ of SCC cases.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "HPV-associated cases of adeno­ carcinoma, which are an uncommon histolog­ ical group globally, are caused half by variants # Fig.1.9 Phylogeny of the alpha human papillomavirus (HPV) types, with species groups and IARC classifications of the branch that contains carcinogenic types !",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "[](images/660258d56fa18e1bb46c602bf7a4c1cbf271fda0152d88171a48798e7e613c85.jpg) Note that almost all alpha-9 types (HPV16-associated) are carcinogenic.The other most important carcinogens are HPV18-associated, in alpha-7.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "There is no absolute division between carcinogenic and not carcinogenic; several of the types in this branch are classified as possibly carcinogenic to humans (Group 2B), because of genetic relatedness and because they have very rarely been associated with cancer cases.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "\\* Carcinogenic to humans (Group 1); probably carcinogenic to humans (Group 2A); possibly carcinogenic to humans (Group 2B) (IARC, 2012).Reprinted from Schiffman et al.(2005).Copyright 2005, with permission from Elsevier.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "of HPV16 and half by HPV18 or HPV45 (and only uncommonly by other types, particularly in alpha-7) (Guan et al., 2013).This grouping is supported by a recent prospective study of large numbers of type-spe­ cific HPV infections and the absolute risk of cervical intraepithelial neoplasia grade 3 (CIN3) and adenocarcinoma in situ (AIS) (Demarco et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).To optimize cervical screening using HPV testing requires knowledge of the relative importance of the carcinogenic HPV types in a specific region.For the purposes of screening and vaccination, each type can be considered as a single invariant virus.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Nonetheless, for deeper understanding, epidemiological study, and possible future applications, each HPV type can be further divided phylogenetically into several variants and subvariants, which in turn consist of many subtly varying genomes (Burk et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2013; Chen et al., 2018).These individual genome differences inform our understanding of evolu­ tion (García-Vallvé et al., 2005; Van Doorslaer & Burk, 2010), fine differences in carcinogenicity (Cullen et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2015), and racial differences in response to specific HPV types (e.g.the preva­ lence of particular variants of HPV35 explains the higher percentage of cancers in women of African ancestry) (Pinheiro et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).Fig.1.10 Relative importance of the carcinogenic human papillomavirus (HPV) types <html><body><table><tr><td>HPV type</td><td>HPV species</td><td>IARC Groupa</td><td>% HPV type prevalence in cancer</td><td>% HPV type prevalence in normal</td><td>Odds ratio</td><td>% Attributable (etiological) fraction</td></tr><tr><td>HPV16</td><td>αx-9</td><td>Group 1</td><td>55.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>2.6</td><td>47.6</td><td>62.4</td></tr><tr><td>HPV18</td><td>α-7</td><td>Group 1</td><td>14.3</td><td>1</td><td>15.7</td><td>15.3</td></tr><tr><td>HPV45</td><td>α-7</td><td>Group 1</td><td>4.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>0.6</td><td>8.3</td><td>4.8</td></tr><tr><td>HPV33</td><td>α-9</td><td>Group 1</td><td>4</td><td>0.6</td><td>7.1</td><td>3.9</td></tr><tr><td>HPV58</td><td>α-9</td><td>Group 1</td><td>4</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>5.1</td><td>3.7</td></tr><tr><td>HPV31</td><td>α-9</td><td>Group 1</td><td>3.5</td><td>1</td><td>3.7</td><td>2.9</td></tr><tr><td>HPV52</td><td>α-9</td><td>Group 1</td><td>3.2</td><td>1</td><td>3.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3</td><td>2.6</td></tr><tr><td>HPV35</td><td>α-9</td><td>Group 1</td><td>1.6</td><td>0.4</td><td>3.9</td><td>1.4</td></tr><tr><td>HPV59</td><td>α-7</td><td>Group 1</td><td>1.2</td><td>0.4</td><td>2.9</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9</td></tr><tr><td>HPV39</td><td>αx-7</td><td>Group 1</td><td>1.3</td><td>0.6</td><td>2.0</td><td>0.8</td></tr><tr><td>HPV68</td><td>αx-7</td><td>Group 2A</td><td>0.6</td><td>0.4</td><td>1.5</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2</td></tr><tr><td>HPV51</td><td>αx-5</td><td>Group 1</td><td>1</td><td>0.9</td><td>1.2</td><td>0.2</td></tr><tr><td>HPV56</td><td>α-6</td><td>Group 1</td><td>0.8</td><td>0.6 0.3</td><td>1.3 1.8</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2 0.2</td></tr><tr><td>HPV73 HPV26</td><td>α-11 α-5</td><td>Group 2B Group 2B</td><td>0.5 0.2</td><td>0.1</td><td>4.1</td><td>0.2</td></tr><tr><td>HPV30</td><td>α-6</td><td>Group 2B</td><td>0.2</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>2.6</td><td>0.1</td></tr><tr><td>HPV69</td><td>α-5 </td><td>Group 2B</td><td>0.2</td><td>0.1</td><td>1.4</td><td>0.1</td></tr><tr><td>HPV67</td><td>α-9</td><td>Group 2B</td><td>0.3</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2</td><td>1.2</td><td><0.1</td></tr><tr><td>HPV82</td><td>α-5</td><td>Group 2B</td><td>0.2</td><td>0.1</td><td>1.2</td><td><0.1</td></tr><tr><td>HPV34</td><td>α-11</td><td>Group 2B</td><td>0.1</td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>1.0</td><td>Not attributable</td></tr><tr><td>HPV66</td><td>α-6</td><td>Group 2B</td><td>0.3</td><td>0.6</td><td>0.4</td><td>Not attributable</td></tr><tr><td>HPV70</td><td>α-7</td><td>Group 2B </td><td>0.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2</td><td>0.8</td><td>0.3</td><td>Not attributable</td></tr><tr><td>HPV53</td><td>α-6</td><td>Group 2B</td><td>0.5</td><td>1.1</td><td>0.4</td><td>Not attributable</td></tr></table></body></html> There is substantial variability in carcinogenicity between HPV types, including those classified by IARC in Group 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "However, for clinical use, commercial HPV screening assays often detect a pool of carcinogenic (or high-risk) HPV types; the 14 types most commonly included in current HPV tests are shown in bold here.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The attributable fraction is the percentage of cancer caused by that type.For each type, a relative risk can be estimated by the odds ratio of positivity in invasive cervical cancer compared with cytologically normal controls.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "A worldwide pooled analysis of invasive cancers $( n = 1 3 7 6 3 - 4 0 7 0 6$ cases, depending on type) and normal controls $( n = 2 6 5 9 9 - 2 6 3 9 7 1$ , depending on type) reveals a five-level natural grouping in attributable fraction, shown by colour bands.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(Attributable fractions are weighted to sum to $100 \\%$ .) HPV16 is uniquely carcinogenic (red).HPV18 and HPV45 are relatively important for cancers (orange), especially adenocarcinomas, rather than precancers.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Then follow other alpha-9 types related to HPV16 (yellow) and a group of less carcinogenic types (dark green), all classified by IARC in Group 1 or Group 2A.Last, there are types classified by IARC in Group 2B (light green), some of which contribute very small attributable fractions and some of which cannot be attributed at all.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "[For HPV66, which is more prevalent in normal cytology than in invasive cervical cancer and is sometimes mistakenly included in HPV screening tests, the attributable fraction is zero.] a Carcinogenic to humans (Group 1); probably carcinogenic to humans (Group 2A); possibly carcinogenic to humans (Group 2B) (IARC, 2012).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Created by the Working Group using data from Combes et al.(2015).Courtesy of Gary Clifford.![](images/b05948010845e9b2453e3479d4fae807725c417ca85186cdc5c4165ebcdce411.jpg) Fig.1.11 Topology of human papillomavirus (HPV) infection of the cervix Most cervical cancers arise in a zone of uniquely susceptible tissue at the dynamic squamocolumnar junction.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Multiple concurrent and asynchronous infections can cause clonal lesions of varying severity, which are difficult to distinguish visually.The cervical intraepithelial neoplasia (CIN) scale is found to be difficult to replicate either visually or microscopically.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The available evidence suggests that a more reliable distinction can be made between signs of HPV infection and high-grade precursor lesions (precancer).From Schiffman et al.(2011).Another area of biology that affects screening strategies is the adequate definition of the cervix from a screening perspective.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Anatomically, the cervix is defined as the terminal part of the uterus extending into the anterior aspect of the vagina, and it is composed of fibrous connective tissue, scant smooth muscle, and overlying epithelial components.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "However, from the perspective of carcinogenesis and screening, the cervix can be viewed as a ring of epithelium positioned at the junction between the glandular endocervix and the adjoining squamous ectocervix (Doorbar & Griffin, 2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Multiple HPV infections and related clonal lesions of differing severity can be observed concurrently by cervical micro­ dissection studies (Fig.1.11) (Quint et al., 2001; Wentzensen et al., 2009; van der Marel et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2014; Venetianer et al., 2020).Cervical lesions can collide and seemingly merge, but each clone contains a single driving HPV infection.Cervical cancers typically arise adjacent to the squamocolumnar junction (SCJ), which is subject to lifelong squamous metaplasia, the inward-moving gradual replacement of singlecell-thick columnar or glandular epithelium by the thicker squamous epithelium.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Thus, the position of the SCJ moves centrally throughout a woman’s life, from its distal origin on the ecto­ cervix or vagina into the endocervical canal, until it has gradually moved out of the visible area in most older women.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The ring of tissue between the early and eventual late SCJ positions, called the transformation zone (TZ), contains a compartment of immortal cells, which have an elevated risk of HPV-induced cervical cancer compared with the flanking tissues of the vagina or the deeper endocervix (Doorbar & Griffin, 2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cell sample collection and destruction of the TZ are the basis of secondary prevention of cervical cancer (see Section 1.2.5).Depending on the position of the SCJ, the cells collected during cervical screening will be mainly glandular cells, a mixture of TZ cell types, or mature squamous cells (Castle et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2006).# 1.2.2 Transmission and natural history of HPV infection and multistage cervical carcinogenesis Each individual case of cervical cancer arises from persistent infection with a specific carcino­ genic HPV genome (Schiffman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2016).Although it is well researched, cervical carcino­ genesis has an unpredictable quality, because a woman may successfully control a large number of concurrent or asynchronous HPV infections but fail, for reasons that are still unexplained, to control the causal one.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The whole process typi­ cally takes decades from acquisition of HPV infection to cancer diagnosis, although more rapid transitions are sometimes seen.There is a well-established set of necessary health states and transitions leading from the normal cervix to invasive cancer (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.12) (Campos et al., 2021).The schema presents the necessary transition states that are currently measurable with reasonable international repro­ ducibility by a combination of HPV typing and expert gynaecological pathology: normal cervix (uninfected), HPV infection (type-spe­ cific carcinogenic), precancer, and cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The transition between normal cervix and HPV infection can be called appearance and disap­ pearance of HPV detection, to acknowledge the limitations of existing measurement assays and the potential for reactivation of latent infections.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The transitions between infection and precancer are described as progression to and regression of precancer.Invasion is considered a typically irreversible transition when HPV-associated cells cross the basement membrane.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Precancers and cancers are subdivided into the predom inant squamous pathway and the uncommon glandular pathway, not only because the histo­ logical types vary clinically but also because the observed transition probabilities from infection to precancer to cancer seem to differ (Schiffman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2016).Fig.1.13 shows the parallel between HPV infection and cervical carcinogenesis at the levels of molecular pathogenesis and clinical microscopic or visual diagnoses.As shown in Fig.1.12, the cervix uninfected by carcinogenic HPV is considered normal from the point of view of cervical cancer risk, i.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "e.at extraordinarily low risk of prevalent or near-term incident cancer.Vertical transmis­ sion is not known to be an important factor in cervical carcinogenesis (Zahreddine et al., 2020).Anogenital HPV infections are very readily transmitted through direct physical, i.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "e.sexual (not necessarily intromissive), contact (Malagón et al., 2019).The average age at the start of sexual activity in a population determines the average starting time point of cervical carcinogenesis (Kjaer et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1992).For any given infection, the moment of acquisition is not precisely known.Detection (i.e.appearance) of HPV can represent primary acquisition or reappearance after one or more episodes of disappearance (the two are, in prac­ tical terms, indistinguishable) (González et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2010).The closer a woman is in age to the start of her sexual activity, the more likely it is that appearance represents a truly new acquisition (Ho et al., 1998; Maucort-Boulch et al., 2010).Following the general epidemiological principle, the prevalence odds of HPV infec­ tion $\\mathbf { \\Sigma } = \\mathbf { \\Sigma }$ incidence $\\times$ duration (i.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "e.persistence); when prevalence is low, the equation reduces to prevalence $\\mathbf { \\Sigma } = \\mathbf { \\Sigma }$ incidence $\\times$ duration.In women without evidence of prevalent precancer, the HPV types most commonly found on screening (i.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "e.prevalent infections) are also the most likely to appear during follow-up (i.e.incident infec­ tions).The strong correlation between HPV appearance and prevalence, which is seen in all age groups, holds because the pattern of disap­ pearance (often called clearance) is nearly the same for all HPV types (including non-carcino­ genic types) in immunocompetent women, irre­ spective of age (Plummer et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2007; Demarco et al., 2020).The clearance curve is very distinct, with extremely rapid disappearance of a high proportion of infections in the initial months, leading to median clearance by about 1 year in most screen-detected infections, with a large fraction undetectable within 2–3 years.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Only a very small proportion of carcinogenic HPV infections are detectable for more than 5 years (without progression to precancer) (Ho et al.1998; Demarco et al., 2020).![](images/347cce77487204d63fbad0758a2899bd941b7ac1c7e9e19f17e122e0b45899db.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "jpg) Fig.1.12 Human papillomavirus (HPV) infection and multistage development of cervical cancer Each box in the figure represents a necessary stage, or health state, on the path to cervical cancer.The arrows represent forward and backward transitions between health states.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The transitional probabilities form a basis of epidemiological research and health decision models.ADC, adenocarcinoma; SCC, squamous cell carcinoma.Reproduced with permission from Campos et al.(2021).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The disappearance of HPV can indicate immune control (resulting in latent infections, which replicate in the basal epithelial layer without a complete life-cycle and full virion production) or complete eradication from the cervix (Doorbar, 2018).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The distinction cannot currently be measured; in any case, only persis­ tently apparent infections, detectable for years by HPV DNA assays, confer risk of precancer.Progression to precancer is a function of HPV type and time of persistence (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.14) (Schiffman et al., 2005; Rodríguez et al., 2010).Compared with these major influences, progres­ sion is increased only slightly by etiological cofactors such as smoking, multiparity, or use of hormonal contraceptives (Perkins et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).Whereas viral clearance follows a curve that is initially very fast and then slows, progression is a more linear product of time spent as persistently detectable.HPV16 has the highest progression rate per time (Demarco et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).The lowestrisk carcinogenic types have considerably lower progression rates.The prevalence of HPV in adult women in a population is a critical determinant of cervical screening and triage strategies, because most infections are acquired in young adulthood and resolve; prevalently detected HPV infec­ tions in mid-adult and older women are more likely to be persistent infections that have not resolved.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In screening, point prevalent infections are observed; if prevalence is high, it becomes impractical to treat all infected women by use of currently available destructive or excisional methods.International studies of prevalence of carcinogenic HPV types indicate that low prevalence in mid-adulthood is characteristic of immunocompetent, frequently screened popu­ lations (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.15) (Bruni et al., 2010).However, a high prevalence throughout adulthood is observed in some important regions, such as sub-Saharan Africa, and may be linked to partial immunodeficiency (or, alternatively, to some unknown behavioural difference combined with lack of screening).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The partial immuno­ deficiency hypothesis suggests that there is a tolerant immune response secondary to chronic parasitoses or gut helminth prevalence (Petry et al., 2003; Gravitt et al., 2016).Women living with HIV are an important special population; they have a high HPV prevalence, and screening and management require separate consideration (see Section 5.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2.1).![](images/260e1ab092f8be328d3eeed910d0e19f26ee25bc5b5040d233e88b8c8d0887fa.jpg) Fig.1.13 Major steps in the development of cervical cancer Reprinted from Schiffman et al.(2007).Copyright 2007, with permission from Elsevier.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Adapted from Schiffman & Castle (2005).Few studies of type-specific regression of precancer have been conducted, because of the ethical requirement for prompt treatment.However, it is well established that HPV type is a key determinant of the precancerous state and the risk of progression.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The carcinogenic and non-carcinogenic HPV types found in precan­ cers, even when stringently defined as CIN3 or AIS, are more numerous (specifically for CIN3) than the types found in invasive cancer (Guan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2012) (Fig.1.10).This shows that current clinical definitions of precancer are not perfect surrogates of cancer risk.HPV31 and HPV51 are examples of HPV types whose role in causing precancers may lead to an exaggerated view of their importance for cancers.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Similarly, HPV53 and HPV66, two types that are possibly carcino­ genic to humans (Group 2B), are frequent causes of precancer but almost never cause cancer (Schiffman & de Sanjose, 2019).Type-specific transition probabilities of invasion cannot be directly observed ethically (McCredie et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2008); however, they can be crudely ranked by the relative proportions of the individual types in cancers versus precancers in a given population (Guan et al., 2012) (Fig.1.10).A higher relative proportion in cancers suggests an association with invasive potential, as exemplified by the predominance of HPV16 in invasive cancers.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "![](images/bba65bda1da55efe1b5a361484da31bd4314e88f9474ab9d09f9d8c48609e9dc.jpg) Fig.1.14 Average clearance, persistence, and progression of carcinogenic human papillomavirus (HPV) infections This figure combines the early natural history of rapid clearance of HPV infection with slower progression to precancers, which can, in turn, eventually invade, as described by McCredie et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2008).CIN3, cervical intraepithelial neoplasia grade 3.Reproduced from Schiffman et al.(2011).The epidemiology of HPV natural history and multistage cervical carcinogenesis can also be viewed in molecular terms describing type-spe­ cific viral carcinogenicity.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Viral genomes persist at low levels in the undifferentiated cells in the lowest layers of the epithelium, typically with only low (and regulated) levels of viral gene expression.This is the reservoir of infection that underlies viral latent persistence.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "As cells from this layer differentiate and migrate towards the epithelial surface, a pattern of gene expression is initiated, which leads to the production of virus particles; these are eventually shed from the epithelial surface (Doorbar, 2018).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The cellular immune system, a combination of intraepithelial and stromal cellular surveillance and destruc­ tion of infected cell clones, plays an important role in controlling HPV infections in cervical tissue (Stanley et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1994).Sometimes, if cellular immune control weakens (e.g.due to immune senescence), infections persisting in a latent, non-infectious state may be reactivated and resume a full viral life-cycle, leading to virion production and release (Schiffman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2016).The risk of subsequent precancer after reappear­ ance is equal to or lower than the risk after first acquisition (Rodríguez et al., 2012; Gage et al., 2014).![](images/414d4b2c599ec2489d91baa9cee9fcda076b01f958070d705acaea7d829a9b3b.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "jpg) Fig.1.15 Factors that influence age-specific human papillomavirus (HPV) prevalence in women, and three patterns of HPV prevalence The prevalence of HPV and associated cellular and visual changes in mid-adulthood is a critical determinant of screening and management strategies.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Prevalence patterns by age vary widely between settings, because of behavioural and immunological variables.Examples are given in (a), (b), and (c).(a) Age at first sexual intercourse determines the beginning of the curve.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(b) Sequential and concurrent multiple sexual partnership (both sexes) determines the height.(c) Partner stability and/or immune response shape the curve descent, and cervical cancer screening practices determine the height at older ages.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Three illustrative examples of age-specific HPV prevalence are given in (d), (e), and (f): (d) more-developed regions, (e) India, and (f) Africa.Adapted from Schiffman et al.(2016).The difference between productive HPV infection and precancer has been studied comprehensively at the molecular level, and there are important changes in both viral and cellular biology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "HPV infections are very common, and even infections with carcinogenic types are usually benign.However, when they are persis­ tent, infections with carcinogenic types may shift from the usual and common productive state (i.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "e.the complete life-cycle designed to produce new virus particles).Instead, the virus can enter an abortive or transforming state characteristic of precancer.This occurs when the viral proteins used for cellular adaptation in the successful vegetative life-cycle disrupt cell differentia­ tion and, as an unintended consequence, are no longer able to generate infectious virus.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The correlated visual, microscopic, and molecular signs or biomarkers of the shift from productive infection to transforming infection underlie almost all cervical screening, triage, and diag­ nostic tests designed to detect precancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "At the molecular level, viral gene expression changes from a productive infection character­ ized by expression of the E4, L2, and L1 viral genes to a strongly increased expression of the viral oncogenes E6 and E7 (Doorbar et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2012; Griffin et al., 2015).This deregulated expression of E6 and E7 in replicating basal cells leads to disturbances of cell-cycle regulation, disrupted differentiation and cell density regulation, and abrogation of apoptosis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The changes include disruption of the retinoblastoma protein (pRB) family regulatory pathway by E7, which results in accumulation of p16; detection by p16/Ki-67 dual staining provides accurate cytological and histological markers of precancer (Wentzensen et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2007, 2019).Deregulated expression of E6 and E7 oncoproteins also affects DNA methyl­ ation; in transformed cells, HPV genomes are highly methylated throughout $\\mathrm { C p G }$ sites, espe­ cially in the capsid encoding the L1 and L2 genes (yielding a biomarker predictive of precancer) (Lorincz et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2013; von Knebel Doeberitz & Prigge, 2019; see also Section 4.6).Table 1.2 Summary of the current WHO classification of tumours of the uterine cervix <html><body><table><tr><td>Squamous cell tumours and precursors</td><td>Germ cell tumours</td></tr><tr><td>Squamous intraepithelial lesions</td><td>Neuroendocrine neoplasia</td></tr><tr><td> Squamous cell carcinoma, HPV-associated</td><td>Neuroendocrine tumour</td></tr><tr><td>Squamous cell carcinoma, HPV-independent</td><td>Neuroendocrine carcinoma</td></tr><tr><td>Squamous cell carcinoma NOS</td><td>Small cell neuroendocrine carcinoma</td></tr><tr><td>Glandular tumours and precursors</td><td>Large cell neuroendocrine carcinoma</td></tr><tr><td>Adenocarcinoma in situ, HPV-associated</td><td>Mixed neuroendocrine-non-neuroendocrine neoplasms</td></tr><tr><td>Adenocarcinoma, HPV-associated</td><td>Carcinoma admixed with neuroendocrine carcinoma</td></tr><tr><td>Adenocarcinoma in situ, HPV-independent</td><td>Mesenchymal tumours of thelower genital tract</td></tr><tr><td>Adenocarcinoma, HPV-independent, gastric type</td><td>Adipocytic tumours</td></tr><tr><td> Adenocarcinoma, HPV-independent, clear cell type</td><td>Fibroblastic and myofbroblastic tumours</td></tr><tr><td>Adenocarcinoma, HPV-independent, mesonephric type </td><td>Vascular tumours</td></tr><tr><td> Other adenocarcinomas of the uterine cervix</td><td>Smooth muscle tumours</td></tr><tr><td>Other epithelial tumours</td><td>Skeletal muscle tumours</td></tr><tr><td>Carcinosarcoma</td><td>Peripheral nerve sheath tumours</td></tr><tr><td>Adenosquamous and mucoepidermoid carcinomas</td><td>Tumours of uncertain differentiation</td></tr><tr><td> Adenoid basal carcinoma</td><td>Undifferentiated small round cell sarcomas</td></tr><tr><td>Carcinoma, unclassifiable</td><td>Melanocytic lesions</td></tr><tr><td>Mixed epithelial and mesenchymal tumours</td><td>Naevi</td></tr><tr><td>Adenomyoma</td><td> Melanoma</td></tr><tr><td>Adenosarcoma</td><td>Metastasis</td></tr></table></body></html> HPV, human papillomavirus; NOS, not otherwise specified.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Adapted from WHO Classification of Tumours Editorial Board (2020).# 1.2.3 Terminology for pathological classification This section provides an overview of the classification and pathology of cervical cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The current WHO classification is summarized in Table 1.2, and the text below focuses on the most common cervical cancer types: SCC and adenocarcinoma, which typically arise in the TZ.These two tumour types account for more than $9 5 \\%$ of all cervical cancers.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "SCC is considerably more common than adenocarcinoma, which accounts for about $5 \\%$ of all cervical carcinomas in non-screened populations, although more recently a higher proportion $( 1 0 - 2 5 \\% )$ has been reported in screened populations (Smith et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2000; Adegoke et al., 2012).Other tumour types are rare, but screening programmes do identify appreciable numbers of them (Lei et al., 2019).The WHO classification of tumours of female genital tumours provides detailed information on all of the tumours and tumour-like lesions that arise in the uterine cervix (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Most cervical cancers are HPV-associated carcinomas, but a small percentage of tumours are not associated with HPV infection.Moreover, there is accumulating evidence that HPV-independent cervical carcinomas are more aggressive than their HPV-associated counter­ parts (Nicolás et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019; Stolnicu et al., 2019).To reflect this, the classification of cervical carcinomas has changed in the latest edition of the WHO classification, to separate tumours associated with HPV infection from those that arise independently of HPV (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# (a) Etiology and pathogenesis The etiology and pathogenesis of epithelial tumours of the cervix are dominated by HPV infection, as discussed in detail in Sections 1.2.1 and 1.2.2.An important consequence of our improved understanding of the relationship between HPV infection and cervical cancer is that it has enabled reconsideration of the terminology of precursor lesions.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "HPV infections occur in two forms: productive and transforming.Productive HPV infection cannot occur in glandular epithe­ lium, because it is tightly linked to squamous differentiation.However, transforming infection can occur in glandular epithelium, and this leads to the development of HPV-associated AIS, the precursor of HPV-associated adenocarcinoma.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This has led to increasing use of a two-tier classi­ fication for HPV-associated squamous precursor lesions (Table 1.2).# (b) Epithelial tumours # (i) Precursors of squamous cell carcinoma The histopathological classification of precursors of cervical SCC has changed over time (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.16).Until the 1960s, non-invasive lesions were subdivided into carcinoma in situ and dysplasias, which were in turn subdivided into three grades (mild, moderate, and severe) of increasing cytological abnormality (Reagan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1953).In 1967, Richart proposed the term cervical intraepithelial neoplasia (CIN) to encompass the spectrum of changes encountered in intraepithelial lesions of squamous epithelium (Richart, 1967).CIN lesions are identified on the basis of full-thickness nuclear abnormality, with the grades (CIN1, CIN2, and CIN3) determined traditionally by the position in the epithelium, in thirds, at which cytoplasmic maturation occurs; these features correlate with increasing risk of progression to invasive disease (Ostör, 1993; Cantor et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2005).Initially, carcinoma in situ (CIS) was separated from CIN3, but reproducible separation was problematic, and CIS was subse­ quently incorporated into the CIN3 category.The CIN system has been used widely, both for the diagnosis of cervical disease and, since the 1980s, in screening programmes, particularly in Europe (Fox et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1999; Hirschowitz et al., 2012).The alternative two-tier system (Lower Anogenital Squamous Terminology [LAST]), which recognizes low-grade and high-grade squamous intraepithelial lesions (SILs), has its origins in the Bethesda system for reporting cyto­ pathology, in the late 1980s (Solomon, 1989), and has been translated into histopathological use, particularly in North America (Tabbara et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1992; Stoler et al., 2001).Broadly, low-grade SIL corresponds to a combination of the categories of CIN1 and HPV-associated changes without CIN; and high-grade SIL corresponds to a combina­ tion of CIN2 and CIN3.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "A detailed review of clas­ sification systems, together with considerations of HPV biology, led to the recommendation in 2012 that the SIL terminology be used (Darragh et al., 2012); this was endorsed in 2014 in the WHO classification (Kurman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2014) and has been retained in the 2020 classification (WHO Classification of Tumours Editorial Board, 2020).Both LAST and WHO recommend that the appropriate CIN term is provided in paren­ theses after the SIL designation, for example “high-grade SIL (CIN2)”.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In cases where there is diagnostic uncertainty, p16 immunostaining, when available, is helpful (Darragh et al., 2012; Castle et al., 2020).For cytology, the Bethesda (SIL) system is widely used, but the Pap and WHO systems are also used in some areas.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This variation is also true for histopathology; both the CIN and LAST (SIL) systems are used in different geographical regions.The relationship between the systems currently in use is shown in Fig.1.16.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This discussion relates to HPV-associated squamous precursor lesions.There are no validated reports of HPV-independent squamous precursor lesions, which are therefore not included in the WHO classification (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Fig.1.16 Classification systems currently used for squamous lesions of the cervix <html><body><table><tr><td colspan=\"2\">Histology</td><td colspan=\"3\">Cytology</td><td>Molecular</td></tr><tr><td>CIN</td><td>LAST</td><td>Pap</td><td>WHO</td><td>Bethesda</td><td></td></tr><tr><td>Normal</td><td>Normal</td><td></td><td>Negative</td><td>NILM</td><td>Normal cervix</td></tr><tr><td rowspan=\"3\">CIN1</td><td rowspan=\"3\">LSIL</td><td></td><td>Squamous atypia</td><td>ASC-US</td><td rowspan=\"3\">HPV infection</td></tr><tr><td></td><td>Mild</td><td>LSIL</td></tr><tr><td>IID</td><td></td><td></td></tr><tr><td>CIN2 CIN3</td><td>HSIL</td><td>IV</td><td>Moderate Severe</td><td>HSIL</td><td>Precancer</td></tr><tr><td>Cancer</td><td>Cancer</td><td>V</td><td>Cancer</td><td>Cancer</td><td>Cancer</td></tr></table></body></html> ASC-US, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasia; HSIL, high-grade squamous intraepithelial lesion; LAST, Lower Anogenital Squamous Terminology; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion and malignancy; Pap, Papanicolaou; WHO, World Health Organization.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Adapted from Schiffman et al.(2016).# (ii) Squamous cell carcinoma SCC is the most common type of cervical cancer, constituting $8 0 - 9 0 \\%$ of cases (de Sanjose et al., 2010).SCC can be defined as a malignant tumour comprising invasive epithelium exhib­ iting squamous differentiation.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This tumour can show several different histological patterns, for example keratinizing, non-keratinizing, basaloid, or papillary.These patterns aid diag nosis but do not influence clinical management.Most cervical SCCs (an estimated $9 3 - 9 5 \\%$ ) are HPV-associated (de Sanjose et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2010; Rodríguez-Carunchio et al., 2015; Nicolás et al., 2019).The presence of HPV can be determined by molecular testing, but p16 immunohisto­ chemistry is an effective surrogate marker of HPV in most cases (Klaes et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2001, 2002; Darragh et al., 2012).Immunohistochemistry for p16 is available in many, but not all, diagnostic laboratories, and therefore the WHO classifica­ tion allows for a diagnosis of SCC not otherwise specified (NOS), in settings where the distinction between HPV-associated and HPV-independent tumours cannot be made by either p16 immu­ nostaining or HPV testing (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# (iii) Precursors of adenocarcinoma In contrast to SILs, both HPV-associated and HPV-independent precursor lesions are recog­ nized for adenocarcinomas of the cervix.The HPV-associated lesions, termed AIS, constitute the majority of cases and can generally be iden­ tified by their typical morphological features and diffuse positivity for p16 (Kurman et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2014; Stolnicu et al., 2018, 2019).The HPV-independent lesions have been increasingly recognized in recent years, particularly as precursor lesions for HPV-independent adenocarcinoma of gastric type, which have been referred to histor­ ically as lobular endocervical glandular hyper­ plasia (LEGH) and atypical LEGH (Kawauchi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2008; McCluggage, 2016; Mikami, 2020).Mesonephric remnant hyperplasia may be a precursor lesion for HPV-independent adeno­ carcinoma of mesonephric type (McCluggage, 2016).# (iv) Adenocarcinoma Adenocarcinomas are defined as malig­ nant tumours comprising invasive epithelium exhibiting glandular differentiation.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "They are also separated into HPV-associated and HPVindependent tumours (Stolnicu et al., 2018).Most cervical adenocarcinomas $( 7 5 - 9 0 \\% )$ are HPV-associated, and typical cases of usual-type adenocarcinoma can be identified on the basis of haematoxylin and eosin morphology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "p16 immu­ nostaining and/or high-risk HPV testing can be helpful in confirming the diagnosis (Stolnicu et al., 2018).HPV-independent adenocarcinomas are less common and include gastric-type adeno­ carcinomas (incorporating adenoma malignum) (Nishio et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019; Mikami, 2020), clear cell carcinoma, and mesonephric carcinoma.Gastric-type adenocarcinomas comprise $1 0 \\mathrm { - } 1 5 \\%$ of all cervical adenocarcinomas worldwide (Stolnicu et al., 2018; Hodgson et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019) and $2 0 \\mathrm { - } 2 5 \\%$ of cervical adenocarcinomas in Japan (Kojima et al., 2007; Kusanagi et al., 2010; Wada et al., 2017).There is accumulating evidence that HPV-independent cervical carcinomas, particu­ larly gastric-type adenocarcinomas, behave more aggressively than their HPV-associated counter­ parts (Nicolás et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019; Stolnicu et al., 2019).[It is important to recognize that screening programmes traditionally are not as effective for the identification of adenocarcinomas or their precursors; however, HPV-associated AIS and adenocarcinomas are identified more effectively by HPV testing than by cytology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "] # (v) Neuroendocrine tumours Low-grade neuroendocrine tumours (carci­ noid and atypical carcinoids) are very rare in the cervix.High-grade neuroendocrine carcinomas of small cell and large cell type occur much more frequently, are typically HPV-associated (small cell, $8 5 \\%$ ; large cell, $8 8 \\%$ ; Castle et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2018), and may be accompanied by an HPV-associated adenocarcinoma component.These tumours tend to present at an advanced stage and behave aggressively (Gibbs et al., 2019).# (vi) Other epithelial tumours This category includes adenosquamous carci­ noma, in which there is a mixture of both adeno­ carcinoma and SCC, and rare tumour types such as adenoid cystic carcinoma and adenoid basal carcinoma.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "True adenoid cystic carcinoma must be distinguished from an HPV-associated carcinoma with an adenoid cystic growth pattern.Carcinosarcomas occur as primary cervical tumours and are considered metaplastic carcinomas (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# (c) Non-epithelial tumours Malignant non-epithelial tumours are rare in the cervix.An important tumour in this cate­ gory is embryonal rhabdomyosarcoma, which typically occurs in young children and may be associated with DICER1 syndrome, where it is associated with other syndromic tumours such as cystic nephroma, pleuropulmonary blastoma, and thyroid tumours (WHO Classification of Tumours Editorial Board, 2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# 1.2.4 Stage at diagnosis and survival Tumour staging assesses the extent of tumour spread, and for many tumours it is the most important determinant of clinical management, largely because it is strongly associated with patient outcome.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Staging assesses spread within the organ of origin, spread to local structures, and spread to lymph nodes and distant sites; this forms the basis of the tumour–node–metastasis (TNM) staging system, which assigns separate categories to the tumour (T), lymph nodes (N), and metastases to distant sites (M) (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.17).Gynaecological tumours are typically also staged using the International Federation of Gynecology and Obstetrics (FIGO) staging system, which, for cervical carcinomas, is tradi­ tionally based on the extent of local spread and is designed to be clinically (rather than patho­ logically or radiologically) assessable.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Most of the recent literature is based on the 2009 FIGO classification, which separates clinically visible disease from microscopically detected disease and assesses spread on the basis of involvement of other pelvic structures (Pecorelli et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2009; Brierley et al., 2017).In 2018, the FIGO staging system was modified to include lymph node metastasis, based on either radiological or patho­ logical assessment (Table 1.3) (Bhatla et al., 2018, 2019; Anonymous, 2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Patients with tumours confined to the cervix but with lymph node metastasis are now considered to have stage III rather than stage I disease.A second significant change in the 2018 system was the removal of lesion width assessment from the microinvasive disease categories.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Thus, stage IA and micro­ scopic stage IB disease are defined solely on the basis of depth of invasion.A comparison of the 2009 and 2018 FIGO staging systems in a study of 1282 patients at a centre in the USA demonstrated upward stage migration in more than $5 0 \\%$ of patients, largely because of the inclusion of lymph node metastasis in the 2018 system.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This resulted in improved stratification of outcome, but hetero­ geneity remained, particularly for patients with stage III disease.Overall, progression-free survival at 5 years by the 2009 FIGO system versus the 2018 FIGO system was: stage I, $8 0 \\%$ versus $8 7 \\%$ $( P = 0 .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0 2 )$ ; stage II, $5 9 \\%$ versus $7 1 \\%$ $( P = 0 .0 0 2 )$ ; stage III, $3 5 \\%$ versus $5 5 \\%$ $\\mathit { \\Omega } ^ { ' } P < 0 .0 0 1 )$ ; and stage IV, $2 0 \\%$ versus $1 6 \\%$ $\\cdot P = 0 .4 1 \\cdot$ ) (Grigsby et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).The differences for stages I, II, and III were statistically significant.Improved discrimination of survival groups was also shown in a study focusing on stage IB and stage III disease using retrospective data from the Surveillance, Epidemiology, and End Results (SEER) Program (Matsuo et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2019).These are early data after these significant changes to the FIGO staging system, but there does appear to be improved patient stratification using the 2018 system.Data from studies describing stage at diag­ nosis and stage-related survival are given in Table 1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4, Table 1.5, Table 1.6, and Table 1.7.# 1.2.5 Treatment of cervical cancer and of precancerous lesions The successful reduction of cervical cancer incidence or mortality requires appropriate follow-up and treatment of screen-positive women.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Women with precancerous lesions are treated in order to prevent invasive cervical cancer.Treatment of precancer can be carried out by biopsies performed during colposcopy or as part of a screen-and-treat approach.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Two main categories of treatment techniques are available: destructive and excisional.These aim to effec­ tively eradicate precancerous lesions of the cervix, with minimal associated morbidity.For cervical cancer, treatment options rely mainly on radical surgery and radiotherapy.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "This section gives a short overview of the treatment options and refers mostly to the recent comprehensive IARC review (Prendiville & Sankaranarayanan, 2017) and WHO reports (WHO, 2014, 2019, 2020).# (a) Treatment of squamous precancerous lesions Comprehensive colposcopic examination before the treatment enables the provider to determine the type and size of the TZ of the cervix and to recognize or rule out cancer, microinva­ sive disease, or precancer (see Section 4.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5).The Table 1.3 Staging of cervical carcinoma according to the 2018 FIGO staging systema <html><body><table><tr><td>FIGO stage (2018)</td><td>Definition</td></tr><tr><td></td><td>The carcinoma is strictly confined to the cervix uteri (extension to the corpus should be disregarded)</td></tr><tr><td>IA</td><td>Invasive carcinoma that can be diagnosed only by microscopy, with maximum depth of invasion < 5 mm (all</td></tr><tr><td>IA1</td><td>macroscopically visible lesions, even those with superficial invasion, are stage IB) Measured stromal invasion < 3 mm in depth</td></tr><tr><td>IA2</td><td>Measured stromal invasion ≥ 3 mm and < 5 mm in depth</td></tr><tr><td>IB</td><td>Clinically visible lesion confined to the cervix or invasive carcinoma with measured deepest invasion ≥ 5 mm (greater than stage IA); lesion limited to the cervix uteri with size measured by maximum tumour diameterb</td></tr><tr><td>IB1</td><td> Invasive carcinoma ≥ 5 mm depth of stromal invasion, and < 2 cm in greatest dimension</td></tr><tr><td>IB2</td><td>Invasive carcinoma ≥ 2 cm and < 4 cm in greatest dimension</td></tr><tr><td>IB3</td><td>Invasive carcinoma ≥ 4 cm in greatest dimension </td></tr><tr><td>II</td><td>The carcinoma invades beyond the uterus but has not extended onto the lower third of the vagina or to the pelvic wall</td></tr><tr><td>IIA</td><td>Involvement limited to the upper two thirds of the vagina without parametrial involvement</td></tr><tr><td>IIA1</td><td>Invasive carcinoma < 4 cm in greatest dimension</td></tr><tr><td>IIA2</td><td>Invasive carcinoma ≥ 4 cm in greatest dimension</td></tr><tr><td>IIB III</td><td>With parametrial involvement but not up to the pelvic wall</td></tr><tr><td></td><td>The carcinoma involves the lower third of the vagina and/or extends to the pelvic wall and/or causes hydronephrosis or non-functioning kidney and/or involves pelvic and/or para-aortic lymph nodes</td></tr><tr><td>IIIA IIIB</td><td>The carcinoma involves the lower third of the vagina, with no extension to the pelvic wall Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney (unless known to be due to</td></tr><tr><td></td><td>another cause)</td></tr><tr><td>IIIC</td><td>Involvement of pelvic and/or para-aortic lymph nodes (including micrometastases), irrespective of tumour size and extent (with r and p notations)d</td></tr><tr><td>IIIC1 IIIC2</td><td>Pelvic lymph node metastasis only Para-aortic lymph node metastasis</td></tr><tr><td>IV</td><td>The carcinoma has extended beyond the true pelvis or has involved (biopsy proven) the mucosa of the bladder</td></tr><tr><td></td><td>or rectum (bullous oedema alone does not indicate stage IV)</td></tr><tr><td>IVA</td><td>Spread to adjacent pelvic organs</td></tr><tr><td>IVB</td><td>Spread to distant organs</td></tr></table></body></html> FIGO, International Federation of Gynecology and Obstetrics.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "a Imaging and pathology can be used, where available, to supplement clinical findings with respect to tumour size and extent, in all stages.Pathological findings supersede imaging and clinical findings.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "b The involvement of vascular or lymphatic spaces does not change the staging.The lateral extent of the lesion is no longer considered.c Isolated tumour cells do not change the stage, but their presence should be recorded.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "d Add the notation r (imaging) or p (pathology) to indicate the findings that are used to allocate the case to stage IIIC.For example, if imaging indicates pelvic lymph node metastasis, the stage allocation would be stage IIIC1r, and if confirmed by pathological findings, it would be stage IIIC1p.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The type of imaging modality or pathology technique should always be documented.When in doubt, the lower stage should be assigned Compiled from Bhatla et al.(2018, 2019) and Anonymous (2019).# FiCge.r1v.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "i1x7UTtuermi our–node–metastasis (TNM) staging of tumours of the cervix uteri (ICD-0-3 C53) The definitions of the T and M categories correspond to the FIGO stages.Both systems are included for comparison.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# Rules for Classification The classification applies only to carcinomas.There should be histological confirmation of the disease.The following are the procedures for assessing T, N, and M categories: T categories Clinical examination and imaging\\* N categories Clinical examination and imaging M categories Clinical examination and imaging # Note \\* The use of diagnostic imaging techniques to assess the size of the primary tumour is encouraged but is not mandatory.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Other investigations, e.g., examination under anaesthesia, cystoscopy, sigmoidoscopy, intravenous pyelography, are optional and no longer mandatory.The FIGO stages are based on clinical staging.For some Stage I subdivisions (IA-IB1) are mainly pathological, including the histological examination of the cervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(TNM stages are based on clinical and/or pathological classification.) # Anatomical Subsites 1.Endocervix (C53.0) 2.Exocervix (C53.1) # Regional Lymph Nodes The regional lymph nodes are the paracervical, parametrial, hypogastric (internal iliac, obturator), common and external iliac, presacral, lateral sacral nodes, and para-aortic nodes.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "\\* # Note \\* In the 7th edition the para-aortic nodes were considered to be distant metastatic but to be consistent with advice from FIGO the para-aortic nodes are now classified as regional.# TNM Clinical Classification T - Primary Tumour <html><body><table><tr><td>Tategries</td><td>Fiages</td><td>Definition</td></tr><tr><td>TX</td><td></td><td>Primary tumour cannot be assessed</td></tr><tr><td>TO</td><td></td><td>No evidence of primary tumour</td></tr><tr><td>Tis</td><td></td><td>Carcinoma in situ (preinvasive carcinoma)</td></tr><tr><td>T1</td><td></td><td>Tumour confined to the cervixa</td></tr></table></body></html> <html><body><table><tr><td>TNM Categories</td><td>FIGO Stages</td><td>Definition</td></tr><tr><td>T1ab.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "c</td><td>IA</td><td>Invasivecarcinoma diagnosedonlyby microscopy.Stromal invasion with a maximal depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or lessd</td></tr><tr><td>T1a1</td><td>IA1</td><td>Measured stromal invasion 3.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0 mm or less in depth and 7.0 mm or less in horizontal spread</td></tr><tr><td>T1a2</td><td>IA2</td><td>Measured stromal invasionmore than 3.0 mm and not more than 5.0 mm with a horizontal spread of 7.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0 mm or less</td></tr><tr><td>T1b</td><td>IB</td><td>Clinically visiblelesion confined to the cervix or microscopic lesion greater than T1a/IA2</td></tr><tr><td>T1b1</td><td>IB1</td><td>Clinically visible lesion 4.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0 cm or less in greatestdimension</td></tr><tr><td>T1b2</td><td>IB2</td><td>Clinicallyvisiblelesion more than 4.0 cm in greatest dimension</td></tr><tr><td>T2</td><td></td><td>Tumour invades beyond uterus but not to pelvic wall or to lower third of vagina</td></tr><tr><td>T2a</td><td>IIA</td><td>Tumour without parametrial invasion</td></tr><tr><td>T2a1</td><td>IIA1</td><td>Clinically visible lesion 4.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0 cm or less in greatestdimension</td></tr><tr><td>T2a2</td><td>IIA2</td><td>Clinically visiblelesion more than 4.0 cm in greatestdimension</td></tr><tr><td>T2b</td><td>IIB</td><td>Tumour with parametrial invasion</td></tr><tr><td>T3</td><td></td><td>Tumour involves lower third of vagina, or extends to pelvic wall,or causes hydronephrosis or non functioning kidney</td></tr><tr><td>T3a</td><td>IIIA</td><td>Tumour involves lower third of vagina</td></tr><tr><td>T3b</td><td>IIIB</td><td>Tumour extends to pelvic wall, or causes hydronephrosis or non functioning kidney</td></tr><tr><td>T4</td><td>IVA</td><td>Tumour invades mucosa of the bladder or rectum, or extends beyond true pelvise</td></tr></table></body></html> Notes • Extension to corpus uteri should be disregarded.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "b The depth of invasion should be taken from the base of the epithelium, either surface or glandular, from which it originates.The depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction of the adjacent most superficial papillae to the deepest point of invasion.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "c All macroscopically visible lesions even with superficial invasion are T1b/1B.d Vascular space involvement, venous or lymphatic, does not affect classification.• Bullous oedema is not sufficient to classify a tumour as T4.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# Fig.1.17 (continued) # N - Regional Lymph Nodes\\* NX Regional lymphnodescannotbeassessed NO Noregionallymphnodemetastasis N1 Regional lymph node metastasis Note \\*No FIGO equivalent.# M-Distant Metastasis MO No distantmetastasis M1 Distantmetastasis(includes inguinal lymphnodes and intraperitonealdisease).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Itexcludesmetastasistovagina, pelvicserosa,andadnexa # pTNM Pathological Classification ThepTandpNcategoriescorrespond to theTandNcategories pNoHistologicalexaminationofapelviclymphadenectomy specimenwillordinarilyinclude10ormorelymphnodes.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "If thelymphnodes arenegative,but thenumberordinarily examined is notmet,classifyas pNo.# pM-DistantMetastasis\\* pM1Distantmetastasismicroscopicallyconfirmed Note \\*pMO and pMX are not valid categories.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "FIGO, International Federation of Gynecology and Obstetrics.Reproduced from Brierley et al.(2017).<html><body><table><tr><td colspan=\"4\"></td></tr><tr><td>Stage Stage 0</td><td>Tis</td><td>No</td><td>MO</td></tr><tr><td>StageI</td><td>T1</td><td>No</td><td>MO</td></tr><tr><td>StageIA</td><td>T1a</td><td>No</td><td>Mo</td></tr><tr><td>Stage IA1</td><td>T1a1</td><td>No</td><td>Mo</td></tr><tr><td>Stage IA2</td><td>T1a2</td><td>No</td><td>MO</td></tr><tr><td>StageIB</td><td>T1b</td><td>No</td><td>MO</td></tr><tr><td>StageIB1</td><td>T1b1</td><td>No</td><td>MO</td></tr><tr><td>StageIB2</td><td>T1b2</td><td>No</td><td>Mo</td></tr><tr><td>StageIl</td><td>T2</td><td>No</td><td>MO</td></tr><tr><td>StageIIA</td><td>T2a</td><td>No</td><td>MO</td></tr><tr><td>StageIIA1</td><td>T2a1</td><td>No</td><td>MO</td></tr><tr><td>Stage IIA2</td><td>T2a2</td><td>No</td><td>MO</td></tr><tr><td>StageIIB</td><td>T2b</td><td>No</td><td>Mo</td></tr><tr><td>StageIll</td><td>T3</td><td>No</td><td>MO</td></tr><tr><td>StageIIA</td><td>T3a</td><td>No</td><td>Mo</td></tr><tr><td>StageIIB</td><td>T3b</td><td>Any N</td><td>Mo</td></tr><tr><td></td><td>T1,T2,T3</td><td>N1</td><td>Mo</td></tr><tr><td>Stage IVA</td><td>T4</td><td>Any N</td><td>MO</td></tr><tr><td>StageIVB</td><td>Any T</td><td>Any N</td><td>M1</td></tr></table></body></html> TZ varies in its size and its precise position on the cervix, and it may lie partially or completely in the endocervical canal.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Determining whether the TZ is fully visible and where it is situated will enable determination of the TZ type (Fig.1.18).A fully visible ectocervical and small TZ (type 1 TZ) is both easy to assess and simple to treat, either by destruction or by simple excision.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "In contrast, a large type 3 TZ cannot be assessed completely, and treatment will be associated with greater difficulty, a higher risk of morbidity (Khalid et al., 2011), and an increased risk of failure (Ghaem-Maghami et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2007).Because the TZ is where cervical SCC orig­ inates, treatment aims to accomplish eradica­ tion of the entire TZ and not only the lesion.Independently of the technique used, ablation to a depth of $7 \\mathrm { m m }$ is considered optimal (Shafi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2006); this gives a sufficient degree of safety, because gland crypts containing CIN can be as deep as $4 \\mathrm { m m }$ (Anderson & Hartley, 1980).The choice of the technique to be used depends on the TZ type, the severity and nature of the cervicallesion,thelocalcircumstances,theequip­ ment and training available, and whether general anaesthesia is accessible.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Table 1.8 summarizes the treatment options, and the different excision types are illustrated in Fig.1.18.# (i) Destructive or ablative methods With ablative techniques, the TZ epithe­ lium is destroyed rather than preserved, thereby negating the opportunity for histopathological examination; these techniques should not be performed when suspicion of malignancy is high.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The most common techniques currently used are cryosurgery (also known as cryocautery, cryo­ therapy, or cryo) and thermal coagulation (also called thermal ablation or misnamed as cold coagulation).Two other destructive methods are not presented here: radical diathermy, which is no longer used, and laser ablation, which is currently less often used (Monaghan, 1995).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Table 1.4 Stage distribution of cervical cancer using FIGO staging at diagnosis, by country or region and period <html><body><table><tr><td rowspan=\"2\">Country (territory or region)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"4\">FIGO stage at diagnosis (%)</td><td rowspan=\"2\">Reference</td></tr><tr><td>1</td><td>I1</td><td>III IV</td><td>Unknown</td></tr><tr><td>Brazil</td><td>Hospital-based cancer registry</td><td>2005-2014</td><td>21.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2</td><td>30.7</td><td>39.9</td><td>8.2</td><td>Vale et al.(2019)</td></tr><tr><td>Canada (Ontario)</td><td>Population-based cancer registry</td><td>2005-2009</td><td>39.8</td><td>16.6 14.5</td><td>7.0</td><td>22</td><td>Liu et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2016)</td></tr><tr><td>Colombia</td><td>Hospital-based cancer registry</td><td>2007-2012</td><td>24.3</td><td>21.0 35.2</td><td>4.5</td><td>15</td><td>Pardo & de Vries (2018)</td></tr><tr><td>Ethiopia</td><td>Hospital or oncology centre</td><td>2014-2016</td><td>9.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9</td><td>24.9</td><td>40.2 24.9</td><td>一</td><td>Wassie et al.(2019)</td></tr><tr><td>France (Martinique)</td><td>Population-based cancer registry</td><td>2002-2011</td><td>66.7</td><td></td><td>33.3</td><td></td><td>Melan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td>India (Mumbai)</td><td>Hospital</td><td>2010</td><td>13.0</td><td>32.0</td><td>33.5 6.0</td><td>14</td><td>Chopra et al.(2018)</td></tr><tr><td>Russian Federation (Arkhangelsk)</td><td>Population-based cancer registry</td><td>2005-2016</td><td>39.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>26.1</td><td>22.7 12.0</td><td></td><td>Roik et al.(2017)</td></tr></table></body></html> FIGO, International Federation of Gynecology and Obstetrics.In the past decade, cryosurgery has become very popular as part of a screen-and-treat approach in many low- and middle-income coun­ tries (LMICs), but difficulties with maintaining a cheap and reliable supply of carbon dioxide $\\mathrm { ( C O } _ { 2 } )$ have limited its popularity.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cryosurgery destroys tissue by freezing to below $- 2 0 { } ^ { \\circ } \\mathrm { C } .$ using a metal probe held in close contact with the TZ epithe­ lium.When the method is used for type 1 TZs that are small enough to be completely covered by the probe, success rates are likely to be high.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Failure rates are high for lesions that extend to four quadrants of the TZ.Unlike cryosurgery, which uses cold temper­ atures to destroy tissue, thermal coagulation uses heat.The probe is heated electrically and reaches temperatures of $1 0 0 { \\mathrm { - } } 1 2 0 \\ \\ ^ { \\circ } \\mathrm { C } .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "$ which causes intracellular boiling and cell necrosis.It achieves tissue destruction to a depth of $4 { \\mathrm { - } } 7 { \\mathrm { m m } }$ (Haddad et al., 1988).Thermal coagulation has success rates similar to those of cryosurgery, is quicker to perform, has low complication rates, and does not require refrigerated gas.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The proce­ dure takes less than 2 minutes to complete and is usually performed without either general or local anaesthesia; it appears to be well tolerated.Newer thermal coagulation units are battery-op­ erated and can provide sufficient battery power for 30 procedures before recharging is necessary (Pinder et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2020).Subsequent pregnancy and fertility rates do not appear to be affected by thermal coagulation.# (ii) Excisional methods There are several ways of excising the TZ.These include hysterectomy, cold-knife exci­ sion (also known as cold-knife cone biopsy or cold-knife conization), laser cone biopsy, and large loop excision of the transformation zone (LLETZ)/loop electrosurgical excision proce­ dure (LEEP).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Hysterectomy has been widely used to treat suspected or proven cervical precancer.However, hysterectomy should not be used as a treatment of CIN.For women with precancerous lesions, hysterectomy offers no advantage over local excision of the lesion, and for women in whom unsuspected invasive disease is revealed at hyster­ ectomy, the patient will have been poorly served.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Table15Stagedistributionfcervicalcancerusing thretiered staging at diagnosis,bycountry oregionand perid <html><body><table><tr><td rowspan=\"2\">Country (region or city)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"4\">Stage at diagnosis (%)a</td><td rowspan=\"2\">Reference</td></tr><tr><td>Localized</td><td>Regional</td><td>Distant</td><td>Unknown</td></tr><tr><td>Australia (New South Wales)</td><td>Population-based cancer registry</td><td>2003-2012</td><td>41.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5, 47.2b</td><td>34.2, 27.8b </td><td>17.1, 8.3b</td><td>7.3, 16.7b</td><td>Diaz et al.(2018)</td></tr><tr><td>Austria</td><td>Population-based cancer registry</td><td>2000-2007</td><td>56</td><td>21</td><td>7</td><td>17</td><td>Minicozzi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td>Costa Rica</td><td>(EUROCARE5) Population-based cancer registry</td><td>1995-2000</td><td>22.4</td><td>40.5</td><td>4</td><td>33.1</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Cuba</td><td>Population-based cancer registry</td><td>1994-1995</td><td>41.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3</td><td>34.3</td><td>1.7</td><td>22.7</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Czechia</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>61</td><td>19</td><td>8</td><td>12</td><td>Minicozzi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td>Estonia</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>60</td><td>26</td><td>8</td><td>6</td><td>Minicozzi et al.(2017)</td></tr><tr><td> Finland</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>43</td><td>5</td><td>24 </td><td>28</td><td>Minicozzi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td> India (Bhopal)</td><td> Population-based cancer registry</td><td>1991-1995</td><td>28.3</td><td>70.5</td><td>0.3</td><td>0.9</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> India (Chennai)</td><td> Population-based cancer registry</td><td>1990-1999</td><td>6.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4</td><td>86.0</td><td>3.7</td><td>3.9</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>India (Karunagappally)</td><td>Population-based cancer registry</td><td>1991-1997</td><td>15.3</td><td>60.6</td><td>8.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>15.3</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> India (Mumbai)</td><td>Population-based cancer registry</td><td>1992-1999</td><td>27.9</td><td>56.8</td><td>8.6</td><td>6.7</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td> Japan (Osaka)</td><td> Population-based cancer registry</td><td>1976-2012</td><td>53</td><td>7, 10c</td><td>10</td><td>20</td><td>Yagi et al.(2019)</td></tr><tr><td>Kuwait</td><td>Population-based cancer registry</td><td>2000-2013</td><td>24.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5</td><td>36.2</td><td>6.1</td><td>33.1</td><td>Alawadhi et al.(2019)</td></tr><tr><td>Norway</td><td> Population-based cancer registry</td><td>1990-2014</td><td>59.6</td><td>29.6</td><td>8.9</td><td>1.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9</td><td>Thogersen et al.(2017)</td></tr><tr><td>Philippines (Manila)</td><td>Population-based cancer registry</td><td>1994-1995</td><td>21.5</td><td>30.5</td><td>10.3</td><td>37.7</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td>Republic of Korea</td><td>Nationwide, hospital-based cancer registry</td><td>2006-2010</td><td>56.4</td><td>25.2</td><td>6.1</td><td>12.4</td><td>Jung et al.(2013)</td></tr><tr><td> Singapore</td><td>Population-based cancer registry</td><td>1993-1997</td><td>45.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5</td><td>5.7</td><td>5.0</td><td>43.8</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Spain (Basque Country)</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>57</td><td>30</td><td>8</td><td>5</td><td>Minicozzi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td> Spain (Cuenca)</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>66</td><td>11</td><td>20</td><td>3</td><td>Minicozzi et al.(2017)</td></tr><tr><td>Switzerland (St Gallen)</td><td>Population-based cancer registry (EUROCARE5)</td><td>2000-2007</td><td>63</td><td>18</td><td>12</td><td>8</td><td>Minicozzi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td>Thailand (Chiang Mai</td><td> Population-based cancer registry</td><td>1993-1997</td><td>26.1</td><td>69.7</td><td>3.7</td><td>0.5</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Thailand (Chang Mai)</td><td>Population-based cancer registry</td><td>2008-2012</td><td>48</td><td>46</td><td>5</td><td>1</td><td>Sripan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019)</td></tr></table></body></html> Table 1.5 (continued) <html><body><table><tr><td rowspan=\"2\">Country (region or city)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"4\"> Stage at diagnosis (%)a</td><td rowspan=\"2\">Reference</td></tr><tr><td>Localized</td><td> Regional</td><td>Distant</td><td>Unknown</td></tr><tr><td>Thailand (Khon Kaen)</td><td> Population-based cancer registry</td><td>1993-1997</td><td>17.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "3</td><td>53.8</td><td>6.3</td><td>22.6</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Thailand (Lampang)</td><td> Population-based cancer registry</td><td>1990-2000</td><td>31.2</td><td>53.9</td><td>5.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "8</td><td>9.2</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Thailand (Songkhla)</td><td> Population-based cancer registry</td><td>1990-1999</td><td>22.3</td><td>54.6</td><td>5.8</td><td>17.3</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td>Turkey (Izmir)</td><td>Population-based cancer registry</td><td>1995-1997</td><td>28.9</td><td>41.8</td><td>6.1</td><td>23.2</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>USA</td><td>Population-based cancer registry (SEER)</td><td>2004-2009</td><td>44.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "7</td><td>35.5</td><td>11.5</td><td>8.4</td><td>Benard et al.(2017)</td></tr><tr><td>USA</td><td>Population-based cancer registry (SEER)</td><td>2014-2016</td><td>42</td><td>36</td><td>17</td><td>5</td><td>Benard et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019)</td></tr></table></body></html> EUROAisSl a sites (e.g.lung or bone) (ACS, 2020)) b Data are shown for Indigenous and non-Indigenous populations, respectively.c For regional lymph nodes reported separately from adjacent organs.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "able 1.6Stage-related survivalofcervical cancerusing FIGO staging at diagnosis,by country orregionand period <html><body><table><tr><td rowspan=\"2\">Country (territory or region)</td><td rowspan=\"2\">Data source</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"5\">FIGO stage at diagnosis (%)</td><td rowspan=\"2\">Follow-up</td><td rowspan=\"2\">Reference</td></tr><tr><td>I</td><td>11</td><td>III</td><td>IV</td><td>Unknown</td></tr><tr><td> India (Mumbai)</td><td>Hospital</td><td>2010</td><td></td><td>62</td><td>45</td><td>4</td><td></td><td>5-yr disease-free survival (3-yr for</td><td>Chopra et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2018)</td></tr><tr><td> Ethiopia</td><td>Hospital or oncology centre</td><td>2014-2016</td><td>81.04</td><td>67.94</td><td>23.33</td><td>20.03</td><td>二</td><td>stage IV) 5-yr survival</td><td>Wassie et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019)</td></tr><tr><td>Colombia</td><td>Hospital-based cancer registry</td><td>2007-2012</td><td>90.3</td><td>75.6</td><td>47.6</td><td>22.6</td><td>50.6</td><td> 2-yr survival</td><td>Pardo & de Vries (2018)</td></tr><tr><td>France (Martinique)</td><td>Population-based cancer registry</td><td>2002-2011</td><td></td><td>71</td><td></td><td>23</td><td>-</td><td> 5-yr survival</td><td>Melan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017)</td></tr><tr><td>Sub-Saharan Africa (excluding Mauritius</td><td>Population-based African Cancer Registry Network</td><td>2008-2014 (varies between</td><td>50.3</td><td></td><td></td><td>20.5</td><td></td><td> 5-yr survival</td><td>Sengayi-Muchengeti et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2020)</td></tr></table></body></html> FIGO, International Federation of Gynecology and Obstetrics; yr, year.Table 1.tage-related suvivalfervicacancerusing thre-tiredstagingat diagnosisbycoutryorreginnd perid <html><body><table><tr><td rowspan=\"2\">Country (region or city)</td><td rowspan=\"2\">Period of diagnosis</td><td colspan=\"4\">Stage at diagnosis (%)</td><td rowspan=\"2\">Follow-up</td><td rowspan=\"2\">Reference</td></tr><tr><td>Localized</td><td>Regional</td><td>Distant</td><td>Unknown</td></tr><tr><td>Costa Rica</td><td>1995-2000</td><td>89.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5</td><td>43.1</td><td>11.3</td><td>43.2</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Cuba</td><td>1994-1995</td><td>73.9</td><td>41.5</td><td>33.3</td><td>45.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "0</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> India (Bhopal)</td><td>1991-1995</td><td>60.6</td><td>22.7</td><td>0.0</td><td>0.0</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td> India (Chennai)</td><td>1990-1999</td><td>69.1</td><td>55.3</td><td>12.4</td><td>43.4</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> India (Karunagappally)</td><td>1991-1997</td><td>72.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>43.5</td><td>23.1</td><td>44.3</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> India (Mumbai)</td><td>1992-1999</td><td>68.3</td><td>35.7</td><td>2.4</td><td>40.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "7</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Japan (Osaka)</td><td>2003-2010</td><td>90.4</td><td>50.3, 59.6b</td><td>6.9</td><td></td><td> 5-yr relative survival</td><td>Yagi et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019)</td></tr><tr><td>Kuwait</td><td>2005-2009</td><td>88.4</td><td>68.3</td><td>—</td><td>72.9</td><td> 5-yr unstandardized</td><td>Alawadhi et al.(2019)</td></tr><tr><td>Philippines (Manila)</td><td>1994-1995</td><td>63.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>29.9</td><td>7.1</td><td>28.2</td><td>net survival 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td> Republic of Koreac</td><td>2006-2010</td><td>91.1</td><td>70.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9</td><td>25.8</td><td>75.1</td><td> 5-yr survival</td><td>Jung et al.(2013)</td></tr><tr><td> Singapore</td><td>1993-1997</td><td>69.7</td><td>48.0</td><td>20.4</td><td>55.7</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td>Thailand (Chiang Mai)</td><td>1993-1997</td><td>81.2</td><td>52.7</td><td>12.2</td><td>75.0</td><td> 5-yr absolute survival</td><td> Sankaranarayanan et al.(2011)</td></tr><tr><td> Thailand (Khon Kaen)</td><td>1993-1997</td><td>65.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1</td><td>48.7</td><td>30.6</td><td>57.0</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Thailand (Lampang)</td><td>1990-2000</td><td>78.7</td><td>57.9</td><td>6.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "5</td><td>70.6</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>Thailand (Songkhla)</td><td>1990-1999</td><td>81.2</td><td>56.3</td><td>15.4</td><td>61.3</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2011)</td></tr><tr><td>Turkey (Izmir)</td><td>1995-1997</td><td>67.7</td><td>54.6</td><td>9.3</td><td>69.1</td><td> 5-yr absolute survival</td><td>Sankaranarayanan et al.(2011)</td></tr><tr><td>USAd</td><td>2004-2009</td><td>85.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9</td><td>55.8</td><td>16.3</td><td>56.2</td><td> 5-yr relative survival</td><td>Benard et al.(2017)</td></tr></table></body></html> yr, year.a Unless otherwise specified, data are from population-based cancer registries.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "b For regional lymph nodes reported separately from adjacent organs.c Nationwide, hospital-based cancer registry.d Surveillance, Epidemiology, and End Results Program (SEER).Table 1.8 Treatment options for precancerous lesions of the cervix <html><body><table><tr><td rowspan=\"2\">Severity and nature of lesion</td><td colspan=\"3\">Treatment options</td></tr><tr><td>Type 1 TZ</td><td>Type 2 TZ</td><td>Type 3 TZ</td></tr><tr><td>No visible lesiona</td><td>Ablation</td><td>LLETZ Ablation when the TZ does not extend beyond 2 mm inside the endocervical canal</td><td>Type 3 excision by LLETZ</td></tr><tr><td>Low-grade or high-grade Ablation (preferred in a squamous lesionsb</td><td>screen-and-treat setting or for low-grade lesions) LLETZ</td><td>LLETZ Ablation when the TZ does not extend beyond 2 mm inside the endocervical canal</td><td>Type 3 excision by LLETZ using a sufficiently long loop, or top- hat excision, SWETZ, or NETZ; CKC (only if the electrosurgical techniques are not feasible)</td></tr><tr><td>Glandular lesionse</td><td colspan=\"3\">Type 3 excision with CKC, SWETZ or NETZ, followed by endocervical cureting LLETZ with a sufficiently long loop, if the other techniques are not feasible</td></tr><tr><td>Microinvasive cancerd</td><td colspan=\"3\">Type 3 excision with CKC, SWETZ, or NETZ, followed by endocervical curetting CKC,colfizat;Hnpailaiushgadqusrapitll;relxif</td></tr><tr><td colspan=\"4\">thraftifthrafoostaht wisotrft transformation zone; VIA, visual inspection with acetic acid.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "a HPV-positive women in a screen-and-treat setting; cytology suspecting HSIL or glandular abnormalities.b Abnormal VIA in a screen-and-treat setting, colposcopically suspected or histopathologically proved.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cytoloyuspetinglanlaiosuspicinfglandlarmaltionpy oraecarcinmnsituconmn histopathology.</td></tr></table></body></html> After a simple hysterectomy, it is not possible to offer the appropriate radiotherapy regime, and radical hysterectomy is also not possible.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cold-knife conization, the oldest method of local excision, is still widely used, especially where colposcopy facilities and/or expertise are not available.The technique leaves a relatively large cervical defect and often removes more tissue than is necessary.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The procedure is usually performed under general anaesthesia.A suture or sutures are often used to achieve post-excision haemostasis.Cold-knife conization is associ­ ated with well-recognized short- and long-term complications, including primary and secondary haemorrhage, cervical stenosis, and cervical incompetence.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "It may be selected for glandular or microinvasive disease, but otherwise cold-knife conization has no advantages over LLETZ/LEEP or laser excision and is associated with greater morbidity and long-term pregnancy-related com­- plications (Jones et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1979; Kristensen et al., 1993; Arbyn et al., 2008).LLETZ/LEEP involves excision of the TZ using a low-voltage diathermy loop of thin wire, usually with blended diathermy under local anaesthesia.This technique is used for a type 1 excision (Fig.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1.18) and is appropriate for most women with CIN (i.e.for a small or medium-sized type 1 TZ).It leads to the excision of the entire TZ and only the TZ, to a depth of about $5 { - } 7 \\mathrm { m m }$ , and the diathermy artefactual damage of the loop will cause necrosis for a further $2 { - } 3 ~ \\mathrm { m m }$ .",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Short-term complications after LLETZ include light vaginal bleeding, mild discomfort, and a little discharge.Alternative electrosurgery techniques for an endocervical TZ.Although type 3 excisions, especially large ones, are known to be associ­ ated with an increase in the risk of subsequent pregnancy-related complications (primarily premature delivery) (Khalid et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2012), a type 3 excision is sometimes necessary, for example for a type $3 \\mathrm { T Z }$ with suspected high-grade SIL, glan dular disease, or even suspected microinvasion.A type 3 excision may require general anaes­ thesia, depending on how large and how long the excision needs to be, access to the cervix, and patient compliance.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Alternative techniques to LLETZ use a straight wire (SWETZ; Russomano et al., 2015) or a needle (NETZ).Top-hat LEEP involves two steps of loop excision: a conven­ tional LEEP followed by a second excision of the residual endocervix using a smaller-diameter loop.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Given the greater extent of endocervical excision compared with conventional LEEP, top-hat LEEP may reduce the risk of incomplete endocervical excision in women with a type 3 TZ (Kietpeerakool et al., 2010).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "![](images/0b1299eeaaae5c3716905ba9183348fd7c676148307054ef69708603cc9814d5.jpg) Fig.1.18 Determination of the transformation zone (TZ) types of the cervix, and TZ excision types # (iii) Follow-up after treatment of squamous precancerous lesions Because treatment methods are not asso­ ciated with a $1 0 0 \\%$ success rate, it is important to establish a follow-up protocol to identify the small percentage $( < 1 0 \\% )$ of women treated who will have residual CIN.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Women who have been treated for cervical precancer are much more likely to develop cervical cancer.This increased risk has been quantified as being 2–5 times the background risk, and much of it is a result of poor long-term follow-up (Soutter et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 1997; Strander et al., 2007).Several case series of cervical cancer have demonstrated that more than $5 0 \\%$ of cancers occur in women who are lost to follow-up (Ghaem-Maghami et al., 2007) and that this increase in risk lasts for 20 years or more.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# (b) Treatment of adenocarcinoma in situ AIS is a precursor of invasive adenocarcinoma.Colposcopic assessment of glandular dysplasia is less reliable than that of squamous disease.Most glandular disease has an endocer­ vical component, and it is often not possible to determine the extent of endocervical involvement of dysplastic epithelium in the endocervical canal.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Therefore, destructive techniques are contraindicated.The definitive management of glandular dysplasia is excision of the TZ and a proportion of full-thickness endocervical canal epithelium.It is crucial that the pathologist has sufficient undamaged tissue with which to make a diagnosis and assess margin involvement.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "A cylindrical type 3 excision should be performed using a straight wire, cold knife, or laser.Such conservative management of AIS is justified in a young woman who is assured of adequate follow-up until she has completed her family, when hysterectomy should be considered.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# (c) Treatment of invasive cervical cancer In general, early cervical cancer (SCC or adenocarcinoma) is treated using surgical exci­ sion with simple or radical hysterectomy and pelvic lymph node evaluation, whereas advanced cervical cancer is treated with concurrent chemo­ therapy and radiation.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Fertility-sparing surgical procedures such as conization or trachelectomy can also be offered to women who have not completed their family.Detailed information can be found elsewhere (e.g.WHO, 2014; Buchanan et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ", 2017; Prendiville & Sankaranarayanan, 2017; Cancer Research UK, 2020; Nica et al., 2021).# References ACS (2020).Early detection, diagnosis, and staging.Survival rates for cervical cancer.Atlanta (GA), USA: American Cancer Society.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Available from: https:// www.cancer.org/cancer/cervical-cancer/detectiondiagnosis-staging/survival.html.Adegoke O, Kulasingam S, Virnig B (2012).Cervical cancer trends in the United States: a 35-year population-based analysis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Womens Health (Larchmt).21(10):1031–7.doi:10.1089/jwh.2011.3385 PMID:22816437 Alawadhi E, Al-Awadi A, Elbasmi A, Coleman MP, Allemani C (2019).Cancer survival by stage at diagnosis in Kuwait: a population-based study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Oncol.2019:8463195.doi:10.1155/2019/8463195 PMID:31662756 Allemani C (2017).The importance of global surveil­ lance of cancer survival for cancer control: the CONCORD programme.Cancer Control.2017:19–22.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Available from: http://www.cancercontrol.info/2017-3/ the-importance-of-global-surveillance-of-cancersurvival-for-cancer-control-the-concord-programme/.Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "; CONCORD Working Group (2018).Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet.391(10125):1023–75.doi:10.1016/ S0140-6736(17)33326-3 PMID:29395269 Anderson MC, Hartley RB (1980).Cervical crypt involve­ ment by intraepithelial neoplasia.Obstet Gynecol.55(5):546–50.PMID:7366912 Anonymous (2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 145(2019) 129–135].Int J Gynaecol Obstet.147(2):279–80.doi:10.1002/ijgo.12969 PMID:31571232 Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2008).Perinatal mortality and other severe adverse pregnancy outcomes asso­ ciated with treatment of cervical intraepithelial neoplasia: meta-analysis.BMJ.337:a1284.doi:10.1136/ bmj.a1284 PMID:18801868 Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2020).Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.Lancet Glob Health.8(2):e191–203.doi:10.1016/ S2214-109X(19)30482-6 PMID:31812369 Benard VB, Greek A, Jackson JE, Senkomago V, Hsieh MC, Crosbie A, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019).Overview of Centers for Disease Control and Prevention’s Case Investigation of Cervical Cancer Study.J Womens Health (Larchmt).28(7):890–6.doi:10.1089/jwh.2019.7849 PMID:31264934 Benard VB, Watson M, Saraiya M, Harewood R, Townsend JS, Stroup AM, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2017).Cervical cancer survival in the United States by race and stage (2001–2009): find­ ings from the CONCORD-2 study.Cancer.123(Suppl 24):5119–37.doi:10.1002/cncr.30906 PMID:29205300 Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2018).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer of the cervix uteri.Int J Gynaecol Obstet.143(Suppl 2):22–36.doi:10.1002/ijgo.12611 PMID:30306584 Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al.(2019).Revised FIGO staging for carcinoma of the cervix uteri.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Gynaecol Obstet.145(1):129–35.doi:10.1002/ijgo.12749 PMID:30656645 Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al.; WHO International Agency for Research on Cancer Monograph Working Group (2009).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "A review of human carcinogens – Part B: biological agents.Lancet Oncol.10(4):321–2.doi:10.1016/S1470- 2045(09)70096-8 PMID:19350698 Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2005).Incidence trends of adeno­ carcinoma of the cervix in 13 European countries.Cancer Epidemiol Biomarkers Prev.14(9):2191–9.doi:10.1158/1055-9965.EPI-05-0231 PMID:16172231 Brierley JD, Gospodarowicz MK, Wittekind C, editors (2017).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "TNM classification of malignant tumours.8th ed.Hoboken, NJ (USA): Wiley Blackwell.Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al.(2020).Impact of HPV vacci­ nation and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income coun­ tries.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet.395(10224):575–90.doi:10.1016/S0140- 6736(20)30068-4 PMID:32007141 Bruni L, Serrano B, Diaz Sanchis M, Bosch José FX, de Sanjosé Llongueras S (2016).Update of global estimates of HPV prevalence: meta-analysis of 2.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4 million women with normal cytology.Presented at International Papillomavirus Conference, Sydney, Australia.Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S (2010).Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Infect Dis.202(12):1789–99.doi:10.1086/657321 PMID:21067372 Buchanan T, Pierce JY, Graybill W, Kohler M, Creasman W (2017).Why do we continue to overtreat stage Ia carci­ noma of the cervix?Am J Obstet Gynecol.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "217(4):413–7.doi:10.1016/j.ajog.2017.05.020 PMID:28522321 Burk RD, Harari A, Chen Z (2013).Human papilloma­ virus genome variants.Virology.445(1–2):232–43.doi:10.1016/j.virol.2013.07.018 PMID:23998342 Bzhalava D, Eklund C, Dillner J (2015).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "International standardization and classification of human papil­ lomavirus types.Virology.476:341–4.doi:10.1016/j.virol.2014.12.028 PMID:25577151 Campos NG, Demarco M, Bruni L, Desai KT, Gage JC, Adebamowo SN, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2021).A proposed new gener­ ation of evidence-based microsimulation models to inform global control of cervical cancer.Prev Med.144:106438.doi:10.1016/j.ypmed.2021.106438 PMID:33678235 Cancer Research UK (2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Treatment for cervical cancer.Oxford, UK: Cancer Research UK.Available from: https://www.cancerresearchuk.org/about-cancer/ cervical-cancer/treatment.Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Follen M, MacAulay C (2005).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Natural history of cervical intraepithelial neoplasia: a meta-analysis.Acta Cytol.49(4):405–15.doi:10.1159/000326174 PMID: 16124170 Castle PE, Adcock R, Cuzick J, Wentzensen N, TorrezMartinez NE, Torres SM, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "; New Mexico HPV Pap Registry Steering Committee; p16 IHC Study Panel (2020).Relationships of p16 immunohistochem­ istry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Arch Pathol Lab Med.144(6):725–34.doi:10.5858/ arpa.2019-0241-OA PMID:31718233 Castle PE, Jeronimo J, Schiffman M, Herrero R, Rodríguez AC, Bratti MC, et al.(2006).Age-related changes of the cervix influence human papillomavirus type distri­ bution.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer Res.66(2):1218–24.doi:10.1158/0008- 5472.CAN-05-3066 PMID:16424061 Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, et al.(2017).Why does cervical cancer occur in a state-of-the-art screening program?",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.146(3):546–53.doi:10.1016/j.ygyno.2017.06.003 PMID:28606721 Castle PE, Pierz A, Stoler MH (2018).A systematic review and meta-analysis on the attribution of human papil­ lomavirus (HPV) in neuroendocrine cancers of the cervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.148(2):422–9.doi:10.1016/j.ygyno.2017.12.001 PMID:29248196 Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, et al.(2018).Classification and evolu­ tion of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Virology.516:86–101.doi:10.1016/j.virol.2018.01.002 PMID:29331867 Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, et al.(2018).Locally advanced cervical cancer: a study of 5-year outcomes.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Indian J Cancer.55(1):45–9.doi:10.4103/ijc.IJC_428_17 PMID:30147092 Combes J-D, Guan P, Franceschi S, Clifford GM (2015).Judging the carcinogenicity of rare human papillo­ mavirus types.Int J Cancer.136(3):740–2.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "doi:10.1002/ ijc.29019 PMID:24917192 Cullen M, Boland JF, Schiffman M, Zhang X, Wentzensen N, Yang Q, et al.(2015).Deep sequencing of HPV16 genomes: a new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Papillomavirus Res.1:3–11.doi:10.1016/j.pvr.2015.05.004 PMID:26645052 Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al.; Members of LAST Project Work Groups (2012).The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "[Erratum in: Arch Pathol Lab Med.2013 137(6):738] Arch Pathol Lab Med.136(10):1266–97.doi:10.5858/ arpa.LGT200570 PMID:22742517 de Martel C, Plummer M, Vignat J, Franceschi S (2017).Worldwide burden of cancer attributable to HPV by site, country and HPV type.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.141(4):664– 70.doi:10.1002/ijc.30716 PMID:28369882 de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al.; Retrospective International Survey and HPV Time Trends Study Group (2010).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospec­ tive cross-sectional worldwide study.Lancet Oncol.11(11):1048–56.doi:10.1016/S1470-2045(10)70230-8 PMID:20952254 de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "; RIS HPV TT, VVAP and Head and Neck study groups (2018).Burden of human papil­ lomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58.JNCI Cancer Spectr.2(4):pky045.doi:10.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1093/jncics/pky045 PMID: 31360870 Demarco M, Hyun N, Carter-Pokras O, Raine-Bennett TR, Cheung L, Chen X, et al.(2020).A study of type-specific HPV natural history and implica­ tions for contemporary cervical cancer screening programs.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "EClinicalMedicine.22:100293.doi:10.1016/j.eclinm.2020.100293 PMID:32510043 Dhillon PK, Yeole BB, Dikshit R, Kurkure AP, Bray F (2011).Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976–2005: an age-period-cohort analysis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Br J Cancer.105(5):723–30.doi:10.1038/bjc.2011.301 PMID:21829198 Diaz A, Baade PD, Valery PC, Whop LJ, Moore SP, Cunningham J, et al.(2018).Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: a semi-national registry-based cohort study (2003–2012).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "PLoS One.13(5):e0196764.doi:10.1371/journal.pone.0196764 PMID:29738533 Doorbar J (2018).Host control of human papilloma­ virus infection and disease.Best Pract Res Clin Obstet Gynaecol.47:27–41.doi:10.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "1016/j.bpobgyn.2017.08.001 PMID:28919159 Doorbar J, Griffin H (2019).Refining our under­ standing of cervical neoplasia and its cellular origins.Papillomavirus Res.7:176–9.doi:10.1016/j.pvr.2019.04.005 PMID:30974183 Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2012).The biology and life-cycle of human papillomaviruses.Vaccine.30(Suppl 5):F55–70.doi:10.1016/j.vaccine.2012.06.083 PMID:23199966 Ferlay J, Colombet M, Bray F (2018).Cancer incidence in five continents, CI5plus: IARC CancerBase No.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9 [Internet].Lyon, France: International Agency for Research on Cancer.Available from: https://ci5.iarc.fr/ CI5plus.Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al.(2020).Global Cancer Observatory: Cancer Today.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lyon, France: International Agency for Research on Cancer.Available from: https://gco.iarc.fr/today.Fox H, Buckley H, Al-Nafussi A, et al.(1999).Histopathology reporting in cervical screening.1st ed.efold Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2014).Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.J Natl Cancer Inst.106(8):dju153.doi:10.1093/jnci/dju153 PMID:25038467 García-Vallvé S, Alonso A, Bravo IG (2005).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Papillomaviruses: different genes have different histo­ ries.Trends Microbiol.13(11):514–21.doi:10.1016/j.tim.2005.09.003 PMID:16181783 Ghaem-Maghami S, Sagi S, Majeed G, Soutter WP (2007).Incomplete excision of cervical intraepithe­ lial neoplasia and risk of treatment failure: a metaanalysis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet Oncol.8(11):985–93.doi:10.1016/ S1470-2045(07)70283-8 PMID:17928267 Gibbs J, Mei S, Economos K, Lee YC, Kanis MJ (2019).Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Am J Obstet Gynecol.221(1):53.e1–6.doi:10.1016/j.ajog.2019.02.052 PMID:30849352 Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al.(2017).The global burden of women’s cancers: a grand challenge in global health.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet.389(10071):847–60.doi:10.1016/S0140-6736(16)31392-7 PMID:27814965 González P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C, Wacholder S, et al.(2010).Behavioral/ lifestyle and immunologic factors associated with HPV infection among women older than 45 years.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer Epidemiol Biomarkers Prev.19(12):3044–54.doi:10.1158/1055-9965.EPI-10-0645 PMID:20952561 Gravitt PE, Marks M, Kosek M, Huang C, Cabrera L, Olortegui MP, et al.(2016).Soil-transmitted helminth infections are associated with an increase in human papillomavirusprevalenceandaT-helpertype2cytokine signature in cervical fluids.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Infect Dis.213(5):723–30.doi:10.1093/infdis/jiv498 PMID:26486638 Griffin H, Soneji Y, Van Baars R, Arora R, Jenkins D, van de Sandt M, et al.(2015).Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Mod Pathol.28(7):977–93.doi:10.1038/modpathol.2015.52 PMID:25953390 Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, et al.(2020).FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.157(3):639–43.doi:10.1016/j.ygyno.2020.03.027 PMID:32248993 Guan P, Clifford GM, Franceschi S (2013).Human papil­ lomavirus types in glandular lesions of the cervix: a meta-analysis of published studies.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.132(1):248–50.doi:10.1002/ijc.27663 PMID:22684765 Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al.(2012).Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.131(10):2349– 59.doi:10.1002/ijc.27485 PMID:22323075 Haddad N, Hussein I, Blessing K, Kerr-Wilson R, Smart G (1988).Tissue destruction following cold coagulation of the cervix.J Gynecol Surg.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4(1):23–7.doi:10.1089/ gyn.1988.4.23 Hirschowitz L, Albus A, Brown C, Das N, Ganesan R, Herrington CS, et al.(2012).Histopathology reporting in cervical screening – an integrated approach.2nd ed.Sheffield, UK: NHS Cervical Screening Programme.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998).Natural history of cervicovaginal papillomavirus infection in young women.N Engl J Med.338(7):423–8.doi:10.1056/NEJM199802123380703 PMID:9459645 Hodgson A, Olkhov-Mitsel E, Howitt BE, Nucci MR, Parra-Herran C (2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "International Endocervical Adenocarcinoma Criteria and Classification (IECC): correlation with adverse clinicopathological features and patient outcome.J Clin Pathol.72(5):347–53.doi:10.1136/jclinpath-2018-205632 PMID:30679193 IARC (2012).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Biological agents.IARC Monogr Eval Carcinog Risks Hum.100B:1–475.Available from: https://publications.iarc.fr/119 PMID:23189750 Islami F, Fedewa SA, Jemal A (2019).Trends in cervical cancer incidence rates by age, race/ethnicity, histolog­ ical subtype, and stage at diagnosis in the United States.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Prev Med.123:316–23.doi:10.1016/j.ypmed.2019.04.010 PMID:31002830 Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok M, Korir A, et al.(2020).Trends in cervical cancer incidence in sub-Saharan Africa.Br J Cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "123(1):148–54.doi:10.1038/s41416-020-0831-9 PMID:32336751 Jones JM, Sweetnam P, Hibbard BM (1979).The outcome of pregnancy after cone biopsy of the cervix: a case-control study.Br J Obstet Gynaecol.86(12):913–6.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "doi:10.1111/j.1471-0528.1979.tb11237.x PMID:575050 Jung KW, Won YJ, Kong HJ, Oh CM, Shin A, Lee JS (2013).Survival of Korean adult cancer patients by stage at diagnosis, 2006–2010: national cancer registry study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer Res Treat.45(3):162–71.doi:10.4143/ crt.2013.45.3.162 PMID:24155674 Kawauchi S, Kusuda T, Liu XP, Suehiro Y, Kaku T, Mikami Y, et al.(2008).Is lobular endocervical glandular hyper­ plasia a cancerous precursor of minimal deviation adenocarcinoma?",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": ": a comparative molecular-genetic and immunohistochemical study.Am J Surg Pathol.32(12):1807–15.doi:10.1097/PAS.0b013e3181883722 PMID:18779726 Khalid S, Carcopino X, Michail G, Metchette S, Conroy R, Prendiville W (2011).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Compliance with follow up cytology after discharge from the colposcopy clinic.Ir Med J.104(6):167–70.PMID:22111391 Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, et al.(2012).The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BJOG.119(6):685–91.doi:10.1111/j.1471-0528.2011.03252.x PMID:22329499 Kietpeerakool C, Suprasert P, Khunamornpong S, Sukpan K, Settakorn J, Srisomboon J (2010).“ Top hat” versus conventional loop electrosurgical excision proce­ dure in women with a type 3 transformation zone.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Gynaecol Obstet.109(1):59–62.doi:10.1016/j.ijgo.2009.11.005 PMID:20022598 Kjaer SK, Dahl C, Engholm G, Bock JE, Lynge E, Jensen OM (1992).Case-control study of risk factors for cervical neoplasia in Denmark.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "II.Role of sexual activity, reproductive factors, and venereal infections.Cancer Causes Control.3(4):339–48.doi:10.1007/ BF00146887 PMID:1617121 Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2002).p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia.Am J Surg Pathol.26(11):1389–99.doi:10.1097/00000478-200211000- 00001 PMID:12409715 Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2001).Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.Int J Cancer.92(2):276–84.doi:10.1002/ijc.1174 PMID:11291057 Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2007).Gastric morphology and immu­ nophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.Am J Surg Pathol.31(5):664–72.doi:10.1097/01.pas.0000213434.91868.b0 PMID:17460448 Kristensen J, Langhoff-Roos J, Kristensen FB (1993).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Increased risk of preterm birth in women with cervical conization.Obstet Gynecol.81(6):1005–8.PMID:8497340 Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors (2014).WHO classification of tumours of female reproductive organs.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4th ed.Lyon, France: International Agency for Research on Cancer.Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, et al.(2010).Absence of high-risk human papillomavirus (HPV) detection in endocer­ vical adenocarcinoma with gastric morphology and phenotype.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Am J Pathol.177(5):2169–75.doi:10.2353/ ajpath.2010.100323 PMID:20829441 Lei J, Andrae B, Ploner A, Lagheden C, Eklund C, Nordqvist Kleppe S, et al.(2019).Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BMJ.365:l1207.doi:10.1136/ bmj.l1207 PMID:30944091 Li X, Zheng R, Li X, Shan H, Wu Q, Wang Y, et al.(2017).Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Chin J Cancer Res.29(6):477–86.doi:10.21147/j.issn.1000- 9604.2017.06.02 PMID:29353970 Liu N, Mittmann N, Coyte PC, Hancock-Howard R, Seung SJ, Earle CC (2016).Phase-specific healthcare costs of cervical cancer: estimates from a popula­ tion-based study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Am J Obstet Gynecol.214(5):615.e1–11.doi:10.1016/j.ajog.2015.11.021 PMID:26627729 Lorincz AT, Brentnall AR, Vasiljević N, ScibiorBentkowska D, Castanon A, Fiander A, et al.(2013).HPV16 L1 and L2 DNA methylation predicts highgrade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.133(3):637–44.doi:10.1002/ijc.28050 PMID:23335178 Malagón T, Louvanto K, Wissing M, Burchell AN, Tellier PP, El-Zein M, et al.(2019).Hand-to-genital and genital-to-genital transmission of human papillo­ maviruses between male and female sexual partners (HITCH): a prospective cohort study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet Infect Dis.19(3):317–26.doi:10.1016/S1473-3099(18)30655-8 PMID:30745276 Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M (2019).Validation of the 2018 FIGO cervical cancer staging system.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.152(1):87–93.doi:10.1016/j.ygyno.2018.10.026 PMID:30389105 Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, Wheeler CM, et al.(2010).Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.126(3):684–91.doi:10.1002/ijc.24752 PMID:19609952 McCluggage WG (2016).Recent developments in non-HPV-related adenocarcinomas of the lower female genital tract and their precursors.Adv Anat Pathol.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "23(1):58–69.doi:10.1097/PAP.0000000000000095 PMID:26645463 McCredie MRE, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al.(2008).Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet Oncol.9(5):425–34.doi:10.1016/ S1470-2045(08)70103-7 PMID:18407790 Melan K, Janky E, Macni J, Ulric-Gervaise S, Dorival MJ, Veronique-Baudin J, et al.(2017).Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002–2011).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Glob Health Action.10(1):1337341.doi:10.1080/1654971 6.2017.1337341 PMID:28649938 Mikami Y (2020).Gastric-type mucinous carcinoma of the cervix and its precursors – historical overview.Histopathology.76(1):102–11.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "doi:10.1111/his.13993 PMID:31846534 Minicozzi P, Innos K, Sánchez MJ, Trama A, Walsh PM, Marcos-Gragera R, et al.; EUROCARE-5 Working Group (2017).Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival esti­ mates: a EUROCARE-5 study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Eur J Cancer.84:335–53.doi:10.1016/j.ejca.2017.07.015 PMID:28865261 Monaghan JM (1995).Laser vaporization and excisional techniques in the treatment of cervical intraepithelial neoplasia.Baillieres Clin Obstet Gynaecol.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "9(1):173–87.doi:10.1016/S0950-3552(05)80365-7 PMID:7600726 Nica A, Marchocki Z, Gien LT, Kupets R, Vicus D, Covens A (2021).Cervical conization and lymph node assess­ ment for early stage low-risk cervical cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Gynecol Cancer.31(3):447–51.doi:10.1136/ijgc-2020- 001785 PMID:33649012 Nicolás I, Marimon L, Barnadas E, Saco A, RodríguezCarunchio L, Fusté P, et al.(2019).HPV-negative tumors of the uterine cervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Mod Pathol.32(8):1189– 96.doi:10.1038/s41379-019-0249-1 PMID:30911077 Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al.(2019).Analysis of gastric-type mucinous carcinoma of the uterine cervix – an aggres­ sive tumor with a poor prognosis: a multi-institu­ tional study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.153(1):13–9.doi:10.1016/j.ygyno.2019.01.022 PMID:30709650 Ojamaa K, Innos K, Baburin A, Everaus H, Veerus P (2018).Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BMC Cancer.18(1):1075.doi:10.1186/s12885-018-5006-1 PMID:30404606 Ostör AG (1993).Natural history of cervical intraepithe­ lial neoplasia: a critical review.Int J Gynecol Pathol.12(2):186–92.doi:10.1097/00004347-199304000-00018 PMID:8463044 Pardo C, de Vries E (2018).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Breast and cervical cancer survival at Instituto Nacional de Cancerología, Colombia.Colomb Med (Cali).49(1):102–8.doi:10.25100/cm.v49i1.2840 PMID:29983470 Pecorelli S, Zigliani L, Odicino F (2009).Revised FIGO staging for carcinoma of the cervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Gynaecol Obstet.105(2):107–8.doi:10.1016/j.ijgo.2009.02.009 PMID:19342051 Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee (2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.J Low Genit Tract Dis.24(2):102–31.doi:10.1097/LGT.0000000000000525 PMID:32243307 Perme MP, Stare J, Estève J (2012).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "On estimation in relative survival.Biometrics.68(1):113–20.doi:10.1111/ j.1541-0420.2011.01640.x PMID:21689081 Petry KU, Scholz U, Hollwitz B, Von Wasielewski R, Meijer CJ (2003).Human papillomavirus, coinfec­ tion with Schistosoma hematobium, and cervical neoplasia in rural Tanzania.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Gynecol Cancer.13(4):505–9.doi:10.1136/ijgc-00009577-200307000- 00015 PMID:12911728 Pinder LF, Parham GP, Basu P, Muwonge R, Lucas E, Nyambe N, et al.(2020).Thermal ablation versus cryotherapy or loop excision to treat women posi­ tive for cervical precancer on visual inspection with trial.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet Oncol.21(1):175–84.doi:10.1016/S1470- 2045(19)30635-7 PMID:31734069 Pinheiro M, Gage JC, Clifford GM, Demarco M, Cheung LC, Chen Z, et al.(2020).Association of HPV35 with cervical carcinogenesis among women of African ancestry: evidence of viral-host interaction with implications for disease intervention.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.147(10):2677–86.doi:10.1002/ijc.33033 PMID:32363580 Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM; ALTS Group (2007).A 2-year prospec­ tive study of human papillomavirus persistence among women with a cytological diagnosis of atyp­ ical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Infect Dis.195(11):1582–9.doi:10.1086/516784 PMID:17471427 Prendiville W, Sankaranarayanan R (2017).Colposcopy and treatment of cervical precancer (IARC Technical Publications, No.45).Lyon, France: International Agency for Research on Cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Available from: https:// publications.iarc.fr/555.Quint WG, Scholte G, van Doorn LJ, Kleter B, Smits PH, Lindeman J (2001).Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general $\\mathrm { { S P F } _ { 1 0 } }$ PCR and HPV genotyping.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Pathol.194(1):51–8.doi:10.1002/path.855 PMID:11329141 Reagan JW, Seidemann IL, Saracusa Y (1953).The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of the uterine cervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer.6(2):224–34.doi:10.1002/1097-0142(195303)6:2<224:: AID-CNCR2820060203>3.0.CO;2-H PMID:13032911 Richart RM (1967).Natural history of cervical intraepithelial neoplasia.Clin Obstet Gynecol.10(4):748–84.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "doi:10.1097/00003081-196712000-00002 PMID:4172733 Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al.(2010).Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Natl Cancer Inst.102(5):315–24.doi:10.1093/jnci/djq001 PMID:20157096 Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al.(2012).Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.131(8):1874–81.doi:10.1002/ijc.27418 PMID:22213126 Rodríguez-Carunchio L, Soveral I, Steenbergen RD, Torné A, Martinez S, Fusté P, et al.(2015).HPV-negative carci­ noma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BJOG.122(1):119–27.doi:10.1111/1471-0528.13071 PMID:25229645 Rohner E, Bütikofer L, Schmidlin K, Sengayi M, Maskew M, Giddy J, et al.(2020).Cervical cancer risk in women living with HIV across four continents: a multicohort study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.146(3):601–9.doi:10.1002/ijc.32260 PMID:31215037 Roik EE, Nieboer E, Kharkova OA, Grjibovski AM, Postoev VA, Odland JØ (2017).Do cervical cancer patients diagnosed with opportunistic screening live longer?",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "An Arkhangelsk Cancer Registry study.Int J Environ Res Public Health.14(12):1500.doi:10.3390/ ijerph14121500 PMID:29186874 Russomano F, Tristao MA, Côrtes R, de Camargo MJ (2015).A comparison between type 3 excision of the transformation zone by straight wire excision of the transformation zone (SWETZ) and large loop excision of the transformation zone (LLETZ): a randomized study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BMC Womens Health.15(1):12.doi:10.1186/ s12905-015-0174-5 PMID:25783647 Ryser MD, Rositch A, Gravitt PE (2017).Modeling of US human papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "J Infect Dis.216(5):604–11.doi:10.1093/infdis/jix333 PMID:28931221 Sankaranarayanan R, Swaminathan R, Lucas E (2011).Cancer survival in Africa, Asia, the Caribbean and Central America (IARC Scientific Publications, No.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "162).Lyon, France: International Agency for Research on Cancer.Available from: https://publications.iarc.fr/317.Schiffman, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007).Human papillomavirus and cervical cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet.370(9590):890–907.doi:10.1016/ S0140-6736(07)61416-0 PMID:17826171 Schiffman M, Castle PE (2005).The promise of glob­- al cervical-cancer prevention.N Engl J Med.353(20): 2101–4.doi:10.1056/NEJMp058171 PMID:16291978 Schiffman M, Clifford G, Buonaguro FM (2009).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Classification of weakly carcinogenic human papil­ lomavirus types: addressing the limits of epidemi­ ology at the borderline.Infect Agent Cancer.4(1):8.doi:10.1186/1750-9378-4-8 PMID:19486508 Schiffman M, de Sanjose S (2019).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "False positive cervical HPV screening test results.Papillomavirus Res.7:184–7.doi:10.1016/j.pvr.2019.04.012 PMID:31029852 Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al.(2016).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Carcinogenic human papillomavirus infection.Nat Rev Dis Primers.2(1):16086.doi:10.1038/nrdp.2016.86 PMID:27905473 Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al.(2005).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The carci­ nogenicity of human papillomavirus types reflects viral evolution.Virology.337(1):76–84.doi:10.1016/j.virol.2005.04.002 PMID:15914222 Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE (2011).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Human papillomavirus testing in the prevention of cervical cancer.J Natl Cancer Inst.103(5):368–83.doi:10.1093/jnci/djq562 PMID:21282563 Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N’da G, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2020).Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: a popula­ tion-based registry study.Int J Cancer.147(11):3037–48.doi:10.1002/ijc.33120 PMID:32449157 Shafi MI, Jordan JA, Singer A (2006).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "The management of cervical intraepithelial neoplasia (squamous).In: Jordan JA, Singer A, editors.The cervix.2nd ed.Oxford, UK: Blackwell Publishing; pp.462–77.doi:10.1002/9781444312744.ch31 Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019).Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study.Lancet Oncol.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "20(3):394–407.doi:10.1016/S1470- 2045(18)30836-2 PMID:30795950 Smith HO, Tiffany MF, Qualls CR, Key CR (2000).The rising incidence of adenocarcinoma relative to squa­ mous cell carcinoma of the uterine cervix in the United States – a 24-year population-based study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Gynecol Oncol.78(2):97–105.doi:10.1006/g yno.2000.5826 PMID:10926787 Solomon D (1989).The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses.Developed and approved at the National Cancer Institute Workshop, Bethesda, Maryland, U.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "S.A., December 12–13, 1988.Acta Cytol.33(5):567–74.PMID:2781957 Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al.(1997).Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Lancet.349(9057):978–80.doi:10.1016/S0140-6736(96)08295-5 PMID:9100623 Sripan P, Chitapanarux I, Fidler-Benaoudia MM, Miranda-Filho A, Bardot A, Pongnikorn D, et al.(2019).Impact of universal health care and screening on incidence and survival of Thai women with cervical cancer: a population-based study of the Chiang Mai Province.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer Epidemiol.63:101594.doi:10.1016/j.canep.2019.101594 PMID:31539716 Stanley M, Coleman N, Chambers M (1994).The host response to lesions induced by human papilloma­ virus.Ciba Found Symp.187:21–32, discussion 32–44.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "PMID:7796671 Stoler MH, Schiffman M; Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group (2001).Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "JAMA.285(11):1500–5.doi:10.1001/jama.285.11.1500 PMID:11255427 Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al.(2018).International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification rcinomas endocervix.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Am J Surg Pathol.42(2):214–26.doi:10.1097/ PAS.0000000000000986 PMID:29135516 Stolnicu S, Hoang L, Soslow RA (2019).Recent advances in invasive adenocarcinoma of the cervix.Virchows Arch.475(5):537–49.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "doi:10.1007/s00428-019-02601-0 PMID:31209635 Strander B, Andersson-Ellström A, Milsom I, Sparén P (2007).Long term risk of invasive cancer after treat­ ment for cervical intraepithelial neoplasia grade 3: population based cohort study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BMJ.335(7629):1077.doi:10.1136/bmj.39363.471806.BE PMID:17959735 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.(2021).Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "CA Cancer J Clin.71(3):209–49.doi:10.3322/caac.21660 PMID:33538338 Tabbara S, Saleh AD, Andersen WA, Barber SR, Taylor PT, Crum CP (1992).The Bethesda classification for squamous intraepithelial lesions: histologic, cytologic, and viral correlates.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Obstet Gynecol.79(3):338–46.doi:10.1097/00006250-199203000-00003 PMID:1738511 Thøgersen H, Møller B, Robsahm TE, Aaserud S, Babigumira R, Larsen IK (2017).Comparison of cancer stage distribution in the immigrant and host popula­ tions of Norway, 1990–2014.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.141(1):52–61.doi:10.1002/ijc.30713 PMID:28369751 UNDP (2020).Human development reports.United Nations Development Programme.Available from: http://hdr.undp.org/en/2020-report.Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2016).Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study.Lancet Oncol.17(10):1445–52.doi:10.1016/S1470-2045(16)30275-3 PMID:27567054 Vale DB, Sauvaget C, Muwonge R, Thuler LCS, Basu P, Zeferino LC, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2019).Level of human development is associated with cervical cancer stage at diagnosis.J Obstet Gynaecol.39(1):86–90.doi:10.1080/01443615.2 018.1463976 PMID:30229689 van der Marel J, van Baars R, Alonso I, del Pino M, van de Sandt M, Lindeman J, et al.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "(2014).Oncogenic human papillomavirus-infected immature metaplastic cells and cervical neoplasia.Am J Surg Pathol.38(4):470–9.doi:10.1097/PAS.0000000000000174 PMID:24503756 Van Doorslaer K, Burk RD (2010).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Evolution of human papillomavirus carcinogenicity.Adv Virus Res.77:41–62.doi:10.1016/B978-0-12-385034-8.00002-8 PMID:20951869 VenetianerR,ClarkeMA,vanderMarelJ,TotaJ,Schiffman M, Dunn ST, et al.(2020).",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Identification of HPV geno­ types causing cervical precancer using tissue-based genotyping.Int J Cancer.146(10):2836–44.doi:10.1002/ ijc.32919 PMID:32037535 von Knebel Doeberitz M, Prigge ES (2019).Role of DNA methylation in HPV associated lesions.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Papillomavirus Res.7:180–3.doi:10.1016/j.pvr.2019.03.005 PMID: 30978415 Wada T, Ohishi Y, Kaku T, Aman M, Imamura H, Yasutake N, et al.(2017).Endocervical adenocarcinoma with morphologic features of both usual and gastric types: clinicopathologic and immunohistochemical analyses and high-risk HPV detection by in situ hybridiza­ tion.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Am J Surg Pathol.41(5):696–705.doi:10.1097/ PAS.0000000000000833 PMID:28296678 Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S (2004).Cervical adenocarcinoma and squa­ mous cell carcinoma incidence trends among white women and black women in the United States for 1976– 2000.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer.100(5):1035–44.doi:10.1002/cncr.20064 PMID:14983500 Wassie M, Argaw Z, Tsige Y, Abebe M, Kisa S (2019).Survival status and associated factors of death among cervical cancer patients attending at Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "BMC Cancer.19(1):1221.doi:10.1186/s12885-019-6447-x PMID:31842805 Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M (2007).Triage of women with ASCUS and LSIL cytology: use of qualitative assess­ ment of p16INK4a positive cells to identify patients with high-grade cervical intraepithelial neoplasia.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer.111(1):58–66.doi:10.1002/cncr.22420 PMID:17186505 Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al.(2019).Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "JAMA Intern Med.179(7):881–8.doi:10.1001/jamainternmed.2019.0306 PMID:31081870 Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al.(2009).Multiple human papil­ lomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Int J Cancer.125(9):2151–8.doi:10.1002/ijc.24528 PMID:19585494 WHO (2014).Comprehensive cervical cancer control.A guide to essential practice.2nd ed.Geneva, Switzerland: World Health Organization.Available from: https:// w w w.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "who.int/reproductivehealth/publications/ cancers/cervical-cancer-guide/en/.WHO (2019).WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions.Geneva, Switzerland: World Health Organization.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Available from: https://apps.who.int/iris/handle/10665/329299.WHO (2020).WHO technical guidance and specifi­ cations of medical devices for screening and treat­ ment of precancerous lesions in the prevention of cervical cancer.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Geneva, Switzerland: World Health Organization.Available from: https://apps.who.int/ iris/handle/10665/331698.WHO Classification of Tumours Editorial Board (2020).Female genital tumours.5th ed.Lyon, France: International Agency for Research on Cancer (WHO Classification of Tumours series, Vol.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "4).Available from: https://publications.iarc.fr/592.Yagi A, Ueda Y, Kakuda M, Tanaka Y, Ikeda S, Matsuzaki S, et al.(2019).Epidemiologic and clinical analysis of cervical cancer using data from the population-based Osaka Cancer Registry.",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "Cancer Res.79(6):1252–9.doi:10.1158/0008-5472.CAN-18-3109 PMID:30635276 Zahreddine M, Mayrand MH, Therrien C, Trevisan A, Dagenais C, Monnier P, et al.(2020).Antibodies to human papillomavirus types 6, 11, 16 and 18: vertical transmission and clearance in children up to two years of age.EClinicalMedicine.21:100334.doi:10.1016/j.eclinm.2020.100334 PMID:32382718",
    "source": "CERVICAL CANCER screening",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/CERVICAL CANCER screening/CERVICAL CANCER screening.md"
  },
  {
    "text": "# HPV (Human Papillomavirus) Vaccine: What You Need to Know # 1.Why get vaccinated?HPV (human papillomavirus) vaccine can prevent infection with some types of human papillomavirus.HPV infections can cause certain types of cancers, including:  cervical, vaginal, and vulvar cancers in women  penile cancer in men  anal cancers in both men and women  cancers of tonsils, base of tongue, and back of throat (oropharyngeal cancer) in both men and women HPV infections can also cause anogenital warts.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "HPV vaccine can prevent over $9 0 \\%$ of cancers caused by HPV.HPV is spread through intimate skin-to-skin or sexual contact.HPV infections are so common that nearly all people will get at least one type of HPV at some time in their lives.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Most HPV infections go away on their own within 2 years.But sometimes HPV infections will last longer and can cause cancers later in life.# 2.HPV vaccine HPV vaccine is routinely recommended for adolescents at 11 or 12 years of age to ensure they are protected before they are exposed to the virus.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "HPV vaccine may be given beginning at age 9 years and vaccination is recommended for everyone through 26 years of age.HPV vaccine may be given to adults 27 through 45 years of age, based on discussions between the patient and health care provider.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Most children who get the first dose before 15 years of age need 2 doses of HPV vaccine.People who get the first dose at or after 15 years of age and younger people with certain immunocompromising conditions need 3 doses.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Your health care provider can give you more information.HPV vaccine may be given at the same time as other vaccines.# 3.\u0007Talk with your health care provider Tell your vaccination provider if the person getting the vaccine:  Has had an allergic reaction after a previous dose of HPV vaccine, or has any severe, lifethreatening allergies  Is pregnant—HPV vaccine is not recommended until after pregnancy In some cases, your health care provider may decide to postpone HPV vaccination until a future visit.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "People with minor illnesses, such as a cold, may be vaccinated.People who are moderately or severely ill should usually wait until they recover before getting HPV vaccine.Your health care provider can give you more information.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "# 4.Risks of a vaccine reaction  Soreness, redness, or swelling where the shot is given can happen after HPV vaccination. Fever or headache can happen after HPV vaccination.People sometimes faint after medical procedures, including vaccination.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Tell your provider if you feel dizzy or have vision changes or ringing in the ears.As with any medicine, there is a very remote chance of a vaccine causing a severe allergic reaction, other serious injury, or death.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "# 5.\u0007What if there is a serious problem?An allergic reaction could occur after the vaccinated person leaves the clinic.If you see signs of a severe allergic reaction (hives, swelling of the face and throat, difficulty breathing, a fast heartbeat, dizziness, or weakness), call 9-1-1 and get the person to the nearest hospital.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "For other signs that concern you, call your health care provider.Adverse reactions should be reported to the Vaccine Adverse Event Reporting System (VAERS).Your health care provider will usually file this report, or you can do it yourself.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Visit the VAERS website at www.vaers.hhs.gov or call 1-800-822-7967.VAERS is only for reporting reactions, and VAERS staff members do not give medical advice.# 6.\u0007The National Vaccine Injury Compensation Program The National Vaccine Injury Compensation Program (VICP) is a federal program that was created to compensate people who may have been injured by certain vaccines.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "Claims regarding alleged injury or death due to vaccination have a time limit for filing, which may be as short as two years.Visit the VICP website at www.hrsa.gov/vaccinecompensation or call 1-800-338-2382 to learn about the program and about filing a claim.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "# 7.How can I learn more? Ask your health care provider. Call your local or state health department. Visit the website of the Food and Drug Administration (FDA) for vaccine package inserts and additional information at www.fda.gov/vaccines-blood-biologics/vaccines. Contact the Centers for Disease Control and Prevention (CDC): --Call 1-800-232-4636 (1-800-CDC-INFO) or --Visit CDC’s website at www.cdc.gov/vaccines.",
    "source": "HPV (Human Papillomavirus) Vaccine-what do you know",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/HPV (Human Papillomavirus) Vaccine-what do you know/HPV (Human Papillomavirus) Vaccine-what do you know.md"
  },
  {
    "text": "# WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition ![](images/d4b8393b871ea7f4775ec162dcfa311598e6c62434e5b5531943535ae139bcd7.jpg) # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition ISBN 978-92-4-003082-4 (electronic version) ISBN 978-92-4-003083-1 (print version) $\\circledcirc$ World Health Organization 2021 Some rights reserved.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services.The use of the WHO logo is not permitted.If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO).WHO is not responsible for the content or accuracy of this translation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "wipo.int/amc/en/mediation/rules/).Suggested citation.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Licence: CC BY-NC-SA 3.0 IGO.Cataloguing-in-Publication (CIP) data.CIP data are available at http://apps.who.int/iris.Sales, rights and licensing.To purchase WHO publications, see http://apps.who.int/bookorders.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Layout and design: Studio FFFOG.# Contents ![](images/74771c7b35c3259c660fda320fa4ac9744fd326c1d694317d01ea0caac73d0ae.jpg) Acknowledgements v Acronyms and abbreviations vii Executive summary viii Background viii Methods \b viii Summary of screening and treatment recommendations to prevent cervical cancer\b x # .",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Introduction 1 1.1 Background 1 1.2 Approaches to screening and treatment 3 1.3 Rationale for this new edition of recommendations 4 1.4 Phased approach for the development of the recommendations 5 1.5 Target audience 6 # 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Methods 7 2.1 Groups contributing to the guideline development process 7 2.2 Scoping review and appraisal of the existing recommendations 9 2.3 Priority questions for review of evidence 10 2.4 Priority algorithms 11 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "5 Outcomes 11 2.6 Syntheses of evidence 12 2.7 Development of the recommendations 18 2.8 Management of the external peer review 19 ![](images/eacc039dbe8023b8f515f95dab73cc24e5f5890228811dd0fc6fa73f91a99f49.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) 3.Important considerations for the recommendations 20 3.1 Programme considerations 20 3.2 Screening and triage tests considered in this guideline 21 3.3 Treatment considerations 23 ![](images/8e6339bb9092d9fd0fffbe3c2e44b9bcafdeb2ec7cb57f0153c841128d947883.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) # 4.Recommendations and good practice statements on screening and treatment to prevent cervical cancer 4.1 Recommendations and good practice statements: 24 general population of women ![](images/eb1b7aed0e16ecd6229a210af3d81198f08da38fd182a8e73abc8296d0339bce.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) 4.2 Recommendations and good practice statements: women living with HIV 31 4.3 Additional recommendation and good practice statement 38 for treatment not covered in previous guidelines for the general population of women and women living with HIV 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Research gaps and further considerations 39 6.Dissemination and updating of the guideline 41 6.1 Guideline dissemination and impact 41 6.2 Guideline update 42 References 43 Annexes 47 Annex 1: Guideline groups 48 Annex 2: Evidence-gathering teams and guideline task groups 58 Annex 3: Declarations of interests 60 Annex 4: Seven algorithms prioritized for Phase 1 of the guideline update 63 Annex 5: Standardized definitions used in this guideline 73 Annex 6: Additional information for screening and treatment 95 recommendations # ADDITIONAL SUPPORTING MATERIALS AVAILABLE ONLINE: # Web annex A: Syntheses of the evidence Available at: https://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/publications/i/item/9789240030824 (Includes IARC handbook materials and Supplementary materials 1–13) Web annex B: Evidence-to-decision (EtD) tables Available at: https://www.who.int/publications/i/item/9789240030824 (Includes EtD for PICO questions 1–10) # Acknowledgements The Department of Sexual and Reproductive Health and Research and the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes at the World Health Organization (WHO) would like to thank members of the Guideline Development Group (GDG) for their consistent availability and commitment to making this guideline possible, and the members of the External Review Group (ERG) and all other external contributors for their work.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The Departments are also grateful to the International Agency for Research on Cancer (IARC) for the literature reviews performed in the context of the updating of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "18 (2021), which were extremely useful for this guideline development process.Special thanks to Nancy Santesso, the guideline methodologist from McMaster University, who also led the systematic review process, and thank you to all the members of the systematic reviews teams, coordinated by Nancy Santesso.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The names of the members of the GDG, ERG and of the other contributors, in particular systematic reviewers, modellers and costing teams, are listed below, with full details provided in Annex 1.We appreciate the overall support of the WHO Guidelines Review Committee Secretariat during the guideline development process, with grateful thanks to Rebekah Thomas Bosco who is leading the GRC Secretariat.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Steering Group was composed of Nathalie Broutet, Shona Dalal, Linda Eckert (who also supported the GDG, the workgroups, and the WHO Secretariat), Morkor Newman and Ajay Rangaraj.This group was assisted by Myriam Cortes and Jane Werunga-Ndanareh.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Nathalie Broutet and Shona Dalal also led the guideline development process.The members of the GDG were Claire Achieng, Silvina Arrossi, Muhammad Atif Waqar, Ruth Awori, Ruanne Barnabas, Itamar Bento Claro, Neerja Bhatla, Marie-Claude Boily, Laia Bruni, Joanna Cain, Lameck Chinula, Mike Chirenje (GDG Co-Chair), Michael Chung, Flavia Miranda Correa, Miriam Cremer, Teresa Darragh, Lynette Denny, Silvia de Sanjose, Mamadou Diop, Wachara Eamratsameekool, Danielle Engel, Julia Gage, Ali Ghanbari-Motlagh, Patti Gravitt, Margaret Happy, Tarek Hashem, Rolando Herrero, Priscilla Ingbian, Ebony Johnson, Sharon Kapambwe, Bayarsaikhan Luvsandorj, Anne Mackie, Mauricio Maza, Sebitloane Motshedisi, Nelly Mugo, Raul Murillo, Laura Muzingwani, Ashrafun Nessa, Dorcas Obiri-Yeboah, Gina Ogilvie, Patrick Petignat, Maria Alejandra Picconi, Leeya Pinder, Walter Prendiville, Veronica Reis, Gracia Violetta Ross Quiroga, Vikrant Sahasrabuddhe, Pete Sasieni, Anna Shakarishvili, Netsanet Shiferaw, Petra Tenhoope-Bender, Myint Myint Thinn, Julie Torode (GDG Co-Chair), Nicolas Wentzensen and Fanghui Zhao.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The members of the ERG were Raveena Chowdhury, Heather Cubie, Suzanne Garland, Sarita Ghimire, Zaki El Hanchi, Ha Hyeong In, Oh Jin-Kyoung, Alejandra Meglioli, Mohammed Moawia, Lim Myong Cheol, Angélica Nogueira, Mark Schiffman, Saritha Shamsunder, Vanita Suri, Carolina Teran, Ted Trimble, Gino Venegas and Heather White.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "External contributors to the evidence profiles were Marc Arbyn, Ruanne Barnabas, Iacopo Baussano, Marie-Claude Boily, Veronique Bouvard, Karen Canfell, Michael Caruana, Ian Cree, Owen Demke, Cindy Gauvreau, Michaela Hall, Eva Herweijer, Iciar Indave, Adam Keane, Helen Kelly, James Killen, Gigi Lui, Diep Nguyen, Bernardo Nuche, Catherine Sauvaget, Holger Schünemann, Kate Simms, Ronaldo Silva, Karin Sundström, Katayoun Thaghavi, Cari van Schalkwyk and Brian Williams.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The following individuals acted as observers at the GDG meeting: Benjamin Anderson, J.(Hans) Berkhof, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose Jeronimo, Somesh Kumar, Ilana Lapidos-Salaiz, David Mesher, Jasantha Odayar, Groesbeck Parham, Carmen Pérez Casas, Felipe Roitberg and Heather Watts.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Secretariat included Maribel Almonte Pacheco, Prebo Barango, Partha Basu, Paul Bloem, Nathalie Broutet, Gary Clifford, Marilys Corbex, Myriam Cortes, Shona Dalal, Jean-Marie Dangou, Maeve De Mello, Gampo Dorji, Linda Eckert, Fayad El Sheikh, Elena Fidarova, Massimo Ghidinelli, Karima Gholbzouri, Rodolfo Gomez Ponce de Leon, Sami Gottlieb, Joumana George Hermez, Raymond Hutubessy, Andre Ilbawi, Naoko Ishikawa, Chandani Anoma Jayathilaka, Rajat Khosla, Warrick Junsuk Kim, Stephanie Yetunde Kuku, Hugues Lago, Beatrice Lauby-Secretan, Silvana Luciani, Priya Mannava, Dara Masoud, Manjulaa Narasimhan, Morkor Newman, Leopold Ouedraogo, Tina Purnat, Neena Raina, Ajay Rangaraj, Leanne Margaret Riley, Anita Sands, Tshidi Sebitloane, Mukta Sharma, Hai-rim Shin, Slim Slama, Vitaly Smelov, Howard Sobel, Ute Ströher, Adriana Velazquez Berumen, Lara Vojnov and Hongyi Xu.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Funding for the preparation, development and printing of the guideline was provided mainly by the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), with the support of the United States President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID), and Unitaid.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This guideline was edited and proofread by Green Ink.# Acronyms and abbreviations AIS adenocarcinoma in situ ART antiretroviral therapy CIN cervical intraepithelial neoplasia CKC cold knife conization DOI declaration of interest ERG External Review Group EtD evidence-to-decision GDG Guideline Development Group GRC Guidelines Review Committee GRADE Grading of Recommendations Assessment, Development and Evaluation HPV human papillomavirus HRP UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction IARC International Agency for Research on Cancer IPD-MA individual patient data meta-analysis LEEP loop electrosurgical excision procedure (also known as LLETZ) LLETZ large-loop excision of the transformation zone (also known as LEEP) NAAT nucleic acid amplification test PEPFAR The United States President’s Emergency Plan for AIDS Relief PICO population (P), intervention (I), comparator (C), outcome (O) SDG Sustainable Development Goal UNAIDS Joint United Nations Programme on HIV/AIDS UNDP United Nations Development Programme UNFPA United Nations Population Fund UNICEF United Nations Children’s Fund USAID United States Agency for International Development VIA visual inspection with acetic acid WHO World Health Organization # Executive summary # Background Cervical cancer is a leading cause of mortality among women.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In 2020, an estimated 604 000 women were diagnosed with cervical cancer worldwide and about 342 000 women died from the disease.Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading cause of cancer death in 36 countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The vast majority of these countries are in sub-Saharan Africa, Melanesia, South America, and South-Eastern Asia.In May 2018, Dr Tedros Adhanom Ghebreyesus, World Health Organization (WHO) Director-General, issued a call to action for the elimination of cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In November 2020, the Director-General launched the Global strategy to accelerate the elimination of cervical cancer, including the following targets for each of the three pillars for $2 0 3 0 \\colon 9 0 \\%$ human papillomavirus (HPV) vaccination coverage of eligible girls, $70 \\%$ screening coverage with a high-performance test and $90 \\%$ of women with a positive screening test or a cervical lesion managed appropriately.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Following the launch of the global strategy, a large panel of experts met to define the key areas of focus to increase access to screening and treatment to reach the 2030 targets.One of the agreed areas of focus was to update the existing WHO recommendations for screening and treatment to prevent cervical cancer, and to simplify the algorithms.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Methods This updated guideline for screening and treatment to prevent cervical cancer was developed in three steps: Review the current guidelines and identify recommendations to update or to develop de novo.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2.Develop questions based on population (P), intervention (I), comparator (C) and outcomes (O) (PICO questions) for the recommendations and conduct new systematic reviews or update those conducted for the previous guideline, and model outcomes when primary research was not available.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3.Apply the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to assess the certainty of evidence and to develop recommendations using evidence-to-decision (EtD) tables.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The Guideline Development Group (GDG) for this guideline was formed in early 2019, and the GDG, WHO Secretariat, methodologists and technical groups (see Annex 1) met several times to establish the PICO questions, methodology and timeline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Secretariat led and coordinated the whole process to ensure recommendations were developed in line with the WHO handbook for guideline development, second edition (2014).The methods for evidence synthesis and mathematical modelling were used as applied in the previous edition of the guideline, WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Based on clinical expertise, research and knowledge of tests in development, the Guideline Development Group (GDG) initially identified the screening tests and clinical algorithms for screening and treatment that could be evaluated.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG prioritized seven algorithms for evaluation, and these informed the systematic reviews.In 2020, the systematic review teams performed the systematic reviews for each of the PICO questions and, in parallel, the systematic reviews that had been prepared for the International Agency for Research on Cancer’s IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "18 (2021) were integrated for the development of these recommendations.When relevant evidence was not available in primary research, a mathematical model was used to estimate the risk of important outcomes (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.recurrence of high-grade cervical intraepithelial neoplasia [CIN], cervical cancer) associated with the use of different screening and treatment strategies.In addition, a modelling group was created to evaluate the impact and cost–effectiveness of the different screening and treatment algorithms.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Furthermore, we searched the published literature for studies providing information on acceptability, feasibility and costing aspects of these algorithms, and conducted a survey on feasibility and values and preferences of people using these services.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "GDG meetings took place on a weekly basis between August 2020 and November 2020 to review and assess the evidence and agree on the final new and updated recommendations and good practice statements presented in this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Summary of screening and treatment recommendations to prevent cervical cancer In this present publication, there is a total of 23 recommendations and 7 good practice statements.Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population.In Table 1 below we have grouped the recommendations and good practice statements in two columns for the general population of women (left column, nos.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1–14) and for women living with HIV (right column, nos.21–34), while in Table 2, the populations are not separated (nos.41 and 42).1 There are currently 11 recommendations and 3 good practice statements for each population in Table 1, and an additional recommendation and good practice statement for both populations in Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "creening and treatmentrecommendations andgod practicestatements forthegeneral populationofwmenandwmenliving with <html><body><table><tr><td>Recommendations for the general population of women?</td><td>Strength of recommendation and level of evidence</td><td> Recommendations for women living with Hiva</td><td>Strength of recommendation and level of evidence</td></tr><tr><td>1.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly because of the inherent </td><td>Strong recommendation, moderate- certainty evidence </td><td>21.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly because of the inherent challenges with quality assurance.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Strong recommendation, moderate certainty of evidence</td></tr><tr><td>2.WHO suggests using an HPV DNA primary screening test either with triage or without triage to prevent cervical cancer among the general population of women.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, moderate- certainty evidence</td><td>22.WHO suggests using an HPV DNA primary screening test with triage rather than without triage to prevent cervical cancer among women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, moderate certainty of evidence</td></tr></table></body></html> o wording of the recommendations difers for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and level of evidence</td><td> Recommendations for women living with Hiva</td><td>Strength of recommendation and level of evidence</td></tr><tr><td>3a.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In a screen-and-treat approach using HPV DNA detection as the primary screening test, WHO suggests treating women who test positive for HPV DNA among the general population of women.3b.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA or </td><td>Conditional recommendation, moderate- certainty evidence</td><td>23.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test (Annex 4)</td><td>Conditional recommendation, moderate- certainty evidence</td></tr><tr><td>cytology to triage women after a positive HPV DNA test (Annex 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Remarks: The benefits, harms and programmatic costs of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance and resources in countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific</td><td></td><td>Remarks: The benefits, harms and programmatic costs of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance and resources in countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).</td><td></td></tr><tr><td>details of the algorithms).4.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>24.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td></tr><tr><td>5.WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.</td><td>Strong recommendation, moderate- certainty evidence</td><td>25.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO suggests starting regular cervical cancer screening at the age of 25 years among women living with HIV.Remarks: Low-certainty evidence found that there are likely to be small numbers of women living with HIV with cervical cancer who are below the age of 25.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This recommendation applies to women living with HIV regardless of when they first tested positive for HIV.</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> <html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and level of evidence</td><td> Recommendations for women living with HIva</td><td>Strength of recommendation and level of evidence</td></tr><tr><td>6.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>26.After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, very low-certainty evidence </td></tr><tr><td>Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Inadequate visualization is typical after the menopause.</td><td></td><td>Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Inadequate visualization is typical after the menopause.</td><td></td></tr><tr><td>7.Priority should be given to screening women aged 30-49 years in the general population of women.When tools are available to manage women aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement</td><td>27.Priority should be given to screening women living with HIV aged 25-49 years.When tools are available to manage women living with HIV aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement</td></tr><tr><td>8.WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>28.WHO suggests a regular screening interval of every 3 to 5 years when using HPV DNA detection as the primary screening test among women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>9.Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>29.Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td></tr></table></body></html> Rowhad wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and level of evidence</td><td>Recommendations for women living with Hiva</td><td>Strength of recommendation and level of evidence</td></tr><tr><td>10.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement </td><td>30.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement</td></tr><tr><td>11.WHO suggests that the general population of women who have screened positive on an HPV DNA primary screening test and then negative on a triage test are retested with HPV DNA testing at 24 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>31.WHO suggests that women living with HIV who have screened positive on an HPV DNA primary screening test and then negative on a triage test, are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>12.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>32.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>13.WHO suggests that women from the general population who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AIS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VlA or co-testing, and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>33.WHO suggests that women living with HIV who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AlS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VlA or co-testing, and, if negative, are retested again at 12 months and, if negative again, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> oar wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and level of evidence</td><td>Recommendations for women living with Hiva</td><td>Strength of recommendation and level of evidence</td></tr><tr><td>14.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.In existing programmes with cytology or VlA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement</td><td>34.As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr></table></body></html> Table 2.Recommendation and good practice statement for treatment not covered in previous guidelines <html><body><table><tr><td>For both the general population and women living with HIv</td><td>Strengthof recommendation and certainty of evidence</td></tr><tr><td>41.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Once a decision to treat a woman is made - whether from the general population of women or women living with HIV - it is good practice to treat as soon as posible within six months to reduce the risk of loss to follow-up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, in women who are pregnant, good practice includes deferral until after pregnancy.</td><td> Good practice statement </td></tr><tr><td>In circumstances when treatment is not provided within this time frame,itis good practice to re-evaluate the woman before treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "42.WHO suggests large-loop excision of the transformation zone (LLETZ) or cold knife conization (CKC)</td><td>Conditional recommendation,</td></tr><tr><td>for women from the general population and women living with HIV who have histologically confirmed adenocarcinoma in situ (AIS).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Remarks: Loop excision maybe preferred in women of reproductive age, in settings with greater availabilityof LLETZandby providers with greater expertise performing LETZ.CKC maybe preferred when interpretationof the</td><td>low-certainty evidence </td></tr></table></body></html> HPV: human papillomavirus; VIA: visual inspection with acetic acid.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Summary recommendation for the general population of women WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: HPV DNA detection in a screen-and-treat approach starting at the age of 30 years with regular screening every 5 to 10 years.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.Summary recommendation for women living with HIV WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: HPV DNA detection in a screen, triage and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/7517b9683bb349fcd48a318ed1361684214d866480080f3bb1e0035e3ada9cc0.jpg) # Introduction # 1.1 Background Cervical cancer is a leading cause of mortality among women.In 2020, an estimated 604 000 women were diagnosed with cervical cancer worldwide and about 342 000 women died from the disease.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Cervical cancer is the most commonly diagnosed cancer in 23 countries and is the leading cause of cancer death in 36 countries.The vast majority of these countries are in sub-Saharan Africa, Melanesia, South America, and South-Eastern Asia $( 7 ) .",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "$ .In May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), issued a call to action for the elimination of cervical cancer.A WHO global strategy to accelerate the elimination of cervical cancer as a public health problem was presented and unanimously endorsed by the Seventy-third World Health Assembly in August 2020.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Subsequently, WHO officially launched the Global strategy to accelerate the elimination of cervical cancer on 17 November 2020.2 The targets of the global strategy are, by 2030: to vaccinate $90 \\%$ of eligible girls against HPV; to screen $70 \\%$ of eligible women at least twice in their lifetimes; and to effectively treat $90 \\%$ of those with a positive screening test or a cervical lesion, including palliative care when needed $( 2 )$ .",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In the context of this global strategy, countries are updating their protocols for the prevention of cervical cancer and for the care and treatment of affected women.Cervical cancer prevention also plays an integral role in reaching the Sustainable Development Goals (SDGs), both for health (SDG 3) and gender equality (SDG 5).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "To prevent cervical cancer, women can be screened using various tests to identify those who have or are at risk of cervical pre-cancer (see Table 1.1).Cervical intraepithelial neoplasia (CIN) is characterized by cellular changes in the transformation zone of the cervix.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "CIN is typically caused by infections with human papillomavirus (HPV), especially the high-risk HPV types such as strains 16 and 18 (these two strains cause more than $70 \\%$ of cervical cancers) (3,4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "CIN1 lesions – also referred to as low-grade squamous intraepithelial lesions– are morphological correlates of HPV infections.CIN2/3 lesions – also referred to as high-grade squamous intraepithelial lesions – are correlates of cervical pre-cancers that, if left untreated, may progress into cervical cancer (for further details, refer to Chapter 1 of WHO’s Comprehensive cervical cancer control guidance [5]).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Table 1.1 Three approaches to cervical cancer screening and future tests <html><body><table><tr><td>Molecular</td><td>Cytologic</td><td>Visual inspection</td></tr><tr><td>Nucleic acid amplification tests (NAAT)a</td><td>Conventional Pap smeara Liquid-based cytology</td><td>Visual inspection with acetic acid or with Lugol's</td></tr><tr><td>》 high-risk HPV DNA/ NAAT 》 mRNA</td><td>(LBC)a</td><td>iodine (VIA/VILI)a naked eye 》 magnified by 》</td></tr><tr><td>DNA methylationb</td><td>Dual staining to identify p16</td><td>colposcope or camera</td></tr><tr><td></td><td>and Ki-67a</td><td>Automated visual</td></tr><tr><td>Protein biomarkersb 》 HPV antibodies</td><td></td><td>evaluation of digital imagesb</td></tr></table></body></html> a Current tests b Tests under evaluation (future tests).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The traditional method to screen women for cervical cancer has been cytology (the Papanicolaou test, also known as the Pap smear or smear test).When cytology results are positive, the diagnosis is confirmed by colposcopy, and appropriate treatment is informed by biopsy of suspicious lesions for histological diagnosis.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In countries with effective cytology-based cervical cancer screening and treatment programmes, the mortality from cervical cancer has been reduced fivefold over the past 50 years $\\underline { { ( 6 ) } } .",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "$ This screening approach has not been as successful in low- and middle-income countries $( 7 )$ .Newer screening tests introduced in the last 15 years include visual inspection with acetic acid (VIA), and molecular tests, mainly high-risk HPV DNA-based tests,3 which are suitable for use in all settings (Table 1.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1).More recently, even newer tests and techniques have been developed: (i) other molecular tests such as those based on HPV mRNA, oncoprotein detection or DNA methylation; (ii) more objective tests performed on cytological samples such as p16/Ki-67 dual staining; and (iii) more advanced visual inspection tests based on artificial intelligence/machine learning platforms (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.automated visual evaluation of digital images) (8–11).# 1.2 Approaches to screening and treatment In this document, two approaches to screening and treatment are distinguished: the screen-and-treat approach and the screen, triage and treat approach.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.![](images/ae62d6f05955c44be31f9f159226e5cf5ebb57bd97b592fb4dee10b850c3868a.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/00573156a165c329cc9b46a4bc932d184b4f6b1d139b72a661b309b970dfb97d.jpg) In a screen-and-treat approach, treatment is provided based on a positive primary screening test alone, without triage (i.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "e.no second screening test and no histopathological diagnosis).When the patient is eligible for ablative treatment, this should ideally be done immediately, at the same visit as the screening test (the single-visit approach).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "At some facilities, this is not feasible and a second visit is needed (the multiple-visit approach).Women who are not eligible for ablation can have excisional treatment on the same day if the clinic has the capacity for large-loop excision of the transformation zone (LLETZ).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4 If LLETZ is not available on-site, women need to be referred for the excisional treatment or for further evaluation.In a screen, triage and treat approach, the triage test is done if the primary screening test is positive, and the decision to treat is made when both the primary test and the triage test are positive.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A positive triage test can lead to colposcopy with biopsy and histopathological examination for diagnosis to determine the appropriate treatment.The implementation of colposcopy and biopsy can be challenging, however, so this guideline also considers triage strategies that are not dependent on the availability of colposcopy.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When the primary screening test is positive, and the triage test is negative, women need appropriate follow-up evaluation at a specified date according to the recommendations.# 1.3 Rationale for this new edition of recommendations Recommendations for screening and treatment to prevent cervical cancer, including for women living with HIV, can be found in four existing WHO guidelines – on screening and treatment of pre-cancer lesions, treatment for CIN2/3 and AIS, cryotherapy for CIN, and thermal ablation for pre-cancer lesions (12–15).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These recommendations (except for those on thermal ablation, published later in 2019) were consolidated in the 2014 second edition of Comprehensive cervical cancer control: a guide to essential practice $( 5 ) ,$ which also includes the WHO recommendations for HPV vaccination, treatment of cervical cancer and palliative care.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In 2020, WHO published guidance documents to support the introduction and scale-up of screening and treatment interventions, specifically relating to HPV testing and relevant medical devices (16,17).Guidelines should be updated when new knowledge or developments could materially influence existing recommendations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "They should also be updated when the publication date, presentation, background text, evidence synthesis methods, or evidence-to-decision (EtD) considerations might threaten their credibility.In addition, end-user feedback might highlight recommendations that are conflicting, ambiguous, out-of-date or difficult to implement, thus also necessitating an update.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The overwhelming approval of the WHO global strategy to accelerate the elimination of cervical cancer by Member States during the World Health Assembly in 2020 underlined the urgent need to provide up-to-date WHO guidance on screening and treatment to prevent cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO guidance on the recommended algorithms and treatments for use in screening and treatment programmes for cervical cancer prevention, previously published in 2013, was assessed as in need of an update, to effectively guide and facilitate country-level decision-making for starting and scaling up programmes.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The updating of this guideline began in 2019 and was informed by implementation experience and research findings, while ensuring that the new and updated recommendations are feasible and acceptable for both the health workers providing the screening and treatment services, and for the end-users of those services (see Chapter 2: Methods).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This guideline will support efforts to reach the 2030 targets of the global strategy.# Guideline objective: To improve national strategies for screening and treatment to prevent cervical cancer in all women, including women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/aa5aa8ebf58ba0c0f40ea900e49ea4674ff84e9948ed0a038e8a229a8bbbb1ae.jpg) Since the publication of the previous edition of this guideline in 2013 $( 1 2 )$ HPV screening tests have been pre-qualified by WHO, and thermal ablation and cryotherapy have been added as recommended ablative treatment methods.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some interventions described in the 2013 guideline, such as cytology or the need for histological diagnosis, may no longer be relevant or commonly used in the screening and treatment protocols of many countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Several high-quality studies have been published in the intervening years evaluating new tests, comparative recurrence rates after treatments and appropriate screening intervals.New information is also available concerning women living with HIV, on the type of screening and treatment and the age at which to start screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This guideline also aims to clarify the optimal number of lifetime screens and, for countries with routine screening programmes, the recommended age for the first screening and the recommended frequency of subsequent screening following negative screening results and following treatment for signs of pre-cancer lesions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 1.4 Phased approach for the development of the recommendations The following are the four phases of the updates to WHO’s cervical cancer screening and treatment recommendations.This guideline delivers the output of Phase 1.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Phase 1 Update the recommendations on screening and treatment and the clinical algorithms for the most commonly used screening and triage strategies for both women in general and those living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Phase 2 pErviaolruitaiztedthien ePvhiadseenc1.e for the clinical algorithms that were not Phase 3 sDcerveelnoipn greacnodmtrmeantdmaetinotnstrfaotretghiesi.mplementation of these Establish a “living guideline” for screening and treatment tests Phase 4 and algorithms which will allow the recommendations to be updated as new evidence becomes available and is evaluated.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 1.5 Target audience This document is intended primarily for policy-makers, programme managers, programme officers and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention, at country, regional and district levels.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Health-care professionals – such as doctors, nurses and community health workers working in reproductive health programmes, antenatal and postnatal services, family planning services, HIV/AIDS control programmes and in clinics that care for women at the district and primary health care levels – may also consult this document to understand how recommendations are developed and why it is vitally important to select and implement evidence-based strategies to prevent cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This document will also be informative in an adapted form for women, girls and their families in making decisions about cervical cancer screening and treatment.All individuals have the right to equality and non-discrimination in sexual and reproductive health care.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In this guideline, we recognize that most of the available evidence on cervical cancer is based on study populations of cisgender women, and we also recognize that cisgender women, transgender men, non-binary, gender fluid and intersex individuals born with a female reproductive system require cervical cancer prevention services.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, to be concise and facilitate readability, we use the term “women” to refer to all gender diverse people at risk for cervical cancer.Sexual and reproductive health service providers and cervical cancer prevention services must consider the needs of – and provide equal care to – all individuals independently of gender identity or its expression.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.Methods This updated guideline was developed in accordance with the methods described in the WHO handbook for guideline development, second edition (18).A summary of the process is provided here.# 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1 Groups contributing to the guideline development process Lists of all members of the Guideline Development Group (GDG), External Review Group (ERG), systematic review teams, modelling teams and other contributors are provided in Annex 1, with details of their expertise and affiliations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Secretariat consisted of staff from various relevant WHO departments, and staff from the International Agency for Research on Cancer (IARC).The Steering Group of the WHO Secretariat led the coordination of the development of this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Members of the Secretariat who were not part of the Steering Group were kept informed of the guideline development process and participated in the discussions, in particular during meetings of the various teams.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG was established during the first half of 2019 to appraise the recommendations in the previous 2013 edition of the guideline $( 1 2 ) ,$ prioritize the key PICO questions for which systematic reviews needed to be updated or developed, provide feedback on the evidence reviews, and make recommendations to be presented in the final guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There were 52 GDG members (34 women, 18 men), representing all six WHO regions as well as civil society organizations and women’s groups, and women living with HIV.The members brought varied expertise on cervical screening and treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Two members acted as co-chairs and moderated the GDG meetings.The WHO Steering Group met regularly with the GDG chairs, the guideline methodologists, and the systematic review and modelling teams to review progress and to ensure evidence presentations and discussions were standardized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "An External Review Group (ERG) was also established.Its 18 members, none of whom was also a member of the GDG, had expertise in research, policy development, programme implementation and clinical care.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Once the GDG had agreed on the recommendations, the ERG reviewed the full draft of the guideline and provided feedback.There were multiple teams preparing evidence: five teams did the evidence reviews one team developed two mathematical models one team ran a survey about the feasibility of screening approaches one team surveyed women about their values and preferences (Annex 2).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The teams were based at different institutions and worked independently to prepare and present evidence during the GDG meetings.A guideline methodologist with experience of using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (19) coordinated the presentation of evidence and decision-making processes that facilitated the development of the recommendations, as stipulated in the WHO handbook for guideline development (18).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Steering Group maintained close communication with the GDG and systematic review teams using multiple platforms: Zoom Meetings; email; surveys and voting on the summaries of the evidence and recommendations using GRADEpro software; a SharePoint site for access to meeting materials, including slides and evidence summaries, and live documents for comment; a chat feature in SharePoint to encourage discussion among the GDG members.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.1.1 Declarations and management of conflicts of interest After being invited to join the GDG by the WHO Secretariat at the beginning of the guideline development process, and in accordance with the WHO handbook for guideline development (18), each prospective GDG member completed a written declaration of interest (DOI) form.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The DOIs were reviewed by two members of the WHO Secretariat and no conflicts of interest were identified (Annex 3).The GDG members’ names and curriculum vitae were subsequently published on the WHO website for the Department of Sexual and Reproductive Health and Research and approved by the WHO Guidelines Review Committee (GRC) in advance of participation in the process.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "At the beginning of every GDG meeting, members were asked to update the WHO Steering Group and other GDG members about any potential new conflicts of interest.# 2.1.2 Confidentiality Each GDG member also signed a confidentiality agreement at the beginning of the GDG process, and the WHO Secretariat restated at the start of each GDG meeting that all discussions and draft recommendations were to remain confidential until publication.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.2 Scoping review and appraisal of the existing recommendations In October 2019, a subgroup of the GDG met in Geneva to review the previously published recommendations and decide which should be removed, validated, edited or updated based on new evidence, and whether any new recommendations should be made for new interventions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This process was informed by a scoping review of the literature and an assessment of changes in disease burden, practice and policy.These decisions were circulated to all members of the GDG for feedback, and agreement on which recommendations to keep, update and add was reached after additional virtual meetings and electronic correspondence.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The scoping document was initially split between screening and treatment recommendations for women living with HIV (approved by the GRC in September 2019) and the general population of women (approved by the GRC in January 2020).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The two scoping documents were then merged and subsequently approved by the GRC in August 2020.# 2.3 Priority questions for review of evidence The GDG identified 14 overarching questions, framed using the population (P), intervention (I), comparator (C), outcomes (O) (PICO) format, as a starting point for formulating recommendations applying to the general population of women and women living with HIV (Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1).![](images/37a905daebfa24832f96345fa2c1b2d484d5a2444d7f0d45b4583c8bb2a53edb.jpg) Table 2.1 PICO questions for the recommendations in women (the general population of women and women living with HIV) # 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4 Priority algorithms Since screening and treatment can be done using different primary screening and triage tests, there are numerous possible combinations or algorithms.In December 2019, GDG members were surveyed to prioritize the screening and/or triage tests and the treatments that should be evaluated.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Following this prioritization exercise, a subgroup of GDG members met to review the results from the survey and to agree on the algorithms to be prioritized.They reached a consensus to address seven priority algorithms in this first phase of the guideline update (Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2; for detailed algorithms please refer to Annex 4).Table 2.2.The seven algorithms considered <html><body><table><tr><td>Screen-and-treat approaches:</td></tr><tr><td>1 VIA as the primary screening test, followed by treatment</td></tr><tr><td>2 HPV DNA detection (self- or clinician-collected) as the primary screening test, followed by treatment </td></tr><tr><td>Screen, triage and treat approaches:</td></tr><tr><td>3 Cytology as the primary screening test, followed by colposcopy triage, followed by treatment 4 HPV DNA detection as the primary screening test, followed by HPV16/18 triage (when already part of the HPV test), followed by treatment, and using VIA triage for</td></tr><tr><td>those who screen negative for HPV16/18 5 HPV DNA detection as the primary screening test, followed by VIA triage, followed by treatment</td></tr><tr><td>6 HPV DNA detection as the primary screening test, followed by colposcopy triage, followed by treatment </td></tr><tr><td>7 HPV DNA detection as the primary screening test, followed by cytology triage, followed by colposcopy and treatment</td></tr></table></body></html> HPV: human papillomavirus; VIA: visual inspection with acetic acid.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.5 Outcomes The GDG agreed that the outcomes previously identified in the 2013 screening and treatment guideline $( 7 2 )$ would also be the critical outcomes for the new PICO questions; the critical outcomes are listed in Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3.To ensure coherence in the systematic reviews and modelling, a working group (subgroup of the GDG) developed standardized definitions for these outcomes (see Annex 5).After reviewing the evidence and modelling a limited number of outcomes, the GDG agreed to consider all outcomes together.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Adverse events were defined as outcomes that were a direct consequence of pre-cancer treatment and were grouped as one category, with the exception of preterm birth, which was considered a critical outcome (see Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3).Table 2.3 Critical outcomes for the screening and treatment recommendations <html><body><table><tr><td>Critical outcomes</td></tr><tr><td>Cervical cancer</td></tr><tr><td>Mortality</td></tr><tr><td>High-grade cervical intraepithelial neoplasia or worse (CIN2+)</td></tr><tr><td>HPV infection</td></tr><tr><td>Preterm birth</td></tr><tr><td>Acceptability</td></tr><tr><td>Pre-cancer treatments</td></tr><tr><td>Adverse events (direct consequence of pre-cancer treatment):</td></tr><tr><td> major infections or bleeding</td></tr><tr><td>procedure-associated pain</td></tr><tr><td>cervical stenosis</td></tr><tr><td>infertility</td></tr><tr><td>spontaneous abortion</td></tr><tr><td>perinatal deaths</td></tr><tr><td> premature rupture of membrane</td></tr><tr><td>unnecessary interventions</td></tr><tr><td>increased viral shedding in women living with HIV</td></tr><tr><td>Costs</td></tr><tr><td>Feasibility</td></tr><tr><td>Equity</td></tr></table></body></html> See Annex 5 for additional details.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.6 Syntheses of evidence Evidence was synthesized for each PICO question according to the methods in the WHO handbook for guideline development and the Cochrane handbook for systematic reviews of interventions (18,20).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The literature review performed for the development of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.18 (to be published in 2021; referred to in brief throughout this guideline as “IARC handbook”) $( 2 7 )$ was also part of the evidence synthesized for the development of this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "We used a hierarchical approach to avoid the duplication of reviews that had been previously published.First, we searched for pre-existing systematic reviews to update (including the systematic reviews published at the time of the previous guideline), and then searched for primary studies (including randomized and non-randomized studies) when no systematic reviews were available.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "New systematic reviews or updates of systematic reviews were conducted to determine the effects of interventions (including screening tests) on outcomes, and the accuracy of screening tests in the general population of women and in women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These systematic reviews and associated details are listed in Table 2.4.Table 2.4 PICO questions with corresponding systematic reviews and reports, evidence-to-decision (EtD) tables and recommendations or good-practice state <html><body><table><tr><td>PICO questions</td><td>List of systematic reviews</td><td>Syntheses of the evidence (Web annex A)a</td><td>Evidence- to-decision tables (Web annex B)b</td><td>Recommendation or good practice statement (as numbered in this guideline)c</td></tr><tr><td rowspan=\"3\">1, 2, 8ii</td><td>Evidence reviews for interventions for the general population of women Evidence reviews of</td><td>IARC handbook materials Supplementary material (SM) 1</td><td>EtD PICO 1 and 2 for the general population of women</td><td>1, 2, 3, 4, 8, 9, 10</td></tr><tr><td>accuracy of triage tests for the general population of women Evidence reviews for interventions and accuracy of tests for</td><td>SM 2</td><td>EtD PICO 1 and 2 for women living with HIV</td><td>21, 22, 23, 24, 28, 29, 30</td></tr><tr><td>women living with HIV 3, 4, 5, 6, 7 Review of reviews of follow-up strategies after screening or treatment</td><td>SM 3</td><td>EtD PICO 3, 4,5, 6, 7</td><td>11, 12, 13, 14, 31, 32, 33,34</td></tr></table></body></html> AIS: adenocarcinoma in situ; CIN: cervical intraepithelial neoplasia; EtD: evidence-to-decision; IARC: International Agency for Research on Cancer; PICO: population (P), intervention (I), comparator (C), outcome (O).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "a Web annex A is available at: https://www.who.int/publications/i/item/9789240030824 b Web annex B is available at: https://www.who.int/publications/i/item/9789240030824 c Number as listed in Tables 1 and 2 in the Executive Summary and as used throughout this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Table 2.4 (continued) <html><body><table><tr><td>PICO questions</td><td>List of systematic reviews</td><td>Syntheses of the evidence (Web annex A)a</td><td>Evidence- to-decision tables (Web annex B)b</td><td>Recommendation or good practice statement (as numbered in this guideline)c</td></tr><tr><td rowspan=\"2\">8i</td><td>Review of reviews of age to start and end screening in the general population of women A systematic literature review and narrative</td><td>SM 4 SM 5 </td><td>EtD PICO 8 age at initiation for the general population of women </td><td>5</td></tr><tr><td>synthesis: age at initiation and frequency of cervical cancer screening in women living with HIV Individual patient data meta-analysis (IPD-MA): age at initiation and end</td><td>SM 6</td><td>EtD PICO 8 age at initiation for women living with HIV EtD PICO 8 age to end</td><td>25 6,7, 26, 27</td></tr><tr><td>9</td><td>of screening in women living with HIV Systematic review for treatment within 6 to 12</td><td>SM 7</td><td>screening</td><td>41</td></tr><tr><td>10</td><td>months Reviews for treatment of histologically confirmed</td><td>SM 8</td><td>EtD PICO 10</td><td>42</td></tr><tr><td>11, 12, 13</td><td>CIN2/3 and AIS Next phase of guideline development </td><td></td><td></td><td></td></tr><tr><td>All</td><td>Understanding acceptability and client preferences for screening and treating cervical pre-cancer lesions: preliminary results of a WHO online survey Report on values, preferences, acceptability and feasibility: results of a systematic review of qualitative literature</td><td>SM 9 SM 10</td><td></td><td></td></tr></table></body></html> AIS: adenocarcinoma in situ; CIN: cervical intraepithelial neoplasia; EtD: evidence-to-decision; IARC: International Agency for Research on Cancer; PICO: population (P), intervention (I), comparator (C), outcome (O).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "a Web annex A is available at: https://www.who.int/publications/i/item/9789240030824 b Web annex B is available at: https://www.who.int/publications/i/item/9789240030824 c Number as listed in Tables 1 and 2 in the Executive Summary and as used throughout this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Table 2.4 (continued) <html><body><table><tr><td>PICO questions</td><td>List of systematic reviews</td><td>Syntheses of the evidence (Web annex A)a</td><td>Evidence- to-decision tables (Web annex B)b</td><td>Recommendation or good practice statement (as numbered in this guideline)c</td></tr><tr><td>All</td><td>Survey report: feasibility concerns with priority algorithms Review of reviews of acceptability, feasibility, resources and equity</td><td>SM 11 SM 12</td><td></td><td></td></tr><tr><td>1, 2, 3, 4, 5, 6, 7, 8 </td><td>Report of modelling</td><td>SM 13</td><td></td><td></td></tr></table></body></html> AIS: adenocarcinoma in situ; CIN: cervical intraepithelial neoplasia; EtD: evidence-to-decision; IARC: International Agency for Research on Cancer; PICO: population (P), intervention (I), comparator (C), outcome (O).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "a Web annex A is available at: https://www.who.int/publications/i/item/9789240030824 b Web annex B is available at: https://www.who.int/publications/i/item/9789240030824 c Number as listed in Tables 1 and 2 in the Executive Summary and as used throughout this guideline.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.6.1 Methods used for systematic literature reviews The detailed methods for each review are reported in the Annex A, Supplementary Materials (Table 2.4).In brief, the systematic review teams applied the following key methods across all systematic reviews for this guideline: develop a systematic review protocol with inclusion and exclusion criteria for studies based on the finalized PICO questions; search multiple databases (including MEDLINE, Embase and the Cochrane Library Epistemonikos) and clinical trial registries, contact investigators in the field for potentially relevant systematic reviews, and look at randomized and non-randomized trials to identify studies for new reviews or to update existing reviews; select literature reviews or studies based on inclusion and exclusion criteria (in duplicate or by one reviewer and verified by a second); extract data (in duplicate or by one reviewer and verified by another) on the benefits and harms (effects) of screening and treatment, the accuracy of screening tests used, end-user values and preferences, equity, feasibility, resources and acceptability; contact study authors for missing data or individual patient data when appropriate; assess the risk of bias in individual studies when available (in duplicate or by one reviewer and verified by another) using an appropriate risk-of-bias tool (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.Cochrane Risk of Bias for randomized controlled trials, ROBINS-I tools for non-randomized studies and QUADAS for diagnostic studies); synthesize the results (narratively or quantitatively) or analyse individual patient data when available; assess the certainty of the evidence using GRADE methodology (19); the levels of certainty used are summarized in Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "5.![](images/d1011a167fa91a357ce6e56cc4650411f6098f1d219dd4647ded465f7412aee3.jpg) Source: GRADE handbook, GRADEpro, 2021 (19).# 2.6.2 Individual patient data meta-analysis We conducted an individual patient data meta-analysis (IPD-MA) to analyse age-specific data for cervical cancer and CIN in women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "We contacted the authors of the studies identified in the systematic review of screening-initiation age (Web annex A, Supplementary material 5) that included at least 40 women living with HIV with CIN2+.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "All the data sets they provided were first reviewed individually, then discrepancies were resolved with investigators, and the aligned data sets were then combined.The IPD-MA used one-stage $( 2 2 )$ random study intercept models to take into account heterogeneity among studies.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Generalized linear mixed models were fitted for binomial or multinomial cervical screening test responses using SAS version 9.4 (SAS Institute, Inc., United States).Random effects models were used to calculate predicted probabilities for cervical screening results by age categories, HIV status and other factors of interest (see Web annex A, Supplementary material 6).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.6.3 Mathematical modelling We used the Policy1-Cervix platform, an extensively validated dynamic model of HPV transmission, vaccination, type-specific natural history, cancer survival, screening, diagnosis and treatment (23–31), to predict outcomes in women across all 78 low- and middle-income countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The Policy-Cervix HIV-HPV model for cervical cancer among women living with HIV was used to evaluate outcomes for women living with HIV in the United Republic of Tanzania $( 3 2 ) ,$ as there was sufficient local data available on cervical cancer control activities and HIV disease burden and control activities (including historical data).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The United Republic of Tanzania has endemic HIV and is a suitable example country for evaluating optimal screening strategies for women living with HIV.The Policy1-Cervix model was one of three models used by the Cervical Cancer Elimination Modelling Consortium (CCEMC) to evaluate the impact of cervical cancer prevention interventions in 78 low- and middle-income countries (23,24).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "We evaluated the impact of the seven algorithms considering different ages and screening intervals, as informed by the GDG (see Table 2.2).For the baseline analysis, we assumed that $70 \\%$ of women attended screening at each routine screening event and $90 \\%$ of women complied with follow-up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Outcomes were assessed over the lifetime of birth cohorts eligible for screening in 2030 onwards and included cervical cancer incidence and mortality, pre-cancer treatments, additional preterm deliveries as a result of pre-cancer treatment and cost-effectiveness.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A range of sensitivity analyses were considered, including probabilistic sensitivity analysis for cost-effectiveness.The detailed methods and results of the modelling work are available in Web annex A, Supplementary material 13.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.6.4 Values and preferences A search for studies and systematic reviews was conducted that addressed, among other considerations, the values and preferences of end-users, health-care providers and other stakeholders.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The literature was organized by study design and methodology, location and population, and presented to the GDG.For primary data, all women and girls aged 15 years and older, regardless of their prior cervical cancer screening or treatment status, were eligible to participate in an anonymous, voluntary survey distributed via SurveyMonkey.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The survey received approval from the WHO Ethics Review Committee and was run in English and French from 22 June to 18 September 2020.Awareness of the survey had been raised among a wide range of civil society groups through a webinar.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The survey was also promoted through the Union for International Cancer Control and the WHO advisory group of women living with HIV, and shared through WHO regional focal points for the Cervical Cancer Elimination Initiative.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The survey responses from the 561 respondents, including their qualitative responses to open-ended questions, were analysed.The detailed methods and results are available in Web annex A, Supplementary materials 9 and 10.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 2.6.5 Feasibility, acceptability, resources and equity considerations A survey of the GDG members was administered via SurveyMonkey to assess the implementation considerations for each priority algorithm.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The survey was developed using the context and implementation of complex interventions (CICI) framework (33).Each GDG member was asked about their level of concern about each algorithm being able to sustainably meet the large-scale goal of cervical cancer elimination.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The following components of cervical cancer screening and management service delivery were queried separately according to the priority algorithm: demand generation, access to screening and the follow-up management of positives, workforce training, infrastructure development and maintenance, development and maintenance of the screening registry, and cost and integration with other priority health services.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The considerations of the GDG members were assessed for the following eight stakeholder groups: health authorities at the national level, health authorities at the regional level, professional societies, providers at both the hospital and primary care levels, community health workers, clients (screened women) and the community.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The detailed methods and results of the survey from the 29 respondents are provided in Web annex A, Supplementary materials 11 and 12.# 2.7 Development of the recommendations All the GDG meetings that focused on formulation of recommendations were held virtually.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Tables to facilitate decision-making for recommendations – evidence-to-decision (EtD) tables – were produced by the guideline methodologist for each recommendation and circulated to the GDG members before each meeting.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These tables included a summary of the evidence (benefits and harms), relevant values and preferences information, and other issues, including use of resources and cost, feasibility, equity and acceptability.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "During the meeting, the EtD tables and evidence were discussed with the GDG.Following the meeting, all GDG members received an email through GRADEpro that solicited direct individual input.Each GDG member saw the EtD tables several times and had opportunities to ask questions and to comment both during and after the meeting.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The methodologist, systematic reviewers, modellers and the WHO Steering Group assessed the GDG input and used it to write the recommendations.Agreement on the recommendations was made by consensus during the GDG meetings, and the final written recommendations were then approved electronically.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The responses solicited via email were either to approve, approve “with the following remarks” or not approve.The GDG had agreed that, if consensus could not be reached, a majority vote of $5 1 \\%$ would have been accepted to make recommendations – yet the group did reach a consensus on all the recommendations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Strong recommendations (worded as “WHO recommends”) were made when all the desirable consequences of the intervention clearly outweighed the undesirable consequences in most settings.Conditional recommendations (worded as “WHO suggests”) were made when the desirable consequences of the intervention probably outweighed the undesirable consequences in most settings.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Table 2.6 describes how strong and conditional recommendations should be interpreted.Additionally, the GDG provided good practice statements when it agreed that this guidance was needed, but a review of the literature was not warranted because the balance of desirable and undesirable consequences of an intervention was unequivocal, and no other criteria needed to be considered.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Table 2.6 Interpretation of strong and conditional recommendations <html><body><table><tr><td>Implications</td><td>Strong recommendation (WHO recommends...)</td><td>Conditional recommendation (WHO suggests.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "..)</td></tr><tr><td>For individuals For</td><td>Most individuals in this situation would want the recommended course of action, and only a small proportion would not.Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>The majority of individuals in this situation would want the suggested course of action, but some may not.Clinicians should recognize that</td></tr><tr><td>health-care providers</td><td>Most individuals should receive the recommended course of action.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Adherence to this recommendation (when it aligns with national guidelines) could be used as a quality criterion or performance indicator.</td><td>different choices may be appropriate for different individuals and that clinicians must help each individual arrive at a management decision consistent with the individual's values and preferences.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Decision aids may be useful to help individuals make decisions consistent with their values and preferences.</td></tr><tr><td>For policy- makers</td><td>The recommendation can be adopted as policy in most situations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Policy-making will require discussion and involvement of various stakeholders.</td></tr></table></body></html> Source: GRADE Handbook, GRADEpro, 2021 (19).# 2.8 Management of the external peer review The draft guideline document was circulated to the External Review Group (ERG) for comment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The WHO Secretariat prepared a summary table with all ERG responses and sorted the comments by topic or section.The WHO Secretariat then identified comments for discussion and presented these to the GDG, and when these issues had been resolved via email correspondence, the guideline document was finalized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 3.Important considerations for the recommendations The WHO recommendations presented in this guideline are intended to support countries to improve the coverage and outcomes of cervical cancer screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Additionally, they are designed to set standards and targets to improve the quality of services and reduce cervical cancer deaths.In many settings, bridging strategies will be needed to move from any existing screening infrastructure to the infrastructure needed to achieve implementation of the recommendations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This transition may take time and, as a first step, providing at least one or two screens over a woman’s lifetime will have an important impact on cervical cancer mortality in settings without a routine screening programme.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In the near future, WHO will develop and publish stepwise implementation guidelines to support the selection of algorithms, adaptation and scale-up of the recommendations.# 3.1 Programme considerations It is appropriate that a multidisciplinary health ministry team, which can consider different factors and make informed decisions, chooses which algorithm (or algorithms) to include in a national programme.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The choice will vary by country – and in different settings within country programmes – and will depend on available resources, feasibility and acceptability.Decisions are also needed about when and who to contact for follow-up care.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This guideline makes recommendations that distinguish between three clinical scenarios in routine screening programmes: ![](images/1a9e2020e8f1eef5468f2b5f9f510a23dbf39d51bec0a24ab102a39a25a92c41.jpg) Regular screening intervals: This applies to women who either had negative screening results or have completed the recommended additional follow-up after treatment and who are thus eligible to return to regular screening intervals.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/dd55e2162a60f3f642f543212f1c62f70656ec6ee8b44b76d7d4d9a780427f72.jpg) Follow-up of women with a positive primary screening test but a negative triage test.![](images/1dc6867d59c9ef586ca3f8d06538e95917c125bb20a62254763cf4894baae3f4.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) # Follow-up of women after treatment.A key requirement for any programme for screening and treatment to prevent cervical cancer is that the screening approach and the tests used should be of the highest quality and standards to produce accurate and reliable results and beneficial outcomes.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Only screening tests approved by regulatory agencies (34) should be considered for introduction.To prevent and treat cervical cancer and reduce mortality, programmes are encouraged to implement population-based screening and treatment strategies.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "All programmes should ensure that women who have screened positive are treated or managed adequately.Screening registries and call-and-recall efforts are important aspects of appropriate management to ensure that women are coming back to the service for treatment and follow-up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For the continuity and completeness of care, strong links need to be established between the multiple levels of the health service (primary and secondary care) and individual patients.A further description of quality assurance and more detailed programmatic guidance can be found in Annex 6 and in other published documents (5,35,36).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Cervical cancer screening and treatment should be provided to transgender men, and non-binary and intersex individuals who have a cervix.More data on cervical cancer screening and treatment are needed for these populations, including people living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO recognizes the need for health-care systems, including screening and treatment services for cervical pre-cancer and cancer, to be more inclusive of transgender, intersex and non-binary people, which may require additional training and sensitization of health workers.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Public health authorities should also prioritize these groups of people for better awareness of and access to cervical cancer screening and treatment.# 3.2 Screening and triage tests considered in this guideline !",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[](images/5a0e423a74568090a5d7e6acc491b3585d7b51857d3a47bbce0ead3089412a57.jpg) High-risk HPV DNA tests: These tests identify a group of high-risk carcinogenic HPV genotypes, typically including up to 14 types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59, which are Group 1 carcinogens, and HPV66 and 68) (37).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV16 and 18 are the highest-risk genotypes and are the most common in cancers.Some of the tests on the market provide information about specific HPV genotypes, such as HPV16 and 18.We refer to HPV tests with partial genotyping when they report HPV16 and 18 (including HPV45 in some cases) and other carcinogenic types separately.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Other HPV tests may provide extended genotyping, when they report additional types, or groups of types, such as HPV31, 33, 35, 45, 52 and 56.This guideline specifically refers to partial genotyping (i.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "e.the detection of HPV16 and 18 versus other carcinogenic types) to identify women at the highest risk of cervical cancer among those testing positive for HPV (Annex 4).Self-sampling or provider sampling can be used for HPV DNA testing.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In this guideline, an HPV DNA test means a high-risk HPV DNA test, which is a nucleic acid amplification test (NAAT).Cytology: Cytology tests (including the Papanicolaou smear test and liquid-based cytology [LBC]) identify atypical cells on the cervix through the preparation and interpretation of slides using microscopy by a trained expert.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "LBC requires sophisticated processing to create slides from liquid specimens.The threshold used in this guideline to identify the need for further evaluation or treatment is a cytological result of atypical squamous cells of undetermined significance (ASCUS) combined with the presence of high-risk HPV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Visual inspection with acetic acid (VIA): VIA testing uses dilute acetic acid (vinegar) on the cervix without magnification to identify aceto-white lesions that need treatment (e.g.ablation or excision) or further evaluation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "VIA is not appropriate for use in women when the transformation zone is no longer visible or after menopause.This guideline makes a distinction between using VIA as a screening or triage test, and assessing eligibility for treatment (after positive screening) using acetic acid and visual evaluation (see Box 3.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1 below; for further information, refer to Annex 5, section 5.1).Colposcopy: Colposcopy is used to assess the epithelium of the transformation zone to determine its type (Annex 5, section 5.4), whether or not there is evidence of abnormality, and, where indicated, to facilitate a biopsy or treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "It is not commonly used as a screening tool.Colposcopy may also be used after a primary positive screening test, to assess whether ablative or excisional therapy is appropriate.![](images/c9e7a98a52e9c09c94e9fd4b3a3a7840e2b760fe3c474812f47c876780e5a2bf.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) Triage tests: The triage tests considered in this guideline include high-risk HPV DNA partial genotyping, cytology, VIA and colposcopy that may or may not include a biopsy for histological diagnosis.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some of these triage tests may be conducted sequentially (e.g.cytology followed by colposcopy with biopsy).Other triage tests are currently undergoing clinical evaluation and may be added to this guideline later as part of the “living guidelines” process.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Further information on these tests is available in Annex 6.Box 3.1: Visual evaluation to assess eligibility for treatment versus visual inspection with acetic acid (VIA) as a screening test ![](images/e83e10e3a23ed1dedea47c109fd8662d553b8d81563b9d1f4e641af755f0b89b.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) There is a distinction in these recommendations between (a) using visual evaluation to assess eligibility for ablative treatment (Annex 5, section 5.1), and (b) using VIA as a screening test as part of an algorithm to determine whether or not to treat (Annex 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This distinction is illustrated in the following scenarios: a.In the HPV test screen-and-treat strategy (i.e.algorithm 2 in Table 2.2), women who are HPV-negative are not treated, nor evaluated further.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Women who are HPV-positive should all be treated but first eligibility for ablative treatment must be assessed with application of acetic acid and visual evaluation using the naked eye or with a colposcope.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Those who are ineligible for ablative treatment should be referred for excisional treatment or further evaluation.b.In the HPV test screen, triage and treat strategy (i.e.algorithms 4 to 7 in Table 2.2), women who are HPV negative are not treated, nor evaluated further.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Women who are HPV-positive undergo VIA as a triage test (i.e.algorithm 5 in Table 2.2) to determine whether they should be treated.Women who are HPV-positive and VIA-positive will be treated with ablation if adequate, or referred for excisional treatment or further evaluation, while women who are HPV-positive and VIA-negative will not be treated but followed-up as indicated in the algorithm.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 3.3 Treatment considerations In a screen-and-treat approach, women who screen positive are treated without histological diagnosis.The treatment aims to destroy or remove the transformation zone of the cervix, or remove areas of the cervix that have been identified as abnormal by screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The methods of treatment may be ablative (destroying abnormal tissue by heating it with thermal coagulation or freezing it with cryotherapy) or excisional (surgically removing abnormal tissue with LLETZ or CKC) (Annex 5, section 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4).Ablative treatments do not result in a tissue specimen for histological evaluation.In this guideline, the term LLETZ is used to refer to excision of the transformation zone.LLETZ uses local anaesthesia, is done in an outpatient setting and yields a tissue specimen for pathology.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In some countries, this terminology was changed to LEEP (loop electrosurgical excision procedure), and the two terms are often used interchangeably (Annex 5, section 5.4).WHO has published technical specifications for ablative therapy and LLETZ (36).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For further summary comparisons of the treatment methods, refer to the WHO Comprehensive cervical cancer control: a guide to essential practice $( 5 )$ and the thermal ablation treatment guidance (15).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Before treatment, all women who have screened positive with any test other than VIA should be visually inspected with acetic acid by a trained health worker to determine the transformation zone type (Annex 5, section 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4), rule out suspected cervical cancer and determine eligibility for ablative therapy.Refer to Annex 5 for the definition of eligibility for ablative treatment (section 5.1 of the annex) and for further description of the transformation zone (section 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4 of the annex).# 4.Recommendations and good practice statements on screening and treatment to prevent cervical cancer In this present publication, there is a total of 23 recommendations and 7 good practice statements.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/73be254ab95bc7a3276df415f6ff283397cb69340b678665975874885472953c.jpg) Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV, and 12 are different and specific for each population.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/52465e4e7c22ca5adddefa1aacdace6976e1129055d4ac9bd4b4175c1bc59a0d.jpg) Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV, and 2 are different and specific for each population.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The recommendations and good practice statements are presented first for the general population of women (section 4.1, nos.1–14) and then for women living with HIV (section 4.2, nos.21–34), and finally an additional recommendation and good practice statement regarding treatment for all women are presented (section 4.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3, nos.41 and 42).5 # 4.1 Recommendations and good practice statements: general population of women6 All screening algorithms are in Annex 4.1.WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Strong recommendation, moderate-certainty evidence] Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly because of the inherent challenges with quality assurance.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2.WHO suggests using an HPV DNA primary screening test either with triage or without triage to prevent cervical cancer among the general population of women.[Conditional recommendation, moderate-certainty evidence] 3.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3a.In a screen-and-treat approach using HPV DNA detection as the primary screening test, WHO suggests treating women who test positive for HPV DNA among the general population of women.3b.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test (Annex 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, moderate-certainty evidence] Remarks: The benefits, harms and programmatic costs of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance and resources in countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).4.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 5.WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.[Strong recommendation, moderate-certainty evidence] 6.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.Inadequate visualization is typical after the menopause.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "7.Priority should be given to screening women aged 30–49 years in the general population of women.When tools are available to manage women aged 50–65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Good practice statement] 8.WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women.[Conditional recommendation, low-certainty evidence] 9.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 10.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Good practice statement] 11.WHO suggests that the general population of women who have screened positive on an HPV DNA primary screening test and then negative on a triage test are retested with HPV DNA testing at 24 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, low-certainty evidence] 12.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 13.WHO suggests that women from the general population who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AIS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VIA or co-testing and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, low-certainty evidence] 14.As programmes introduce HPV DNA testing, use this test at the woman’s next routine screening date regardless of the test that was used at prior screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Good practice statement] Summary recommendations for women in the general population ![](images/9f48ead885540a8f69d36f6ca29f17db04cbdd011c2229b2e50c6773d22d5c89.jpg) WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: HPV DNA detection in a screen-and-treat approach starting at the age of 30 years with regular screening every 5 to 10 years.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.# 4.1.1 Justification A strong recommendation was made for using HPV DNA detection as a primary screening test when part of a screen-and-treat approach or a screen, triage and treat approach because a higher value was placed on the greater reductions in cervical cancer and deaths that are likely with HPV DNA detection compared with using VIA or cytology as a primary screening test (moderatecertainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There may also be fewer harms, such as preterm deliveries, when screening with an HPV DNA test compared with VIA.HPV DNA testing by the provider or by self-sampling may have similar effects, so either method of testing was suggested (low-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV DNA testing is largely acceptable to women and providers, is feasible and is more likely to lead to more equitable access to screening.A conditional recommendation was made to use either HPV DNA detection followed by treatment or HPV DNA detection with a triage test because the balance of benefits and harms may be similar for either approach (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The benefits and harms may also be similar with any of the triage tests considered (moderate-certainty evidence), but the choice of approach should be made depending on context, because the feasibility and the resources needed for triage tests vary across settings.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "On the age at which to start screening, there is evidence from modelling and large databases measuring the incidence of cervical cancer and CIN that supports the initiation of screening at the age of 30 years (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Starting screening at this age is likely to be acceptable to stakeholders, is feasible and needs fewer resources than starting at an earlier age.There is low-certainty evidence from longitudinal studies of the benefits of screening and of the continued risk of CIN and cervical cancer after the age of 50 years; the evidence suggests there are benefits of continued screening, following regular screening intervals until there have been two consecutive negative screening results after the age of 50.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Conditional recommendations were made on the screening intervals and the age at which to stop screening based on modelled evidence showing greater benefits and fewer harms with 5- to 10-year screening intervals with HPV DNA testing, compared with more frequent screening or similar intervals using cytology or VIA (low-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Conditional recommendations were made for HPV DNA testing 12 months after treatment and 24 months after a negative triage test, if screened initially with an HPV DNA test, or 12 months after a positive cytology test (but negative colposcopy); this is because there may be greater benefits and fewer harms compared with alternative follow-up times (low-certainty evidence based on modelling).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 4.1.2 Summary of the evidence For further details on the following, refer to the summaries in Web annex A (Syntheses of the evidence) and Web annex B (EtD tables) – web links provided at the end of the Table of Contents.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Primary screening tests (Recommendations 1, 3 and 4): The GDG considered evidence for the effects of different primary screening tests and found moderate-certainty evidence from a synthesis of two randomized controlled trials and modelling that HPV DNA testing followed by treatment is more likely to lead to greater reductions in $C | \\mathsf { N } 2 +$ lesions, advanced (stage $| | + \\rangle$ ) cervical cancer and cervical cancer deaths at follow-up, compared with VIA testing (Web annex A, IARC handbook materials and Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "VIA has limitations, such as subjectivity and wide variation in accuracy.The modelling also showed that primary HPV DNA testing followed by treatment may result in fewer treatments overall and fewer preterm deliveries in the screened population compared with primary VIA testing, even when assuming favourable VIA test performance.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Evidence from randomized controlled trials and cohort studies indicated a substantially lower 3- to 10-year $\\mathsf { C l N 3 + }$ risk and a lower cancer risk (up to $70 \\%$ lower) after a negative HPV DNA test compared with the risk after negative cytology (IARC handbook materials).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The modelling showed that discounted costs were similar to HPV DNA testing and VIA testing, and lower compared with cytology (followed by colposcopy).HPV DNA testing was most cost-effective.Although it was not modelled, the sensitivity and specificity of self-collected upper vaginal samples for HPV testing may be similar to those of cervical samples taken by health-care providers for the detection of $C | \\mathsf { N } 2 +$ using clinically validated polymerase chain reaction (PCR)-based high-risk HPV DNA tests.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The effects of the HPV screening algorithms may therefore be similar using different sampling methods (low-certainty evidence) (Web annex A, IARC handbook materials and Supplementary material 1).Screen-and-treat versus screen, triage and treat (Recommendations 2 and 3): Studies measuring outcomes from the published literature did not directly compare screen-and-treat algorithms with screen, triage and treat algorithms.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The longitudinal studies assessing HPV DNA screening did, however, include strategies with HPV DNA alone, and with cytology and/ or colposcopy as triage, and found that there are likely to be similar benefits across the strategies (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "We also mathematically modelled outcomes.The modelling found that there may be similar reductions in cervical cancer and related deaths with HPV DNA detection as the primary screening test in either a screen-and-treat approach or a screen, triage and treat approach, but there may be slightly more treatments and preterm deliveries with a screen-and-treat approach.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When comparing the effects of different triage tests after HPV DNA primary screening, there may be slightly fewer cervical cancers and related deaths when HPV16/18 genotyping is used as a triage compared with the use of colposcopy, VIA or cytology as a triage test.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Age to initiate or stop screening (Recommendations 5, 6 and 7): Evidence to determine the ages at which to start and stop screening was reviewed from both the published literature and from mathematical modelling.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Moderate-certainty evidence found that there are likely to be small numbers of women with cervical cancer before the age of 30 years (3/100 000 at age 20; 5/100 000 at age 25; and 12/100 000 at age 30), and a small proportion of women between the ages of 15 and 29 years with CIN2 or $\\mathsf { C l N 3 + }$ (1400/100 000 and 700/100 000, respectively; Web annex A, Supplementary materia 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Another review found that a greater proportion $( 6 0 \\% )$ of women younger than 30 with CIN2 may regress back to CIN1 or normal after 24 months of surveillance, compared with $4 4 \\%$ of women older than 30.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Low-certainty evidence from modelling also found that when screening is started at the age of 30 years using strategies with HPV DNA screening, there are greater reductions in cervical cancer and deaths compared with starting at the age of 35 years, but there may be slightly more harms, such as more treatments and a higher risk of preterm deliveries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There were also greater costs associated with starting at 30 years of age (compared with starting at age 35) since more resources are needed for screening and treatment (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Starting screening at 30 or 35 years of age is likely to be acceptable to women.Moderate-certainty evidence found that, in countries where screening was available, there were fewer women aged 50 years and older with cervical cancer (30/100 000), and in countries where screening was not available, there were more (80/100 000) (Web annex A, Supplementary material 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Longitudinal studies showed the proportion of women with cervical cancer was similar between the age groups under and over 65 years (and that cervical cancer was primarily in women who had not been screened in the preceding interval); the risk of death from cervical cancer was also similar between age groups under and over 55 years (IARC handbook materials).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This provided indirect evidence for screening strategies after the age of 50 years (low-certainty evidence).The GDG agreed that in countries where cervical cancer screening may not have been widely available, women who were older than 50 years would be at greater risk of CIN2/3 and cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, the age to stop screening was dependent on the population risk, the resources available and the frequency of screening between the ages of 30 and 49 years, when the risk is greatest.Barriers to screening for older women may include embarrassment, lack of knowledge about the need for screening (in particular when they have no symptoms) and fear of discomfort (Web annex A, Supplementary material 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Screening intervals (Recommendations 7, 8, 9 and 10): Screening intervals were also modelled (low-certainty evidence).A 5-year screening interval may result in greater benefits, fewer harms and lower costs than a 10-year one when providing HPV DNA testing with or without triage.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These effects may be similar to those with cytology testing (followed by colposcopy) every three years, but better than those with cytology every five years, and better than VIA every five years (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Based on previous modelling to evaluate the impact of the WHO Global strategy to accelerate the elimination of cervical cancer, which demonstrated greater benefit with screening a woman twice in her lifetime compared with once (23,24), the GDG agreed that, at a minimum, twice-in-a-lifetime screening would be feasible and provide benefits, and therefore made it a good practice statement.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Acceptability, equity, feasibility, resources (all recommendations): Studies have identified potential provider perceptions that may impact the acceptability and implementation of recommendations for different screening and treatment approaches (Web annex A, Supplementary material 12).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some providers perceive that screening approaches using HPV DNA detection will increase uptake, lead to more treatment and be more sensitive in detecting lesions, whereas VIA may require more standardized training since it is subjective and dependent on expertise.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some providers also perceive that self-sampling could reduce their opportunities to provide other care for the person.Overall, it may be challenging for providers during the shift from cytology and/or VIA to HPV DNA testing as new infrastructure (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.a laboratory) and training are needed.A survey of women found that multiple visits can be difficult for them, and immediate treatment may be preferred (Web annex A, Supplementary material 9).A systematic review of the literature, primarily in high-income countries, found that HPV DNA testing by self-sampling is likely to improve screening uptake and may improve follow-up care slightly (Web annex A, Supplementary material 12).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A survey of GDG members identified concerns that were generally more serious when considering VIA- or cytology-based screening programmes compared with HPV DNA-based screening programmes – these concerns related to maintaining a trained workforce, generating demand for screening and ensuring high compliance with management following a positive screening test (Web annex A, Supplementary material 11).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There were greater concerns about cost with HPV DNA and cytology than with VIA-based programmes.Screen-and-treat algorithms were generally more acceptable to stakeholders involved in ongoing service delivery, while screen, triage and treat algorithms were perceived to be more acceptable to health authorities, policy-makers and experts on cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When choosing a triage test, providing cytology or colposcopy would be a challenge where it is not currently available and quality controlled and assured.However, if the HPV DNA primary screening test also gave HPV16/18 genotype information (see algorithm 4 in Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2, Chapter 2), there would be no additional test to do, making it important for a self-sampling strategy.HPV DNA testing by self-sampling also has the potential to reduce cultural, socioeconomic and gender barriers to screening, which is likely to increase equity.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Follow-up after negative triage test or after treatment (Recommendations 11, 12, 13 and 14): The evidence for screening after a positive HPV DNA primary screening test and negative triage test was based on modelling of follow-up screening at 12 or 24 months, or both (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The modelling found that results may be dependent on the triage test.There is low-certainty evidence showing that after a negative triage test using HPV16/18 genotyping or colposcopy, follow-up screening at 24 months or at 12 months may result in similar benefits, but there may be fewer cancer treatments and lower costs at 24 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "After a negative triage test with VIA or cytology, screening at 24 months leads to slightly fewer benefits than at 12 months, but there may be fewer cancer treatments and lower costs with follow-up at 12 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For screening at both 12 and 24 months after a negative result with any triage test, there may be slightly better reductions in cervical cancer and deaths, compared with screening at one time point only (12 or 24 months), but there may be greater harms due to more treatments and greater cost.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG agreed that the harms outweighed the benefits for screening at both 12 and 24 months, and although the benefits and harms at 12 months and 24 months varied slightly by triage test, a conditional recommendation was made to retest after 24 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The evidence on which screening test to use for follow-up after treatment following a positive screening test or after treatment for histologically confirmed CIN2/3 came from literature comparing cures and failures after treatment and on the accuracy of tests to measure failure.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "It also came from modelling the use of HPV DNA testing at 12 or 24 months follow-up, or co-testing with HPV DNA and cytology at 12 months (Web annex A, IARC handbook materials and Supplementary materials 3 and 13), Systematic reviews providing moderate- and low-certainty evidence on treatment failure in the general population of women suggests it may be around $10 \\%$ after ablative treatments, and lower after excisional treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There is high-certainty evidence from reviews of the accuracy of different tests to predict recurrence or persistence after treatment in women with histologically confirmed CIN2/3 or positive screening results; this evidence indicates that the HPV DNA test is more sensitive and slightly less specific than cytology alone or co-testing with HPV DNA and cytology.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "High-certainty evidence also shows that positive margin status of an excised cone was less sensitive than the HPV DNA test as a predictor of failure.There is very low-certainty evidence for the sensitivity and specificity of HPV genotyping due to inconsistent results.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Low-certainty evidence from modelling studies showed that retesting women after treatment with an HPV DNA test at 12 or 24 months follow-up, or with HPV DNA/cytology co-testing at 12 months may result in similar reductions in cervical cancer and deaths; using co-testing is likely to increase treatments and costs (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Recommendations to extend the length of time before follow-up testing may be of some concern to practitioners, as shorter durations (e.g.12 months) may be practised in some settings.There may also be a challenging period for a programme when transitioning from VIA or cytology to HPV DNA testing, when women may be screened with VIA or cytology but retested at follow-up with HPV DNA testing.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 4.2 Recommendations and good practice statements: women living with HIV7 21.WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Strong recommendation, moderate-certainty evidence] Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly because of inherent challenges with quality assurance.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "22.WHO suggests using an HPV DNA primary screening test with triage rather than without triage to prevent cervical cancer among women living with HIV.[Conditional recommendation, moderate-certainty evidence] 23.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test (Annex 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, moderate-certainty evidence] Remarks: The benefits, harms and programmatic costs of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance and resources in countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).24.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 25.WHO suggests starting regular cervical cancer screening at the age of 25 years among women living with HIV.[Conditional recommendation, low-certainty evidence] Remarks: Low-certainty evidence found that there are likely to be small numbers of women living with HIV with cervical cancer who are below the age of 25.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This recommendation applies to women living with HIV regardless of when they first tested positive for HIV.26.After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, very low-certainty evidence] Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Inadequate visualization is typical after the menopause.27.Priority should be given to screening women living with HIV aged 25–49 years.When tools are available to manage women living with HIV aged 50–65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Good practice statement] 28.WHO suggests a regular screening interval of every 3 to 5 years when using HPV DNA detection as the primary screening test among women living with HIV.[Conditional recommendation, low-certainty evidence] 29.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 30.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Good practice statement] 31.WHO suggests that women living with HIV who have screened positive on an HPV DNA primary screening test and then negative on a triage test, are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, low-certainty evidence] 32.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Conditional recommendation, low-certainty evidence] 33.WHO suggests that women living with HIV who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AIS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VIA or co-testing, and, if negative, are retested again at 12 months and, if negative again, move to the recommended regular screening interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, low-certainty evidence] 34.As programmes introduce HPV DNA testing, use this test at the woman’s next routine screening date regardless of the test that was used at prior screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "\\* [Good practice statement] # Summary recommendation for women living with HIV ![](images/8e83d16d4f7bd2f7379c985f723ed54945467bcb77ad48a74b663acb16cdd923.jpg) WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: HPV DNA detection in a screen, triage and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 4.2.1 Justification For women living with HIV, a strong recommendation was made for using HPV DNA testing as a primary screening test because a higher value was placed on the reductions in cervical cancer and deaths that are likely with this approach than on the potential harm that may occur, such as preterm deliveries (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When compared with VIA or cytology as a primary screening test, greater benefits are also more likely with HPV DNA testing.HPV DNA testing is acceptable to women and providers, is feasible and is not likely to lead to inequities.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In some settings, HPV DNA testing is not yet available, though, and there will be a period when existing quality-assured programmes will need to remain until HPV DNA testing becomes operational.A conditional recommendation was made to use HPV DNA testing with a triage test rather than HPV DNA testing followed by treatment because providing a triage test may lead to reduced potential harms, with minimal change in benefits (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The feasibility and resources needed to provide different triage tests vary across settings, thus influencing which test is chosen.Overall, with all screening and treatment strategies, there are greater reductions in cervical cancer, deaths and CIN2/3 lesions for women living with HIV compared with the general population of women.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For women living with HIV on antiretroviral therapy (ART), there were few data regarding the impact of ART on HPV-associated lesions, although the evidence is growing; therefore, recommendations based on use of antiretrovirals were not made.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For the age at which to start screening, there was low-certainty evidence from an individual patient data meta-analysis (IPD-MA), mathematical modelling and studies about cervical cancer incidence and CIN by age that supported the initiation of screening at 25 years of age rather than at age 20 or 30.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Starting at this age is likely to be acceptable to stakeholders, is feasible and needs fewer resources than starting screening at an earlier age.There was very low-certainty evidence from the studies mentioned above (given the small numbers of women followed and reporting cervical cancer or CIN lesions) that found that the risk of cervical cancer and lesions may continue after the age of 50 years.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Screening was therefore suggested to continue at regular screening intervals, until there have been two consecutive negative screening results after the age of 50.Conditional recommendations were made for screening intervals based on modelled evidence showing greater benefits may occur with three- to five-year screening intervals with HPV DNA testing (or cytology or VIA), though there may be more treatments and therefore harms compared with a longer interval (low-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Conditional recommendations were made for HPV DNA testing 12 months after treatment and after a negative triage test, regardless of initial screening test, as there may be greater benefits and fewer harms (low-certainty evidence based on modelling).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 4.2.2 Summary of the evidence For further details on the following, refer to the summaries in Web annex A (Syntheses of the evidence) and Web annex B (EtD tables) – web links provided at the end of the Table of Contents.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Primary screening tests (Recommendations 21, 23 and 24): Moderate-certainty evidence from a randomized controlled trial, longitudinal studies and modelling found that HPV DNA as the primary screening test in screening and treatment services is likely to result in greater reductions in $C | \\mathsf { N } 2 +$ than VIA, but may result in similar reductions to cytology (followed by colposcopy).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There may be similar harms (including harms from treatments and preterm deliveries) when using either HPV DNA testing or VIA as the primary screening test, but fewer harms with cytology followed by colposcopy.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The costs, however, may be greater when using cytology followed by colposcopy (Web annex A, IARC handbook materials and Supplementary materials 2 and 13).# Screen-and-treat versus screen, triage and treat (Recommendations 22, 23, 28, 29 and 30): Studies measuring outcomes found in the published literature did not directly compare different screen-and-treat algorithms against screen, triage and treat algorithms.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The longitudinal studies assessing HPV DNA-based screening did, however, include strategies with HPV DNA alone, and with cytology and/or colposcopy as triage, and found that there are likely to be similar benefits across the strategies (moderate-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Outcomes were also mathematically modelled, showing that there may be similar benefits from using HPV DNA screening with or without triage testing, but that harms may be reduced with triage due to fewer treatments for pre-cancer (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When screening is provided every five years, HPV DNA without triage may result in slightly greater harm (including more treatments and preterm deliveries) than with triage; and the harms may be similar across different triage tests.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Modelled evidence also found that greater benefits may occur with three- to five-year screening intervals with HPV DNA testing (or cytology or VIA) although there may be more treatments and therefore harms when compared with a longer interval (low-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In addition, HPV DNA testing followed by triage at five-years intervals may have similar benefits and harms when compared with cytology (followed by colposcopy) every three years, but it is more cost-effective than cytology and colposcopy at any interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Although data were not available for women living with HIV, and this evidence was not modelled, the sensitivity and specificity of clinically validated PCR-based high-risk HPV DNA testing for the detection of $C | \\mathsf { N } 2 +$ on self-collected upper vaginal samples versus cervical samples taken by health-care providers may be similar for women in the general population (Web annex A, IARC handbook materials and Supplementary material 1) and for women living with HIV (low-certainty evidence).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Based on previous modelling in 78 low- and middle-income countries (including some with a high burden of HIV) to evaluate the impact of the WHO Global strategy to accelerate the elimination of cervical cancer (23,24), the GDG agreed that, at a minimum, twice-in-a-lifetime screening would be feasible and provide benefits, because the modelling demonstrated benefits with screening twice in a lifetime compared with once.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG thus made a good-practice statement to screen twice.Age to initiate or stop screening (Recommendations 25, 26 and 27): Low-certainty evidence from an IPD-MA found that there may be a substantially lower risk (6 per 100) of histologically confirmed CIN2 or CIN3 among girls aged between 15 and 19 years compared with older age groups.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In young adult women aged 20–24 years, the risk may be 32 per 100, and in women aged 45–49 years, 58 per 100.There is low-certainty evidence from modelling that screening starting at 20 years of age in women living with HIV, using strategies with HPV DNA testing, may lead to slightly more reductions in cervical cancer incidence and deaths compared with starting at 25 or 30 years of age.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There may be more harms, however, from substantially more pre-cancer treatments and therefore a greater risk of preterm deliveries.There may also be higher costs since more resources are needed for screening and treatment when started at an earlier age (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Starting screening at the age of 20, 25 or 30 is likely to be acceptable to women living with HIV.Only sparse data were available for cervical cancer and CIN2/3 or HPV incidence in women living with HIV after the age of 50.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A large database of cervical cancer cases indicated that of all cases of cervical cancer, $20 \\%$ were diagnosed in women in their 50s and $1 \\%$ of them were diagnosed in women in their 70s (Web annex A, Supplementary material 5).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This very low-certainty evidence provides indirect support for screening strategies continuing after the age of 50.Literature on the general population of women found that barriers for older women included embarrassment, lack of knowledge about the need for screening (in particular when they have no symptoms) and fear of discomfort (Web annex A, Supplementary material 4).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Acceptability, equity, feasibility, resources (all recommendations): Some studies have identified provider perceptions that may impact the acceptability of recommendations for different screening and treatment approaches (Web annex A, Supplementary material 12).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some providers perceive that screening approaches with HPV DNA detection may increase uptake, lead to more treatment and be more sensitive in detecting lesions, whereas VIA may require more standardized training since it is subjective and dependent on expertise.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Providers may also perceive that self-sampling could reduce opportunities to provide the person with other care.Overall, it may be challenging for providers during a transition from cytology or VIA-based screening to HPV DNA testing as new infrastructure (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.laboratory) and training are needed.A global online survey of women found that multiple visits may be difficult, particularly for those living with HIV, and immediate treatment may be preferred (Web annex A, Supplementary material 9).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A systematic review of the literature, primarily in high-income countries, found that HPV DNA testing by self-sampling is likely to improve screening uptake and may improve follow-up care slightly (Web annex A, Supplementary material 12).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A survey of GDG members identified concerns that were generally more serious when considering VIA- or cytology-based screening programmes compared with HPV DNA-based screening programmes – these concerns related to maintaining a trained workforce, generating demand for screening and ensuring high compliance with management following a positive screening test (Web annex A, Supplementary material 11).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There were greater cost concerns with HPV DNA and cytology than with VIA-based programmes.Screen-and-treat algorithms were generally more acceptable to stakeholders involved in ongoing service delivery, while screen, triage and treat algorithms were perceived to be more acceptable to health authorities, policy-makers and experts in cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "When choosing a triage test, providing cytology or colposcopy would be a challenge where it is not currently available and quality controlled and assured.However, if the HPV DNA primary screening test also gave HPV16/18 genotyping information (see algorithm 4 in Table 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2), there would be no additional test to perform, making it important for a self-sampling strategy.HPV DNA testing by self-sampling also has the potential to reduce cultural, socioeconomic and gender barriers to screening, which is likely to increase equity.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Follow-up after negative triage test or after treatment (Recommendations 31, 32, 33 and 34): The evidence for follow-up screening after a positive HPV DNA primary screening test and negative triage test was based on modelling of follow-up screening at 12 or 24 months, or both (Web annex A, Supplementary material 13).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There is low-certainty evidence showing that after a negative triage test, there are greater benefits when retesting at 12 months compared with 24 months, but similar harms; and similar benefits and harms at 12 months compared with retesting at both 12 and 24 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Therefore, screening at 12 months is suggested.The evidence on which screening test to use for follow-up after treatment following a positive screening test or after treatment for histologically confirmed CIN2/3 came from literature comparing cures and failures after treatment and literature on the accuracy of tests to measure failure.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "It also came from modelling the use of HPV DNA testing at 12 or 24 months follow-up or co-testing with HPV DNA and cytology at 12 months (Web annex A, Supplementary materials 2 and 13).Systematic reviews providing moderate- and low-certainty evidence on treatment failure in women living with HIV suggest it may be around $30 \\%$ after ablative treatment, and lower after excisional treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There is high-certainty evidence from reviews of the accuracy, in the general population, of different tests to predict recurrence or persistence after treatment; this evidence indicates that the HPV DNA test is more sensitive and slightly less specific than cytology alone or co-testing with HPV DNA and cytology.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "High-certainty evidence also shows that positive margin status of an excised cone was less sensitive than the HPV DNA test as a predictor of failure.There is very low-certainty evidence for the sensitivity and specificity of HPV genotyping due to the few studies and inconsistent results.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Low-certainty evidence from modelling studies showed that retesting women with an HPV DNA test at 12 or 24 months after treatment or with HPV DNA and cytology co-testing at 12 months follow-up may result in similar reductions in cervical cancer and deaths; but using co-testing is likely to increase treatments and costs.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For women living with HIV, however, there is low-certainty evidence from two studies that the specificity of HPV DNA testing may be lower than for the general population of women, meaning there is less certainty in the applicability of the results from the general population of women.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Additional follow-up visits were therefore suggested by the GDG.Recommendations to extend the interval before follow-up may concern some practitioners working in settings that use shorter durations (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.12 months).There may also be a challenging time for programmes when transitioning from VIA or cytology to HPV DNA testing, when women may be screened with VIA or cytology but retested with HPV DNA testing at follow-up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 4.3 Additional recommendation and good practice statement for treatment not covered in previous guidelines for the general population of women and women living with HIV 41.Once a decision to treat a woman is made – whether from the general population of women or women living with HIV – it is good practice to treat as soon as possible within six months to reduce the risk of loss to follow-up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, in women who are pregnant, good practice includes deferral until after pregnancy.In circumstances when treatment is not provided within this time frame, it is good practice to re-evaluate the woman before treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Good practice statement] 42.WHO suggests large-loop excision of the transformation zone (LLETZ) or cold knife conization (CKC) for women from the general population or women living with HIV who have histologically confirmed adenocarcinoma in situ (AIS).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[Conditional recommendation, low-certainty evidence] Remarks: Loop excision may be preferred in women of reproductive age, in settings with greater availability of LLETZ and by providers with greater expertise performing LLETZ.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "CKC may be preferred when interpretation of the margins of the histological specimen is imperative.# 4.3.1 Justification and evidence summary Low-certainty evidence from a systematic review of the literature found that there may be little to no difference in the recurrence rate of AIS with CKC or electrosurgical excision, or in the incidence of complications such as major infection and bleeding, and found that more women may have premature deliveries in subsequent pregnancies following a CKC compared with electrosurgical excision.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The studies included in the systematic review did not confirm HIV status, but the GDG agreed that the data could be extrapolated to women living with HIV and applied directly.CKC is performed in the operating theatre, so access to CKC may be limited in some settings, more costly and less preferred by women compared with LLETZ.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In addition, greater expertise may be needed for successful electrosurgical excision.# 5.Research gaps and further considerations # Selection of one strategy over another (PICOs 1 and 2)8 Regarding the screening tests, it would be useful to have data on using different genotypes of HPV in both the general population of women and women living with HIV to see if specificity could be improved without losing too much sensitivity.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Additionally, the GDG noted that more data are needed about the specificity and sensitivity of tests among women living with HIV, including those taking ART.Another special population needing research is transgender men, non-binary and intersex individuals who have a cervix, to determine the prevalence of cervical pre-cancer and the appropriate screening frequency and approach.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Special implementation considerations and successful interventions for overcoming barriers to screening are also needed for these groups of people.Whether there is an upper age cut-off for self-sampling for screening was another area noted for more research.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Different duration of follow-up with the same or a different screening test (PICO 3–7) The GDG would like to expand studies that evaluate the best follow-up interval after treatment.The group noted that a comparison of two negative screens (at either 12 or 24 months follow-up) versus one negative screen (at 12 months) before returning to regular screening would be important, as the evidence is currently based on modelled data.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This would be potentially more important in women living with HIV due to the high recurrence rate.The GDG would like better longitudinal data on the recurrence of HPV after treatment.Given the debate about progression in women living with HIV compared with that in women in the general population, and about progression by age, more research is needed in these groups to quantify the differences in progression, over 3, 6 and 12 months, of CIN2/3 to invasive cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Age at first screening, and minimum number of lifetime screenings (PICO 8i and 8ii) We have suggested to start screening at the age of 25 years for women living with HIV.The GDG would like data that could identify whether there are subgroups of women who could be screened later (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.those on ART with well controlled disease) or earlier (e.g.those with perinatally acquired HIV).The GDG would also like better data on histologically confirmed cervical pre-cancer and cancer occurring before 25 years of age in women living with HIV, as the evidence from empirical studies and programmes in this age group is sparse.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# Timing of treatment after positive screening or diagnosis (PICO 9 and 10) The GDG noted that in women living with HIV, more research is needed about the efficacy of CKC and LLETZ in the treatment of AIS.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Evidence is needed for the costs and cost-effectiveness of CKC versus LLETZ for AIS in both the general population of women and in women living with HIV.For the future implementation recommendations (Phase 3; see section 1.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4), the GDG also discussed some research gaps to be addressed.One would be the integration of screening to prevent cervical cancer into HIV treatment programmes: will the screening be overlooked, or will this integrated approach lead to increased uptake of screening?",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG mentioned that more research would be important into why women who screen positive are subsequently lost to follow up and do not get treatment.For initiating or transitioning to HPV DNA screening, it would be beneficial to have research on the training and retraining costs (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.transitioning from VIA to HPV DNA screening).# 6.Dissemination and updating of the guideline # 6.1 Guideline dissemination and impact The final published guideline document will be disseminated using WHO's worldwide network to make sure that the guideline reaches health-care providers and programme managers so that the most recent evidence is integrated and accessible for clinical decision-making to prevent cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A link to download the guideline will be available at the WHO website and in HRP News,9 and printed copies, if requested, will be disseminated to health ministries, WHO country and regional offices, WHO collaborating centres on cervical cancer, and other cervical cancer collaborators and partners.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The print and electronic copies will be disseminated at high-level meetings for advocacy, and at international conferences to reach a large audience, especially through special sessions, seminars and satellite sessions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Policy briefs for women living with HIV and for sexual and reproductive health programmes will also be developed.The new recommendations regarding women living with HIV will be included in the forthcoming third edition of the WHO consolidated guideline on HIV (38).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This represents an opportunity for dissemination through other WHO department networks and to ensure that the community of people living with HIV is aware of and implements the relevant recommendations.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These dissemination plans also include partners involved in the implementation and roll-out of cervical cancer screening and treatment.These include other United Nations agencies, the United States President’s Emergency Fund for AIDS Relief (PEPFAR), the Global Fund and Unitaid.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lastly, an app will be developed to make the guideline interactive and accessible on smartphones.In the context of the Global strategy to accelerate the elimination of cervical cancer, launched in November 2020, this guideline is particularly important in shaping national plans to meet the 2030 targets.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "These recommendations will inform programme development, and WHO and partners will make every effort to support countries to update their national cervical cancer guidelines.The guideline will be translated into the six WHO official languages.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO headquarters will work with WHO regional offices and country offices to ensure that countries will be supported in the adaptation, implementation and monitoring of the guideline.For this purpose, regional workshops and webinars in different languages will be organized to present, discuss and plan guideline adaptation and implementation, as well as to update current national guidelines.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "At all levels (headquarters, regional offices and countries), WHO will work with regional and national partners, as well as other United Nations agencies such as the United Nations Population Fund (UNFPA), the United Nations Children’s Fund (UNICEF), the International Atomic Energy Agency (IAEA) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) (39).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The guideline will be disseminated at upcoming major conferences related to sexual and reproductive health and rights, HPV, HIV and public health.Other WHO guidance is available to support impact evaluation, national programme reviews, planning, implementation and scale-up (40,41,42).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In addition, impact will be measured by developing and disseminating surveys for both health workers and clients, as was done during the guideline development for values and preferences.This will be done a year after release to assess any changes in country policies and national guidelines.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This will also assess the reach of the guideline and ultimately its impact in changing practice.Over the next year, WHO’s Comprehensive cervical cancer control: a guide to essential practice, which was last published in 2014 $( 5 ) ,$ will be revised to provide an up-to-date and global consolidation of all recommendations to prevent cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 6.2 Guideline update In this guideline, the GDG prioritized seven algorithms.Additional algorithms that will be covered in a future version of this guideline will include the use of HPV mRNA detection, DNA methylation, p16/Ki-67 dual-staining cytology and automated visual evaluation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Evidence for the sensitivity and specificity of these tests and the impact on important outcomes of using them in programmes is accumulating, and syntheses of this evidence are needed.These syntheses will be used in a continual process to develop new recommendations, as “living recommendations” in Phase 4 of the guideline update.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG will continue to work with the WHO Secretariat in an ad hoc manner, so that the research gaps identified during the process can be addressed.Additionally, Phase 4 of this guideline update process is to establish living recommendations (43) for screening and treatment tests and algorithms.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The GDG anticipates that as data and experience with new screening tests and modalities advance, new recommendations will be needed through a living guideline process that is able to rapidly respond and evolve.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# References 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "CA Cancer J Clin.2021:71:209–49.doi:10.3322/caac.21660.2.Global strategy to accelerate the elimination of cervical cancer as a public health problem.Geneva: World Heatlh Organization; 2020 (https://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/publications/i/ item/9789240014107).3.Human papillomaviruses.IARC monographs on the evaluation of carcinogenic risks to humans, Vol.90.Lyon: International Agency for Research on Cancer; 2007 (https://publications.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "iarc.fr/ Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-Hazards-ToHumans/Human-Papillomaviruses-2007).4.de Martel C, Plummer M, Vignat J, Franceschi S.Worldwide burden of cancer attributable to HPV by site, country and HPV type.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Int J Cancer.2017;141(4):664–70.doi:10.1002/ijc.30716.5.Comprehensive cervical cancer control: a guide to essential practice, second edition.Geneva: World Health Organization; 2014 (https://www.who.int/reproductivehealth/publications/cancers/ cervical-cancer-guide/en/).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "6.Habbema D, De Kok IM, Brown ML.Cervical cancer screening in the United States and the Netherlands: a tale of two countries.Milbank Quarterly.2012;90(1):5–37.doi:10.1111/j.1468- 0009.2011.00652.x.7.Denny L, Kuhn L, Hu CC, Tsai WY, Wright TC, Jr.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial.J Natl Cancer Inst.2010;102(20):1557-67.doi:10.1093/jnci/djq342.8.Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B, et al.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women.Clin Cancer Res.2018;24(9):2194–202.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "doi:10.1158/1078-0432.CCR-17-3251.9.Hu L, Bell D, Antani $\\mathsf { S } , \\mathsf { X u e } \\mathsf { Z } , \\mathsf { Y u } \\mathsf { K } ,$ Horning MP, et al.An observational study of deep learning and automated evaluation of cervical images for cancer screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "J Natl Cancer Inst.2019;111(9):923–32.doi:10.1093/jnci/djy225.10.Lie AK, Kristensen G.Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.Expert Rev Mol Diagn.2008;8(4):405–15.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "doi:10.1586/14737159.8.4.405.11.Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE.Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.BMJ Open.2016;6(8):e011981.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "doi:10.1136/bmjopen-2016-011981.12.WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.Geneva: World Health Organization; 2013 (https://www.who.int/reproductivehealth/ publications/cancers/screening_and_treatment_of_precancerous_lesions/en/).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "13.WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ: cryotherapy, large loop excision of the transformation zone, and cold knife conization.Geneva: World Health Organization; 2014 (https://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/reproductivehealth/publications/ cancers/treatment_CIN_2-3/en/).14.WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia.Geneva: World Health Organization; 2011 (http://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/reproductivehealth/publications/cancers/9789241502856/ en/).15.WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions.Geneva: World Health Organization; 2019 (https://apps.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/iris/bitstream/ handle/10665/329299/9789241550598-eng.pdf).16.Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step by step guide.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Geneva: World Health Organization; 2020 (https://www.who.int/publications/i/item/9789240015166).17.WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Geneva: World Health Organization; 2020 (https://apps.who.int/iris/bitstream/handle/10665/331698/9789240002630-eng.pdf).18.WHO handbook for guideline development, second edition.Geneva: World Health Organization; 2014 (https://apps.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/iris/handle/10665/145714).19.Schünemann H, Brożek J, Guyatt G, Oxman A.GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach [website].",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "GRADEpro; updated October 2013 (https://gdt.gradepro.org/app/handbook/handbook.html).20.Cochrane handbook for systematic reviews of interventions.The Cochrane Collaboration; 2021 (https://training.cochrane.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "org/handbook).21.International Agency for Research on Cancer.IARC handbooks of cancer prevention: cervical cancer screening, Vol.18.Lyon, France: IARC Press; 2021 (in press).22.Kontopantelis E.A comparison of one-stage vs two-stage individual patient data meta-analysis methods: a simulation study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Res Synth Methods.2018;9(3):417–30.doi:10.1002/jrsm.1303.23.Canfell K, Kim JJ, Brisson M, Adam Keane, Kate T Simms, Michael Caruana, et al.Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet.2020;395(10224):591–603.doi:10.1016/S0140-6736(20)30157-4.24.Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al.Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet.2020;395(10224):575–90.doi:10.1016/ S0140-6736(20)30068-4.25.Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ.Projected time to elimination of cervical cancer in the USA: a comparative modelling study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet Public Health.2020.5(4):e213–e222.doi:10.1016/S2468-2667(20)30006-2.26.Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M, et al.The projected timeframe until cervical cancer elimination in Australia: a modelling study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet Public Health.2018;4(1):e19–e27.doi:10.1016/S2468-2667(18)30183-X.27.Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Health Technol Assess.2014;18(23):1–196.doi:10.3310/hta18230.28.Lew J-B, Simms K, Smith M, Lewis H, Neal H, Canfell K.Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "PLoS ONE.2016;11(5):e0151619.doi:10.1371/journal.pone.0151619.29.Lew J-B, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al.Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet Public Health.2017;2(2):e96-e107.doi:10.1016/S2468-2667(17)30007-5.30.Shi JF, Canfell K, Lew JB, Zhao F-H, Legood R, Ning Y, et al.Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "BMC Cancer.2011;11:239.doi:10.1186/1471- 2407-11-239.31.Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Lancet Oncol.2019;20:394–407.doi:10.1016/S1470-2045(18)30836-2.32.Hall MT, Smith MA, Simms KT, Barnabas $\\mathsf { R } ,$ Canfell K, Murray JM.The past, present and future impact of HIV prevention and control on HPV and cervical disease in Tanzania: a modelling study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "PLoS One.2020;15(5):e0231388.doi:10.1371/journal.pone.0231388.33.Pfadenhauer LM, Gerhardus A, Mozygemba K, Bakke Lysdahl K, Booth A, Hofmann B, et al.Making sense of complexity in context and implementation: the context and implementation of complex interventions (CICI) framework.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Implement Sci.2017;12(1):1–17.doi:10.1186/s13012-017- 0552-5.34.Public reports of WHO prequalified IVDs.Geneva: World Health Organization; 2021 (https:// www.who.int/diagnostics_laboratory/evaluations/pq-list/public_report_hpv/en/).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "35.Cervical cancer: screening and treatment of pre-cancerous lesions for secondary prevention of cervical cancer.Technology Landscape.Geneva: World Health Organization; 2019 (https:// unitaid.org/assets/Cervical_Cancer_Technology-landscape-2019.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "pdf).36.WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.Geneva: World Health Organization; 2020 (Chapters 5–7 and Annexes 5–7) (https://apps.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/iris/bitstream/ handle/10665/331698/9789240002630-eng.pdf).37.IARC monographs on the evaluation of carcinogenic risks to humans, Vol.100B: Biological agents.Lyon, France: International Agency for Research on Cancer; 2012.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "38.WHO consolidated guideline on HIV prevention, testing, treatment and service delivery: recommendation on a public health approach, third edition.Geneva: World Health Organization; 2021.39.UN Joint Global Programme on Cervical Cancer Prevention.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "WHO, IAEA, IARC, UNAIDS, UNFPA, UNICEF and UNWomen.Geneva: World Health Organization; 2016 (WHO/NMH/ NMA/16.96; https://www.who.int/ncds/un-task-force/un-joint-action-cervical-cancer-leaflet.pdf).40.Nine steps for developing a scaling-up strategy.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Geneva: World Health Organization; 2010 (https://www.who.int/reproductivehealth/publications/strategic_approach/9789241500319/en/).41.Beginning with the end in mind: planning pilot projects and other programmatic research for successful scaling up.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Geneva: World Health Organization; 2011 (https://www.who.int/ reproductivehealth/publications/strategic_approach/9789241502320/en/).42.Practical guidance for scaling up health service innovations.Geneva: World Health Organization; 2009 (https://www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/reproductivehealth/publications/strategic_approach/9789241598521/ en/).43.Keeping global recommendations up-to-date: a “living guidelines” approach to maternal and perinatal health.BMJ Glob Health.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2019;4(4):e001683.doi:10.1136/bmjgh-2019-001683.![](images/4218c2c5633aa175bd97bc0b0833616098a3338c3136869122d9e0ba2753f47a.jpg) # ANNEX 1: GUIDELINE GROUPS Guideline Development Group (GDG) members GDG Co-Chairs: Julie Torode and Mike Chirenje <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td> African </td><td>Achieng</td><td>Claire Judith Ikate </td><td>Uganda Cancer Society</td><td>Uganda</td></tr><tr><td>African </td><td>Awori</td><td>Ruth</td><td>Representative from communities of women living with HIV </td><td>Uganda</td></tr><tr><td>African </td><td>Chinula</td><td>Lameck</td><td>Kamuzu Central Hospital</td><td>Malawi</td></tr><tr><td> African </td><td>Chirenje</td><td>Mike</td><td>University of Zimbabwe</td><td>Zimbabwe</td></tr><tr><td>African </td><td>Chung </td><td> Michael</td><td>Aga Khan University</td><td>Kenya </td></tr><tr><td> African </td><td>Denny</td><td>Lynette</td><td>University of Cape Town </td><td>South Africa</td></tr><tr><td>African </td><td>Diop</td><td>Mamadou</td><td>Joliot Curie Cancer Institute </td><td>Senegal </td></tr><tr><td>African </td><td>Happy</td><td>Margaret </td><td>Advocacy for Quality Health Uganda</td><td>Uganda</td></tr><tr><td>African </td><td>Ingbian </td><td> Priscilla</td><td>Community health support and empowerment initiative </td><td>Nigeria</td></tr><tr><td>African </td><td>Kapambwe</td><td> Sharon </td><td>Department of Health Promotion, Environment and Social Determinants,</td><td>Zambia </td></tr><tr><td>African </td><td>Motshedisi</td><td>Sebitloane</td><td>Ministry of Health University of Kwazulu-Natal </td><td>South Africa</td></tr><tr><td>African </td><td>Mugo</td><td>Nelly</td><td>Kenya Medical Research</td><td>Kenya </td></tr><tr><td> African </td><td>Muzingwani</td><td>Laura S.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "</td><td>Institute I-TECH Namibia</td><td> Namibia</td></tr><tr><td>African </td><td>Obiri-Yeboah</td><td>Dorcas </td><td>University of Cape Coast</td><td>Ghana </td></tr><tr><td>African </td><td> Shiferaw</td><td>Netsanet </td><td>Pathfinder International</td><td>Ethiopia</td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>Centro de Estudios</td><td>Argentina</td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne</td><td>de Estado y Sociedad (CEDES) University of Washington</td><td>United </td></tr><tr><td></td><td></td><td></td><td></td><td>States of America (USA)</td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar </td><td>National Cancer Institute José Alencar Gomes da Silva (INCA)</td><td> Brazil</td></tr><tr><td>The Americas </td><td>Correa </td><td>Flavia Miranda</td><td>Brazilian National Cancer Institute</td><td> Brazil</td></tr><tr><td>The Americas</td><td>Cremer </td><td>Miriam</td><td>Basic Health International</td><td>USA</td></tr><tr><td>The Americas</td><td>Darragh</td><td>Teresa</td><td>University of California San Francisco</td><td>USA</td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>National Cancer Institute </td><td>USA</td></tr><tr><td>The Americas </td><td>Gravitt </td><td> Patti</td><td>University of Maryland School of Medicine</td><td>USA</td></tr><tr><td>The Americas</td><td>Herrero</td><td> Rolando </td><td>Costa Rican Agency for Biomedical Research</td><td>USA</td></tr><tr><td>The Americas</td><td>Johnson </td><td>Ebony</td><td>Representative from communities of women living with HIV </td><td>USA</td></tr><tr><td>The Americas</td><td>Maza</td><td>Mauricio</td><td> Basic Health International</td><td> El Salvador</td></tr><tr><td>The Americas</td><td>Murillo</td><td>Raul</td><td>Hospital Universitario San Ignacio</td><td>Colombia</td></tr><tr><td>The Americas</td><td> Ogilvie</td><td>Gina</td><td>BC Women's Hospital and Health Centre</td><td>Canada</td></tr><tr><td>The Americas</td><td>Picconi</td><td>Maria Alejandra </td><td>HPV Reference Laboratory, National Institute for Infectious Diseases -</td><td>Argentina</td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya</td><td>ANLIS Dr Malbran University of Washington</td><td>USA</td></tr><tr><td>The Americas</td><td>Reis</td><td>Veronica</td><td>Jhpiego</td><td>USA</td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta </td><td>Bolivian Network of People Living with HIV/AIDS</td><td>Bolivia</td></tr><tr><td>The Americas</td><td>Sahasrabuddhe</td><td>Vikrant </td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Wentzensen </td><td>Nicolas</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>Eastern Mediterranean </td><td> Atif Waqar </td><td>Muhammad </td><td>Aga Khan University Hospital</td><td> Pakistan </td></tr><tr><td>Eastern Mediterranean </td><td>Ghanbari-Motlagh </td><td>Ali</td><td> Ministry of Health </td><td>Iran </td></tr><tr><td>Eastern Mediterranean </td><td>Hashem </td><td>Tarek </td><td>Menofyia University</td><td>Egypt</td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>European</td><td>Bruni</td><td>Laia </td><td>Catalan Institute of Oncology</td><td> Spain </td></tr><tr><td>European </td><td>Boily</td><td>Marie-Claude</td><td>Imperial College London</td><td>United Kingdom of Great Britain and Northern Ireland (United </td></tr><tr><td>European</td><td>Cain </td><td>Joanna</td><td>International Federation of Obstetrics and Gynecology</td><td>Kingdom) United Kingdom</td></tr><tr><td>European </td><td>de Sanjose</td><td> Silvia</td><td>(FIGO) PATH</td><td> Spain</td></tr><tr><td>European </td><td>Mackie</td><td>Anne</td><td>Public Health England Screening and Screening Quality Assurance Service</td><td>United Kingdom</td></tr><tr><td>European</td><td> Petignat </td><td> Patrick </td><td>Hopitaux Universitaires de Geneve</td><td>Switzerland</td></tr><tr><td>European</td><td> Prendiville </td><td>Walter</td><td>International Agency for Research on Cancer (IARC)</td><td>France</td></tr><tr><td>European</td><td>Sasieni</td><td>Peter</td><td>King's College London</td><td>United Kingdom</td></tr><tr><td>European </td><td>Torode </td><td>Julie</td><td>Union for International Cancer Control (UICC)</td><td> Switzerland </td></tr><tr><td>South-East Asia</td><td>Bhatla </td><td>Neerja</td><td>All India Institute of Medical Sciences</td><td>India</td></tr><tr><td>South-East Asia</td><td>Eamratsameekool</td><td>Wachara</td><td>Phanomphrai Community Hospital</td><td>Thailand </td></tr><tr><td>South-East Asia</td><td>Nessa</td><td> Ashrafun </td><td>Bangabandhu Sheikh Mujib Medical University</td><td>Bangladesh</td></tr><tr><td>South-East Asia</td><td>Thinn </td><td>Myint Myint</td><td> Central Women's Hospital</td><td>Myanmar </td></tr><tr><td>Western Pacific</td><td>Luvsandorj </td><td> Bayarsaikhan</td><td>National Cancer Center of Mongolia </td><td>Mongolia</td></tr><tr><td>Western Pacific</td><td>Zhao</td><td>Fanghui</td><td> China Cancer Institute</td><td>China</td></tr></table></body></html> # Representatives from United Nations agencies <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>The Americas</td><td> Engel</td><td> Danielle</td><td>United Nations Population Fund (UNFPA)</td><td>USA</td></tr><tr><td>European</td><td>Shakarishvili</td><td>Anna</td><td>Joint United Nations Programme on HIV/AIDS (UNAIDS)</td><td>Switzerland</td></tr><tr><td>European</td><td>Tenhoope- Bender</td><td> Petra</td><td>UNFPA Switzerland</td><td>Switzerland</td></tr></table></body></html> # External Review Group (ERG) members <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>The Americas</td><td>Meglioli</td><td> Alejandra</td><td>Parenthood Federation/ Western Hemisphere Region</td><td>United Kingdom</td></tr><tr><td>The Americas</td><td>Nogueira</td><td>Angelica</td><td>Federal University of Mina Gerais, Brazilian Society of Medical Oncology</td><td>Brazil</td></tr><tr><td>The Americas</td><td>Schiffman</td><td>Mark </td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Teran</td><td>Carolina</td><td>Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca</td><td>Bolivia</td></tr><tr><td>The Americas</td><td>Trimble</td><td>Ted</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Venegas</td><td>Gino</td><td>Facultad de Medicina, Universidad de Piura</td><td> Peru</td></tr><tr><td>The Americas</td><td>White</td><td>Heather</td><td>Population Services International (PSI)</td><td>USA</td></tr><tr><td>Eastern Mediterranean </td><td>Moawia</td><td>Mohammed</td><td>National Cancer Institute, University of Gezira</td><td> Sudan</td></tr><tr><td>Eastern Mediterranean</td><td>El Hanchi</td><td> Zaki</td><td>National Institute of Oncology, CHU</td><td>Morocco</td></tr><tr><td>European</td><td>Chowdhury</td><td>Raveena</td><td>MSI Reproductive Choices UK</td><td>United Kingdom</td></tr><tr><td>European</td><td>Cubie</td><td>Heather</td><td>University of Edinburgh</td><td>United Kingdom</td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>South-East Asia</td><td>Ghimire</td><td> Sarita </td><td>Nepal Cancer Care Foundation</td><td>Nepal</td></tr><tr><td>South-East Asia</td><td>Shamsunder</td><td> Saritha</td><td>Safdarjung Hospital</td><td>India</td></tr><tr><td>South-East Asia</td><td>Suri</td><td>Vanita</td><td>Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research</td><td>India</td></tr><tr><td>Western Pacific</td><td>Garland</td><td>Suzanne</td><td>University of Melbourne</td><td>Australia</td></tr><tr><td>Western Pacific</td><td>In</td><td>Ha Hyeong</td><td>Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td>Jin-Kyoung</td><td>Oh</td><td>Department of Cancer Control and Population Health Research, National</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td>Myong Cheol</td><td>Lim</td><td>Cancer Center Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr></table></body></html> # Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist supporting guideline development Nancy Santesso Department of Health Research Methods, Evidence and Impact McMaster University, Toronto, Canada Area of expertise: guideline development, systematic reviews, clinical epidemiology # Systematic review teams <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Arbyn</td><td>Marc</td><td>Unit Cancer Epidemiology - Belgian Cancer Centre - Sciensano</td><td>Belgium</td></tr><tr><td>Bouvard</td><td>Veronique</td><td>International Agency for Research on Cancer (IARC)</td><td>France</td></tr><tr><td>Herweijer</td><td>Eva</td><td>Karolinska Institutet</td><td>Sweden</td></tr><tr><td>Indave</td><td>Iciar </td><td>IARC</td><td>France</td></tr><tr><td>Kelly</td><td>Helen</td><td>London School of Hygiene and Tropical Medicine</td><td>United Kingdom</td></tr><tr><td>Lauby- Secretan</td><td>Beatrice</td><td>IARC</td><td>France</td></tr><tr><td>Sauvaget Silva</td><td>Catherine Ronaldo</td><td>IARC Department of Infectious, Tropical</td><td>France Italy </td></tr><tr><td></td><td></td><td>Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella</td><td></td></tr><tr><td>Sundstrom</td><td> Karin</td><td>Karolinska Institutet</td><td>Sweden</td></tr><tr><td>Thaghavi</td><td>Katayoun</td><td>University of Bern</td><td>Switzerland</td></tr></table></body></html> # Modelling team The modelling team supported the development of these guidelines for women in the general population and women living with HIV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The modelling work was performed by the team led by Karen Canfell at Cancer Council NSW, Sydney, Australia (now the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW) using the Policy1-Cervix platform.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The team members are listed in the table below.The modelling team gratefully acknowledges: John Murray from the University of New South Wales, Sydney, who was also involved in the development of the HIV/HPV model used for the evaluation of screening in women living with HIV; Megan Smith from Cancer Council NSW, who contributed to past model development and discussions about model validation for newly emergent technologies; and Susan Yuill from Cancer Council NSW, who contributed to the systematic review of the evidence on HPV triage strategies led by Marc Arbyn of the Belgian Cancer Centre (see Systematic review teams above), which was used to inform the modelling.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "<html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Canfell</td><td> Karen</td><td>The Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW</td><td>Australia</td></tr><tr><td>Caruana</td><td>Michael</td><td>The Daffodil Centre</td><td> Australia</td></tr><tr><td>Hall</td><td>Michaela</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Keane</td><td>Adam</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Killen</td><td>James</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Lui</td><td>Gigi</td><td>The Daffodil Centre</td><td> Australia</td></tr><tr><td>Nguyen</td><td>Diep</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Simms</td><td>Kate</td><td>The Daffodil Centre</td><td>Australia</td></tr></table></body></html> # Costing expertise <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Demke</td><td>Owen</td><td>Clinton Health Access Initiative</td><td>Rwanda</td></tr><tr><td>Gauvreau</td><td>Cindy</td><td>Hospital for Sick Children/ University of Toronto</td><td>Canada</td></tr></table></body></html> # Observers <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Anderson</td><td>Benjamin</td><td>University of Washington</td><td>USA</td></tr><tr><td>Berkhof</td><td>J.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "(Hans)</td><td>Vrije Universiteit</td><td>Netherlands</td></tr><tr><td>de Lussigny</td><td>Smiljka</td><td>Unitaid</td><td>Switzerland</td></tr><tr><td>Franco</td><td>Eduardo</td><td>Division of Cancer Epidemiology, McGill University</td><td>Canada</td></tr><tr><td>Huang</td><td>Lisa Pei-Ching</td><td>Expertise France</td><td>France</td></tr><tr><td>Jafa</td><td>Krishna</td><td>Bill & Melinda Gates Foundation</td><td>USA</td></tr><tr><td>Jerónimo</td><td>José</td><td>Cancer Consulting</td><td>USA</td></tr><tr><td>Kumar </td><td>Somesh</td><td>Jhpiego</td><td>USA</td></tr><tr><td>Lapidos-Salaiz Mesher</td><td>llana David</td><td>United States Agency for International Development (USAID) Public Health England, International Agency</td><td>USA United</td></tr><tr><td>Odayar</td><td>Jasantha</td><td>for Research on Cancer (IARC) University of Cape Town</td><td>Kingdom South Africa</td></tr><tr><td>Parham</td><td>Groesbeck</td><td>University of North Carolina</td><td>USA</td></tr><tr><td>Pérez Casas</td><td>Carmen</td><td>Unitaid</td><td>Switzerland</td></tr><tr><td>Roitberg</td><td>Felipe</td><td>WHO</td><td>Switzerland</td></tr><tr><td>Watts</td><td>Heather</td><td>President's Emergency Plan for AIDS Relief (PEPFAR)</td><td>USA</td></tr></table></body></html> # WHO Secretariat – headquarters members (Geneva, Switzerland) <html><body><table><tr><td>Last name</td><td>First name</td><td>Departments</td></tr><tr><td>Anderson</td><td>Benjamin </td><td>Department of Noncommunicable Diseases </td></tr><tr><td>Bloem</td><td>Paul</td><td>Department of Immunization, Vaccines and Biologicals</td></tr><tr><td>Broutet </td><td>Nathalie</td><td> Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Cortes</td><td>Myriam </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Dalal</td><td>Shona </td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td>Eckert </td><td>Linda </td><td> Department of Sexual and Reproductive Health and Research</td></tr><tr><td>El Sheikh </td><td>Fayad </td><td> Department of Immunization, Vaccines and Biologicals</td></tr><tr><td>Fidarova</td><td>Elena</td><td>Department of Noncommunicable Diseases </td></tr><tr><td>Gottlieb</td><td> Sami</td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Hutubessy </td><td>Raymond</td><td> Department of Immunization, Vaccines and Biologicals</td></tr><tr><td>lbawi</td><td>Andre</td><td>Department of Noncommunicable Diseases </td></tr><tr><td>Khosla</td><td>Rajat </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Kuku </td><td>Stephanie Yetunde</td><td>Department of Digital Health and Innovation</td></tr><tr><td>Narasimhan </td><td>Manjulaa </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Newman</td><td>Morkor</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes</td></tr><tr><td> Purnat </td><td>Tina</td><td>Department of Digital Health and Innovation </td></tr><tr><td>Rangaraj </td><td>Ajay</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td>Riley</td><td>Leanne </td><td>Department of Noncommunicable Diseases</td></tr><tr><td> Sands</td><td>Margaret Anita</td><td> Department of Regulation and Prequalification</td></tr><tr><td>Strher</td><td>Ute</td><td>Department of Regulation and Prequalification</td></tr><tr><td>Velazquez</td><td> Adriana </td><td>Department of Health Product Policy and Standards</td></tr><tr><td>Berumen Vojnov</td><td>Lara </td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes</td></tr><tr><td>Xu</td><td>Hongyi</td><td>Department of Noncommunicable Diseases </td></tr></table></body></html> WHO Secretariat – regional advisers and International Agency for Research on Cancer (IARC) staff <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td></tr><tr><td>African </td><td>Barango</td><td> Prebo</td></tr><tr><td>African </td><td>Dangou</td><td>Jean-Marie</td></tr><tr><td>African </td><td>Lago</td><td>Hugues</td></tr><tr><td>African </td><td> Ouedraogo</td><td>Leopold</td></tr><tr><td>African </td><td>Sebitloane</td><td>Tshidi</td></tr><tr><td>The Americas</td><td> Ghidinelli </td><td> Massimo</td></tr><tr><td>The Americas</td><td>Gomez Ponce de Leon </td><td>Rodolfo </td></tr><tr><td>The Americas</td><td>Luciani </td><td>Silvana</td></tr><tr><td>Eastern Mediterranean</td><td> Gholbzouri</td><td>Karima</td></tr><tr><td>Eastern Mediterranean </td><td>Hermez</td><td>Joumana George</td></tr><tr><td>Eastern Mediterranean </td><td>Slama </td><td>Slim</td></tr><tr><td>European </td><td>Corbex</td><td>Marilys</td></tr><tr><td>European </td><td>Masoud</td><td>Dara</td></tr><tr><td>European </td><td>Smelov </td><td>Vitaly</td></tr><tr><td>South-East Asia</td><td>Dorji</td><td>Gampo</td></tr><tr><td>South-East Asia</td><td>Jayathilaka</td><td> Chandani Anoma</td></tr><tr><td>South-East Asia</td><td>Raina </td><td>Neena</td></tr><tr><td>South-East Asia</td><td>Sharma</td><td>Mukta</td></tr><tr><td>Western Pacific</td><td>Ishikawa</td><td>Naoko</td></tr><tr><td>Western Pacific</td><td>Mannava</td><td> Priya</td></tr><tr><td>Western Pacific</td><td>Shin </td><td>Hai-rim </td></tr><tr><td>Western Pacific</td><td>Sobel </td><td>Howard </td></tr><tr><td>IARC</td><td>Almonte Pacheco</td><td>Maribel </td></tr><tr><td>IARC</td><td>Basu</td><td> Partha</td></tr><tr><td>IARC</td><td>Clifford </td><td>Gary</td></tr><tr><td>IARC</td><td>Lauby-Secretan</td><td>Beatrice</td></tr><tr><td>IARC</td><td>Sauvaget </td><td>Catherine</td></tr></table></body></html> # ANNEX 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "EVIDENCE-GATHERING TEAMS AND GUIDELINE TASK GROUPS <html><body><table><tr><td>PICO 1and 2</td><td>PICO 1and 2</td><td>PICO 3, 4, 5, 6, 7,8</td><td>PIC0 3, 4, 7, 8</td><td>PIC0 9, 10</td></tr><tr><td>Screen- and-treat Screen, triage and treat (follow-up studies)</td><td>Screen- and-treat Screen, triage and treat (diagnostic studies)</td><td>Follow-up after positive or negative tests</td><td>Follow-up after positive or negative tests in women living with HIV</td><td>Duration between test and treatment Treatment of cervical intraepithelial neoplasia</td></tr><tr><td>Lead: Beatrice Lauby-Secretan</td><td>Lead: Marc Arbyn and Helen Kelly </td><td>Lead: Nancy Santesso</td><td>Lead: Karin Sundstrom</td><td>(severity) Lead: Catherine Sauvaget</td></tr><tr><td>Véronique Bouvard Iciar Indave Isabel Mosquera Nicolas Wentzensen IARC handbook Working Group: Marc Arbyn Hans Berkhof</td><td>Karen Canfell Nancy Santesso European Risk group, European Society of Gynaecological Oncology: Partha Basu Paolo Rossi Fanghui Zhao</td><td>Jasantha Odayar Karin Sundstrom Ronaldo Silva</td><td>Eva Herweijer Nancy Santesso Katayoun Taghavi Ronaldo Silva</td><td>Partha Basu Isabel Mosquera Li Zhang</td></tr></table></body></html> PICO: population (P), intervention (I), comparator (C), outcome (O).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "<html><body><table><tr><td>Modelling PIC0 1, 2, 3, 4, 5, 6, 7, 8</td><td>Values and preferences</td><td>Feasibility and implementation</td></tr><tr><td>Lead: Karen Canfell</td><td>Lead: Ajay Rangaraj Advisory group of women living with HIV</td><td>Leads: Patti Gravitt and Nancy Santesso</td></tr><tr><td>Maribel Almonte Ruanne Barnabas Partha Basu lacopo Baussano Marie-Claude Boily Marc Brisson Jane Kim Peter Sasieni Cari VanSchalkwik Brian Williams</td><td>Nathalie Broutet Shona Dalal Linda Eckert Morkor Newman Nancy Santesso Julie Torod</td><td>Case experiences: Prajakta Adsul Maribel Almonte André Carballo Lisa Huang José Jeronimo Somesh Kumar Najat Lahmi</td></tr></table></body></html> PICO: population (P), intervention (I), comparator (C), outcome (O).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "<html><body><table><tr><td>Outcome definitions</td><td>Eligibility for ablation or referral</td><td>Clinical algorithms</td><td>Terminology</td></tr><tr><td>Lead: Partha Basu Maribel Almonte</td><td>Lead: Jose Jeronimo Neerja Bhatla Miriam Cremer Lynette Denny Silvia de Sanjose</td><td>Lead: Partha Basu Maribel Almonte Silvina Arrossi Neerja Bhatla Nathalie Broutet Karen Canfell Z Mike Chirenje Miriam Cremer Shona Dalal</td><td>Lead: Lynette Denny Partha Basu Neerja Bhatla Nathalie Broutet Joanna Cain Lameck Chinula Mike Chirenje Teresa Darragh Linda Eckert Jose Jeronimo Mauricio Maza Raul Murillo</td></tr></table></body></html> # ANNEX 3.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "DECLARATIONS OF INTERESTS <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>African </td><td>Achieng </td><td>Claire Judith Ikate </td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Awori</td><td>Ruth</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td> Chinula </td><td>Lameck </td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td> Chirenje</td><td>Mike</td><td>No interests declared </td><td> Received</td></tr><tr><td>African </td><td>Chung </td><td>Michael</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Denny </td><td>Lynette </td><td>No interests declared </td><td>Received </td></tr><tr><td>African </td><td>Diop</td><td>Mamadou</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Happy </td><td>Margaret</td><td>No interests declared </td><td>Received </td></tr><tr><td>African </td><td>Ingbian</td><td> Priscilla</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Kapambwe</td><td>Sharon</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Motshedisi</td><td>Sebitloane</td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Mugo</td><td>Nelly </td><td>No interests declared </td><td>Received</td></tr><tr><td>African </td><td>Muzingwani</td><td>Laura </td><td>No interests declared </td><td>Received </td></tr><tr><td>African </td><td>Obiri-Yeboah</td><td>Dorcas </td><td>No interests declared </td><td>Received </td></tr><tr><td>African </td><td> Shiferaw </td><td>Netsanet</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>No interests declared</td><td>Received </td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne </td><td>No interests declared</td><td>Received</td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar </td><td>No interests declared </td><td>Received </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>The Americas </td><td>Correa </td><td> Flavia Miranda</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Cremer </td><td>Miriam </td><td>No interests declared </td><td> Received</td></tr><tr><td>The Americas</td><td>Darragh </td><td>Teresa </td><td>No interests declared</td><td>Received </td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Gravitt </td><td> Patti</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Herrero </td><td>Rolando </td><td>No interests declared</td><td>Received </td></tr><tr><td>The Americas</td><td> Johnson</td><td>Ebony</td><td>No interests declared </td><td>Received</td></tr><tr><td>The Americas</td><td>Maza</td><td>Mauricio</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Murillo</td><td>Raul</td><td>No interests declared </td><td>Received</td></tr><tr><td>The Americas</td><td> Ogilvie</td><td>Gina </td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td> Picconi</td><td>Maria Alejandra</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Reis</td><td>Veronica</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta</td><td>No interests declared </td><td> Received</td></tr><tr><td>The Americas</td><td>Sahasrabuddhe</td><td>Vikrant</td><td>No interests declared </td><td>Received </td></tr><tr><td>The Americas</td><td>Wentzensen</td><td>Nicolas</td><td>No interests declared </td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Atif Waqar </td><td>Muhammad</td><td>No interests declared </td><td>Received </td></tr><tr><td>Eastern Mediterranean </td><td>Ghanbari-Motlagh</td><td>Ali</td><td>No interests declared </td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Hashem</td><td>Tarek </td><td>No interests declared </td><td>Received </td></tr><tr><td>European </td><td>Bruni</td><td>Laia</td><td>No interests declared </td><td>Received </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>European</td><td>Boily</td><td>Marie-Claude</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td>Cain</td><td>Joanna </td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td>de Sanjose</td><td> Silvia</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td>Mackie</td><td>Anne</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td>Petignat </td><td>Patrick</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td> Prendiville</td><td>Walter</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td> Sasieni</td><td> Peter</td><td>No interests declared</td><td>Received</td></tr><tr><td>European</td><td>Torode</td><td>Julie</td><td>No interests declared</td><td>Received</td></tr><tr><td>South-East Asia</td><td>Bhatla</td><td>Neerja</td><td>No interests declared</td><td>Received</td></tr><tr><td>South-East Asia</td><td>Eamratsameekool </td><td>Wachara</td><td>No interests declared</td><td> Received</td></tr><tr><td>South-East Asia</td><td>Nessa</td><td> Ashrafun</td><td>No interests declared</td><td>Received</td></tr><tr><td>South-East Asia</td><td>Thinn</td><td>Myint Myint</td><td>No interests declared</td><td>Received</td></tr><tr><td>Western Pacific Western Pacific</td><td>Luvsandorj Zhao</td><td>Bayarsaikhan Fanghui</td><td>No interests declared No interests declared</td><td>Received Received</td></tr></table></body></html> # ANNEX 4.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "SEVEN ALGORITHMSPRIORITIZED FOR PHASE 1 OF THEGUIDELINE UPDATE Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/4c6769257be447a6ce3d325114afa297934a117ae5d7427bdb248afb540bc879.jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "![](images/0d2c0b94cf3311d6697598896dc3384f4d3c8c8c7a178ae5abb06681d2388e42.jpg) # Screen-and-treat approaches: 1.Visual inspection with acetic acid (VIA) as the primary screening test, followed by treatment 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV DNA (self- or clinician-collected) as the primary screening test, followed by treatment # Screen, triage and treat approaches: 3.Cytology as the primary screening test, followed by colposcopy triage, followed by treatment 4.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "HPV DNA as the primary screening test, followed by HPV16/18 triage (when already part of the HPV test), followed by treatment, and using VIA triage for those who screen negative for HPV16/18 5.HPV DNA as the primary screening test, followed by VIA triage, followed by treatment 6.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "High-risk HPV DNA as the primary screening test, followed by colposcopy triage, followed by treatment 7.HPV DNA as the primary screening test, followed by cytology triage, followed by colposcopy and treatment # ALGORITHM 1.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "PRIMARY VIA SCREENING (SCREEN-ANDTREAT APPROACH) For both the general population of women and women living with HIV ![](images/4f54199fb6d632017c3e4aeebe28192e209407059e1f4ac9ac350cb07a163e6e.jpg) # ALGORITHM 2.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "PRIMARY HPV DNA TEST SCREENING(SCREEN-AND-TREAT APPROACH) For the general population of women ![](images/4918737cc8adf6408d849fa3c0aa7fbc927680a8556b22cfa2312df6f8a91a25.jpg) a Ablative treatment includes cryotherapy and thermal ablation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "b Cold knife conization (CKC) if LLETZ not available.c LLETZ and LEEP (loop electrosurgical excision procedure) indicate the same procedure.d Histology may not be available in certain settings; women should be advised to attend follow-up after 1 year or to report earlier, if they have any of the symptoms of cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "AIS: adenocarcinoma in situ; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; LLETZ: large-loop excision of the transformation zone.# ALGORITHM 3.PRIMARY CYTOLOGY SCREENING AND COLPOSCOPY TRIAGE (SCREEN, TRIAGE AND TREAT APPROACH) For both the general population of women and women living with HIV !",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[](images/daedb1f6ec02050a1e0ab2dfd59effbbff56248e032a73e68c4049be2d83fa4b.jpg) # ALGORITHM 4.HPV DNA SCREENING AND HPV16/18 TRIAGE (SCREEN, TRIAGE AND TREAT APPROACH) For both the general population of women and women living with HIV !",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[](images/d368254cdf9e3defc7b29d03546632add01d37b27698ba7ff968806e99aee4c1.jpg) # ALGORITHM 5.PRIMARY HPV DNA SCREENING AND VIA TRIAGE (SCREEN, TRIAGE AND TREAT APPROACH) For both the general population of women and women living with HIV !",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "[](images/3249f90631866528c06ed37f7ddd6d163d2005e65b85028cb0b6de064321a1af.jpg) a Ablative treatment includes cryotherapy and thermal ablation.b Cold knife conization (CKC) if LLETZ not available.c LLETZ and LEEP (loop electrosurgical excision procedure) indicate the same procedure.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "d Histology may not be available in certain settings; women should be advised to attend follow-up after 1 year or to report earlier, if they have any of the symptoms of cervical cancer.AIS: adenocarcinoma in situ; CIN: cervical intraepithelial neoplasia; HPV: human papillomavirus; LLETZ: large-loop excision of the transformation zone; VIA: visual inspection with acetic acid.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# ALGORITHM 6.PRIMARY HPV DNA SCREENING AND COLPOSCOPY TRIAGE (SCREEN, TRIAGE AND TREAT APPROACH) For both the general population of women and women living with HIV ![](images/1226fb9b876b9120a155e4ddc2c58ded04d1ac6e24e0a8838d7e90ed8288d3eb.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) # ALGORITHM 7.PRIMARY HPV SCREENING AND CYTOLOGY TRIAGE FOLLOWED BY COLPOSCOPY (SCREEN, TRIAGE AND TREAT APPROACH) For both the general population of women and women living with HIV ![](images/190f5c71d900641b219fc8ed23ab00337ee70b9b1e46ed8d47184d6dbd46924f.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) # FOLLOW-UP TESTS AT 12 MONTHS POST-TREATMENT FOR THE GENERAL POPULATION OF WOMEN If treated with ablation or LLETZ without histopathology ![](images/890d850b90b779f89da45d95133448a721abc6b0badd888d37d393b4bea1f5c0.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) # FOLLOW-UP TESTS AT 12 MONTHS POST-TREATMENT FOR WOMEN LIVING WITH HIV ![](images/232184a96fa682cb028979fe1cef4971776dc1f4c2668d80fd98665f01667d37.jpg) # ANNEX 5.STANDARDIZED DEFINITIONS USED IN THIS GUIDELINE # 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1.Eligibility for ablative treatment Women who screen positive with a human papillomavirus (HPV) nucleic acid amplification test (NAAT) are assessed for eligibility for ablative treatment so that women with or without a visible lesion (or lesions), who are eligible for ablation, can receive an ablative treatment (see section 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "1.2).An assessment of eligibility for ablative treatment is done by identifying the transformation zone type (i.e.the visibility and position of the transformation zone) (see section 5.1.1), and the location and size of the lesion if the patient has a visible lesion.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "To assess eligibility, visualization of the cervix with magnified or naked-eye view after application of $3 - 5 \\%$ acetic acid is required; histological diagnosis is not required.![](images/38e38a6f695114bb21ab8752af45521c51bd351107b328213da2f137adccabe9.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "jpg) Algorithm to determine eligibility for ablative treatment # 5.1.1.Types of transformation zone (section 5.5)1 On evaluation, the visibility and position of the transformation zone can be described as: Type 1: The entire transformation zone is visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The transformation zone is entirely visible and only ectocervical.Type 2: The entire transformation zone is visible.The transformation zone is entirely visible and has an endocervical component.Type 3: The transformation zone is not entirely visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The transformation zone extends into the endocervical canal and is not fully visible.# 5.1.2.Criteria for eligibility for ablative treatment1 There is no suspicion of invasive cancer or glandular disease (i.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "e.adenocarcinoma or adenocarcinoma in situ, AIS).The transformation zone is fully visible, the whole lesion is visible, and it does not extend into the endocervix.The lesion is type 1 transformation zone.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Interventions may be constrained by feasibility, training, programme quality-assurance and resources.In the absence of certain infrastructure, such as the availability of large-loop excision of the transformation zone (LLETZ) or of safe surgical settings, bridging strategies may be considered in carefully selected circumstances, to extend access to treatment rather than provide no treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "For example, ablation may be an option for a carefully chosen, small type 2 transformation zone where the probe tip will achieve complete ablation of the squamocolumnar junction epithelium – that is, where it can reach the full extent, depth and upper limit of the transformation zone – and where adequate training for selection and follow-up is available.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 5.1.3.Criteria for referral1 There is any suspicion of invasive cancer or glandular disease (i.e.adenocarcinoma or AIS).The transformation zone is not fully visible because it is endocervical (type 2 or 3 transformation zone).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 5.2.Outcome definitions # 5.2.1 Persistent, residual or recurrent disease (histopathologically verified) Definition: Persistent or residual disease is the detection of a histopathological high-grade lesion – including histological high-grade squamous intraepithelial lesions (HSIL) as per LAST terminology2 (HSIL-cervical intraepithelial neoplasia grade 2 [CIN2] and HSIL-CIN3); high-grade CIN as per CIN terminology (CIN2 and CIN3); HSIL not specified; and AIS – diagnosed from a punch biopsy or a subsequent surgical specimen (including hysterectomy, cold knife conization [CKC] and LLETZ) at any time interval after the initial treatment was performed with no intervening documented absence of disease.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Persistent or residual disease excludes cancers that have been confirmed after diagnosis with surgical specimen.Recurrent disease is defined as detection of a histopathological high-grade lesion (as described above) that was diagnosed from a biopsy or a subsequent surgical specimen (including hysterectomy, CKC and LLETZ) following a documented absence of high-grade lesions at any time interval after the initial treatment was performed.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Caveats: Studies have used the terms “persistent/residual disease” and “recurrence” to indicate the detection of disease post-treatment without making any distinction between them.Sub-analysis may be considered to distinguish between them.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, both conditions are treatment failures.Some studies use the terms “cure” or “treatment success” to indicate the absence of persistent/ residual/recurrent disease following initial treatment and have estimated the rates.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The specific location of the lesion on the cervix detected at follow-up is not important since the aim of the treatment of cervical pre-cancer is to treat the entire transformation zone and not any particular lesion.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Any lesion detected at follow-up should be considered as representing treatment failure.The final diagnosis is the worst outcome found on histopathology.Symptoms: Non-specific.Consequences: Patient needs retreatment for high-grade lesions; adverse psychological impact; resource implications (including cost, human resources, hospital services).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Different studies may use different assessment protocols at follow-up.Some studies may take random punch biopsies from all the treated women undergoing follow-up.Other studies may have considered negative HPV test, cytology, VIA or normal colposcopy as evidence of absence or persistent/residual/recurrent disease.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Such studies do biopsies only on selected patients who are positive on HPV test, cytology, VIA and/or colposcopy.These different methods of assessment should not exclude any studies, but a sensitivity analysis should then be conducted.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Diagnosis of cancer at follow-up should ideally be excluded from verification of treatment outcome, as cancer should have been ruled out at baseline diagnosis.Threshold: HSIL-CIN2 and HSIL-CIN3; high-grade CIN as per CIN terminology (CIN2 and CIN3); HSIL not specified; AIS.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Some studies may consider low-grade squamous intraepithelial lesions (LSIL) or CIN1 as the threshold.Data that use ${ \\mathsf { L S l L } } +$ or ${ \\mathsf { C l N 1 + } }$ as the threshold should not be included but, if presented separately, data for HSIL-CIN2+ should be used.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Treatment: Treatment of recurrent or persistent HSIL/CIN2/CIN3 includes LLETZ or ablation (depending on the eligibility for ablation and the availability of treatment techniques).AIS is treated by LLETZ or CKC.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Such treatment may be administered by a colposcopist, a general practitioner or a nurse.Time horizon: In assessing research, the presence of disease should be measured beyond six months after treatment – and 1–3 years is preferred.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A sensitivity analysis should exclude six months.Recurrence may be detected several years after treatment.5.2.2 Persistent, residual or recurrent disease (not histopathologically verified) Definition: Persistence or residual disease may be defined as a positive follow-up screening test (e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.VIA, HPV test or cytology) at any time after the initial treatment.The women with positive tests were not further verified by histopathology.This is usually applicable in settings that use screen-and-treat approaches.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Recurrent disease may be defined as a positive follow-up screening test (e.g.VIA, HPV test or cytology) following a documented negative test at any time after the initial treatment in a screen-and-treat approach setting.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There was no histopathological verification after a positive follow-up screening test.Caveats: Studies have used the terms “persistent/residual disease” and “recurrence” to indicate the detection of disease post-treatment without making any distinction between them.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Sub-analysis may be considered to distinguish between them.However, both conditions are treatment failures.Symptoms: Non-specific.Consequences: Patient needs retreatment, or verification with colposcopy and/or histopathology; adverse psychological impact; resource implications (including cost, human resources, hospital services).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Usually the same screening test at baseline is used to detect persistent/residual/ recurrent disease at follow-up.HPV type-specific persistence/recurrence (detection of same HPV genotype at different time points) may be studied with an appropriate HPV detection test.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Threshold: The cytology threshold may vary between atypical squamous cells of uncertain significance (ASCUS), LSIL and HSIL.Ideally, HSIL should be used (LSIL could be used if identified).Other thresholds: VIA-positive and HPV-positive tests (any high-risk type detected by a validated HPV test).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Treatment: Treatment may include ablation or excision.Such treatment may be administered by a colposcopist, a general practitioner or a nurse.Time horizon: In assessing research, the presence of disease should be measured beyond six months of treatment – and 1–3 years is preferred.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There should be a sensitivity analysis to exclude six months.Recurrence may be detected several years after treatment.# 5.2.3 Incidence of histopathological high-grade lesions and cancers Definition: New (incident) cases of histopathological high-grade lesions and cancers $\\mathrm { \\langle H S | L + }$ or $C \\mathsf { I N } 2 + \\mathsf { ) }$ detected following treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This includes histological HSIL as per LAST terminology (HSIL-CIN2 and HSIL-CIN3); high-grade CIN as per CIN terminology (CIN2 and CIN3); HSIL not specified; AIS, invasive squamous cell cancer, adenocarcinoma, carcinoma unspecified.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "All categories are combined together as HSIL $\\cdot +$ or $\\mathsf { C l N } 2 +$ .Symptoms: Non-specific.Consequences: Patient needs treatment for high-grade lesions or invasive cancer; adverse psychological consequences; resource implications (including cost, human resources, hospital services).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: New cases are detected either through linkage with the screening registry or by active follow-up of the screening cohort.The treated women without any disease at first follow-up are advised to attend regular screening.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Further evaluation and histopathology are performed if the screening test is positive (any screening tests at any follow-up visit).Rates of ${ \\mathsf { H S I L } } +$ or $\\mathsf { C l N } 2 +$ may be computed by each year since the index treatment on the basis of the number of women under active surveillance, with the number of women in active surveillance diagnosed with CIN2/3 in that year divided by the number in active surveillance screened in that year.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The cumulative rates of $\\mathsf { H S I L + }$ or $\\mathsf { C l N } 2 +$ or of invasive cancer alone may be estimated as number per 100 000 person-years of observation.Threshold: The studies may have used $H S l L + / C | N 2 +$ or $\\mathsf { C l N 3 + }$ (HSIL-CIN3/CIN3, AIS, invasive cancer) or only invasive cancer as the end point.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The studies should be analysed separately.Treatment: The treatment of high-grade lesions requires ablation or excision depending on eligibility.AIS/microinvasive cancer requires excision (CKC or LLETZ).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Such treatment may be administered by a colposcopist, a general practitioner or a nurse.Invasive cancer needs radical surgery or radiation therapy in a specialized setting.Additional testing for metastasis may be needed in patients with invasive cancers.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: Incident CIN/cancer may be detected between six months and several years after treatment.5.2.4 Incidence of cervical cancer (includes squamous cell carcinoma, adenocarcinoma or invasive cancer unspecified) Definition: Newly diagnosed cases of invasive cervical cancer in the population under consideration within a defined time period, typically at least six months after screening and treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Symptoms such as vaginal discharge, irregular bleeding, pain.Consequences: Needs further investigations and treatment; adverse psychological consequences; disability; may be fatal, depending on stage at diagnosis; resource implications (including cost, human resources, hospital services).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: The new cases of cancers are histopathologically diagnosed through active follow-up and/or linkage to the screening registry and/or population-based cancer registry.The incidence is usually documented as number per 100 000 person-years of observation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Surgery or radiation therapy with concomitant chemotherapy, depending on stage.Time horizon: Any time after initial treatment of premalignant lesions.5.2.5 Mortality from cervical cancer (includes squamous cell carcinoma, adenocarcinoma or unspecified invasive cancer) Definition: Deaths reported from cervical cancer in the population under consideration following treatment within a defined time period.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Not applicable.Assessed by: Linkage with the population-based cancer registry and mortality databases, active follow-up.Thresholds: Not applicable.Treatment: Not applicable.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: Any time following treatment.# 5.2.6 Coverage of treatment # a.Treatment coverage Definition: The proportion of eligible women treated in a population.The number of women completing treatment in a defined time frame divided by the total number of screen-positive women who were eligible to be treated in the same time frame and multiplied by 100; the time frame is not usually more than 12 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: A low proportion of treatment will increase the risk of individual women detected with invasive cancer dying from the disease; low coverage will also prevent the screening programme from having the desired impact on cervical cancer incidence and mortality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Data collected through an information system/screening registry, with linkage between screening and treatment services.Thresholds: None; the higher the value, the better the impact.Treatment: Not applicable.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: 12 months.# b.Treatment rate Definition: The proportion of eligible women treated in a study.The number of women who were treated divided by the number of women who were eligible to be treated.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Higher rates of treatment will increase the chances that the programme will have the desired impact on cervical cancer incidence and mortality.Assessed by: Data will be recorded during the study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Cryotherapy, thermal ablation, LLETZ, referral.Time horizon: Duration of the study.# 5.2.7 Same-day treatment rate # a.Population-level same-day treatment rate Definition: Same-day treatment rate in a screen-and-treat approach setting is the number of eligible women treated on the same day of screening in a defined time frame divided by the total number of screen-positive women who are eligible for treatment on the same day during the same time frame and multiplied by 100.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Low compliance will increase the risk of being detected with invasive cancer, and of death from invasive cancer; low compliance will also prevent the screening programme from having the desired impact on cervical cancer incidence and mortality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Systematic data collection; health information system.Thresholds: Not applicable.Treatment: Not applicable.Time horizon: Same day or same visit.# b.Study-level same-day treatment rate Definition: The proportion of eligible women treated in a study on the same day in a screen-and-treat approach setting.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This is the number of women who were treated on the same day divided by the number of women who were eligible to be treated on the same day.Symptoms: Not applicable.Consequences: Higher rates of treatment will increase the chances that the programme will have the desired impact on cervical cancer incidence and mortality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Data will be recorded during the study.Thresholds: Not applicable.Treatment: Cryotherapy, thermal ablation, LLETZ, referral.Time horizon: Duration of the study.# 5.2.8 Coverage of screening # a.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Screening coverage Definition: At the population level, the cervical cancer screening coverage is the number of screening-eligible women undergoing screening in a defined time frame divided by the total number of screening-eligible women during the same time frame and multiplied by $1 0 0 ;$ the time frame is equal to the defined screening interval or the reporting period.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Low screening coverage will increase the risk of individual women detected with invasive cancer, and dying from invasive cancer; low coverage will also prevent the screening programme from having the desired impact on cervical cancer incidence and mortality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Data may be collected through an information system/screening registry or a survey.As population-based denominators are difficult to compare across studies, these data should be abstracted.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Not applicable.Time horizon: Each programme has its own cycle of estimating coverage, ranging from one year to five years, but calculating annually is preferable.# b.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Rate of participation in screening Definition: At the study level, the rate of participation in screening is the number of screeningeligible women who were screened divided by the number of women who were invited to participate in a screening programme and multiplied by 100.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Higher rates of participation will increase the chances that a screening programme will have the desired impact on cervical cancer incidence and mortality.Assessed by: Data will be recorded during the study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Not applicable.Time horizon: Duration of the study.# 5.2.9 Treatment side-effects and complications Definition: A complication is a condition or an event unfavourable to the patient’s health, causing irreversible damage or needing a change in therapeutic approach, including prolonged hospital stay.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Side-effects are unwanted symptoms due to treatment that are mostly temporary and resolve spontaneously.These two terms are often used interchangeably.Complications are graded as grade I (no pharmacological treatment or surgical intervention other than mild analgesics, antipyretics or antiemetics needed), grade II (needing pharmacological treatment, including intravenous fluid or blood transfusion), grade III (needing surgical intervention, e.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "g.cervical stiches), grade IV (life-threatening) and grade V (death).Most studies evaluating cervical pre-cancer treatment do not use such systematic classification or distinguish clearly between side-effects and complications.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The most commonly evaluated significant treatment complications are described below.The proportion of treated women having one or several of these complications is assessed.# a.Major infections (grade II+) Definition: Post-operative infection of the genital tract needing antibiotics and/or hospital admission.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Systemic: fever, nausea, vomiting, dehydration; local: foul-smelling discharge, pain.Consequences: Hospitalization, antibiotic therapy, loss of workdays, psychological harm, long-term sequelae such as infertility, chronic pelvic inflammatory disease.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: The diagnosis of major infection is mostly based on history and clinical assessment during follow-up.Acute pelvic inflammatory disease (presence of fever and/or lower abdominal pain and/or foul-smelling purulent vaginal discharge and/or adnexal tenderness and/or pain during cervical movement) is included in major infection.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The diagnosis of major infection can also require blood tests, ultrasound and/or culture/sensitivity testing to adjust treatment.Thresholds: Minor infections causing vaginal discharge and mild pain are often indistinguishable from side-effects and are not usually considered.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Major infections can be distinguished from minor infections as they may include foul-smelling discharge plus other signs such as fever, tenderness on examination or severe pain.Treatment: Hospitalization, antibiotics and rehydration, depending on the severity of the condition.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: Usually 3–4 days after treatment and within one month; may take a few days to a few weeks to recover.# b.Major bleeding (grade II+) Definition: Post-operative bleeding needing intervention (vaginal packing, cervical sutures), with or without hospitalization, with or without intravenous fluid or blood transfusion.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Vaginal bleeding, usually with the passage of clots, with or without pain.May have symptoms due to hypotension and shock (weakness, giddiness, vomiting, loss of consciousness).Consequences: Shock, death in severe cases; may lead to anaemia; psychological harms; loss of workdays.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: History and clinical examination, routine blood tests.Thresholds: Major bleeding may be distinguished from minor bleeding as major bleeding may be accompanied by the passage of clots, a fall in blood pressure and/or significant drop in haemoglobin levels, or it may require intervention, such as vaginal packing or cervical sutures.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Treatment: Hospitalization followed by vaginal packing and antibiotics, and treatment of any shock; stitches may sometimes be needed under anaesthesia, and very rarely hysterectomy will be needed.Time horizon: During the treatment and within one month of treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Recovery depends on severity – bleeding usually stops within a few days.c.Procedure-associated pain Symptoms: Pain, lower abdominal cramps during and/or immediately after the procedure.Consequences: Medications; psychological harm; loss of workdays.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Feedback from the patient using a visual assessment scale; assessment by the treatment provider.Thresholds: Exceeds pain that is mild and tolerable or the pain experienced during normal menstrual cycles.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Treatment: Analgesics advised depending on the severity of the pain.Time horizon: During the procedure and up to one week after.# d.Cervical stenosis Definition: Narrowing of the endocervical canal of the cervix to the extent that a cotton bud/swab or a uterine sound (diameter 3 mm) cannot be introduced.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: May lead to dysmenorrhoea (rare) and/or haematocolpos.Consequences: Dysmenorrhoea, decreased fertility (no consistent evidence), difficulty in obtaining endocervical samples during screening, difficulty in VIA or colposcopic assessment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Clinical examination Thresholds: Not applicable.Treatment: May need dilatation of cervix.Time horizon: Up to three years.# e.Spontaneous abortions Definition: Clinically recognized spontaneous pregnancy loss before 20 weeks of gestation, or spontaneous expulsion of an embryo or fetus weighing 500 g or less.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Also referred to as miscarriage.Symptoms: In pregnant women, spotting, bleeding, pain, passage of fleshy mass through the vagina.Consequences: Loss of pregnancy, hospitalization, psychological harm, loss of workdays.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: History, clinical examination and ultrasound, or as reported by the patient, which may be less reliable.Thresholds: Pregnancy may or may not be confirmed.Treatment: Bed rest, hospitalization, tocolytic medications, evacuation in the case of incomplete abortion.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: Not applicable.f.Premature rupture of membranes Definition: Rupture of membrane before the onset of labour at any gestational age (also known as pre-labour rupture of membranes).Symptoms: Watery vaginal discharge in later gestational ages not associated with other signs of labour.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Consequences: Preterm labour, low birthweight, perinatal death, hospitalization, caesarean section, psychological harms.Assessed by: Clinical examination, ultrasound, tests to detect amniotic fluid.Thresholds: Not applicable.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Treatment: Bed rest, fetal monitoring, induction of labour, caesarean section.Time horizon: Not applicable.g.Preterm birth (early/late) Definition: Delivery of fetus before 37 weeks of pregnancy.Early preterm birth is delivery before completion of 32 weeks of gestation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Hospitalization, tocolytics, caesarean section, low birthweight, perinatal loss, psychological harms.Assessed by: Gestational age is not always accurately determined; the best accuracy is obtained by ultrasound, but gestation could be clinically assessed or self-reported.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Vaginal delivery or caesarean section.Time horizon: Not applicable.# h.Perinatal deaths Definition: Death during the perinatal period between 22 completed weeks (154 days) of gestation and 7 days after birth.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Not applicable.Assessed by: Standard definition as available from medical provider, but may be assessed by individual report, which is not confirmed by a medical provider.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Not applicable.Time horizon: Not applicable.# i.Infertility Definition: Women of reproductive age (15–49 years) at risk of becoming pregnant (not pregnant, sexually active, not using contraception and not lactating) who report trying unsuccessfully for a pregnancy for 12 months or more of regular unprotected sexual intercourse.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: No pregnancy.Assessed by: Self-reported.Thresholds: Unsuccessful in becoming pregnant at 12 months.Treatment: Various treatments can be provided to improve the chance of conception.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: After treatment but before the first pregnancy following treatment.# $j _ { \\ast }$ Stigmatization Definition: Stigma is a mark of disgrace associated with a particular circumstance or quality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Stereotypes, prejudice and discrimination are the main components of any type of stigma.Also, as defined by study authors.Symptoms: Experience of fear, avoidance, depression, and so on.Consequences: Stigma generally causes social and psychological harms, and may cause physical harm to the individual.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The consequences include social isolation, intimate partner abuse, negative personal image, altered health-seeking behaviour.Assessed by: There is no standardized tool.Assessment may be qualitative, by questionnaire surveys or the use of scales to measure stigma, which could be continuous or dichotomous.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: To be determined.Treatment: Community education and support for the individual experiencing stigma.Time horizon: Any time after the receipt of screening results or after treatment.k.Increased viral shedding in women living with HIV Definition: Detection of HIV RNA in the genital tract of women living with HIV with or without detectable plasma viral loads.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Infection of non-infected partner.Assessed by: mRNA-based viral load detection from vaginal fluid.Thresholds: Vary from 40–200 copies per sample.Treatment: None.Time horizon: Usually estimated at baseline and then at 2 to 14 weeks at variable intervals.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 5.2.10 Acceptability by women, providers or programme managers Definition: The extent to which women receiving a screening test and/or treatment intervention consider it to be appropriate, based on anticipated or experienced cognitive and emotional responses to the intervention.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This is a multicomponent construct based on an individual’s experience with side-effects, convenience, and perceived satisfaction with treatment and with services.It is also the extent to which providers and programme managers providing a screening test and/or treatment intervention consider it to be appropriate.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Authors’ definitions of acceptability may also be used.Symptoms: Not applicable.Consequences: Better compliance with future screening and treatment, better community acceptance, better provision of screening and treatment interventions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Questionnaires assessing the intensity of side-effects and complications, the level of satisfaction with the procedure and the services, and whether the treated person would recommend the services to others; visual scales are often used.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Scales may be dichotomized into acceptable or not acceptable.Treatment: Not applicable.Time horizon: May be immediately after treatment and/or during follow-up visits.# 5.2.11 Screening test performance # a.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Positive predictive value (PPV) to detect HSIL $^ { , + , }$ CIN2+ or CIN3+ Screen-and-treat studies usually report the outcomes only in the screen-positive women.Some of these studies may include cervical biopsy prior to administering ablative treatment.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Such studies will allow an estimation of the PPV of the screening test to detect HSIL+, CIN2+ or $\\mathsf { C l N 3 + }$ .The PPV to detect $\\mathsf { H S I L + }$ or $\\mathsf { C l N } 2 +$ is the number of histopathological high-grade lesions – includes histological HSIL as per LAST terminology (HSIL-CIN2 and HSIL-CIN3); high-grade CIN as per CIN terminology (CIN2 and CIN3); HSIL not specified; AIS – divided by the total number of women who tested positive and had satisfactory histopathology results and multiplied by 100.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The PPV is directly related to overtreatment.Overtreatment rate: The number of treated women without any CIN or AIS, on histopathology report made available after treatment, divided by the total number of women treated and with histopathology report available after treatment and multiplied by 100.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "b.Sensitivity, specificity and negative predictive value (NPV) to detect HSIL+, CIN2+ or CIN3+ Screen-and-treat studies will rarely have these accuracy statistics because the screen-negative populations are not further evaluated, but it is ideal if sensitivity, specificity and the NPV are provided.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 5.3 Outcome definitions: outcomes that required modelling 5.3.1 Modelled number of true positives, false positives, true negatives and false negatives to detect histopathologically verified HSIL+, CIN2+ or CIN3+ For example, screening with HPV test at a three-year interval compared with a five-year interval may detect few true positives, and at the cost of detecting a larger number of false positives.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "# 5.3.2 Reduction in incidence of cervical cancer (squamous cell carcinoma or adenocarcinoma or cancer unspecified) over time Definition: Reduction in the rate of newly diagnosed cases of cervical cancer in the population under consideration over a defined time period.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Not applicable.Assessed by: The new cancer cases are histopathologically diagnosed through active follow-up and/or linkage to the screening registry and/or the population-based cancer registry.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Not applicable.Time horizon: Reduction in incidence may be observed over 5–10 years.# 5.3.3 Reduction in mortality from cervical cancer over time Definition: Reduction in the rate of deaths from cervical cancer following treatment, within a defined time period, reported in the population under consideration.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Not applicable.Assessed by/with: Linkage with the population-based cancer registry or the mortality databases, active follow-up.Thresholds: Not applicable.Treatment: Not applicable.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: Reduction in mortality may be observed over 5–10 years.# 5.3.4 Cervical cancer and death from the disease The biggest negative impact of extending the interval between routine screening tests is cervical cancer and possible deaths from cervical cancer occurring in the interval.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The most important consideration for defining an appropriate screening interval is to prevent such cancers and/or deaths.This kind of evidence can come only from modelling studies.# 5.3.5 Cost and resource implications (load on services) Every round of screening has its cost.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Too-frequent screening will have a cost not only in the screening services, but also the associated false-positive diagnoses, overtreatment, and so on.# 5.3.6 Number of screening tests provided Likely calculated from modelling.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "5.3.7 Coverage of screening As above (see section 5.2.8a).# 5.3.8 Coverage of treatment As above (see section 5.2.6a).5.3.9 Acceptability by the women, providers or programme managers As above (see section 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "2.10).# 5.3.10 Unnecessary interventions or overtreatment Definition: Every round of screening is associated with unnecessary interventions such as colposcopy and biopsy (on women who received false-positive results) and overtreatment (treated but no CIN detected on histopathology; treated for CIN, many of which will not progress).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Side-effects and complications of biopsy and treatment, including psychological harms and resource implications.Assessed by: To be estimated based on the false-positive rate of the screening test and colposcopy (since it is unlikely to be measured in studies); rate of progression of different grades of CIN are available from some of the natural history studies.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Threshold: Not applicable.Treatment: Not applicable.Time horizon: Depends on the interval being considered.# 5.3.11 Consequential harms See harms as above (see section 5.2.9).# 5.4 Treatment definition # 5.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "4.1 Treatment coverage Definition: The proportion of eligible women treated in a population.The number of women completing treatment in a defined time frame divided by the total number of screen-positive women who were eligible to be treated in the same time frame and multiplied by 100; the time frame is not usually more than 12 months.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: A low proportion of treatment will increase the risk of individual women being detected with invasive cancer, and of death from invasive cancer; low coverage will also prevent the screening programme from having the desired impact on cervical cancer incidence and mortality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Assessed by: Data collected through an information system/screening registry with linkage between screening and treatment services.Thresholds: None; the higher the value, the better the impact.Treatment: Not applicable.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Time horizon: 12 months.# 5.4.2 Treatment rate Definition: The proportion of eligible women treated in a study.The number of women who were treated divided by the number of women who were eligible to be treated.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Symptoms: Not applicable.Consequences: Higher rates of treatment will increase the chances that the programme will have the desired impact on cervical cancer incidence and mortality.Assessed by: Data will be recorded during the study.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thresholds: Not applicable.Treatment: Cryotherapy, thermal ablation, LLETZ, referral.Time horizon: Duration of the study.# 5.4.3 Treatment intervention Therapeutic intervention: A treatment for a diagnosed cervical lesion with the intention of completely removing the transformation zone either through ablation or excision.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This is when there are no contraindications to ablation or local excision.Diagnostic intervention: A procedure intended to obtain more tissue for analysis to guide further therapy.# 5.4.4 Cervical anatomical description for treatment Transformation zone: The region of the cervix where the columnar epithelium has been replaced and/or is being replaced by metaplastic squamous epithelium (squamous metaplasia).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This corresponds to the area of the cervix bound by the original squamocolumnar junction, and proximally by the furthest extent that squamous metaplasia has occurred, as defined by the new squamocolumnar junction.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Types of transformation zone: On evaluation, the visibility and position of the transformation zone can be described as: Type 1: The entire transformation zone is visible.The transformation zone is entirely visible and only ectocervical.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Type 2: The entire transformation zone is visible.The transformation zone is entirely visible and has an endocervical component.Type 3: The transformation zone is not entirely visible.The transformation zone extends into the endocervical canal and is not fully visible.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Squamocolumnar junction (SCJ): the region of the cervix where the surface squamous epithelium is in continuity with the surface columnar epithelium.This varies over a woman’s lifetime.The zone between the original SCJ and the new SCJ undergoes squamous metaplasia, creating a transformation zone.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The new SCJ defines the proximal border of the transformation zone.# Figure: Transformation zone (TZ) types ![](images/14a5426b3b751254cf3b1151dd75e6a8e4800393ca5268e02c625158ee8522a5.jpg) Source: Colposcopy and treatment of cervical precancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "IARC Technical Publication No.45.Lyon: International Agency for Research on Cancer; 2017.Annex 1, p.157 (https://publications.iarc.fr/555).Shared with permission.# 5.4.5 Methods of treatment for preinvasive cervical disease Large-loop excision of the transformation zone (LLETZ): An excisional method for the treatment of CIN.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "A wire loop electrode powered by an electrosurgical unit (ESU) is used to resect the transformation zone along with the lesion.It removes the entire transformation zone (not just the lesion) along with an adequate extent of normal adjacent epithelium, to ensure there is a disease-free margin of at least $2 \\div 3 = \\mathsf { m m }$ and the full depths of the crypts in the transformation zone have been removed.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "LLETZ is used for both diagnostic and therapeutic interventions.Loop electrosurgical excision procedure (LEEP): See definition for LLETZ above.This terminology has commonly been replaced by the more specific and original term LLETZ for therapeutic interventions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Small-loop electrosurgical biopsy: A small loop $3 \\mathrm { - } 5 ~ \\mathsf { m m }$ diameter) excision as a directed diagnostic biopsy, as an alternative to punch biopsy, especially where cancer, microinvasive cancer or glandular disease is suspected.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Thermal ablation: Refers to the destruction of abnormal cervical tissue by extreme temperature, commonly used for hyperthermia (elevated tissue temperatures of at least $1 0 0 ^ { \\circ } \\mathrm { C } )$ .",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Cryotherapy: The application of extreme hypothermia to the cervix by applying a highly cooled metal disc (cryoprobe) to the cervix and freezing the abnormal areas (along with normal areas) covered by it.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This is another form of ablative treatment.Cold knife conization (CKC): The surgical removal of the central cervix, including portions of the outer (ectocervix) and inner cervix (endocervix) using a scalpel.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "It is usually performed with anaesthesia in a hospital.The amount of tissue removed will depend on the size and site of the transformation zone and the likelihood of finding invasive cancer.Excision treatments have been subdivided by type.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "3 # ANNEX 6.ADDITIONAL INFORMATION FOR SCREENING AND TREATMENT RECOMMENDATIONS Quality assurance: A quality-assured programme is one that is monitored to give assurance that the results consistently achieve the highest level of accuracy and reliability for the detection and treatment of cervical abnormalities by the modality chosen.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Other programme information: Screening registries, and call-and-recall efforts to ensure that women are managed appropriately are essential for both organized and opportunistic programmes.Strong links need to be established between individual patients and the multiple levels of health services (primary care level, hospital level) to ensure the continuity and completion of care.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Self-collected samples: When a patient obtains the swab from their vagina for the screening test (high-risk human papillomavirus, HPV, DNA test).The majority of current laboratory-based HPV screening tests rely on cervical specimen collection by a clinician.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "However, self-collected samples for HPV testing provide an additional strategy to overcome cultural and logistical barriers towards accessing the health system and the reference laboratory or hospital screening programme.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "There are many products for the self-collection of cervical specimens designed as kits with a single-use swab or cervical brush and a tube containing the collection/transport medium.The self-collection process follows similar steps for most products: (i) insert the swab/brush into the vagina and gently rotate for 10–30 seconds; (ii) remove the swab/brush and transfer it into the collection tube; (iii) snap off the swab/brush shaft and cap the collection tube; (iv) discard the shaft; and (v) label the collection tube and send the sample to a laboratory.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Specimens are stable at room temperature for at least 24 hours (and for some kits, for more than 30 days).For the most part, the self-collection process is acceptable to women and perceived as discreet, private and time-saving.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "The process is described by participants as female-friendly, painless and quick.4 HPV tests: The nucleic acid amplification testing (NAAT) technologies have led to the development of HPV in vitro diagnostic medical devices for screening that focus on the qualitative detection of the high-risk genotypes of HPV.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Several in vitro diagnostic medical devices for HPV NAAT have been developed to specifically detect the most common oncogenic genotypes, HPV types 16/18, and in turn to identify those women at the highest risk of developing cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Molecular HPV testing is based on the detection of HPV DNA from high-risk HPV types in vaginal and/or cervical samples, and most laboratory tests can detect up to 15 HPV types.HPV tests can either detect the high-risk HPV genotypes in bulk without distinguishing the individual types or can detect separate HPV types via genotyping capacity.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "See WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.5 There are a large number of HPV tests available in different formats, and new ones continue to become available; clinicians and public health decision-makers should be very careful when selecting one technique from the broad variety available in the market, using analysis on the basis of documented information about the clinical validation for the required purpose.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "See Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide.6 The effect of the HPV vaccination effort to reduce the prevalence of HPV will affect the characteristic positive and negative predictive values of HPV tests.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Recommendations will soon be re-evaluated to take this into consideration as more women who have been previously vaccinated move into the age ranges for cervical cancer screening.Visual inspection with acetic acid (VIA): VIA is a direct visual assessment of the cervix using a $3 - 5 \\%$ acetic acid solution to visibly whiten cervical lesions, which temporarily produces what is known as an acetowhite lesion.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This appears after 1 minute and may last 3–5 minutes in the case of CIN2/3 and invasive cancer.VIA is appropriate to use in women whose transformation zone is visible (typically in those younger than 50 years).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This is because once menopause occurs, the transformation zone, where most pre-cancer lesions occur, frequently recedes into the endocervical canal and prevents it from being fully visible.It is difficult to establish and maintain quality assurance with VIA programmes.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "This can make the sensitivity and specificity of VIA testing quite variable.See WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "7 Cytology: The Papanicolaou (Pap smear) or liquid-based smear test checks whether cells in the cervix are abnormal.Cells are collected via speculum examination with a brush and swab, and placed either directly onto a slide to which a fixative is added (conventional cytology) or placed in a bottle with a liquid storage media (liquid-based cytology).",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Abnormal cervical cells testing as “atypical squamous cells of uncertain significance (ASCUS), low grade to high grade” may mean that there are pre-cancer changes in the cervix that may lead to cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In this guideline, ASCUS in the presence of high-risk HPV DNA was used as the cut-off for an abnormal test that would need further evaluation.If a cytology test is positive, a woman may need to have the cervix examined or may need a further test (such as an HPV DNA test), or could receive ablative or excisional treatment to have the pre-cancer lesion removed.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "8 Colposcopy: A colposcope is a low-magnification, light-illuminated visualization instrument primarily used alongside screening tools for screening, diagnosing and managing cervical pre-cancer lesions.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "It allows the examiner to view the epithelial tissues of the cervix and anogenital areas.For the purposes of cervical pre-cancer assessment, it helps to determine the transformation zone type and the grade of suspected epithelial abnormality.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "In addition, colposcopy facilitates and optimizes biopsy and excisional treatment.Training and supervision are needed to acquire colposcopy proficiency.Traditionally, a colposcope is a free-standing machine held on a stand or legs, with magnification.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "Newer types of colposcopes are portable, and some can even attach to a typical mobile phone.This has made colposcopy much more accessible to all resource settings.See WHO technical guidance and specifications of medical devices for screening and treatment of precancerous lesions in the prevention of cervical cancer.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "9 Histology: The diagnosis of CIN is established by a histopathological examination of tissue such as obtained through cervical punch biopsy or endocervical curettage or excision.The accuracy of the histological diagnosis of CIN is dependent on the quality of the sample, the site of the biopsy, its preparation in the laboratory and its interpretation.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "10 For more information, please contact: Department of Sexual and Reproductive Health and Research World Health Organization 20, avenue Appia 1211 Geneva 27 Switzerland Email: srhhrp@who.int Website: www.",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "who.int/teams/sexual-and-reproductive-health-and-research Department of Global HIV, Hepatitis and STIs Programmes World Health Organization 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int Website: www.who.int/hiv",
    "source": "WHO guideline for screening and treatment ",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/WHO guideline for screening and treatment /WHO guideline for screening and treatment .md"
  },
  {
    "text": "NATIONAL # CERVICAL SCREENING PROGRAM A joint Australian, State and Territory Government Program ![](images/6df73e6339a9092247d68422e139a1fe4fd91b32880dd9f6d64926ed7e4e6182.jpg) 一份让您了解宫颈癌筛查结果的指南 ![](images/158d7fe076dfa95e66efb0951126cfd6ef71269f5f4f05afa25012c18ebcb5af.",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "jpg) ![](images/bc81e3c34ab2951952a7f1267e6e57a35904c29839d30b6a3dd68b62e29b9b62.jpg) 本手册为您提供的信息可以助您更好地了解您的宫颈癌筛查(Cervical ScreeningTest)结果。您的医疗保健师会与您讨论筛查结果以及下一步安排。如果您出现任何症状， 例如异常的阴道出血、疼痛或分泌物，请务必立即与您的医疗保健师联系。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "![](images/71ca7edda6621e71242dcc048467b0b73aab6a528a91df913840587949ad8e4b.jpg) # 宫颈癌筛查 新的宫颈癌筛查与巴氏涂片检查(Paptest)非常相似。基于最新的医疗与科学证明，它能更有效地在早期检测出引起宫颈异常的病毒。现在人们对于宫颈癌的形成已有了更好的了解。宫颈癌比较罕见，并且造成大多数癌前病变的病毒发展成为宫颈癌症需要十年甚至更长的时间。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "继推出新的宫颈癌筛查之后，全国宫颈癌筛查计划(National Cervical ScreeningProgram)的一系列变化预计将会保护近$30 \\%$ 的女性免患宫颈癌。# 宫颈癌筛查可以检测出什么?宫颈癌筛查可以检测出宫颈内的人类乳突病毒(HPV)感染。HPV非常常见，许多人一生中都会感染此病毒，但却并不自知。因为感染此病毒通常不会表现出任何症状。# 什么是HPV?HPV感染有许多种类，其中大多数都会在1-2年内被人体的免疫系统自然地清除而不会引起任何问题。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "HPV是一种在发生性行为时通过生殖道皮肤与皮肤接触而传播的常见病毒感染。HPV非常普遍，以至于许多人一生中某个时刻感染了此病毒却不自知，因为通常感染该病毒没有任何症状。极少数情况下，某些类型的HPV感染没有被人体清除，就可能引起宫颈细胞异变。![](images/2bd52e682559fc83eb6528f914a5fd4ea3251ba302e8e99a493eaae92daeeb60.jpg) # 宫颈癌筛查结果 # 我的筛查结果说明什么?",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "您的医疗保健师会就您的筛查结果与您沟通。可能出现的结果有以下几种： • 五年后再次筛查• 12个月后复检HPV• 将您转介给专科医生筛查结果不符合要求 # 五年后再次筛查 您的筛查结果显示您并未感染HPV。全国宫颈癌筛查计划会向您发出邀请，建议您五年后再做一次宫颈癌筛查。最新的医疗和科研证据表明这五年内您不会有患上宫颈癌的危险。# 12个月后复检HPV 您的筛查结果表明您无需接受进一步的检查，但是您需要在12个月后重新做一次测试。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "这是因为您的HPV感染有可能在12个月内被人体自然清除。12个月后的复查会检测您的感染是否已被清除，是否可以于五年后再做筛查。如果复查结果显示感染并未消除，您可能会需要接受专科医生进一步的检查。这并不表明您已患宫颈癌。因为检测出HPV感染后需要10-15年时间才有可能形成宫颈癌，而且患上宫颈癌的几率很低。# 将您转介给专科医生 您的筛查结果显示您感染了一种HPV，需要接受专科医生的进一步检查，或者显示您有异常需要接受治疗。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "但这并不表明您已患上宫颈癌。HPV感染后需要10-15年时间才有可能形成宫颈癌，而且患上宫颈癌的几率很低。您将被转介给专科医生做进一步的后续检查，即阴道镜检查(colposcopy test)(查看“什么是阴道镜检查” 了解更多信息)。如果您收到这样的筛查结果，请务必遵从医疗保健师的建议。# 筛查结果不符合要求 筛查结果不符合要求并不意味着有问题。一份不符合要求的筛查结果表示您的样本不能被正常化验，需要六周后进行重新测试。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "当实验室不能正常化验您的样本时，您的测试结果就会显示为不符合要求。造成这种情况的原因有多种，例如采集的细胞数过少。如果发现较早，异常是可以很容易被治疗的。但是如果不进行治疗，则有很大几率发展成宫颈癌。宫颈癌筛查意在预防宫颈癌。如果您担心筛查结果或对此感到焦虑，请与您的医疗保健师进行沟通。![](images/902063f55d55881df05818de78ed96e4b78af9a2a7feb9a43a01963326f8539e.",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "jpg) 如果发现较早，异常是可以很容易被治疗的。但是如果不进行治疗，则有很大几率发展成宫颈癌。![](images/cbec22cd5c0ec6e7bf577e72d258e8f2200da67d640853bb2d458cde433732e4.jpg) 宫颈癌筛查意在预防宫颈癌。如果您担心测试结果或对此感到焦虑，请与您的医疗保健师进行沟通。![](images/540f5e6262f976ead80aee2339221d0cb0576339e76dde0e4ef27f8c8687dd6b.",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "jpg) # 如果您被转介给专科医生会是什么情况?根据您的筛查结果，您的医疗保健师可能会将您转介给专科医生做进一步检查。以下是一些相关程序和治疗方案的信息。# 什么是阴道镜检查?阴道镜检查是对宫颈的一种检查方法。检查过程中，医生会使用一种称作阴道镜的设备，它看起来像一副放在架子上的望远镜。通过这个设备，医生可以看到宫颈内部的放大图像。阴道镜检查是由专科医生提供，通常是妇科医师。您的医疗保健师会建议您去哪里做阴道镜检查。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "# 阴道镜检查是如何完成的?当您按照约定到达检查地点时，您可以提问任何关于检查的问题。如果您觉得对您有帮助的话，可以要求专科医生对检查中所进行的操作向您做详细介绍。进行阴道镜检查时，您会被要求平躺于检查床上，双腿撑起，类似于宫颈癌筛查时的姿势。与宫颈癌筛查一样，医生会在您阴道放入一个窥镜。然后医生会在您子宫颈涂抹一种特殊液体，以突显任何异常的区域。接下来医生会通过阴道镜仔细检查您的子宫颈。阴道镜本身并不会进入您的体内。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "检查正常会持续10-15分钟，多数人不会感到任何疼痛。但是，当窥器置入您体内时，您可能会感到些许不适。如检查过程中发现任何问题，可以要求医生对您解释其意义。# 什么是活体组织切片检查(Biopsy)?如果阴道镜检查中发现子宫颈有任何异常，医生会从子宫颈异常处取小块组织样本切片。切片会被送往实验室检验。您的活体组织切片结果将会在最多两周后发给您的医疗保健师。您应约见您的医疗保健师，就切片结果以及治疗方案(如果需要的话)进行沟通。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "如需对您做活体组织切片，您会有短暂的疼痛感。切片后，请避免剧烈运动，最好在1-2天内避免性生活。您可以淋浴，但是请不要在1-2天内游泳、沐浴或水疗。以上注意事项会减少您流血或感染的风险。切片后数小时内您可能会有一些分泌物和“污渍”，所以去做切片检查时最好带一些薄的卫生巾或护垫。# 针对异常的治疗 如果阴道镜检查出宫颈任何异常，就需要进一步治疗。医生会就适合您个人情况的一些最佳治疗方案与您进行沟通。治疗方案可能包括钢丝线圈切除术(wire loop)，激光(laser)或锥形切除术(cone biopsy)。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "接下来一部分提供了每一种治疗方案的简单解释。# 钢丝线圈切除术 异常细胞会在此过程中被钢丝线圈移除出宫颈。手术持续15-30分钟。多数女性会在局部麻醉的情况下接受治疗，但是部分女性需要全身麻醉。如果医生建议您全身麻醉，您需要住院一天。# 激光治疗 激光治疗法利用激光束的热能将异常细胞移除。该过程持续15-30分钟。多数女性会在局部麻醉的情况下接受治疗，但是部分女性需要全身麻醉。如同钢丝线圈切除术一样，如果医生建议全身麻醉，您需要住院一天。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "# 锥形切除术 宫颈内含异常细胞的锥形区域会在这个小手术中被切除。这一过程中患者通常需要全身麻醉，住院一天或一晚进行恢复是必要的。如果异常细胞位于子宫颈管的高位或者影响了腺体细胞，这种情况下，建议采取该手术。腺体细胞在子宫颈管较高的位置。注意：无论采取哪种治疗方法，请避免在之后的3-4周内游泳、使用卫生棉条或进行阴道性交，直到宫颈愈合。避免在7-10天内剧烈运动，因为这可能会增加流血或感染的风险。# 务必谨遵医嘱。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "![](images/6d7cd6f8a3643a390e4181d742d2d067f850b57b6915c14f2ea92f43d255d3b9.jpg) # 常见问题 # 治疗会影响我怀孕的几率吗?一些治疗方案例如锥形切除术或者是钢丝线圈切除术有可能会造成宫颈脆弱。虽然仍然有可能怀孕，但是可能需要在子宫颈缝针以加强肌力，降低流产风险。务必向您的医疗保健师告知您过去接受过的任何宫颈治疗。# 我是如何感染然HPV的?",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "HPV是在发生性行为时通过生殖道肌肤触碰而传染的。您第一次性行为时，就可能从唯一的性伴侣处感染该病毒。大多数人在一生中的某个时刻都会感染HPV，但是人体通常会清除这些病毒。这一病毒非常普遍，所以可被认为是性生活中的一个正常的部分。避孕套可能可以避免一些HPV感染，但是避孕套并不能完全覆盖生殖道处的皮肤。从感染HPV病毒到患上子宫颈癌通常需要10-15年时间。男女同性恋、双性恋、变性人及双性人也会感染这种病毒吗?",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "是的。任何与他人(无论性别)发生生殖道皮肤触碰的人都可能感染HPV。# 如果我感染了HPV，是否要避免发生性行为?如果您的宫颈癌筛查结果显示您已感染HPV，您也无需避免发生性行为。HPV非常普通，您无法知道伴侣是否已感染或曾经感染过该病毒，因为大多情况下，人体会自动清除这一病毒，因而不会给您带来任何问题。# 应该告诉我的伴侣我感染了HPV吗?感染了HPV并不一定表示您或您的伴侣不忠，因为这种病毒会潜伏很久。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "HPV可以很长时间保持不活动的状态。对大多数人来说，您并不可能知道何时或从何处感染了这一病毒。HPV也可能造成生殖器疣或其它癌症，例如肛门癌、阴道癌以及口咽癌(咽喉癌)，外阴癌和阴茎癌。如果您感染了HPV，您可以选择告知您的伴侣。是否将您的宫颈癌筛查结果告知您的伴侣完全是您的个人决定。如果您担心将HPV传染给您的伴侣，可以与您的医疗保健师进一步沟通。# 怎样治疗HPV?目前还没有针对HPV的任何治疗方法。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "大多数情况下，人体的免疫系统会随着时间自然的清除体内的HPV，并不会产生持续影响。多数感染HPV的人不会表现出任何症状，也不会知道自己已感染此病毒。对于在宫颈癌筛查中发现的由HPV病毒引起的宫颈细胞变化，应做进一步的测试，如有需要需接受治疗。医疗保健师可以对由某种类型HPV引起的生殖器疣进行治疗。# 我有可能反复感染HPV吗?HPV有不同的类型，一旦您感染了某一种HPV，就不太可能再次感染同类HPV，因为身体通常会对该种病毒免疫。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "然而，病毒仍可能潜伏在您的体内并在数年后重新活跃。所以，即使您不再进行性生活或者只有一个性伴侣，您仍然应该持续筛查。# 我已经接种了HPV疫苗，是否仍然可能感染HPV?是的。即使您已经接种了HPV疫苗，仍然应该做常规的宫颈癌筛查。HPV有许多种类，疫苗并不针对所有种类。您可能已经在接种疫苗之前就通过性行为感染了HPV。HPV疫苗并不能针对您已感染的HPV。# 我应该接种HPV病毒疫苗吗?在感染HPV前，以及发生性行为前接种HPV疫苗最为有效。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "如果您已感染了HPV，疫苗的作用会降低。在澳大利亚，HPV疫苗是通过学校的疫苗计划项目提供给青少年的，并且被批准使用于年龄为9-45岁的女性以及9-26岁的男性。您可以与您的医疗保健师就疫苗对您个人的好处进行沟通。您可以在学校资助的项目外购买疫苗，医疗保健师可能会收取额外的咨询费用。目前建议的接种计量为三剂。疫苗是安全的，可以针对两种类型的HPV(种类16与种类18)，这两种病毒造成约 $70 \\%$ 的宫颈癌，以及肛门癌、阴道癌还有口咽癌，外阴癌和阴茎癌。",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "该疫苗还针对两种不引起癌症的HPV，这两种病毒造成近 $90 \\%$ 的生殖器疣。# 从哪里可以了解更多信息?如果英语不是您的第一语言，而您需要翻译协助的话，可以拨打13 14 50获得翻译服务。通话费与拨打本地电话的费用相同。# 全国宫颈癌筛查计划 如果您想了解更多有关宫颈癌筛查的信息，以及了解这一计划是如何在澳大利亚实施的，请访问全国宫颈癌筛查计划的网站，或拨打电话13 15 56。www.cancerscreening.",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "gov.au/cervical # 全国癌症筛查登记处 如果您想更新您的联系方式并了解您下一次宫颈癌筛查的时间，请拨打电话1800 627 701。全国宫颈癌筛查计划是一项澳大利亚国家、州及领地政府的联合计划。全国HPV疫苗登记处 如果您想查看自己是否已接种HPV病毒疫苗，包括已接种的计量，请访问全国HPV疫苗登记处网站，或者拨打电话1800 478 734。www.hpvregister.org.au",
    "source": "一份让您了解宫颈癌筛查结果的指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/一份让您了解宫颈癌筛查结果的指南/一份让您了解宫颈癌筛查结果的指南.md"
  },
  {
    "text": "议程项目 7 EB156(22) 2025 年 2 月 10 日 # 世界消除宫颈癌日 执行委员会审议了总干事的报告1，决定建议第七十八届世界卫生大会通过下述决议： 第七十八届世界卫生大会，审议了总干事的报告； 回顾 WHA73.2 号决议（2020 年），其中除其他外，通过了《加速消除作为公共卫生问题的宫颈癌全球战略》，敦促会员国采取行动，通过预防，包括接种疫苗、发现和治疗，以及对宫颈癌规划采取整体系统方法，加速消除宫颈癌；呼吁国际组织和利益攸关方优先开展活动，通过预防，包括接种疫苗、发现和治疗，消除宫颈癌；请总干事支持会员国实施全球战略并加强利益攸关方的参与，以实现 2030 年目标； 还回顾《2030 年可持续发展议程》，特别是目标 1（在全世界消除一切形式的贫困）、目标 3（确保健康的生活方式，促进各年龄段人群的福祉）、目标 5（实现性别平等，增强所有妇女和女童的权能）和目标10（减少国家内部和国家之间的不平等）； 认识到每个人都有权不受歧视地享有能达到的最高标准身心健康； 还认识到必须优先重视妇女和女童，特别是感染艾滋病毒的妇女和女童的健康，并解决相关的污名和性别不平等问题，消除影响获得宫颈癌相关卫生保健服务的障碍，根据国家重点和国情，作为综合卫生保健系统的一部分，促进普遍提供性和生殖卫生保健服务、人乳头状瘤病毒疫苗接种以及宫颈癌筛查和治疗； 进一步认识到感染艾滋病毒的女性承受过重的负担，她们更有可能罹患宫颈癌； 认识到宫颈癌如果得到及早发现和充分治疗，是可以预防、治疗和治愈的，但它仍然是全世界女性癌症相关发病和死亡的最常见原因之一，并可增加不孕症，给发展中国家造成过重的负担； 还认识到世卫组织（包括其区域和国家办事处）、国际癌症研究机构和其他国际组织在通过对筛查和治疗技术进行培训以及疫苗教育，努力加强一线卫生工作者的能力； 进一步认识到需要促进获得宫颈癌筛查服务，这可能包括提供自我采样工具，从而给予一种赋权和参与感； 认识到人乳头状瘤病毒是女性宫颈癌的主要原因，也可能导致男性和女性的其他癌症，尽管有疫苗，但 15 岁以下女童的人乳头状瘤病毒疫苗接种覆盖率与 2030 年 $90 \\%$ 的目标相距甚远； 还认识到有效的一级预防（人乳头状瘤病毒疫苗接种）和二级预防（癌前病变筛查和治疗）措施可防止大多数宫颈癌病例。",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "强调接种人乳头状瘤病毒疫苗以及筛查和治疗癌前病变是预防宫颈癌的极具成本效益的策略； 认识到提高公众认识、获得信息和服务是在生命全程预防和控制疾病的要素； 回顾 WHA73.2 号决议的历史意义，这是有史以来第一项旨在全球消除一种癌症的决议，而且随此决议于 2020 年 11 月 17 日推出了《加速消除作为公共卫生问题的宫颈癌全球战略》； 注意到所有区域都对推出全球战略作出了积极响应，并且继续在每年 11 月 17 日这一天开展持续的宣传、计划、行动和健康促进活动以示纪念，由此鼓励社区合作，促进对宫颈癌的预防、早期发现和治疗服务，并始终重视团结各国共同努力实现在全世界首次消除一种癌症的目标， # 1.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "敦促会员国： (1) 将11 月17 日定为世界消除宫颈癌日，自 2025 年11 月起每年举办纪念活动，以进一步促进和维持全球消除宫颈癌的努力； (2) 根据国家重点和国情，并在努力实现全民健康覆盖的背景下，提供充足的资源，用以扩大卫生保健服务，促进消除宫颈癌的努力； (3) 促进和支持每年举办世界消除宫颈癌日纪念活动，以公平实现全民健康覆盖； # 2.要求总干事： (1) 利用世界消除宫颈癌日，根据《与非国家行为者交往的框架》，继续加强利益攸关方参与协调、创新和资源调动活动，目的是支持会员国根据 WHA73.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "2 号决议和其他适用的任务授权努力消除宫颈癌； (2) 继续强调会员国应努力加速消除宫颈癌这一公共卫生问题，加强基于人口的癌症登记系统，并采用宫颈癌疫苗接种和筛查登记系统以便衡量实现消除目标的进展，同时强调这些措施是确保及早和便捷获取人乳头状瘤病毒疫苗接种的关键； (3) 协调世卫组织所有三个层级的努力和参与，包括在区域一级，目的是协调开展活动，促进合作，最大限度发挥宣传和预防运动的影响，以消除宫颈癌； 3.",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "建议利益攸关方和/或合作伙伴： (1) 加强多边和国际合作，促进人人享有知识以及安全、负担得起的优质服务、卫生保健产品和干预措施，以便根据实现全民健康覆盖的目标和其他相关区域承诺，并考虑到任何利益冲突，加快消除宫颈癌这一公共卫生问题；以及(2) 利用世界消除宫颈癌日，根据国家重点和国情加深对会员国在实现相关目标方面工作的支持和参与； 4.决定，根据第 1(1)段将 11 月 17 日定为世界消除宫颈癌日，并自 2025 年 11 月起每年举办纪念活动，以进一步促进和维持全球消除宫颈癌的努力。2025 年 2 月 10 日，第十八次会议EB156/SR/18",
    "source": "世界消除宫颈癌日",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/世界消除宫颈癌日/世界消除宫颈癌日.md"
  },
  {
    "text": "# 儿童和青少年HPV 疫苗接种家长指南 为何要给 11-12 岁的儿童接种 HPV 疫苗？相比在较大的年龄接种疫苗，在较小的时候接种疫苗产生的预防感染的免疫力更强。2 如果早在他们进行首次性接触前接种全部三剂 HPV 疫苗，那么接种 HPV 疫苗预防疾病和癌症的效果将好很多。3 大多数美国男人和女人在他们一生中的性活跃时期都会至少感染一种类型的 HPV。HPV 很容易通过性活动过程中的肌肤接触传播。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "即使没有进行性交也会感染HPV。终身只有一位性伴侣的人也可能感染HPV，如果其伴侣之前的伴侣曾被感染过。6 经全世界数千名受试者证实 HPV 疫苗无严重副反应。HPV 疫苗对癌前病变的保护效应几乎是$100 \\%$ ；其中两种疫苗可预防生殖器疣。# 人乳头状瘤病毒(HPV) ![](images/ab6a3163fc40e72a16689750c165d77ffaa099063c8d739e4f94e7ee708a2d38.",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "jpg) # 什么是 HPV？HPV 是一种常见的家族病毒，可导致皮肤感染或人体各部位的黏膜感染。目前有100 多种不同类型的 HPV。不同类型的 HPV 感染会感染身体的不同部位。例如，有些类型的 HPV 可导致生殖器部位长疣，其他类型可导致子宫颈、外阴、肛门、阴茎、口腔和喉咙细胞异常，有时导致癌症。# HPV 有多常见？HPV 非常常见！据疾病控制和预防中心 (CDC) 称，几乎所有男人和女人在其一生中的性活跃期都会感染至少一种 HPV。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "目前，在美国约有 7900 万人口已感染HPV，且每年有约 1400 万新增感染人口。因此，HPV 被认为是美国最常见的性传播疾病。# HPV 有多严重？HPV 非常严重！每年约有 17,500 名女性和 9,300 名男性患 HPV 感染所致的癌症。HPV 是几乎所有女性宫颈癌的主要致病原因。美国每年约新增加 12,000 例宫颈癌，每年有 4,000 人死于宫颈癌。# HPV 如何传播？HPV 感染的最常见方式是与受感染的人进行阴道性交或肛交；但这并非是感染HPV 的唯一方式。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "口交或任何与感染 HPV 的部位进行的肌肤接触都会导致感染。在最近的一项研究中， $4 6 \\%$ 感染 HPV 的女性参与者此前从未有过阴道性交。一个人很可能感染了 HPV 但并不知情，因此可能不知不觉地将 HPV 传染给他人。以下行为不会感染 HPV，包括公厕，牵手和拥抱，公共泳池或浴缸，共同进食或共用餐具，或卫生条件差。![](images/d3b8492bb28ed47ec584b459d2eb719c6a6e3d755b0824e9ea7a8431a714146d.",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "jpg) “大多数感染?HPV 的人甚至不知道自己已经被感染。y 如要了解更多信息… 请联系您的医疗服务人员或国家卫生部 密歇根卫生与人类服务部 www.michigan.gov/immunize 密歇根卫生与人类服务部 www.michigan.gov/teenvaccines 疾病控制与预防中心 (CDC) www.cdc.gov/vaccines 疫苗教育中心 www.chop.edu/vaccine 儿童疫苗计划 www.",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "cdc.gov/vaccines/programs/vfc/index.html # 参考资料： 美国妇产科医生协会。HPV 资源 综述。http://www.acog.org/Womens-Health/Human-Papillomavirus-HPV.访问于 4/6/15.疾病控制和预防中心（CDC).HPV 与癌症。http://www.cdc.gov/hpv/cancer.html.更新于 1/22/15.",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "访问于 3/30/15.CDC.HPV 疫苗问答。http://www.cdc.gov/vaccines/vpd-vac/hpv/vac-faqs.htm.更新于 8/6/14.访问于 3/30/15.CDC.宫颈癌统计分析。http://www.cdc.gov/cancer/cervical/statistics/.更新于 9/2/14.访问于 3/30/15.美国癌症协会。HPV 与癌症。http://www.",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/hpv/hpv-and-cancer-info.更新于 2/2/15.访问于 4/6/15 Shew、ML 等人。纵向队列研究显示，在女性进行首次阴道性交前，需要非常频繁地进行阴道人乳头状瘤病毒检测。感染性疾病杂志。2013 年 3 月 15 日；207(6):1012-5。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "# 人乳头状瘤病毒 (HPV) 是否可以治 目前尚无 HPV 感染的治疗方法。仅有 HPV 引起的健康问题的治疗方法，如生殖器疣、子宫颈的变化和宫颈癌等问题。在一些情况下，身体会自然而然地与病毒斗争。如果身体无法自然对抗病毒，则很可能引发严重并发症，如癌症。大多数 HPV可自行消退，但不是在所有病例中，针对这个问题目前仍缺乏解释。究竟哪些人会进展为癌症或其他疾病也无法预测。# 什么是 HPV 疫苗？",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "在美国，HPV 疫苗亚型涵盖约 $7 5 \\%$ 的 HPV 相关侵入性癌症 。HPV 疫苗获得美国食品和药品安全局的认证及 CDC 的推荐。HPV 疫苗接种方法为六个月内接种三次。为达到最佳保护效应，完成三次疫苗接种很重要。# 我的孩子何时能接种 HPV 疫苗？建议所有 11 至 12 岁的男孩和女孩都接种三剂 HPV 疫苗。最早可以在 9 岁接种该疫苗。女孩的后续强化接种年龄为 13-26 岁，男孩为 13-21 岁。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "如果您的儿子或女儿未在推荐的年龄期内接种疫苗，他们仍可以接种疫苗。为了使 HPV 疫苗发挥最佳作用，青春期前的孩子务必要在开始任何性活动前接种全部三剂疫苗。他们可能在第一次与他人进行性接触时感染 HPV，即使没有性交。同时，青春期前接种相比青春期后及青年成人接种产生的抗感染免疫更强。# 疫苗是否安全有效？该疫苗在预防引发癌症的 HPV 类型方面显示有显著效果。《传染性疾病》杂志最近发表的研究显示，自 2006 年引进该疫苗后，14-19 岁已接种疫苗的女性青少年患HPV 的情况已下降 $56 \\%$ 。",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "在获得 FDA 许可前，美国使用的所有疫苗都需要经过多年广泛的安全测试。仍会通过三个监控系统持续监视疫苗的安全和有效性。这些系统可监视已知由疫苗引起的不良反应，以及检测罕见反应。自 2006 年以来，在美国已经接种超过 7600 万剂 HPV 疫苗。自 2007 年建议在美国常规使用以来，未确认严重的安全问题。常见的温和副作用包括接种部位疼痛、发烧、头痛和呕吐。马上与您的医疗服务人员讨论如何防止您的孩子感染 HPV！",
    "source": "人乳头状瘤病毒",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/人乳头状瘤病毒/人乳头状瘤病毒.md"
  },
  {
    "text": "首页  癌症护理  关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防。关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防。经 Apollo Hospitals 验证，1 年 2024 月 XNUMX 日 癌症护理 子宫颈癌 ![](images/f5a272f8510e4586db70adbe18e4e8750ed049bfcbb81b9060ede6806dd560dc.",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "jpg) ![](images/e643daab909388de52271fc56db8b3615c67f4fcd204ce6894e685fa009df0d4.jpg) 宫颈癌是全球女性中最常见的癌症之一，也是重大的健康问题。早期发现和预防对于降低患上这种疾病的风险至关重要。本指南深入了解了宫颈癌，包括其病因、症状、分期、诊断、治疗、预防和常见问题。# 什么是宫颈癌？宫颈癌是一种发生在宫颈（子宫下部，与阴道相连）的癌症。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "宫颈是女性生殖系统的关键部位，是经血、精子和分娩的通道。当宫颈内的健康细胞发生异常变化，导致不受控制的生长，最终形成肿瘤时，就会引发宫颈癌。宫颈癌的主要病因是持续感染高危型人乳头瘤病毒 (HPV)，这是一种性传播病毒。虽然大多数HPV 感染可被人体免疫系统清除，但某些高危菌株（如 HPV-16 和 HPV-18）可导致宫颈细胞发生长期变化，随着时间的推移增加患癌风险。通过定期筛查（如巴氏涂片和 HPV 检测）进行早期发现，对预防宫颈癌和改善治疗效果至关重要。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 宫颈癌的类型 根据癌症起源细胞的类型，宫颈癌可分为不同类型。了解这些类型对预后至关重要。# 1.鳞状细胞癌 鳞状细胞癌是最常见的宫颈癌类型，约占 $70 - 9 0 \\%$ 。鳞状细胞癌发生于鳞状细胞，鳞状细胞是构成宫颈外层（宫颈外口）的薄而扁平的细胞。这种类型的宫颈癌通常发生在鳞状细胞与腺细胞相遇的转化区。定期筛查有助于在早期发现鳞状细胞癌。# 2.腺癌 腺癌起源于宫颈腺细胞，负责产生粘液。这些细胞位于宫颈管内，即宫颈管的内层。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "尽管腺癌比鳞状细胞癌少见，但约占宫颈癌病例的 $10 \\%$ 。这种类型的宫颈癌有时很难通过常规巴氏涂片检测出来，因为它发生在宫颈管内。# 3.混合癌 （腺鳞癌） 混合癌又称腺鳞癌，是一种罕见的宫颈癌，既有鳞状细胞癌也有腺细胞癌。这种类型的宫颈癌比鳞状细胞癌或腺癌少见，但可能兼具两者的特征。无论何种类型，早期发现和治疗对于提高患者存活率和生活质量都至关重要。定期进行宫颈癌筛查，包括巴氏涂片和 HPV 检测，在早期发现和治疗这些癌症方面发挥着关键作用。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 宫颈癌的原因 宫颈癌主要由持续感染高危型人乳头瘤病毒 (HPV)（一种性传播病毒）引起。然而，其他一些因素也会增加患宫颈癌的风险。了解这些原因和风险因素对于预防和早期发现至关重要。# 1.持续性 HPV 感染 HPV 高危菌株，尤其是 HPV-16 和 HPV-18，是大多数宫颈癌病例的罪魁祸首。这些菌株会干扰正常细胞功能，导致癌前病变，随着时间的推移，这些病变可能会发展为癌症。# 2.吸烟 吸烟会削弱免疫系统，使身体更难清除 HPV 感染此外，烟草中的致癌化学物质会损害宫颈细胞，进一步增加患癌症的风险。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 3.免疫系统减弱 损害免疫系统的疾病，例如 艾滋病毒 或长期使用免疫抑制药物（例如移植后治疗），会降低身体抵抗 HPV 感染的能力，从而增加持续感染和随后患宫颈癌的可能性。# 4.长期服用口服避孕药 研究表明，服用口服避孕药五年或五年以上的女性罹患宫颈癌的风险可能增加。这种关联的确切原因尚不清楚，但可能与影响宫颈的激素变化有关。# 5.多次怀孕 有过三次或三次以上足月妊娠的妇女患宫颈癌的风险可能更高。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "分娩期间的荷尔蒙变化和宫颈创伤可能会增加这种风险。# 6.早期性行为 年纪较小时发生性行为会增加接触 HPV 的可能性，因为青春期时宫 虽然这些因素会增加罹患宫颈癌的风险，但定期进行巴氏涂片和HPV检测、接种HPV疫苗以及采取健康的生活方式可以显著降低罹患该疾病的可能性。# 宫颈癌的症状 在早期阶段，宫颈癌通常没有明显的症状，因此定期筛查对于早期发现至关重要。然而，随着癌症的进展，可能会出现某些症状，表明存在疾病。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "了解这些症状及其进展对于及时就医至关重要。# 宫颈癌的常见症状 随着宫颈癌的进展，可能出现以下症状： # 1.阴道异常出血 异常 阴道出血 是宫颈癌最常见的症状之一。包括月经间期出血、性交后出血或绝经后出血。任何异常出血都应由医疗保健提供者进行评估。# 2.月经量过多或经期延长 患有宫颈癌的女性可能会出现月经量异常多或月经延长的情况，持续时间比正常情况更长或月经量更大。# 3.不寻常的阴道分泌物 宫颈癌的另一个症状是异常 白带 流出的液体可能呈水状、有异味或带血。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "这可能是宫颈感染或癌症相关变化的征兆。# 4.性交疼痛 性交疼痛，被称为 性交困难，当肿瘤生长并影响宫颈时，就会出现疼痛。这种不适可能是由于癌症对附近组织的影响引起的。# 5.骨盆或下背部疼痛 随着宫颈癌的进展，它会引起骨盆区域或下背部持续疼痛，这通常表明癌症已经扩散到附近的器官。# 宫颈癌的早期症状 虽然宫颈癌在早期阶段通常无症状，但一些早期症状可能包括： # 1.性活动后出现少量点滴出血或流血 性交后可能会出现少量出血或点滴出血，这通常与疾病引起的宫颈变化有关。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# .阴道分泌物轻微变化 +91 80699910阴道分泌物的早期变化，例如量增加或质地改变，可能预示着宫颈 在晚期阶段，宫颈癌可能会出现更明显的症状，例如： # 1.显着减肥 在癌症晚期，常常会出现不明原因的体重快速下降。# 2.排尿困难 如果癌症扩散到膀胱或泌尿道，可能会导致疼痛或排尿困难。# 3.腿部肿胀 由于淋巴阻塞或癌症扩散到盆腔区域，可能会出现腿部肿胀。# 4.持续性骨盆疼痛 骨盆区域持续疼痛且没有改善可能预示着癌症的进展。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 什么时候去看医生 如果您发现任何宫颈癌症状，尤其是异常出血或分泌物变化，请务必及时就医。通过定期进行子宫颈抹片检查和 HPV 检测，可以尽早发现宫颈癌，从而尽早接受治疗并获得更好的治疗效果，从而大大降低患宫颈癌的风险。# 宫颈癌的阶段 根据宫颈癌的扩散程度，宫颈癌可分为不同阶段。分期对于确定最合适的治疗方案和评估预后至关重要。分期范围从早期癌症（局限于宫颈）到晚期癌症（癌症可能已扩散到附近器官）。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 宫颈癌 0 期：原位癌 (CIS) 0 期也称为原位癌，癌细胞局限于宫颈表层。这是宫颈癌的早期形式，在许多情况下，这种癌症是可以治愈的。在这个阶段，癌症尚未扩散到更深的组织或宫颈的其他部位。# 宫颈癌 I 期：癌症局限于宫颈 在第一阶段，癌症仍然局限于宫颈，尚未扩散到周围组织或器官。此阶段进一步分为两个子阶段： 第一阶段： 仅在显微镜下才可检测到的微观癌症。IB阶段： 可通过影像学检查或体检发现的可见病变或较大的肿瘤。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "在 II 期，癌症已扩散至宫颈和子宫以外，但尚未到达盆壁或阴道下部。此阶段进一步分为两个子阶段： 第二阶段： 癌症已扩散至阴道上三分之二或宫旁组织（子宫周围的组织），但尚未扩散至盆壁。第二阶段： 癌症涉及宫旁组织但不涉及盆壁。# 宫颈癌 III 期：癌症扩散至盆壁和阴道下部 在第三期，癌症已扩散至盆壁或阴道下部。它还可能导致输尿管阻塞，从而导致肾脏问题和泌尿问题。此阶段分为： 阶段 IIIA： 癌症已扩散至阴道下三分之一，但尚未扩散至盆壁。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "IIIB阶段： 癌症扩散到盆壁并可能导致输尿管阻塞，从而损害肾功能。# 宫颈癌 IV 期：晚期宫颈癌 第四期是宫颈癌的最晚期阶段，癌症已扩散至附近器官（如膀胱或直肠）或身体的远处部位。此阶段分为两个子阶段： IVA阶段： 癌症已扩散至附近的器官，例如膀胱、直肠或骨盆的其他部位。IVB阶段： 癌症已扩散至远处器官，如肺或肝。# 宫颈癌诊断和筛查 早期发现宫颈癌可显著改善治疗效果，而定期筛查是发现异常情况，防止其发展为癌症的关键。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "筛查宫颈癌有多种诊断方法，每种方法在发现早期症状或确认诊断方面都有独特的用途。# 巴氏涂片测试 - 子宫颈抹片检查 宫颈抹片检查（也称为巴氏试验）是检测宫颈细胞异常变化（在它们转变为癌症之前）的最常见和最有效的方法之一。在这项检查中，医生会从宫 +91 80699910下检查是否有任何异常情况，这些异常情况可能预示着癌前病变或早期癌症。频率： 建议 21 至 65 岁的女性每 3 年进行一次巴氏涂片检查。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "目的： 检测宫颈癌的癌前病变或早期迹象。# HPV检测 - HPV测试 用于检测高危型人乳头瘤病毒 (HPV)，尤其是 HPV-16 和 HPV-18，这两种病毒是大多数宫颈癌的罪魁祸首。该检测通常与巴氏涂片检查相结合，以进行更全面的筛查，尤其是针对 30 岁以上的女性。频率： 建议 30 岁以上的女性进行，可以与巴氏涂片检查同时进行，也可以单独进行。目的： 识别可能导致宫颈癌的高危HPV毒株。# 阴道镜检查 A 阴道镜 是使用一种称为阴道镜的特殊放大仪器对宫颈进行的详细检查。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "该程序通常在巴氏涂片或 HPV 检测结果异常后进行。它允许医生仔细检查宫颈是否有任何可能需要进一步检查或活检的异常区域。频率： 当巴氏涂片检查或 HPV 检测结果异常时进行。目的： 识别宫颈异常区域，以便进行进一步检查或治疗。# 活检 A 活检 是确认癌症存在的最终检查。在此过程中，会从子宫颈取出一小块组织样本，并在显微镜下检查以检查癌细胞。如果发现任何异常组织，可在阴道镜检查期间进行活检。频率： 当存在可疑区域或异常情况需要确认时完成。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "目的： 通过在显微镜下检查组织来确认癌症的存在。# 女性应该多久进行一次宫颈癌筛查？宫颈癌筛查的频率取决于年龄、健康史和所进行的检查类型： 巴氏涂片： 3 至 21 岁的女性每 65 年一次。咨询医生： 女性应该遵循医疗保健提供者的建议，特别是当她们有诸如巴氏涂片异常或HPV 感染史等风险因素时。# 宫颈癌筛查建议 定期进行宫颈癌筛查对于早期发现至关重要，可以大大降低罹患晚期宫颈癌的风险。女性应根据自己的年龄、性史和风险因素，与医疗保健提供者讨论最适合自己的筛查计划。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 预防宫颈癌 虽然宫颈癌可能是一个严重的健康问题，但通过积极措施可以在很大程度上预防。预防策略主要侧重于降低 HPV感染 并检测 癌前病变 尽早发现。通过采取正确的措施，女性可以显著降低罹患宫颈癌的风险。# HPV疫苗接种 预防宫颈癌最有效的方法是 宫颈癌疫苗可预防人乳头瘤病毒 (HPV)。某些高危 HPV 毒株是大多数宫颈癌的病因，而 Gardasil、Gardasil 9 和 Cervarix 等疫苗专门用于预防这些类型的病毒。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "推荐年龄： 接种疫苗对两者都是理想的 9 至 26 岁的男孩和女孩，最好在性活动开始前进行，以最大限度地提高疗效。优点： HPV疫苗可以预防高危HPV毒株的感染，显著降低宫颈癌的风险。# 定期筛查 常规筛查 巴氏涂片 和 HPV 检测 是关键的预防措施。这些测试有助于检测 癌前病变 宫颈癌变之前，及时发现异常细胞变化，可以治疗和管理这些变化，防止其发展为癌症。巴氏涂片检查： 通过识别宫颈上的异常细胞变化来检测宫颈癌的早期迹象。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "HPV 检测： 识别可能导致宫颈癌的高危 HPV 毒株的存在。# 生活方式修改 采取健康的生活方式可以进一步降低患宫颈癌的风险： 预约健康检查 进行安全性行为： 运用 避孕套 在性活动期间持续接种疫苗有助于降低 HPV 感染风险，尽管这并不能提供 $100 \\%$ 的保护。避免吸烟： 吸烟会削弱免疫系统，使人体更难抵抗 HPV 感染。吸烟还会增加罹患 HPV 相关癌症（包括宫颈癌）的风险。维持健康的免疫系统： 均衡饮食、规律锻炼和控制压力有助于增强免疫系统，提高身体抵抗HPV 等感染的能力。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 宫颈癌可以预防吗？是的，宫颈癌可以通过疫苗接种、定期筛查和健康的生活方式来预防。通过采取这些积极措施，女性可以降低风险并增加早期发现的机会，从而改善整体健康状况。# 宫颈癌的治疗 宫颈癌的治疗方法取决于 阶段 癌症、患者年龄、整体健康状况和其他个人因素。一般来说，治疗旨在去除或摧毁癌细胞并防止癌症进一步扩散。主要治疗方案包括手术、放射疗法、化疗以及靶向疗法和免疫疗法等较新的方法。# 早期治疗 当宫颈癌在早期被发现时，治疗方案通常更加局部化，成功率也更高。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 手术 早期宫颈癌通常采用手术治疗，以切除癌组织并防止进一步扩散。手术类型包括： 锥切术： 也称为 锥形活检，该手术仅切除宫颈癌组织，保留周围健康组织。该手术通常推荐用于极早期癌症（0 期或 IA 期）。子宫切除术： 如果癌症已经扩散至宫颈以外但仍局限于子宫内， 子宫切除术 （切除子宫和宫颈）可能是必要的。在某些情况下，如果担心癌症扩散，卵巢也可能被切除。# 放射治疗 外部光束辐射： 从体外攻击癌症。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "近距离放射治疗： 将放射源直接放置在肿瘤内部或附近。# 晚期治疗 当宫颈癌扩散到宫颈以外的身体部位时，治疗会变得更积极，并且可能涉及多种疗法。# 化疗 化疗 使用强效药物摧毁或缩小全身癌细胞。它通常用于晚期宫颈癌或癌症已扩散到其他器官的情况。化疗药物可以静脉注射或口服。化疗药物： 治疗宫颈癌的常用药物包括 顺铂, 紫杉醇及 拓扑替康.联合疗法： 化疗通常与放射疗法相结合，以便在晚期患者身上取得更好的效果。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 靶向治疗 靶向治疗 是一种较新的治疗方法，主要针对与癌症生长相关的特定分子。这些疗法旨在通过针对促进癌症进展的特定蛋白质或基因来阻止癌细胞的生长。靶向疗法通常与化疗或放射疗法结合使用。贝伐单抗（阿瓦斯丁）： 一种常见的靶向疗法，用于阻断肿瘤的血液供应，抑制肿瘤的生长。# 免疫治疗 免疫治疗 增强人体免疫系统识别和攻击癌细胞的能力。这种疗法对于对传统疗法反应不佳的癌症越来越受欢迎。免疫疗法通常用于对化疗或放射疗法没有反应的晚期宫颈癌。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "检查点抑制剂： 药物像 派姆单抗（Keytruda） 和 纳武单抗（Opdivo） 通过阻断某些阻止免疫细胞识别癌细胞的蛋白质，帮助免疫系统更有效地攻击癌细胞。# 宫颈癌可以治愈吗？预约健康检查 是的，宫颈癌是可以治愈的，如果及早发现，就有可能治愈。宫颈癌早期的存活率明显较高，因此 早期检测 和 定期检查 对于成功的治疗结果至关重要。接受定期筛查检查的女性，例如 巴氏涂片 和 HPV检测，在可治疗阶段发现癌症的机会更高，从而增加了完全康复的可能性。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 宫颈癌认知 提高对宫颈癌的认识对于减少其影响至关重要。重点关注领域包括： 促进疫苗接种和筛查： 鼓励接种 HPV 疫苗并定期 巴氏涂片 or HPV 检测 有助于预防宫颈癌并及早发现癌前病变。向女性普及症状和风险因素： 向女性告知 症状 （例如异常出血、盆腔疼痛）和 风险因素（如 HPV 感染和吸烟）使他们能够采取预防措施。鼓励定期健康检查： 定期检查有助于女性保持健康，确保及早发现和治疗宫颈癌。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "![](images/d1b9aecaab3a4f18ea19974d758b72c1284f9b293a511ba2b5603a827354436a.jpg) # 常见问题解答 (FAQs) 1.接种宫颈癌疫苗的推荐年龄是多少？HPV 疫苗建议 9 至 26 岁之间的人接种。最好在开始任何性活动之前接种疫苗，因为这样可以最好地预防 HPV 感染。早期接种疫苗可显著降低成年后患宫颈癌的风险。# 2.",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "吸烟会增加宫颈癌的风险吗？是的，吸烟是导致宫颈癌的重要风险因素。吸烟会削弱免疫系统， $+ 9 1$ 难80抵69抗9H91P0V染。慢性 HPV 感染是导致宫颈癌的主要原因，而吸烟会导致感染持续存在， 从而增加宫颈癌 # 3.没有 HPV 的情况下也会发生宫颈癌吗？虽然 HPV 是导致宫颈癌的主要原因，但吸烟、免疫系统减弱（例如 HIV 或免疫抑制治疗）和多次怀孕等其他风险因素也可能导致宫颈癌的发生。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "然而，没有 HPV 感染的宫颈癌很少见，而且通常与其他潜在健康状况有关。# 4.宫颈癌是如何检测出来的？宫颈癌通常通过巴氏涂片检查（检查宫颈细胞异常变化）、HPV 检测（检查高危 HPV 菌株）、阴道镜检查（对宫颈的详细检查）和活检（采集组织样本以确认癌症）检测出来。定期筛查有助于及早发现癌前病变，提高成功治疗的机会。# 5.宫颈癌可以预防吗？是的，宫颈癌可以通过 HPV 疫苗接种、定期筛查（如巴氏涂片和 HPV 检测）和健康的生活方式来预防。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "在接触 HPV 之前接种疫苗，结合定期筛查，有助于识别癌前病变，并在其发展为癌症之前进行治疗。不吸烟等健康习惯也可以降低风险。# 6.HPV 感染总是与宫颈癌有关吗？不会，大多数 HPV 感染会自行痊愈，不会造成伤害。但是，持续感染高危型 HPV 会随着时间的推移导致宫颈癌。这些感染的慢性性质是最大的风险。定期筛查有助于及早发现这些感染并预防癌症发展。# 7.如何诊断宫颈癌？宫颈癌的诊断需要综合筛查和诊断程序。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "这些检查包括巴氏涂片检查、HPV 检测、阴道镜检查（使用放大镜检查宫颈）和活检（组织样本分析）。在某些情况下，影像学检查（如 CT 扫描或 MRI）可用于确定癌症扩散的程度。# 8.HPV疫苗在预防宫颈癌方面起什么作用？HPV 疫苗在预防宫颈癌方面发挥着至关重要的作用，它可以预防最常见的高危 HPV 毒株，尤其是 16 型和 18 型，这两种毒株是造成大量宫颈癌病例的元凶。接种疫苗可显著降低罹患宫颈癌的风险，还可降低宫颈癌前病变的风险。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 9.宫颈癌是如何发生的？宫颈癌主要由高危型 HPV（人乳头瘤病毒）持续感染引起。这些感染可导致宫颈细胞异常，久而久之，可能发展为癌症。吸烟、免疫系统减弱和多次怀孕等其他风险因素也可能导致宫颈癌的发生。# 结语 宫颈癌是一种可预防和治疗的疾病，只要及早发现即可。定期筛查、接种疫苗和提高认识对于降低其患病率至关重要。女性应将自己的健康放在首位，及时了解信息并安排常规妇科检查，以确保及早发现和干预。通过采取积极措施，可以大大减少宫颈癌的影响。",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "# 相关文章 宫颈癌 - 类型、症状、治疗和预防 ![](images/02d76957f65324178cd1b7190ced151cbb20006fc4faa4af39874e529f5028c5.jpg) 2024 年 10 月 1 日 ![](images/4518e994b3495fefa273d6cb2381da456896573492e901f9f0cc8584f559f873.jpg) 2024 年 10 月 1 日 # 订阅我们 输入您的电子邮件ID !",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "[](images/cacbca9b9c22b60b0eac9594fcdf4303f4c0d51f620f1d5d7ca14b380fffdd62.jpg) https://www.apollohospitals.com/zh-CN/corporate/diseases-and-conditions/all-you-need-to-know-about-cervical-cancer/ <html><body><table><tr><td>观看我们的视频</td><td>合项癌-吴至、症伙、治疗 急救护理</td></tr><tr><td>媒体联系</td><td>耳鼻喉</td></tr><tr><td>阿波罗医院评论</td><td>血管外科</td></tr><tr><td></td><td>儿科</td></tr><tr><td></td><td>皮肤科</td></tr><tr><td></td><td>妇产科</td></tr><tr><td></td><td>基因组医学</td></tr><tr><td>医疗程序</td><td>公司</td></tr><tr><td>质子疗法治疗癌症</td><td>公司介绍</td></tr><tr><td>美容和整形外科</td><td>我们的医生取得</td></tr><tr><td>骨髓移植</td><td>阿波罗精神</td></tr><tr><td>口腔颌面外科</td><td>阿波罗的故事</td></tr><tr><td>手部显微外科</td><td>投资者关系</td></tr><tr><td>G扫描-开放式站立式MRI扫描</td><td>投资者介绍</td></tr><tr><td>髋关节镜检查</td><td>倡议</td></tr><tr><td>微创心脏外科</td><td>奖项和荣誉</td></tr><tr><td>膝关节置换术</td><td>加入我们</td></tr><tr><td>耳蜗植入手术</td><td>医院</td></tr><tr><td>博客文章</td><td></td></tr><tr><td>卫生图书馆</td><td>印度的医院</td></tr><tr><td>Covid 19更新</td><td>国际医院</td></tr><tr><td>Covid19常见问题解答</td><td>阿波罗诊所</td></tr><tr><td>COVID-19疫苗接种</td><td>到达医院</td></tr><tr><td>COVID-19新症状</td><td>阿波罗摇篮</td></tr><tr><td></td><td>阿波罗生育力</td></tr><tr><td></td><td>阿波罗癌症中心</td></tr><tr><td></td><td>阿波罗质子中心</td></tr></table></body></html> # 学术与研究 课程 学术概况 临床研究 荣誉榜单 阿波罗火炬：校友网络 网络广播 合作论坛 什么是新的发布查询 在线咨询医生预约体检 提供您的反馈阿波罗生命线 我们的支架定价 点击此处 招聘免责声明 全膝关节置换植入物定价 点击此处 Covid-19 RT-PCR 检测 移植免责声明 # 阿波罗的医疗保健触手可及 下载的应用程序 Apple Store Play商店",
    "source": "关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防/关于宫颈癌的全部内容——类型、原因、症状、阶段、诊断、治疗和预防.md"
  },
  {
    "text": "子宫癌子宫内膜癌子宫肉瘤 ![](images/1d357e988dc0206cde824519d66d344fe4a5ffa1422a66b6ee42b4ca12f61547.jpg) # 关于患者 NCCN Guidelines® National Comprehensive NCCN Cancer Network 您知道全美的顶级癌症中心在共同努力改善癌症治疗吗？这个由领先的癌症中心组成的联盟称为 NationalComprehensive Cancer Network® (NCCN®)。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "癌症护理一直在变化。NCCN 制定了循证癌症护理建议， 供全球医护人员使用。这些经常更新的建议就是 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)。患者 NCCNGuidelines 清楚地解释了这些针对癌症患者和护理人员的专家建议。![](images/79c0c8c86b53052d3203bfdea6913f45f6ed09c8e5ab174b0b5db290d0be5061.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) 这些患者 NCCN Guidelines 基于子宫肿瘤 NCCN ClinicalPractice Guidelines in Oncology (NCCN Guidelines®) 2023 年第 1 版 — 2022 年 12 月 22 日。# 资助单位 # 患者 NCCN Guidelines 由 NCCN Foundation® 资助 # NCCN Foundation 衷心感谢以下企业支持者对患者 NCCNGuidelines 发布的协助：Eisai, Inc.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "和 GSK。NCCN 独立改编、更新和管理患者 NCCN Guidelines。企业支持者不参与患者 NCCN Guidelines 的制定，也不对其中包含的内容和建议负责。要制作礼物或了解更多信息，请在线访问或发送电子邮件 # 目录 # 4 子宫癌基础知识 10 子宫癌检查 16 子宫癌的治疗 30 子宫内膜癌的治疗 45 子宫肉瘤的治疗 56 生存状况 62 做出治疗决定 71 词汇表 74 NCCN 编著者 75 NCCN 癌症中心 76 索引 NCCN Foundation 旨在通过资助和分发患者 NCCN Guidelines 来支持数百万受癌症诊断影响的患者及其家人。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "NCCN Foundation 还致力于通过资助国内位于癌症研究创新中心的有前途的医生以推进癌症治疗。如需更多详细信息以及完整的患者和护理者资源库，请访问NCCN.org/patients。# 1 子宫癌基础知识 5 子宫 6 子宫癌的两种主要类型 9 关键点 # 子宫癌基础知识 » 子宫 子宫癌有两种主要类型。子宫内膜癌很常见，通常可以通过治疗治愈。子宫肉瘤很罕见，而且很难治疗。这两种疾病最常在绝经后被诊断出来。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "子宫癌最有效的治疗方法是手术。对您的癌症护理感到舒适很重要。要知道，您有权选择治疗方法。# 子宫 子宫，有时也称为母胎，是生殖系统的一部分。这是怀孕期间婴儿生长发育的地方。子宫的大小和形状通常类似于梨，中间是空的。女性生殖系统的其他部分包括卵巢、输卵管、子宫颈和阴道。子宫两侧各有一个卵巢和一个输卵管。输卵管连接到子宫的顶部。子宫的下部称为子宫颈。子宫颈连接子宫和阴道。尽管子宫颈是子宫的一部分，但子宫颈癌（宫颈癌）的诊断和治疗与子宫癌不同。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "本指南不涉及宫颈癌。# 女性生殖系统 女性生殖系统由子宫、子宫颈、阴道、输卵管和卵巢构成。子宫是怀孕期间婴儿生长发育的地方。![](images/b625dd146baab64ce4eee8e004396d68fb352151bf355040f8547ac2a2e696d1.jpg) 子宫分为三个主层： h 子宫内膜是排列在子宫内部的薄层组织。h 子宫肌层是子宫壁的中间肌肉层。h 子宫外膜或浆膜是子宫的薄外层。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "![](images/8c52992b8f939cce83d83b9b108fee0e412f4cf5ea7189a587d48b48aeb29a99.jpg) # 我应该接受子宫癌检查吗？不。在没有任何症状的情况下进行疾病检测称为“筛查”。例如，宫颈涂片检查用于筛查宫颈癌，乳房 X 光片用于筛查乳腺癌。目前还没有针对子宫内膜癌或子宫肉瘤的筛查测试。# 子宫癌的两种主要类型 有两种主要类型的癌症原发于子宫： 子宫内膜癌h 子宫肉瘤 下面将介绍这些子宫癌类型之间的差异。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 子宫内膜癌 子宫内膜癌很常见，通常在扩散到子宫外之前就会被发现。它被称为子宫内膜癌是因为它原发于子宫内膜，即子宫内层。子宫内膜癌最常见的症状是阴道异常出血。通常，这意味着绝经期间或绝经后出血。绝经前患者可能会出现异常长和/或大量的月经（经期）出血。对于绝经后患者，任何阴道出血都是不正常的，应进行检查，以确保它不是癌症的体征。子宫内膜癌分为不同类型。最常见的类型称为子宫内膜样癌。本书和其他地方有关子宫内膜癌的大部分信息均适用于子宫内膜样癌。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "还有其他不太常见的子宫内膜癌类型。它们生长得更快， # 子宫癌基础知识 » 子宫癌的两种主要类型 也更难治疗。这些高危子宫内膜癌包括： 浆液性癌透明细胞癌未分化/去分化癌h 癌肉瘤，也称为恶性苗勒管混合瘤 (MMMT) 由于这些癌症更具侵袭性，因此其治疗方法与大多数子宫内膜样癌不同。这些类型将在第4部分：子宫内膜癌的治疗中单独讨论。# 风险因素 确诊患有癌症后，想知道癌症为什么会发生是很正常的。有些癌症是遗传性的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这意味着您的父母通过基因将更高的风险遗传给了您。对于其他癌症，生活方式比基因起着更大的作用。对于许多类型的癌症来说，基因和生活方式都在您是否患上这种癌症方面发挥着作用。医学术语将增加患病几率的东西称为风险因素。下图显示了一些子宫内膜癌的风险因素。许多风险因素与体内雌激素过多有关。# 子宫内膜癌的风险因素 子宫内膜癌的许多风险因素都与体内雌激素过多有关。肥胖是一个主要风险因素，因为体内的脂肪组织可以将体内的天然类固醇转化为雌激素。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "![](images/df1c623906523444bd8c55cc25270a1bf66090e773eca397f93ee1ac7c77e0fa.jpg) # 子宫癌基础知识 » 子宫癌的两种主要类型 # 子宫肉瘤 子宫肉瘤原发于子宫的结缔组织细胞。它通常形成于子宫的肌肉层（子宫肌层）或子宫内膜的结缔组织细胞中。子宫肉瘤很罕见，可能比子宫内膜癌更难治疗。它们也被称为恶性间叶瘤。与子宫内膜癌一样，子宫肉瘤也有不同类型。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "本指南讨论了下面列出的肿瘤类型和其他类型h 子宫内膜间质肉瘤 (ESS)腺肉瘤子宫平滑肌肉瘤 (uLMS)未分化子宫肉瘤 (UUS)血管周上皮样细胞瘤 (PEComa)h 炎性肌纤维母细胞瘤 (IMT) ![](images/a283cf1f9f3a466dc5d57dfdcf71dc2f007638573a6754e5caed3142a0f3d772.jpg) # 关键点 # 子宫 h 子宫是生殖系统的一部分。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "怀孕期间，婴儿在子宫内生长发育。h 子宫分为三个主层。从内到外，这些层包括子宫内膜、子宫肌层和子宫外膜（浆膜）。有两种主要类型的癌症原发于子宫：子宫内膜癌和子宫肉瘤。# 子宫内膜癌 h 子宫内膜癌很常见，通常发现得很早。最常见的症状是阴道异常出血。h 子宫内膜样瘤是最常见的子宫内膜肿瘤类型。h 高危子宫内膜癌包括浆液性癌、透明细胞癌、未分化/去分化癌和癌肉瘤。h 这些不太常见的类型生长得更快，且更难治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 子宫肉瘤 h 子宫肉瘤原发于子宫壁或子宫肌肉。h 这种类型的子宫癌比子宫内膜癌更罕见，且更具侵袭性。h 子宫肉瘤通常在子宫切除术后发现。与您的护理团队建立个人关系。相信他们的技能和奉献精神可以帮助您！他们是您最大的财富。![](images/09040aa653cb4597dfa8cb3dae7d5d38949228bc42689c86b43d1aac8a65875a.jpg) # 2子宫癌检查 11 活检 11 血液检查 12 影像学检查 14 家族史和基因检测 14 肿瘤组织检查 15 关键点 医生会为您制定一个治疗计划。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "首先，他们需要收集关于癌症和您总体健康状况的信息。本章介绍了您可能需要的检查，以及制定治疗计划所需的其他步骤。对于疑似或确诊子宫癌，医生会进行全面身体检查。这通常包括用于检查子宫大小和活动能力的骨盆检查。医生会想了解有关您过去和当前健康状况的很多信息。他们还会询问您可能与子宫癌有关的症状，例如阴道出血。# 活检 # 子宫内膜活检 如果有阴道出血或其他可能的子宫癌症状，通常会进行子宫内膜活检。这通常可以在妇科医生办公室完成。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "子宫内膜活检涉及从子宫内膜（子宫内膜）取出组织样本。取出的组织由称为病理学家的专业医生进行检查。如果可能，病理学家会确定癌症类型和亚型。子宫内膜活检在诊断子宫内膜癌方面比诊断子宫肉瘤要好得多。# 宫颈活检 如果医生认为癌症可能已经扩散到子宫颈，可能还需要做宫颈活检。宫颈活检与子宫内膜活检类似，但细胞是取自子宫颈而不是子宫内膜。# 血液检查 全血细胞计数 (CBC) 是一种常见的血液检查。它提供了血液样本中红细胞、白细胞和血小板数量的信息。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "红细胞将氧气输送到全身。白细胞能够抵抗感染。血小板有助于控制出血。血细胞计数可能会因为癌症或其他问题而偏高或偏低。可能还会做一个称为化学概况的血液检查。它测量血液中某些物质的含量，例如代谢物、电解质、脂肪和蛋白质。这项检查提供了有关肾脏、肝脏和其他器官工作状况的信息。# 影像学检查 # 超声检查 超声检查利用声波拍摄体内照片。它能很好地显示子宫的大小、形状和位置。有两种类型的超声检查可用于评估子宫癌。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "在经腹超声检查中，会在腹部和髋骨之间的区域涂一种凝胶。凝胶有助于增强图像的清晰度。医生或技术人员会将探头放在皮肤上，并在凝胶中来回导引。对于经阴道超声检查，会将探头插入阴道。这可以帮助医生更清楚地看到子宫和附近区域。超声检查一般是无痛的。插入探头时可能会感到有些不适。# 胸部 X 线检查 对于疑似或确诊子宫内膜癌，可能需要做胸部 X线检查。目的是寻找胸部及其周围的疾病体征。X线检查是无痛的，使用的辐射量非常小。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果发现任何异常或可疑区域，可能会要求做胸部计算机断层 (CT) 扫描，以便更好地查看。接下来介绍 CT。# CT 可能会对胸部、腹部和骨盆进行 CT 扫描。医生正在寻找癌症在这些区域扩散的体征，尤其是高危肿瘤。CT 扫描是一种更详细的 X 线检查。它会从不同角度拍摄许多图像。计算机将这些图像组合起来制成三维 (3D) 图像。CT 扫描是一种更详细的 X 线检查。它是无痛且非侵入性的。CT 从不同角度拍摄许多图像。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "计算机将这些图像组合起来制成 3D 图像。![](images/51b5050681120d34303874866f22d4c8d93133662b16bceec69e8ef2d17094c3.jpg) 在扫描过程中，患者面朝上躺在扫描台上，扫描台会穿过一个像隧道一样的大机器。为了看得更清楚，可能会在静脉中注射一种称为造影剂的物质。也可能会要求您喝液体造影剂以突显肠道。造影剂会使 CT 图像更清晰。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "造影剂可能会引起皮肤潮红或荨麻疹。扫描期间您将是独自一人，但技术人员会在附近。您能够随时听到技术人员的声音，并与之交谈。扫描期间可能会听到嗡嗡声或咔哒声。# PET/CT 扫描 如果医生怀疑癌症已扩散到骨盆以外（转移），可能会将 CT 与另一种称为正电子发射断层扫描(PET) 的影像学检查结合使用。PET 会使用少量称为放射性示踪剂的放射性物质。大约在扫描前一小时，会给您一种注射糖放射性示踪剂。放射性示踪剂会释放出少量能量，可以通过影像机看到。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "癌症在图像中显得更明亮，因为癌细胞消耗糖的速度比正常细胞更快。# 骨盆 MRI 可能需要对骨盆进行磁共振成像 (MRI)。MRI 可以清晰地显示子宫和子宫颈的组织。MRI 可以显示癌症是否已经扩散到子宫颈或其他附近的器官。MRI 使用强磁场和无线电波对人体内部区域进行成像。它特别擅长拍摄软组织区域的清晰图像。与 CT 扫描或胸部 X 线检查不同，MRI 不使用辐射。如果您在狭小的空间内感到紧张，请告诉医生。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "MRI 在不使用辐射的情况下拍摄身体内部区域的图像。MRI 可以清晰地显示子宫和子宫颈的组织。如果您在狭小的空间内感到紧张，请告诉护理团队。![](images/2f54742921a6a2450d4485f965ba24500170e3b636a120a26b99a9222062c126.jpg) # 家族史和基因检测 大多数子宫内膜癌是由 DNA 的随机（非遗传性）突变引起的。只有大约 $5 \\%$ 是由遗传风险引起的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "然而，医生会想知道您是否有癌症家族史，或者可能会增加患癌症风险的其他疾病。林奇综合征，也称为遗传性非息肉病性结直肠癌 (HNPCC)，是一种遗传性癌症综合征。林奇综合征与结直肠癌、子宫内膜癌、卵巢癌和其他癌症密切相关。与没有遗传风险的患者相比，患有林奇综合征的人患子宫内膜癌的发病时间往往要早 10 到 20 年。李-佛美尼症候群 (LFS)是另一种遗传性癌症风险综合征。LFS 患者患子宫肉瘤的风险更高。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "为了确定哪些人应该接受林奇综合征检测，需要检测肿瘤的错配修复 (MMR)蛋白表达。# 错配修复 (MMR) 在正常细胞中，一种称为 MMR 的过程可以修复DNA 分裂及其自我复制时发生的错误。细胞的MMR 系统不能正常工作时，错误会累积，并导致DNA 变得不稳定。这称为微卫星不稳定性 (MSI)。有两种实验室检查来检测这种生物标志物。根据所使用的方法，异常结果称为高度微卫星不稳定性 (MSI-H) 或错配修复缺陷 (dMMR)。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "非 dMMR/MSI-H 肿瘤被称为微卫星稳定 (MSS) 或错配修复正常 (pMMR)。建议每个诊断为子宫内膜癌的人都要进行 MMR/MSI 检测，子宫肉瘤也可能需要进行 MMR/MSI 检测。使用活检样本或手术期间切除的肿瘤进行检测。如果癌症是 dMMR/MSI-H，可能还需要做林奇综合征检测。如果肿瘤没有异常 MMR 结果，但有子宫内膜癌和/或结直肠癌的持久家族史，建议进行遗传咨询和遗传（种系）突变检测。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果您患有林奇综合征或 LFS，我们将对您进行密切监测，并就如何降低患其他癌症的风险提供建议。# 肿瘤组织检查 # 激素受体检测 一些癌细胞含有雌激素和孕激素可以附着的蛋白质。这些蛋白质称为受体。一旦附着，激素可能会帮助肿瘤生长或抑制肿瘤生长。了解肿瘤细胞是否具有激素受体可能会影响治疗计划。检测包括在实验室分析一小块肿瘤。如果肿瘤细胞具有激素受体，则这种癌症称为雌激素和/或孕激素受体“阳性”。建议对大多数子宫肉瘤以及复发性或晚期子宫内膜癌进行激素受体检测。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# HER2 HER2 是一种存在于细胞表面的蛋白质。一些子宫内膜癌含有过多的 HER2 蛋白。这会导致癌症快速生长和扩散。建议对某些晚期或复发性高危子宫内膜肿瘤进行 HER2 检测。# 关键点 # 活检 h 子宫内膜癌通常通过子宫内膜活检来诊断。这涉及从子宫内膜取出组织样本。h 子宫内膜活检通常可以很好地诊断子宫内膜癌，但对子宫肉瘤的诊断并不可靠。# 其他检查 h 治疗前的其他检查包括体检、健康史和血液检查。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 也可能建议做影像学检查，包括超声检查、胸部 X 线检查、CT、骨盆 MRI，可能还有PET/CT。# 家族史和基因检测 h 大多数子宫内膜癌是由 DNA 的随机（非遗传性）突变引起的。h 林奇综合征是一种遗传综合征，与结直肠癌、子宫内膜癌、卵巢癌和其他癌症密切相关。h 如果您有癌症家族史或可能增加患癌症风险的其他疾病，请告诉医生。h 为了确定哪些人应该接受林奇综合征检测，需要检测肿瘤的 MMR 蛋白表达。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 建议每位确诊患有子宫内膜癌的人做MMR/MSI 检测。# 肿瘤组织检查 h 建议对大多数子宫肉瘤和晚期（III 期或 IV期）或复发性子宫内膜癌进行激素受体检测。h 激素受体检测是在手术后使用切除的肿瘤进行的。# 3 子宫癌的治疗 17 手术 18 手术分期 24 放疗 26 全身性治疗 27 临床试验 29 关键点 # 子宫癌的治疗 » 手术 本章介绍了子宫癌的主要治疗方法。您的治疗方案将取决于您是否适合手术，以及其他因素。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 手术 如果可能，手术是子宫癌的首选治疗方法。最常见的手术是全子宫切除术和双侧输卵管卵巢切除术 (BSO)。全子宫切除术切除子宫，包括子宫颈。BSO 切除双侧卵巢和双侧输卵管。子宫切除术后不可能再怀孕。如果您愿意，保留生育能力疗法可能是一种选择。有关保留生育力疗法的更多信息，请参见第4部分：子宫内膜癌的治疗。不太常用的子宫癌手术包括： h 根治性子宫切除术：子宫、子宫颈、子宫颈附近的一些组织和部分阴道都会被切除。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 全子宫切除术和单侧输卵管卵巢切除术(USO)：子宫、子宫颈、一个卵巢和一根输卵管被切除。h 全子宫切除术和双侧输卵管切除术 (BS)：子宫、子宫颈和两根输卵管均被切除。卵巢留在体内。# 全子宫切除术和 BSO 子宫癌最常用的手术，包括切除子宫（包括子宫颈）、双侧卵巢和双侧输卵管。![](images/a11dd814be15371306147d4379c52b9a6ee15794fa496d5a3d0c5c078dba7d4d.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) 微创手术只需在身体上做几个小切口即可进行。微创手术通常会减少疼痛和疤痕。此外，与腹部切口较大的手术相比，恢复所需的时间通常更短。根据子宫癌的类型和程度，微创手术可能是一种选择。有时，肿瘤最终会比预期的要大，或者扩散到其他部位。在这种情况下，肿瘤减积手术可能是一种合适的治疗方法。在肿瘤减积手术中，外科医生尝试切除所有看得见或摸得着的肿瘤。如果所有肿瘤都被切除，或者除了直径不超过 1 厘米的植入物之外的所有肿瘤都被切除（理想减积手术），则认为肿瘤减积手术是成功的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "在安全情况下，减积手术对于子宫内膜癌来说是一个好主意，因为这可能意味着其他治疗方法有更好的机会杀死残留的肿瘤细胞。# 手术分期 在手术过程中，外科医生会非常仔细地观察最靠近骨盆的组织和器官是否有癌症体征，并对任何可疑区域取样进行检测。外科医生可能会将液体注入腹部的开放空间，然后将其取出，查看是否有癌细胞。这就是所谓的腹腔灌洗。通常会切除淋巴结并进行癌症检查。这可以通过称为前哨淋巴结活检的程序来完成。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "手术期间获得的第一手信息与手术前进行的检查一起用于确定癌症的分期（程度）。这个过程称为手术分期。癌症分期有助于医生决定手术后是否需要进一步治疗。有两个系统用于子宫癌分期：国际妇产科联合会(FIGO) 系统和美国癌症联合委员会 (AJCC) 肿瘤、淋巴结、转移 (TNM) 系统。两个系统都使用以下有关癌症的关键信息进行分期： h 肿瘤大小或程度/深度 h 淋巴结是否有癌变 h 癌症是否已扩散到身体的其他部位（转移） 子宫内膜癌和子宫肉瘤有四个主要分期。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "接下来将更详细地介绍每个分期。一般来说，处于较早癌症分期的患者会有更好的预后，但并非总是如此。有些患者在他们的分期中会好于预期，而有些患者则会比预期更差。# 子宫内膜癌的分期 在 FIGO 分期系统中，子宫内膜癌有四个主要分期：I 期、II 期、III 期和 IV 期。有些分期又分为子分期，子分期可能标有字母，也可能还标有数字。例如 IIIB 期和 IIIC2 期。以下几页的插图显示了这些分期。# I 期子宫内膜癌 肿瘤位于子宫主体。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "还没有长到子宫颈。![](images/f78c9c8204520b3a077ca4899e9b057aeaa2900869aaaa4f7806709585c4cc85.jpg) II 期子宫内膜癌肿瘤已长入子宫颈。![](images/c941cc0b560315a8dbc2a9d80798309ab6d35162931c2619a6e26e52beeb8da1.jpg) # IIIA 期子宫内膜癌 肿瘤已生长到子宫外层、卵巢或输卵管。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "![](images/eba3aec32666039d10f03589367d178250e1429dd581324302b136350c4a0bbd.jpg) # IIIB 期子宫内膜癌 阴道或子宫周围的脂肪和结缔组织中有癌症。![](images/1dda284f030d67f05eefd072fae1aec5c47df65d0e41e4c0d0b5a03af2a7ac5b.jpg) # IIIC 期子宫内膜癌 最靠近子宫的淋巴结（称为骨盆淋巴结，IIIC1 期）或靠近脊柱底部的淋巴结（称为主动脉旁淋巴结，IIIC2 期）中有癌症。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# IVA 期子宫内膜癌 癌症已经扩散到膀胱或肠道的内层。![](images/591277905642603de71f11a31b9514d4be4fee77b2b7e73660876ab37f913812.jpg) ![](images/f048650b3e3b7643e99b95c3967837e51bb3f9594ba75bd24d8f8f236d0c1fe3.jpg) # IVB 期子宫内膜癌 癌症已扩散到远离子宫的区域，例如腹部、骨骼或肺部。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "腹部包括胰腺、胃、肠、肝脏和胆囊。![](images/d1161e1de1f2feb9b847f650f755e6bdb7af16e3c42ea385834564174e841a4c.jpg) # 子宫肉瘤的分期 在 FIGO 分期系统中，子宫肉瘤有四个主要分期：I 期、II 期、III 期和 IV 期。所有分期又分为标有字母的子分期。请参见指南 1。# 指南 1平滑肌肉瘤 (LMS)、子宫内膜间质肉瘤 (ESS) 和腺肉瘤的分期 <html><body><table><tr><td colspan=\"2\">1期－肿瘤很小且仅位于子宫内。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "</td></tr><tr><td>IA期</td><td>对于 LMS和 ESS:肿瘤为5厘米(约 2英寸)或更小 对于腺肉瘤：肿瘤仅存在于子宫内膜中。</td></tr><tr><td>IB期</td><td>对于LMS和 ESS:肿瘤大于5 厘米。对于腺肉瘤：肿瘤生长到子宫肌层的一半以下。</td></tr><tr><td>IC期</td><td>腺肉瘤:肿瘤生长到子宫肌层的一半以上。</td></tr><tr><td colspan=\"2\">ⅡI期－肿瘤已扩散到子宫外，但仍在骨盆内。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "</td></tr><tr><td>IIA期</td><td>肿瘤已长入卵巢或输卵管。</td></tr><tr><td>IIB期</td><td>肿瘤也已经生长到骨盆的其他组织中。</td></tr><tr><td colspan=\"2\">川I期-腹部有癌症，附近的淋巴结也可能有癌症。</td></tr><tr><td>IIA期</td><td>肿瘤已生长到腹部的一个区域。</td></tr><tr><td>IIIB期</td><td>肿瘤已生长到腹部的两个区域。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "</td></tr><tr><td>IIIC期</td><td>附近的淋巴结有癌症。</td></tr><tr><td colspan=\"2\">IV期－膀胱或直肠有癌症，远离子宫的区域也可能有癌症。</td></tr><tr><td>IVA期</td><td>肿瘤已长入膀胱或直肠。</td></tr><tr><td>IVB期</td><td>癌症已扩散到远离子宫的区域，例如肺部。</td></tr></table></body></html> # 放疗 放疗使用类似于 X 射线的高能波来杀死癌细胞。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这是子宫内膜癌和子宫肉瘤的常用治疗方法。接下来介绍可用于治疗子宫癌的放疗类型。您可能会接受不止一种类型的治疗。# 外照射放疗 在外照射放疗 (EBRT) 中，一台大型机器将射线瞄准癌症灶。射线穿过皮肤和其他组织到达肿瘤。EBRT 以小剂量给药，称为分次给药。对于子宫癌的治疗，EBRT 通常每周进行 5 天，持续 5 至6 周。在治疗开始前需要进行疗程规划，称为模拟。您首先要摆好治疗体位。将要求您仰卧并保持不动。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "可能会给您放一个支撑物，帮助您在放射疗程期间保持不动。将通过 CT 扫描获取癌症灶的图像。放射肿瘤医生将使用 CT 扫描图像和复杂的计算机软件制定一个治疗计划，将放射束瞄准肿瘤和附近的淋巴结。这个计划阐述了适用于您的最佳放射剂量，以及所需的疗程次数。治疗过程中，您将像模拟时一样躺在治疗台上。可能会使用阻止您移动的装置。这有助于瞄准肿瘤。皮肤上的墨迹有助于您在日常治疗中准确摆好体位。您独自一人待在治疗室。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "技术人员在旁边的房间里操作机器。技术人员能够随时看到、听到您，并能够与您交谈。进行治疗时，您可能会听到噪音。您不会看到、听到或感觉到辐射。一次疗程大约需要 20 分钟，光束开启时间大约为两分钟。# 外照射放疗 (EBRT) 一台大型机器将射线瞄准肿瘤，穿过皮肤和其他组织到达肿瘤。![](images/d22f74602c3b95b42bb2a4ce9f280bd9702a78adb2ba4ebce47df86bb6ceb6fe.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) # IMRT 有一种先进类型的 EBRT，称为调强放疗 (IMRT)，可用于治疗子宫癌。IMRT 使用许多不同强度的小射束。这使得高剂量辐射能够瞄准肿瘤，同时限制了对周围正常组织的辐射量。通过 IMRT，可以减少对附近重要器官和结构的辐射，例如肠道和膀胱。这有助于减少与治疗相关的副作用。# SBRT 立体定向放疗 (SBRT) 是一种高度专业化的EBRT 类型。它可用于治疗已扩散到肝脏、肺部或骨骼的子宫内膜癌。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "使用非常精确的射束将高剂量辐射传递到一个或多个转移灶。SBRT 通常需要 5 次或更少的疗程。# 立体定向放射外科 (SRS) SRS 是一种非手术高精度放疗。它可用于治疗小型脑瘤或脊椎肿瘤。# 副作用 在 5 至 6 周的体外照射治疗期间，治疗部位的常见副作用包括皮肤刺激、压痛和发红。放疗的其他短期副作用包括疲劳、腹泻、尿频或排尿时疼痛、以及恶心。治疗结束后，这些副作用大多数会随时间推移而减轻。放疗的副作用可能不会马上感觉到。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "它们可能会在治疗周期后期，甚至在治疗结束后出现并恶化。子宫癌的放疗还可能对生育能力、性健康、以及肠道和膀胱功能产生长期且可能严重的副作用。请参见第 ${ \\pmb 6 }$ 部分：生存状况，了解有关帮助预防、限制或管理这些副作用的方法的信息。# 近距离放疗 另一种用于子宫癌的放疗称为近距离放疗或体内照射。之所以称为体内治疗，是因为会将抗癌放射性物质放入患者体内，要么直接进入肿瘤，要么靠近肿瘤。通过放置在阴道或子宫内的空心管，可以将小辐射颗粒递送到肿瘤区域。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这样就可以进行多次递送安全剂量。# 全身性治疗 全身性治疗是使用能够在血液中流动、到达并影响全身细胞的物质进行的治疗。全身性治疗的类型包括化疗、靶向治疗、免疫治疗和内分泌治疗。# 化疗、靶向治疗和免疫治疗 化疗是子宫癌最常用的全身性治疗类型。它通过杀死细胞或阻止癌细胞分裂来阻止癌细胞的生长。大多数化疗药物通过输注给药。这意味着它们是通过静脉缓慢注入血液的液体。靶向治疗和免疫治疗是较新类型的全身性治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "它们可能是对化疗无缓解、化疗后复发（复发性）、或扩散到骨盆以外（转移性）的子宫癌的治疗选择。与化疗不同，靶向治疗和免疫治疗对于治疗具有特定特征（称为生物标志物）的癌症最有效。化疗、靶向治疗和免疫治疗除了杀死癌细胞外，还可以杀死健康细胞。对健康细胞的损害会导致潜在的严重副作用，例如脱发、皮肤皲裂和口腔溃疡。这些类型的全身性治疗通常以治疗日加休息日为疗程进行。这样能让身体充分恢复，然后再接受下一个疗程的治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "例如，您可能连续 1 周每天接受化疗，然后 3 周不接受化疗。这 4 周构成一个疗程。疗程的长短取决于所使用的药物。# 内分泌治疗 雌激素和孕激素都是激素。它们会影响子宫中癌细胞的生长。内分泌治疗是一种改变体内某些激素水平的癌症治疗方法。它与可用于控制更年期症状的激素治疗不同，后者称为激素替代疗法(HRT)。接下来介绍可用于治疗子宫癌的内分泌治疗类型。孕激素是激素孕酮的实验室制造版本。它们有助于减缓子宫内膜癌细胞的生长。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "用于治疗某些子宫癌的孕激素包括： 醋酸甲羟孕酮（安宫黄体酮）（口服） 醋酸甲地孕酮（口服） 左炔诺孕酮（曼月乐）（一种释放孕激素的宫内节育器 (IUD)） 芳香化酶抑制剂是口服药物。它们可以阻止体内脂肪组织产生雌激素。结果，体内雌激素的总量降低。芳香化酶抑制剂包括： 阿纳托唑（瑞宁得）来曲唑（弗隆）依西美坦（阿诺新） 他莫昔芬是一种用于降低体内雌激素含量的药物。它是口服药。他莫昔芬不用于子宫肉瘤。氟维司群（芙仕得）阻断可导致癌细胞生长的雌激素受体。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "氟维司群通过注射（推注）给药。促性腺激素释放激素 (GnRH) 激动剂通过降低卵巢功能正常患者的雌激素水平发挥作用。# 副作用 内分泌治疗可能会引起副作用。更年期症状很常见。这些症状包括潮热、情绪变化、阴道干燥、睡眠困难和盗汗。内分泌治疗的其他常见副作用包括阴道分泌物、体重增加、手脚肿胀、疲劳和性欲降低。血栓是他莫昔芬的一种罕见但严重的副作用。芳香化酶抑制剂会削弱骨骼，还可能导致关节和肌肉疼痛。向治疗团队索要您正在接受的每种全身性治疗的常见和罕见副作用的完整列表。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 临床试验 临床试验是医学研究的一种。在开发出潜在抗癌新方法并经过实验室测试后，需要在人体内进行研究。如果在临床试验中发现药物、设备或治疗方法安全有效，则可能会获得美国食品和药物管理局 (FDA) 的批准。所有癌症患者都应仔细考虑所有适用于其癌症类型的治疗方案，包括标准治疗和临床试验。请与医生讨论临床试验是否对您有意义。# 分期 大多数癌症临床试验都侧重于治疗。治疗试验分期进行。h I 期试验研究试验性药物或治疗方法的安全性和副作用。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "他们还寻找药物或治疗方法可以起作用的早期体征。h II 期试验研究药物或方法针对特定类型癌症的疗效。h III 期试验将药物或方法与标准治疗进行对比。若结果良好，就可能获得 FDA 的批准。h IV 期试验研究 FDA 批准治疗的长期安全性和获益。# 谁能入选？每项临床试验都有参加的规则，这叫做入排标准。规则可能与年龄、癌症类型和分期、治疗史或一般健康状况有关。这些要求确保受试者在特定方面相似，并且试验对受试者尽可能安全。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 知情同意 临床试验由一组称为研究团队的专家管理。研究团队将与您详细审查研究，包括其目的以及加入的风险和获益。还将以知情同意书的形式提供所有这些信息。请仔细阅读同意书，并在签署前提出问题。花些时间与家人、朋友或您信任的其他人讨论。请记住，您可以随时离开，寻求临床试验之外的治疗。# 开始对话 不要等医生提出临床试验。由您开始对话，了解所有治疗方案。如果您发现一项可能有资格参加的研究，请询问治疗团队您是否符合要求。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果无法加入，请不要气馁。总会有可用的新临床试验。# 常见问题 围绕临床试验存在许多谬见和误解。许多癌症患者并不清楚可能的获益和风险。# 我会不会服用安慰剂？几乎不会进行仅使用安慰剂（真正药物的非活性版本）的癌症临床试验。但接受标准治疗联合安慰剂或标准治疗联合新药的情况很常见。如果安慰剂是临床试验的一部分，将会在您入组前通过口头和书面形式通知您 # 我必须付费才能参加临床试验吗？这种情况很少。这取决于研究、您的健康保险和您的居住地。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "您的治疗团队和研究团队可以帮助确定您是否需要承担任何费用。670 寻找临床试验 # 在美国 GOG Foundation gog.org NCCN 癌症中心NCCN.org/cancercenters 国家癌症研究所 (NCI)cancer.gov/about-cancer/treatment/clinical-trials/search NRG 肿瘤学会 nrgoncology.org # 全球 美国国家医学图书馆 (NLM)clinicaltrials.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "gov # 在寻找临床试验方面需要帮助？NCI 的癌症信息服务 (CIS)1.800.4.CANCER (1.800.422.6237)cancer.gov/contact # 关键点 # 手术和分期 h 全子宫切除术联合双侧输卵管卵巢切除术(BSO) 是治疗子宫癌最常用的手术。手术和检查结果用于对癌症进行分期。这称为手术分期。h 手术分期描述了体内癌症灶的数量及其扩散的部位。h 子宫内膜癌和子宫肉瘤的分期不同。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "每种类型都有四个主要分期。# 放疗 h 放疗使用高能射线杀死癌细胞或阻止产生新的癌细胞。h 外照射放疗 (EBRT) 和阴道近距离放疗通常用于治疗子宫癌。# 全身性治疗 h 全身性治疗是使用能够在血液中流动、到达并影响全身细胞的物质进行的治疗。h 化疗、内分泌治疗、靶向治疗和免疫治疗都是全身性治疗的类型。# 临床试验 h 临床试验给人们提供了试验性测试和治疗的机会，这些测试和治疗可能会及时得到FDA 的批准。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 4 子宫内膜癌的治疗 31 子宫内膜样癌 37 高危子宫内膜癌 40 治疗结束后 41 复发 44 关键点 本章介绍子宫内膜癌的推荐治疗方案。首先讨论最常见类型子宫内膜肿瘤（子宫内膜样肿瘤）的治疗，然后讨论高危类型的治疗。在开始治疗前，了解癌症是否已经扩散非常重要。它在如何治疗方面（以及在多大程度上）是否发挥了作用。主要有以下三种可能性： h 癌症仅发生在子宫的主要部分（而不是子宫颈）。h 癌症已经生长到子宫颈。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 癌症已从子宫扩散到身体的其他部位。接下来讨论每种情况下的治疗方法。# 子宫内膜样癌 # 癌症只存在于子宫内 子宫内膜癌通常在扩散到子宫体以外之前就被发现。在这种情况下，最有效的治疗方法是手术。如果您愿意并且能够进行手术，建议做全子宫切除术 (TH) 和双侧输卵管卵巢切除术 (BSO)。TH切除子宫和子宫颈。有必要切除子宫颈，因为子宫癌可以扩散到子宫颈。BSO 切除卵巢和输卵管。也许可以保留卵巢。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "卵巢保留将在下面详细讨论。子宫切除术后不可能再怀孕。如果还有可能怀孕且希望如此，保留生育能力的治疗可能是一种选择。请参阅下一页了解更多信息。如果可能，对于尚未扩散到子宫体以外的子宫内膜样癌，首选微创手术。在手术过程中，外科医生将评估癌症的程度，并切除组织和淋巴结进行检查。手术和检查结果用于对癌症进行分期。这称为手术分期。这个分期用于确定手术后所需的治疗。请参阅第 36 页上的术后治疗了解后续步骤。# 卵巢保留 绝经前，卵巢会产生雌激素和孕激素。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "切除卵巢会导致雌激素突然丧失。这称为手术绝经。手术绝经的副作用包括潮热、睡眠问题、情绪变化和阴道萎缩。阴道萎缩是一种阴道内壁变薄、干燥和发炎的病症。雌激素不足还存在长期风险。这些风险包括心脏或血管问题（心血管疾病）和骨质流失（骨质疏松症）。如果您处于绝经前，保留卵巢可能是安全的。这称为卵巢保留。在以下情况下，这可能是一个选择： h 癌症处于 I 期影像学检查显示卵巢正常 h 没有乳腺癌、卵巢癌或林奇综合征的家族史 如果能够保留卵巢，仍然建议将输卵管随子宫一起切除。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 拒绝或不能先做手术 如果不想做手术或因其他健康原因不能做手术，则首选放疗。可以使用外照射放疗 (EBRT)、近距离放疗（内照射），或两者联合治疗。另一种选择是内分泌（激素）治疗。激素治疗通常仅考虑用于小型或生长缓慢的子宫内膜样肿瘤。优选口服孕激素，例如醋酸甲羟孕酮（安宫黄体酮）和醋酸甲地孕酮。在某些情况下，释放孕激素的宫内节育器 (IUD) 可能是更好的选择。曼月乐就是一个例子。它含有孕激素左炔诺孕酮。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 保留生育能力疗法 切除子宫、子宫颈、输卵管和卵巢的手术是尚未扩散到子宫外的子宫内膜癌的标准治疗方法。没有子宫就不可能怀孕。对于一些确诊为子宫内膜癌的人来说，这可能很难接受。如果您患有低风险子宫内膜癌，想要治疗癌症，但也希望尝试在未来有一个孩子，保留生育能力疗法可能是一种选择。它包括推迟手术，并首先采用激素治疗来治疗癌症。如果激素治疗效果良好，杀死了所有癌症，您可以尝试怀孕。保留生育能力疗法只是某些低风险子宫内膜癌的一种选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "在以下情况下，这可能是一种选择： h 肿瘤为子宫内膜样瘤（最常见的类型）。h 影像学检查显示癌症并没有超出子宫内膜。h 癌细胞为 1 级。这意味着它们在显微镜下看起来与健康细胞相似。h 没有任何医学原因证明您不能（或不应该）怀孕。h 没有任何医学原因证明您不能或不应该接受激素治疗。激素治疗的禁忌症包括中风、心肌梗塞、肺栓塞、深静脉血栓形成和吸烟。h 您完全了解保留生育能力疗法不是子宫内膜癌的标准治疗方法。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 您同意定期进行子宫内膜活检，以检查治疗是否有效。在开始保留生育能力疗法治疗之前，建议咨询生育专家。您可能还需要进行遗传咨询和检测。# 子宫内膜癌的治疗 » 子宫内膜样癌 在保留生育能力疗法治疗期间，保持健康的体重和生活方式非常重要。它可能会带来更好的治疗效果。预期医生会询问您的饮食、活动水平和其他与生活方式相关的因素。激素治疗有 3 种选择。全部使用人造孕激素： 醋酸甲羟孕酮（安宫黄体酮）（口服）醋酸甲地孕酮（口服）h 孕激素宫内节育器 (IUD)（例如曼月乐） 为了了解激素治疗是否有效，每 3 至 6 个月会从子宫内膜取组织样本进行检测。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这通过子宫内膜活检或扩张和刮宫术（“D&C”）来完成。如果激素治疗效果良好并且癌症在 6 个月后消失，则可以停止激素治疗并开始尝试怀孕。尝试怀孕期间，将继续每 6 个月检测一次子宫内膜。如果激素治疗成功，但您没有立即开始尝试怀孕，医生可能会建议您继续接受基于孕激素的激素治疗，以保持良好效果。如果在尝试怀孕期间癌症复发，医生会建议您做手术。如果激素治疗无效且 6 至 12 个月后癌症仍然存在，则建议做手术。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "保留卵巢可能是一种选择。# 宫内节育器 (IUD) 释放左炔诺孕酮的宫内节育器是保留生育能力疗法中使用的激素治疗方法之一。![](images/eafddd27c432ee3298af4db5a13024c9de3bd5565cb01a14165f51824b3c66ab.jpg) # 癌症已扩散至子宫颈 如果宫颈活检或骨盆磁共振成像 (MRI) 显示癌症已生长到子宫颈，治疗方案取决于是否可以先做手术。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果可能，最好先做手术。如果您同意手术并且身体健康，建议做全子宫切除术或根治性子宫切除术，并结合 BSO 切除输卵管和卵巢。外科医生将在手术过程中评估癌症的程度，并取出组织和淋巴结进行检测。病理学家将检查取出的组织并确定癌症分期。这称为手术分期。这个分期用于确定手术后所需的治疗。请参阅第 36页上的术后治疗了解后续步骤。在某些情况下，可能会在手术前先采用 EBRT 联合近距离放疗来尝试缩小癌症。然而，如果可能，通常建议直接进行手术。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果术前做了放疗，术后就不会再做了。请参阅第 40 页上的治疗结束后了解后续步骤。# 拒绝或不能先做手术 如果您不想做手术或因其他健康原因不能做手术，还有其他治疗选择。最常见的是，首先采用放疗尝试缩小肿瘤。做 EBRT 联合近距离放疗。除放疗外，还可做铂基化疗。当与放疗联合时，化疗可以使放疗更容易杀死癌细胞。这些治疗的联合使用称为放化疗。如果放疗（和化疗（如果做）效果良好且您同意，则做手术可能是一种选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "对于不能先做手术的人来说，另一种选择是单独化疗来尝试缩小癌细胞。此时，首选方案是卡铂联合紫杉醇。如果效果良好，做手术可能是一种选择。如果仍然不能做手术，推荐 EBRT 联合近距离放疗。# 癌症已扩散到子宫外 对于已经扩散到子宫外的癌症的治疗，取决于癌症扩散的程度以及是否可以先通过手术切除。# 您愿意且有能力先做手术 如果癌症尚未扩散到骨盆或腹部之外，建议做全子宫切除术和 BSO。外科医生会尝试尽可能多地切除肿瘤。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "有些人会在术前接受化疗，尝试缩小肿瘤。在手术过程中，外科医生将评估癌症的程度，并切除组织和淋巴结进行检查。病理学家将检查取出的组织并确定癌症分期。这称为手术分期。这个分期用于确定手术后所需的治疗。已扩散到子宫外的子宫内膜癌为 III 期或 IV 期。请参阅第 36页上的术后治疗。如果癌症已扩散到远离骨盆的区域（已转移），建议进行全身性治疗。此时，首选方案是卡铂联合紫杉醇。除化疗外还可使用 EBRT。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "也可以考虑手术（全子宫切除术和 BSO），但目的不是治愈癌症。目的是缓解癌症引起的症状并进一步限制其扩散。这称为姑息性手术。如果计划做手术，立体 定向放疗 (SBRT) 可用于摧毁小的转移性肿瘤。请参阅第 40 页上的治疗结束后了解后续步骤。# 拒绝或不能先做手术 如果不想手术或因其他健康原因不能做手术，治疗方案取决于癌症扩散的程度。如果癌症尚未扩散到骨盆或腹部之外，建议 EBRT。除体外照射外，还可以做近距离放疗、全身性治疗，或两者联合治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果治疗效果良好且您愿意，也可以做手术。如果癌症已发生转移，建议全身性治疗。如果效果良好且您愿意，也可以做手术。否则，放疗可能是一种选择。![](images/5dbe5294a8ab7f2b9a3ef6fc267215316fa2c0fb65da04854b7b41f84a95787d.jpg) # 子宫内膜癌会遗传吗？通常不会。大多数子宫内膜癌病例是由DNA 随机（非遗传性）突变引起的。只有大约 $5 \\%$ 的子宫内膜癌是由遗传风险引起的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这包括患有称为林奇综合征的遗传性疾病患者。林奇综合征患者一生中患子宫内膜癌的风险很高（约 $6 0 \\%$ ）。林奇综合征患者应受到密切监测，并就如何降低患子宫内膜癌和其他癌症的风险为其提供建议。# 术后治疗 接下来将根据分期介绍手术后的治疗方法。此信息仅适用于子宫内膜样癌。# I 期 对于某些 I 期子宫内膜样癌，建议进行术后治疗。医生会考虑下面列出的因素，以确定更多治疗是否有助于降低癌症复发的风险。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 癌症分期（IA 期或 IB 期） h 癌症等级（显微镜下肿瘤细胞的异常程度）年龄肿瘤向子宫肌肉层延伸了多远（如果有）主肿瘤以外的血管或淋巴管内是否有肿瘤细胞，称为淋巴管间隙侵犯 (LVSI)。如果有，则意味着癌症更有可能已经扩散到淋巴结。权衡这些因素后，医生可能会决定您不需要更多的治疗。在这种情况下，采用观察和等待的方法。将开始监测。如果您确实需要更多治疗，I 期子宫内膜癌术后使用的主要治疗方法有： 阴道近距离放疗 EBRT 对于一些高等级、IB 期子宫内膜样肿瘤，除了上述一种或两种治疗外，还可以做化疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "在术后做任何治疗后，开始随访护理。# II 期 对于所有 II 期子宫内膜癌，建议术后进行放疗。首选 EBRT。阴道近距离放疗也是一种选择，可以单独进行，也可以与 EBRT 一起进行。对于极低危 II 期癌症，可以考虑单独进行阴道近距离放疗。在某些情况下，除了 EBRT 和/或阴道近距离放疗外，还会做化疗或激素治疗。激素治疗通常仅考虑用于小型或生长缓慢的子宫内膜样肿瘤。术后治疗后，开始随访护理。# III 期和 $\\boldsymbol { \\mathsf { I V } }$ 期 III 期和 IV 期子宫内膜样癌的术后主要治疗方法是全身性治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "也可以采用化疗或激素治疗。激素治疗通常仅考虑用于小型或生长缓慢的子宫内膜样肿瘤。除了全身性治疗外，还可以接受EBRT 和/或阴道近距离放疗。全身性治疗（和放疗（如果做）后，开始随访护理 # 高危子宫内膜癌 大多数子宫内膜癌都是早期发现的，并且对治疗反应良好。其他不太常见的类型可以迅速扩散，并且更难治疗。在确诊时，这些高危子宫内膜癌可能已经扩散到子宫以外。高危子宫内膜癌包括： h 浆液性癌透明细胞癌癌肉瘤 h 未分化/去分化癌 癌肉瘤在显微镜下表现为部分子宫内膜癌和部分子宫肉瘤。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "它们也称为恶性中胚叶混合瘤或恶性苗勒管混合瘤 (MMMT)。与子宫内膜样肿瘤一样，高危子宫内膜肿瘤的第一体征是阴道出血。然而，这些类型的子宫内膜癌也会引起以下体征和症状： h 骨盆区域有肿块h 宫颈涂片检查结果异常h 腹部积液或肿胀（也称为腹水） 检查有助于确定癌症是否已经扩散到子宫以外。如果您尚未做影像学检查，请在治疗前做一次。医生也可能要求做癌症抗原 125 (CA-125) 血液检测。血液中这种物质含量高可能意味着癌症已扩散到子宫以外。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果有，CA-125 检测也可用来观察治疗是否有效。对于晚期或转移性浆液性癌或癌肉瘤，还建议做 HER2 检测。高危子宫内膜癌最有效的治疗方法是手术。建议做全子宫切除术和 BSO。将进行手术分期，以了解癌症的程度，并确定分期。如果可能，首选微创手术。不建议将保留生育能力疗法用于这些肿瘤类型。如果您不适合做手术，请参阅第 39 页。# 术后治疗 高危子宫内膜癌术后几乎都需要治疗。推荐的治疗方案取决于肿瘤类型和分期。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 浆液性癌和透明细胞癌 如果手术期间所有肿瘤均被切除，则无需进一步治疗。建议观察。对于非浸润性 IA 期疾病，术后治疗取决于腹腔灌洗（“洗液”）的结果。外科医生可能会将液体注入腹部的开放空间，然后将其取出，查看是否有癌细胞。如果没有发现癌细胞，则称为“洗液阴性”。阴道近距离放疗是一种推荐方案。如果计划做近距离放疗，有时也会做化疗。如果洗液呈阴性，观察也是一种选择。如果洗液中含有癌细胞，则称为“洗液阳性”。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "建议术后做化疗联合阴道近距离放疗。对于患有浸润性 IA 期、IB 期或 II 期疾病的患者，化疗是手术后的一种选择。可以增加 EBRT 和/或近距离放疗。这些分期的术后第二选择是 EBRT。可以增加近距离放疗。对于 III 期或 IV 浆液性癌或透明细胞癌患者，术后的主要治疗方法是化疗。除化疗外，医生也可能建议做体外照射和/或近距离放疗。刚刚介绍的选项见指南 2。# 癌肉瘤 对于 IA 期癌肉瘤，建议术后做化疗联合阴道近距离放疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "在某些情况下，还会做 EBRT。对于 IB 期、II 期、III 期和 IV 期，建议术后化疗。可以增加体外照射治疗、阴道近距离放疗，或两者联合治疗。无论分期如何，化疗最早可在术后 3 至 6 周开始。从术后 6 周开始，近距离放疗可以增加到化疗中。指南 2浆液性癌和透明细胞癌：术后治疗选择 <html><body><table><tr><td>分期</td><td>术后治疗选择</td><td>可以增加的治疗方法</td></tr><tr><td rowspan=\"2\">非浸润性IA期</td><td>如果洗液阴性: 阴道近距离放疗或观察</td><td>可近距离放疗的基础 是增加化疗</td></tr><tr><td>如果洗液阳性: 化疗加阴道近距离放疗</td><td></td></tr><tr><td>·浸润性IA期</td><td>化疗</td><td>体外照射 阴道近距离放疗</td></tr><tr><td>·IB期 ·I期</td><td>体外放疗</td><td>阴道近距离放疗</td></tr><tr><td>川I期或IV期</td><td>化疗</td><td>体外照射 阴道近距离放疗</td></tr></table></body></html> # 未分化/去分化癌 对于未分化/去分化癌，建议术后进行化疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "除化疗外，还可做体外放疗和/或阴道近距离放疗。# 高危子宫内膜癌的全身性治疗 如果高危子宫内膜癌手术后计划做化疗，首选方案是卡铂联合紫杉醇。对于 III 期或 IV 期 HER2阳性浆液性癌或癌肉瘤肿瘤，可以在化疗的同时做一种称为曲妥珠单抗的靶向治疗。# 如果不能先做手术 可能由于一个或多个原因而没有计划做手术。手术切除肿瘤可能不可行。或者，可能因其他健康问题而无法做手术。或者，可能不想做手术。在任何这些情况下，大多数高危子宫内膜癌都有两种主要治疗选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "首选体外放疗。除放疗外，还可做阴道近距离放疗、化疗，或两者联合治疗。治疗后，医生会检查肿瘤的大小，以确定是否可以手术。第二种选择是单独全身性治疗。通常会做化疗。全身性治疗的目标是将肿瘤缩小到足以通过手术切除的程度。治疗后，医生将检查肿瘤的大小，以确定是否可以做手术和/或放疗。![](images/f72c810670390c3f6fb37ab7ac49110f61b93dbc238e3c797690f1efabd6d320.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) 参与调查，让患者 NCCNGuidelines 变得更好，让每位患者受益！NCCN.org/patients/comments # 治疗结束后 治疗后再无癌症体征时，便可开始监测。监测用于发现癌症复发的早期体征。请参阅指南 3。# 体检 体检是监测子宫内膜癌的主要方法。预计会定期做体检。在治疗后的前 2 至 3 年内，建议每 3 至 6个月做一次体检。然后每隔 6 至 12 个月做一次检查，直至治疗后的第 5 年。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "第 5 年后，建议每年做一次体检。# 其他监测检查 如果 CA-125 水平在治疗前较高，则可以作为监测检查的一部分进行测量。子宫内膜癌治疗后， 根据需要进行影像学检查。如果出现症状或怀疑癌症复发或扩散，可能需要做影像学检查。# 其他护理 除监测检查外，一系列其他护理对于子宫癌幸存者也很重要。这包括学习如何发现复发的症状。请参见第6部分：生存状况了解更多信息。<html><body><table><tr><td colspan=\"3\">指南3 子宫内膜癌复发的监测</td></tr><tr><td>体检</td><td></td><td>前2至3年：每3至6个月检查一次 接下来的2至3年(直至第5年)：每6至12个月检查一次 5年后：每年检查一次</td></tr><tr><td rowspan=\"2\">其他监测检查</td><td></td><td>如果怀疑复发，则根据需要安排影像学检查。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "</td></tr><tr><td></td><td>如果治疗前测量了 CA-125 水平且较高,则可以将其作为监测检查 的一部分进行测量。</td></tr></table></body></html> # 复发 癌症的再次发病称为复发或重新恶化。如果根据症状或体检结果怀疑复发，则需要做影像学检查。可能需要做以下一项或多项影像学检查。h 使用造影剂对腹部、骨盆和/或胸部进行 CT扫描 全身 PET/CT 对腹部和骨盆进行 MRI 检查 对于复发的治疗，部分取决于新肿瘤生长的位置。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "全子宫切除术和 BSO 后，子宫内膜癌可能会在阴道再次发病。治疗取决于癌症是仅存在于阴道内，还是也存在于附近区域或器官中。还会考虑既往受过的治疗。例如，体外放疗通常不会多次用于治疗同一区域。如果确认复发且尚未做生物标志物检测，则建议此时做。# 生物标志物 生物标志物是癌症的特定特征。检测这些特征，寻找有针对性的改变，以帮助指导您的护理。生物标志物通常是特定基因的突变（改变）。它们也可以是对癌症做出反应的蛋白质。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "生物标志物检测不同于血液遗传（种系）突变的基因检测。肿瘤或癌症本身的突变称为体细胞突变、获得性突变、或简称为肿瘤突变。如果发现有任何突变，可以选择特定的靶向治疗或免疫治疗。生物标志物的检测结果还可用于确定您是否符合参加某些临床试验的标准。生物标志物检测包括在实验室中分析一块肿瘤组织或检测血液样本。生物标志物的检测可以单独进行，也可以作为一个更大板（组）的一部分进行。一次检测多种生物标志物称为二代基因测序(NGS)。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "生物标志物检测的其他名称包括分子检测、肿瘤分析、基因组检测、肿瘤基因检测、体细胞基因组检测和突变检测。# dMMR/MSI-H 所有子宫内膜癌都应该检测错配修复缺陷(dMMR)/高微卫星不稳定性 (MSI-H)。如果肿瘤具有这种生物标志物，可能还需要做称为林奇综合征的遗传性癌症综合征检测。非 dMMR/MSI-H肿瘤称为微卫星稳定 (MSS) 或错配修复正常(pMMR)。有关这种生物标志物的更多信息，请参见第 14 页。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 不太常见的生物标志物 可能还需要检测下面列出的不太常见的生物标志物。h 肿瘤突变负荷高 (TMB-H)h NTRK 基因融合 # 局部复发 如果子宫内膜癌再次出现在阴道、骨盆或腹部，则属于“局部”复发。治疗选择将取决于是否接受过癌症灶放疗。如果癌症灶尚未接受 EBRT 治疗，这将是一种推荐方案。除 EBRT 外，还可做近距离放疗和/或全身性治疗。对于以前没有做过复发灶体外照射治疗的患者，另一个选择是探查性手术。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这包括打开腹部，了解癌症扩散的程度，并通过手术将其切除。如果手术发现癌症仅存在于阴道或已扩散至附近淋巴结，建议术后做 EBRT。除 EBRT 外，还可做全身性治疗。如果新肿瘤的生长仅限于阴道，将考虑近距离放疗。然而，如果肿瘤已扩散到上腹部，建议进行全身性治疗。如果肿瘤非常小，除全身性治疗外，还可以做 EBRT。如果上腹部有大量肿瘤，请参阅本页的远处复发。如果新肿瘤生长区域已经接受过 EBRT 治疗，则不应再次使用 EBRT 来治愈癌症。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "治疗方案可能包括： h 探查性手术，旨在了解癌症是否已扩散到阴道以外，并切除新生长的肿瘤 h 全身性治疗伴或不伴姑息性 EBRT（低剂量EBRT 用于缓解症状） h 近距离放疗联合或不联合全身性治疗 # 远处复发 如果子宫内膜癌在初步治疗后复发，并在身体其他部位发现，则称为远处复发。癌症是转移性的。新的癌症生长或肿瘤称为转移。如果只有少量转移，则可以使用下面列出的一种或多种局部疗法来切除或破坏肿瘤。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "手术（如果肿瘤足够小） EBRT 立体定向放疗 (SBRT) 适用于转移 如果只有少量转移，也可以考虑全身性治疗。如果有多个新癌症生长区域，建议进行全身性治疗。也可以做以缓解症状为目的的放疗。这称为姑息性放疗。目前，复发性和/或转移性子宫内膜癌的首选化疗方案是卡铂和紫杉醇。对于 HER2 阳性浆液性或癌肉瘤肿瘤，可以增加一种称为曲妥珠单抗的靶向治疗。如果不能服用紫杉醇，可以用多西他赛代替。如果癌症对一线全身性治疗无缓解或缓解停止，还有其他选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果肿瘤具有某些生物标志物，免疫治疗或靶向治疗可能是一种选择。这些较新的全身性治疗通常仅考虑用于化疗后复发或扩散且没有其他治疗选择的癌症。接下来列出了推荐方案。# 错配修复正常 (pMMR) 肿瘤： h 乐伐替尼 (Lenvima) 加帕博利珠单抗（可瑞达）MSI-H 或 dMMR 肿瘤：帕博利珠单抗（可瑞达）（首选） 纳武单抗（欧狄沃）Dostarlimab-gxly (Jemperli)h 阿维鲁单抗 (Bavencio) TMB-H 肿瘤： 帕博利珠单抗（可瑞达）NTRK 基因融合阳性肿瘤：拉罗替尼 (Vitrakvi)恩曲替尼 (Rozlytrek) 如果计划进行免疫治疗，请参阅患者NCNGuidelines：免疫治疗的副作用–免疫检查点抑制剂，载于 NCCN.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "org/patientguidelines 和应用程序 NCCN 癌症患者指南 # 内分泌治疗 下面列出了针对复发性或转移性子宫内膜癌的推荐内分泌治疗方案。内分泌治疗通常用于小型或生长缓慢的子宫内膜样肿瘤。此时，首选方案包括： h 醋酸甲地孕酮（美可治）与他莫昔芬交替使用依维莫司 (Afinitor) 和来曲唑（弗隆） # 支持治疗 如果癌症在全身性治疗期间有所进展，或者如果您不想接受癌症治疗，则支持治疗是一种选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "由于癌症无法治愈，支持治疗的目标是让您感到更舒适，并帮助控制癌症。支持治疗还有助于延长寿命，使总体感觉更好。当用于晚期癌症时，支持治疗通常称为姑息性治疗。# 临床试验 参加临床试验可能是一种选择。请向治疗团队咨询是否有开放性临床试验可以参与。临床试验将在第3部分：子宫癌的治疗的末尾进行更详细的讨论。![](images/bef566382cf83ec33506af5de696e9fe85bb9932f6eb4546098ced38f7a20e8d.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) # 关键点 h 在可能情况下，手术是大多数子宫内膜癌的首选治疗方法。# 子宫内膜样癌 h 保留生育能力疗法可能是一些绝经前子宫内膜样肿瘤患者的一种选择。它包括推迟手术，并首先进行激素治疗。h 建议对所有 II 期、III 期和 IV 期子宫内膜样肿瘤进行术后治疗。一些 I 期子宫内膜样肿瘤患者可能会从术后治疗中获益。# 高危子宫内膜癌 h 高危子宫内膜癌类型包括浆液性癌、透明细胞癌、未分化/去分化癌和癌肉瘤。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 癌肉瘤也称为恶性中胚叶混合瘤或恶性苗勒管混合瘤。h 高危子宫内膜癌最有效的治疗方法是手术。通常需要术后治疗。# 监测 随访护理包括定期体检，并对复发症状保持警惕。# 复发 h 癌症的再次发病称为复发或重新恶化。h 复发性子宫内膜癌的治疗取决于新肿瘤生长的位置和治疗史。![](images/d3098efd1c7437895805dbf58d8dd44d510baee58db511e3fe556c877d0a4999.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) # 期盼您的回复！我们的目标是提供有帮助且通俗易懂的癌症信息。请参与我们的调查，帮助我们了解做得正确的方面和可以改进的方面。NCCN.org/patients/feedback # 5 子宫肉瘤的治疗 46 初步阶段 47 治疗 51 监测 52 复发 55 关键点 本章介绍了一种罕见子宫癌（称为子宫肉瘤）的推荐治疗方案。解释了检测、治疗和随访护理。子宫肉瘤原发于子宫的支持结缔组织或肌肉。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这种类型通常比子宫内膜癌具有更高的扩散机会，并且可能更难治疗。子宫肉瘤与子宫内膜癌的不同之处在于，它们通常在子宫切除术后被发现。这是因为在子宫切除术之前诊断子宫肉瘤的方法有限。子宫肉瘤有不同类型。本书讨论了以下类型： h 子宫内膜间质肉瘤 (ESS)腺肉瘤子宫平滑肌肉瘤 (uLMS)未分化子宫肉瘤 (UUS)血管周上皮样细胞瘤 (PEComa)炎性肌纤维母细胞瘤 (IMT) # 初步阶段 # 影像学检查 开始治疗前需要进行影像学检查。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "建议对胸部、腹部和骨盆（使用造影剂）进行计算机断层 (CT)扫描。还可能对骨盆、腹部或两者进行磁共振成像 (MRI) 检查。其他可用于评估癌症扩散的影像学检查包括对颈部、胸部、腹部、骨盆和腹股沟进行正电子发射断层 (PET)/CT 联合扫描。是否需要其他影像学检查将取决于症状以及医生是否认为癌症已经扩散（转移）。# 激素受体检测 卵巢产生激素。如果肉瘤呈激素受体阳性，则意味着激素可能有助于肿瘤生长。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "激素受体检测有助于决定是否应该切除卵巢。这是根据育龄期患者的具体情况决定的。激素受体检测通常考虑用于 ESS、uLMS 和腺肉瘤。使用活检样本或手术期间切除的肿瘤组织进行检测。# 治疗 子宫肉瘤的治疗取决于它是如何被发现的。它们通常在子宫切除术后被发现。有时，病理学家能够通过检测组织样本（活检）来诊断子宫肉瘤。但是，活检在鉴别子宫肉瘤方面并不像鉴别子宫内膜癌那样可靠。这是因为肉瘤通常位于子宫肌壁深处。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "发现子宫肉瘤的第三种方式是在手术中切除纤维瘤。纤维瘤是一种非癌性肿瘤，可以在子宫中生长并引起症状。对于有子宫的患者，全子宫切除术和可能的双侧输卵管卵巢切除术 (BSO) 是治疗子宫肉瘤的最有效方法。如果癌症不能通过手术切除，治疗选择包括放疗和全身性治疗。# 通过活检或纤维瘤切除发现肉瘤 癌症只存在于子宫内 如果癌症只存在于子宫内，建议做全子宫切除术。卵巢和输卵管也可能被切除（做 BSO）。这是根据育龄期患者的具体情况决定的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果癌症呈激素受体阳性，医生可能会建议切除它们。如果是绝经期患者，建议做 BSO。如果在手术过程中发现癌症已扩散到子宫以外，则可能需要做更多手术来切除它。这一决定也是根据具体情况做出的。请参阅下一页的术后治疗。# 可能扩散到子宫以外 如果癌症已经（或可能已经）扩散到子宫以外，将考虑手术。外科医生会考虑癌症的程度、症状以及通过手术切除癌症的效果。如果计划手术，建议做全子宫切除术。如果可能，已经扩散到子宫外的癌症也将被切除。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "卵巢和输卵管也可能被切除。这是根据育龄期患者的具体情况决定的。如果癌症呈激素受体阳性，医生可能会建议切除它们。请参阅下一页的术后治疗。# 先做手术不是一种选择 如果您不想或不能做手术，建议进行全身性治疗、姑息性体外放疗，或两者联合治疗。除了这些治疗中的一种或两种之外，还可以使用近距离放疗。全身性治疗通常需要先做化疗。对于具有某些生物标志物的肿瘤，可以代之以针对该生物标志物的其他全身性治疗。对于不能手术的肉瘤，推荐的一线全身性治疗方案列于第 50 页上的指南 5。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 先前子宫切除术期间发现的肉瘤 如果在部分或全部子宫切除术后发现肿瘤，治疗将取决于最初子宫切除术的结果，以及是否切除了卵巢和输卵管。如果肿瘤没有完整切除或者没有切除子宫颈，可能需要做另一次手术来切除肿瘤和剩余的子宫颈。如果手术期间没有切除卵巢和输卵管，现在可能会切除。如果最初仅切除了一个卵巢及其输卵管，则可以切除剩余的卵巢和输卵管。这可能是低级别 ESS 肿瘤、腺肉瘤和雌激素受体阳性肿瘤的最佳选择。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 术后治疗 术后治疗取决于肿瘤类型。# 低级别 ESS 或低风险腺肉瘤 如果仍然有卵巢和输卵管，建议对 I 期肿瘤进行手术切除（做 BSO）。如果已经做了 BSO，或者正处于绝经期，建议观察（不治疗）。还建议对 II 期、III 期、IVA 期和 IVB 期低级别ESS 肿瘤和低风险腺肉瘤做 BSO。除手术外，还可以做以下一种或两种治疗： h 抗雌激素治疗h 体外放疗 芳香化酶抑制剂是低级别 ESS 和低风险腺肉瘤的首选抗雌激素治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "指南 $4$ 中列出了所有推荐的抗雌激素治疗方案。如果放疗用于 IVB 期癌症，则被认为是姑息性治疗。这意味着目标不是治疗癌症，而是控制或预防肿瘤引起的症状。# 指南 4低级别 ESS、低风险腺肉瘤或激素受体阳性子宫肉瘤的抗雌激素治疗 芳香化酶抑制剂（首选用于低级别 ESS 和低风险腺肉瘤） 氟维司群 醋酸甲地孕酮 醋酸甲羟孕酮 GnRH 类似物（适用于至少具有一个功能性卵巢的人） # 高危腺肉瘤 如果仍然有卵巢和输卵管，建议对 I 期高危腺肉瘤进行手术切除（做 BSO）。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果已经做了 BSO，或者正处于绝经期，建议观察（不治疗）。还建议对 II 期、III 期、IVA 期和 IVB 期高危腺肉瘤做 BSO。医生会考虑术后全身性治疗。通常会给予化疗或靶向治疗药物。或者，如果癌症呈激素受体阳性，医生可能会建议抗雌激素治疗。如果计划做全身性治疗，还可以增加姑息性体外放疗。# 其他肿瘤类型 以下信息适用于以下肿瘤类型： 高级别 ESS uLMS UUS 其他肉瘤（例如 PEComa） 炎性肌纤维母细胞瘤 (IMT) 这些肿瘤类型的术后推荐治疗是根据分期提出的。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果癌症处于 I 期，术后无需进一步治疗。将对肿瘤进行观察。可以开始监测和随访护理 对于 II 期和 III 期癌症，有些人会在术后接受更多治疗。医生会考虑全身性治疗和/或体外放疗。如果手术结果非常好，观察（不治疗）可能是一种选择。如果癌症处于 IV 期，则术后需要更多治疗。对于IVA 期疾病，建议采用全身性治疗、体外放疗、或两者联合治疗。对于 IVB 期疾病，主要采用全身性治疗。姑息性放疗可用于预防或控制癌症引起的症状。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果需要全身性治疗，通常会给予化疗或靶向治疗药物。或者，如果癌症呈激素受体阳性，医生可能会建议抗雌激素治疗。# 关于术后全身性治疗 术后最常采用的全身性治疗是化疗。如果计划做化疗，有几种首选方案。大多数包括多柔比星（阿霉素）。医生在推荐化疗方案时会考虑几个因素。请参见指南 5。如果肿瘤具有某些生物标志物（特征），酪氨酸激酶抑制剂 (TKI) 靶向治疗可能是比化疗更好的选择。少数子宫肉瘤具有称为NTRK 基因融合的生物标志物（特征）。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这些肿瘤术后将考虑 TKI 治疗。对于伴有 ALK 易位的炎性肌纤维母细胞肿瘤(IMT)，也会考虑这种疗法。<html><body><table><tr><td colspan=\"2\">指南5 晚期、复发性/转移性或不能手术的子宫肉瘤的一线药物治疗</td></tr><tr><td rowspan=\"6\">首选方案</td><td>多柔比星</td></tr><tr><td>多西他赛+吉西他滨</td></tr><tr><td>多柔比星+异环磷酰胺</td></tr><tr><td>多柔比星+达卡巴嗪</td></tr><tr><td>多柔比星+曲贝替定(适用于uLMS)</td></tr><tr><td></td></tr><tr><td rowspan=\"10\"></td><td>对于NTRK基因融合阳性肿瘤：</td></tr><tr><td>拉罗替尼(Vitrakvi)或恩曲替尼(Rozlytrek)</td></tr><tr><td>对于伴有ALK易位的炎性肌纤维母细胞肿瘤（IMT)：</td></tr><tr><td>克唑替尼 (Xalkori)</td></tr><tr><td>色瑞替尼 (Zykadia)</td></tr><tr><td></td></tr><tr><td>布加替尼 (Alunbrig) 劳拉替尼 (Lorbrena)</td></tr><tr><td>艾乐替尼 (Alecensa)</td></tr><tr><td></td></tr><tr><td>对于 PEComas: 白蛋白结合型西罗莫司</td></tr></table></body></html> # 监测 治疗后再无癌症体征时，便可开始监测。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "监测用于发现癌症复发的早期体征。体检和影像学检查用于监测子宫肉瘤的复发。请参见指南 6。如果出现以下情况，可能需要做指南 6 中未列出的其他影像学检查： 出现症状医生怀疑癌症可能已经转移h 体检结果有异常 除监测检查外，一系列其他护理对于癌症幸存者也很重要。这包括对癌症症状保持警惕。请参见第 ${ \\pmb 6 }$ 部分：生存状况了解更多信息。<html><body><table><tr><td colspan=\"3\">指南6 子宫肉瘤复发的监测</td></tr><tr><td>体检</td><td></td><td>前2至3年：每3至4个月检查一次 此后：每年体检一到两次。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "</td></tr><tr><td>建议：</td><td></td><td>前3年：每3至6个月做一次影像学检查</td></tr><tr><td>使用造影剂对胸部、腹部和骨盆进 行CT扫描</td><td></td><td>第4年和第5年：每6至12个月做一次影像学检查</td></tr><tr><td>可选：</td><td></td><td>也可以每1到2年做一次影像学检查，持续5年以上。医生将 根据癌症特征(肿瘤类型、分期、分级)决定是否继续做影像学</td></tr><tr><td>对腹部和骨盆进行MRI检查以及不 使用造影剂对胸部进行CT扫描</td><td>检查</td><td></td></tr></table></body></html> # 复发 无癌期后的癌症再次发病称为复发。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果怀疑复发，可能需要做影像学检查。如果怀疑癌症已扩散到远离骨盆的区域（已转移），影像学检查可能包括对颈部、胸部、腹部、骨盆和腹股沟进行 PET/CT 扫描。复发的治疗部分取决于新肿瘤生长的位置。在切除子宫、卵巢和输卵管的手术后，癌症可能会在阴道、靠近阴道的区域或远离骨盆的区域复发。复发性子宫肉瘤的治疗还取决于是否接受过外照射放疗 (EBRT)。EBRT 通常不会多次用于同一区域的治疗，因此在决定如何治疗复发性癌症时，这一点非常重要。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 癌症在阴道或骨盆复发 # 既往体外照射 如果之前接受过 EBRT 治疗，以下方法之一可用于治疗在阴道或骨盆复发的癌症： h 手术，伴或不伴全身性治疗 h 全身性治疗 h 使用 EBRT 对选定区域进行仔细的再治疗h 近距离放疗，伴或不伴选定区域的 EBRT 如果计划做全身性治疗（单独或联合手术），则低级别 ESS 和低风险腺肉瘤首选抗雌激素治疗。# 无既往体外照射 如果没有做过 EBRT，治疗再次发病于骨盆的子宫肉瘤的选择包括手术和 EBRT。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果计划做手术，可以先做 EBRT（伴或不伴全身性治疗），以尝试缩小肿瘤。如果手术期间没有切除全部肿瘤，则可在术后使用 EBRT 来治疗残留灶。但是，如果在术前使用过，则不会再次使用。如果在术后使用，除 EBRT 外，还可做近距离放疗和/或全身性治疗。如果计划做 EBRT 代替手术治疗，也可以使用近距离放疗和/或全身性治疗。对于低级别 ESS 和低危腺肉瘤，全身性治疗首选抗雌激素治疗。# 远处复发 如果子宫肉瘤复发并扩散到身体的其他部位，例如肝脏或肺部，则称为远处复发。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "癌症是转移性的。新的癌症生长或肿瘤称为转移。# 生物标志物检测 如果尚未做生物标志物检测，则建议此时做。生物标志物是癌症的可靶向特征。它们通常是特定基因的突变（改变）。对这些突变的检测有助于指导复发性转移性子宫肉瘤的治疗。检测结果还可用于确定您是否符合参加某些临床试验的标准。生物标志物检测包括在实验室中分析一块肿瘤组织或检测血液样本。建议检测以下生物标志物： h 微卫星不稳定性 (MSI)肿瘤突变负荷高 (TMB-H)h NTRK 基因融合h 携带 ALK 重排的 IMT 炎性肌纤维母细胞瘤 (IMT) 是一种罕见的子宫肉瘤。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "大多数 IMT 都携带一种称为 ALK 易位或重排的生物标志物。具有这种生物标志物的肿瘤称为 ALK 阳性或 $A L K +$ 。生物标志物的检测可以单独进行，也可以作为一个更大板（组）的一部分进行。一次检测多种生物标志物称为二代基因测序 (NGS)。NGS 可能会发现可以进行靶向治疗的其他基因突变。# 微小转移 如果只有少量转移，通过手术切除或消融疗法摧毁它们可能是一种选择。消融疗法包括图像引导消融和立体定向放疗 (SBRT)。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "消融使用热、冷或光激活药物来破坏癌细胞。SBRT 是一种高度专业化的体外照射，需要 5 次或更少的疗程。如果可以手术，则可在术后使用全身性治疗和/或 EBRT 来杀死任何残留的癌细胞。如果不能通过手术切除转移灶，建议采用全身性治疗和/或局部治疗。局部治疗包括 EBRT 和消融。如果全身性治疗效果良好，手术可能成为一种选择。# 广泛转移 如果骨盆外有许多新肿瘤生长区域，建议进行全身性治疗。对于复发性、转移性疾病，通常先做化疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "有几种首选的一线方案。大多数包括多柔比星（阿霉素）。请参见指南 5。如果肿瘤具有某些生物标志物，酪氨酸激酶抑制剂 (TKI) 靶向治疗可能是比化疗更好的选择。少数子宫肉瘤具有称为 NTRK 基因融合的生物标志物。这些肿瘤将考虑 TKI 治疗。对于伴有 ALK易位的 IMT，也会考虑这种疗法。除全身性治疗外，还可使用姑息性 EBRT。目标是缩小肿瘤以缓解或预防症状。在此分期进行的任何治疗的另一种选择是开始支持（也称为姑息性）治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "由于癌症无法治愈，支持治疗的目标是让您感到更舒适，并帮助控制癌症。支持治疗还有助于延长寿命、改善饮食，让患者整体感觉良好。当用于晚期癌症时，支持治疗通常称为姑息性治疗。参加临床试验也可能是一种选择。请向治疗团队咨询是否有开放性临床试验可以参与。临床试验将在第3部分：子宫癌的治疗的末尾进行更详细的讨论。# 二线及以上全身性治疗 如果癌症对一线全身性治疗无缓解或缓解停止，还有其他选择。可以尝试 指南 $\\pmb { 5 }$ 中的其他一线治疗方案。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "否则，指南 $\\mathbf { 7 }$ 中列出了接下来可以尝试的方案（二线方案）。如果肿瘤具有某些生物标志物，免疫治疗或靶向治疗可能是一种选择。# 指南 7晚期、复发性/转移性或不能手术的疾病的二线治疗或全身性治疗后 <html><body><table><tr><td rowspan=\"7\">推荐治疗方案</td><td colspan=\"2\"></td></tr><tr><td>曲贝替定(仅适用于uLMS)</td><td>·异环磷酰胺</td></tr><tr><td>·吉西他滨+达卡巴嗪</td><td>·多柔比星脂质体</td></tr><tr><td>·吉西他滨+长春瑞滨</td><td>·帕唑帕尼</td></tr><tr><td>·达卡巴嗪</td><td></td></tr><tr><td>·吉西他滨</td><td>·替莫唑胺</td></tr><tr><td>表柔比星</td><td>艾日布林</td></tr><tr><td rowspan=\"9\">在某些情况下可能使用的治 疗方案</td><td></td><td></td></tr><tr><td>对于PEComas:</td><td></td></tr><tr><td>·西罗莫司</td><td></td></tr><tr><td>·依维莫司</td><td></td></tr><tr><td>·替西罗莫司</td><td></td></tr><tr><td>对于TMB-H肿瘤：</td><td></td></tr><tr><td>帕博利珠单抗</td><td></td></tr><tr><td>对于BRCA2改变的uLMS:</td><td></td></tr><tr><td>·奥拉帕尼</td><td></td></tr><tr><td>·鲁卡帕尼</td><td></td></tr><tr><td>·尼拉帕利</td><td></td></tr></table></body></html> # 关键点 h 子宫肉瘤很罕见。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "它们原发于子宫壁或子宫肌肉。子宫肉瘤可以迅速扩散并且难以治疗。它们通常是在因其他原因进行子宫切除术后或在手术过程中切除纤维瘤时发现的。# 检查 h 开始治疗前需要进行影像学检查。建议使用造影剂对胸部、腹部和骨盆进行 CT 扫描。还可能对骨盆、腹部或两者进行 MRI 检查。h 如果这些检查查不清楚，可以安排 PET/CT扫描。其他影像学检查因人而异。h 将考虑对 ESS、uLMS 和腺肉瘤进行激素受体检测。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这有助于决定育龄期患者是否应该切除卵巢。# 通过活检或纤维瘤切除发现肉瘤 h 如果可能，建议做全子宫切除术。对于育龄期患者，是否做 BSO 的决定因人而异。如果癌症呈激素受体阳性，通常建议做 BSO。如果您不想或不能做手术，建议进行全身性治疗、体外放疗，或两者联合治疗。# 先前子宫切除术期间发现的肉瘤 h 如果肿瘤没有完整切除或者没有切除子宫颈，可能需要做另一次手术来切除肿瘤和剩余的子宫颈。h 如果子宫切除术期间没有切除卵巢和输卵管，现在可能会切除。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这可能是低级别 ESS、腺肉瘤或雌激素受体阳性肿瘤的最佳选择。# 监测 h 建议在治疗后的前 2 至 3 年，每 3 至 4 个月做一次体检。此后，每年体检一到两次。建议在治疗后的前 3 年，每 3 至 6 个月做一次影像学检查。在第 4 年和第 5 年，建议每6 至 12 个月做一次影像学检查。h 也可以每 1 到 2 年做一次影像学检查，持续5 年以上。这因人而异。# 复发 h 子宫切除术和 BSO 后，癌症可能会在阴道、靠近阴道的区域或远离骨盆的区域复发。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "h 复发的治疗取决于新肿瘤生长的位置，以及是否接受过体外放疗。# 6 生存状况 57 保持警惕以防复发或扩散 58 早发、迟发和长期副作用 60 健康习惯 61 更多信息 # 生存状况 » 保持警惕以防复发或扩散 生存状况关注癌症幸存者特有的身体、情绪和经济问题。管理癌症及其治疗的长期副作用、与初级保健医生保持联系并保持健康的生活方式是生存状况的重要组成部分。完成癌症治疗后，初级保健医生，也称为全科医生(GP) 或主治医生 (PCP)，将在患者护理中发挥关键作用。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "肿瘤科医生（肿瘤医生）和 PCP 应共同努力，确保患者获得所需的随访护理。为此，请向肿瘤科医生索要一份书面生存护理计划，其中包括： h 癌症治疗史摘要（包括手术、放疗和/或化疗）h 对可能的早发、迟发和长期副作用的描述对监测癌症复发的建议h 何时将护理转移至 PCP 的相关信息h 明确癌症护理团队和 PCP 的角色和职责h 关于患者总体健康和福祉的建议 # 保持警惕以防复发或扩散 癌症治疗团队和 PCP 将共同努力，确保患者获得建议的随访检查。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "但是，患者也有一项任务，即密切关注自己的身体状况。有些癌症可能会在身体没有任何感觉的情况下复发。如果子宫癌确实复发，它通常会以可以感觉到或注意到的方式影响身体（症状）。医生会告诉您可能意味着子宫癌复发或扩散的症状。他们包括： 阴道出血 尿液或粪便中带血 食欲不振 体重下降 胃部、腹部、臀部或背部疼痛 咳嗽 呼吸急促 腹部或腿部肿胀 如果发现任何这些症状，请立即联系医生。不要等到下次预定的访视。# 早发、迟发和长期副作用 子宫癌治疗的一些副作用可能会提前出现，并且持续时间比预期更长。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "另一些副作用可能要等到治疗结束后很长时间才会出现。许多子宫癌幸存者会经历肠道、泌尿系统和性功能的变化。# 过早绝经 如果还没有进入更年期，切除双侧卵巢的手术（或全骨盆放疗）会导致过早绝经。这称为手术绝经。这是由于体内雌激素突然下降引起的。这种下降可能会导致更年期症状，包括： 潮热 睡眠问题 盗汗 体重增加 情绪变化 阴道内膜变薄、干燥和刺激（阴道萎缩） 当由手术引起时，更年期症状可能是突然的，且更严重。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "雌激素不足还存在长期风险。它们风险包括心脏或血管问题（心血管疾病）和骨质流失（骨质疏松症）。# 激素替代疗法 如果有手术绝经的症状，医生可能会建议激素替代疗法 (HRT)。一种选择是全身性 HRT。雌激素以口服药丸或皮肤贴剂形式给药。HRT 的另一种选择是阴道雌激素霜或片剂。对于主要影响阴道的症状（例如干燥），这种类型可能是最佳选择。建议与更年期症状小组讨论，以确定这种治疗方法是否适合您。# 肠道和膀胱的变化 子宫癌手术或放疗后，膀胱内憋尿可能会更困难。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这称为尿失禁。也可能会感到尿急，即突然强烈地需要小便。也可能出现水样便和/或频繁排便（腹泻）。# 盆底理疗 盆底是一组支撑骨盆器官的肌肉。这些肌肉在肠道和膀胱控制以及性功能和性唤起方面发挥着关键作用。在治疗前后都有一些方法可以增强这些肌肉。这称为盆底理疗，有专门从事这方面的保健专业人士。盆底治疗可以包括收紧和放松阴道和肛门肌肉的家庭练习（凯格尔练习），还有理疗师的实际操作技巧。请治疗团队帮助寻找您所在地区的盆底专家。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 性和阴道健康 子宫癌治疗后可能会出现性副作用，包括： 性欲（力比多）降低 阴道干燥 性交时疼痛 阴道变窄和缩短（阴道狭窄） # 阴道保湿霜 年龄较大、更年期和一些子宫癌治疗可能会导致阴道变得干燥且缺乏弹性。为了抵消这种副作用，鼓励使用水基阴道保湿霜。阴道保湿霜可恢复阴道水分，有助于保持阴道组织健康。它们可以每天使用，许多都配有涂抹器，使用更方便。# 阴道扩张器治疗 骨盆区域的放疗可能会导致阴道变得更短、更窄。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "这称为阴道狭窄。阴道狭窄会使性生活或接受阴道检查时感到不舒服，甚至疼痛。阴道扩张器治疗可能有所帮助。阴道扩张器是一种用于逐渐拉伸或扩宽阴道的装置。可以在放疗结束后 2至 4 周内开始使用扩张器，并且可以根据需要继续使用。阴道扩张器不是万能的。有不同尺寸可供选择，包含不同尺寸装置的扩张器套件也是如此。随着阴道的延长和变宽，扩张器的尺寸可以随时间推移而增加。# 性健康治疗师 虽然谈论性健康可能会让人感到不舒服，但请记住，这些副作用很常见，并且通常可以控制或减轻。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "考虑去看性健康治疗师。这些医疗保健专业人员专门帮助癌症幸存者和其他人克服和管理癌症治疗的性副作用。许多癌症治疗中心都有专门针对癌症治疗后性健康的项目。向医生咨询您所在癌症中心可以提供的资源，这些资源有助于最大限度地减少癌症治疗对性健康的影响。# 其他生理副作用 除了对肠道、膀胱和性功能的影响外，疲劳、呼吸困难和睡眠困难等更常见的影响也很常见。骨盆放疗会削弱骨盆中的骨骼。这会增加骨折风险。医生可能会开始监测您的骨密度。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "化疗会损害感觉神经。这称为神经病变。这种损害会导致身体不同部位的疼痛、麻木、刺痛、肿胀或肌肉无力。它通常从手或脚开始，随着时间推移会变得更糟。神经性疼痛通常被描述为刺痛或灼痛。子宫癌的治疗通常涉及在手术中切除淋巴结。淋巴结切除后，淋巴可能无法正常排出。这可能会导致淋巴水肿。淋巴水肿是由淋巴液在组织中积聚引起的肿胀。对于子宫癌幸存者来说，它最常发生在下半身。向治疗团队索取一份可能的迟发和长期副作用的完整列表。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 心理健康 子宫癌及其治疗的影响可能难以应对。许多幸存者报告癌症治疗后总体生活质量下降。抑郁、焦虑、害怕复发以及难以适应身体的变化都是可能的。许多人还面临经济压力，例如对重返工作岗位的担忧或犹豫以及保险范围问题。人际关系、性行为和亲密关系也可能受到癌症诊断或癌症治疗的影响。如果您感到焦虑、苦恼、抑郁，或者只是在应对癌症后的生活方面遇到困难，那么您并不孤单。告诉治疗团队这些症状。期待治疗团队询问您的心理健康状况。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果他们没有这样做，就大声说出来。有许多可用资源可以改善癌症幸存者的心理健康。治疗中心的社会工作者通常是帮助您联系心理健康和经济资源的绝佳资源。更多信息请参阅患者NCNGuidelines：癌症治疗期间的痛苦，载于 NCCN.org/patientguidelines和应用程序 NCCN 癌症患者指南 ![](images/ce53981b830c8d87ad0293952a45009db6792a610c7a6cd7a66392f7edcba90c.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "jpg) # 健康习惯 治疗结束后，监测子宫癌的复发至关重要。同时保持其他方面的健康也很重要。以下介绍了一些帮助预防其他健康问题和改善生活质量的措施。# 癌症筛查 接受其他类型癌症的筛查，例如乳腺癌、皮肤癌和结直肠癌。初级保健医生可以根据您的年龄和风险级别告知您推荐的筛查测试。如果子宫颈和/或卵巢没有作为治疗的一部分被切除，请咨询医生有关这些癌症类型的筛查。# 其他医疗保健 接受针对您年龄的其他推荐的医疗保健，例如血压筛查、丙型肝炎筛查和免疫接种（如流感疫苗）。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 饮食和运动 引领健康的生活方式包括保持健康体重。尝试每周进行至少 150 分钟的中等强度锻炼。所有患者在开始新的锻炼方案之前都应与医生讨论。健康饮食，多吃植物性食物。酒精可能会增加患某些癌症的风险。少喝酒或不喝酒。# 戒烟 如果您吸烟，请戒掉它！医生会向您提供戒烟咨询或将您转诊给其他医生。# 更多信息 有关癌症幸存者的更多信息，请访问 NCCN.org/patientguidelines 和应用程序 NCCN 癌症患者指南： h 以健康生活为目标的生存护理h 针对癌症相关晚期和长期影响的生存护理这些资源涉及与子宫癌幸存者相关的主题，包括： 焦虑、抑郁和痛苦 疲劳 疼痛 性问题 睡眠问题 健康生活方式 免疫接种 就业、保险和残疾 !",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "[](images/a99ab8467d7feebee7e63d6a4660f33b8e1bfa9aaebded5292764cf08aee0a64.jpg) ![](images/2f1d1a51c5b59017aa5f777a3f9484e7784ffc9bf291ce5a85dc0f59385c3f34.jpg) # 我需要第二意见吗？子宫癌是一个严重的诊断。考虑与不同的医生进行一次面对面会谈，看看他们是否同意您的诊断和治疗计划。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "下一章将提供更多有关寻求第二意见的信息。# 7做出治疗决定 63 这是您自己的选择 63 要问的问题 69 资源 # 做出治疗决定 » 这是您自己的选择 对自己选择的治疗方案感到满意很重要。要进行选择，首先要与医护团队进行公开和诚实的对话。# 这是您自己的选择 在共享决策中，您和医护团队需要共享信息、讨论选项并就治疗计划达成一致。这要从您和医护团队之间公开和诚实的对话开始。治疗决定是一件非常私人的事。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "对您来说重要的事情对其他人来说可能并不重要。有些事情可能会影响您的决策： h 您想要什么，以及它与其他人想要的有何不同您的宗教和精神信仰您对某些治疗的感受 您对疼痛或副作用的感受 治疗费用、前往治疗中心的旅费，以及辍学和停工的时间 h 生活质量和寿命 h 您的活动程度以及对您很重要的活动 请考虑您想从治疗中获得的内容。公开讨论特定治疗和程序的风险和获益。权衡选择并与您的医生分享疑虑。如果您花时间与团队建立关系，将有助于在考虑选择和做出治疗决定时感受到支持。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 第二意见 希望尽早开始治疗很正常。虽然癌症不容忽视，但还是有时间让另一位癌症护理人员复查您的检查结果，并提出一个治疗计划。这称为征求第二意见，这是癌症治疗的正常组成部分。甚至医生也要获取第二意见！您可以做的准备工作： h 与您的保险公司核实关于第二意见的规则。在您的保险计划之外的医生处就诊可能需要自付费用。h 计划将您所有结果的副本发送给提供第二意见的医生。# 支持小组 许多癌症确诊患者发现支持小组很有帮助。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "支持小组通常包括处于不同治疗阶段的患者。有些人可能是新诊断患者，而另一些人可能已经完成了治疗。如果您所在的医院或社区没有癌症患者支持小组，请查看本书中列出的网站。# 要问的问题 以下几页列出了可以询问癌症护理团队的问题。可以随意使用这些问题，或提出自己的问题。请明确您的治疗目标，并了解对治疗的期望。# 关于癌症检测的问题 1.我将进行哪些检查？2.这些检查有任何风险吗？3.我的保险会支付我的癌症检测费用吗？",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "4.我需要为检测做些什么准备吗？5.我需要找人陪同去检测吗？6.我应该去哪里做检测，需要多长时间？7.如果有的检测项目会带来伤害，您会采取什么措施来让我感到舒适？8.我多久会知道结果，由谁向我解释结果？9.我如何获得病理报告和其他检查结果的副本？10.有没有一个在线门户网站显示我的检查结果？# 有关治疗选择的问题 1.我有什么治疗选择？2.有没有适合我的临床试验？3.如果我什么都不做会怎样？4.除 NCCN 建议之外，您还有其他建议吗？",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "如果有，为什么？5.我的年龄、性别、总体健康状况和其他因素对我的选择有什么影响？6.如果我怀孕了，或者打算怀孕，该怎么办？7.是否有任何选择能治愈或长期控制癌症？8.这种治疗有哪些副作用？9.我如何获得第二意见？10.我有多长时间来决定治疗选择，有没有社工或其他人可以帮我做出决定？# 有关预期结果的问题 1.这家医院或癌症中心能为我提供最好的治疗吗？2.我可以选择何时开始治疗吗？3.治疗会持续多长时间？",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "4.我的保险能报销您推荐的治疗吗？5.有什么项目可以帮助支付治疗费用吗？6.我和我的护理者可以获得哪些支持治疗和服务？7.如果办公室关门了，我应该联系谁解决问题或疑虑？8.您如何知道治疗是否有效？9.癌症恶化或复发的可能性有多大？10.治疗后需要哪些随访护理？# 关于副作用的问题 1.治疗可能出现哪些并发症和副作用？2.癌症本身会引起什么副作用吗？3.哪些副作用最常见，通常持续多长时间？4.哪些副作用是严重的或危及生命的？",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "5.有什么长期或永久性副作用吗？6.我应该立即报告哪些症状，我应该联系谁？7.我能做些什么来预防或减轻治疗的副作用？8.有什么药物会加重副作用吗？9.副作用会随着时间推移减轻或加重吗？10.如果出现严重副作用，您会停止或改变治疗吗 # 关于临床试验的问题 1.您建议我考虑参见临床试验来治疗吗？2.如何找到我可以参加的临床试验？3.这项临床试验使用了什么治疗方法？4.这种疗法是否已用于其他类型的癌症？",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "5.这种治疗的风险和获益是什么？6.我应该预期哪些副作用，如何控制它们？7.我将参加临床试验多长时间？8.如果试验无效，我还能接受其他治疗吗？9.您如何知道治疗是否有效？10.我需要为临床试验缴费吗？# 资源 American Association for Cancer Research (AACR) aacr.org American Cancer Society (ACS) cancer.org/cancer/endometrial-cancer.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "html cancer.org/cancer/uterine-sarcoma.html CancerCare cancercare.org Cancer.Net cancer.net/cancer-types/uterine-cancer Cancer Support Community cancersupportcommunity.org ECANA: Endometrial Cancer Action Network for African-Americans ecanawomen.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "org FORCE: Facing Our Risk of Cancer Empowered facingourrisk.org Foundation for Women’s Cancer foundationforwomenscancer.org Go Girls gogirlssupport.org GOG Foundation gog.org National Cancer Institute (NCI) cancer.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "gov/types/uterine National Coalition for Cancer Survivorship canceradvocacy.org NCCN Patient and Caregiver Resources nccn.org/patientresources NRG Oncology nrgoncology.org Ovarian Cancer Research Alliance (OCRA) ocrahope.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "org PAN Foundation panfoundation.org SHARE sharecancersupport.org U.S.National Library of Medicine Clinical Trials Database clinicaltrials.gov # 词汇表 # 腹部 胸部和骨盆之间的肚腹部位。# 腺癌 排列器官并产生液体的细胞发生的癌症。大多数子宫内膜癌是腺癌。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "腹水腹部或骨盆内的异常积液。# 活检 取一小部分组织或液体以检查是否有疾病。# 双侧输卵管卵巢切除术 (BSO) 切除双侧卵巢和双侧输卵管的手术。# 近距离放疗 一种放疗，将密封在针、种状物、线、筒或导管中的放射性物质直接放入肿瘤内或肿瘤附近。也称为体内放疗。# 癌症抗原 125 (CA-125) 血液中这种物质含量高可能意味着子宫内膜癌已扩散到子宫以外。# 癌症等级 对异常癌细胞在显微镜下的外观进行的评级。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 癌症分期 根据癌症的生长和扩散对癌症的前景进行的评级。# 癌肉瘤 子宫内膜癌的一种高危类型。也称为恶性苗勒管混合瘤 (MMMT)。# 子宫颈 连接阴道（产道）的子宫下部。# 透明细胞癌 子宫内膜癌的一种高危类型。临床试验 一种涉及人的研究，用于评估试验性测试或药物。# 计算机断层扫描 (CT) 一种使用 X 射线从多个角度拍摄身体内部区域图像的成像检查。# 造影剂 置入体内以在影像学检查时拍摄更加清晰图像的制剂。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 减积手术 尽可能多地切除肿瘤的手术。也称为细胞减灭术。# 内分泌治疗 停止体内激素的产生或作用的治疗方法。也称为激素治疗。# 子宫内膜样癌 最常见的子宫内膜癌类型。子宫内膜子宫内衬的组织层。# 外照射放疗 (EBRT) 使用体外机器接受辐射来治疗癌症。输卵管卵子从卵巢进入子宫的细管。# 遗传咨询师 接受过特殊培训的健康专家，可以帮助患者了解与疾病相关的基因变化。# 妇科肿瘤专科医生 外科医生，是女性生殖器官癌症的专家。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "许多妇科肿瘤专科医生也是肿瘤内科医生。# 人表皮生长因子受体 2 (HER2) 一种参与正常细胞生长的蛋白质。某些类型的癌细胞可能会产生比正常数量更多的癌细胞。这可能会导致癌症生长得更快。# 输液 一种将药物通过针头缓慢注入静脉的方法。# 淋巴液 一种富含可抵抗感染和疾病的白细胞的透明液体。# 淋巴结 由特殊抗病细胞所组成的小集群并且遍及全身。# 林奇综合征 基因内的异常变化会增加患结肠癌、直肠癌、子宫内膜癌、卵巢癌和其他癌症的机会。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "它也称为遗传性非息肉病性结直肠癌 (HNPCC) 综合征。# 医学肿瘤学家 擅长使用药物（例如化疗）治疗癌症的医生。许多肿瘤医学专家专门研究特定癌症，例如妇科癌症或肉瘤。# 更年期 生命中卵巢停止产生激素且月经停止的时期。# 转移 癌细胞从首个肿瘤扩散至身体其他部位的转移过程。# 微转移 癌细胞已从第一个肿瘤扩散到身体的另一个部位，并且太小而无法用肉眼看到。# 神经病变 导致手脚疼痛、刺痛和麻木的神经问题。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 观察 观察和等待癌症生长或复发的一段时期。# 卵巢 产生用于繁殖的卵子和产生激素的一对器官之一。# 病理学家 擅长评估细胞和组织以诊断疾病的医生。# 骨盆检查 对阴道、子宫颈、子宫、输卵管和卵巢进行体检。骨盆髋骨之间的身体部位。# 腹膜腔 腹部（腹腔）内的空间，包含肠、胃和肝脏等腹部器官。# 腹腔灌洗 使用特殊液体清洗腹部（腹膜腔）内部以检查癌细胞的检测。# 腹膜 排列在腹部（腹腔）和骨盆内部的组织层，覆盖了该区域的大部分器官。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 铂基化疗 使用两种或两种以上化疗药物进行治疗，主要药物是铂。此类药物包括顺铂和卡铂。# 正电子发射断层扫描 (PET) 一种使用糖放射性示踪剂（一种糖的形式，它被放入体内，释放出少量能量，这些能量被活跃细胞吸收）进行的检测，来观察体内器官和组织的形状和功能。# 放射科医生 擅长解释影像学检查的医生。# 复发 癌症治疗后的再次发病。也称为重新恶化。# 治疗方案 指定药物、剂量、时间表和治疗时长的治疗计划。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 生殖系统 协同工作进行有性生殖的一组器官。女性生殖系统包括卵巢、输卵管、子宫、子宫颈和阴道。# 浆液性癌 子宫内膜癌的一种高危类型。# 支持治疗 改善癌症患者生活质量的护理。有助于预防或缓解癌症或癌症治疗引起的症状。也称为姑息性治疗。# 手术绝经 卵巢切除手术引起的月经停止。# 手术分期 在切除癌症的手术过程中确定癌症阶段（程度）的过程。# 靶向治疗 利用药物对癌细胞的某项特定或唯一特征开展的治疗。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "# 肿瘤 因细胞过度生长而形成的异常肿块。# 未分化/去分化癌 子宫内膜癌的一种高危类型。# 单侧输卵管卵巢切除术 (USO) 切除一侧卵巢和附属输卵管的手术。子宫 怀孕期间胎儿生长和发育的器官。也叫母胎。阴道婴儿出生时通过的肌肉管道。# 洗液 “清洗”腹腔（腹膜腔）的液体样本，用于检测癌细胞。# NCCN 编著者 本患者指南根据子宫肿瘤 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2023 年第 1 版编著。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "由下列人士协助改编、修订和发表： Dorothy A.Shead, MS SeniorDirector PatientInformationOperations Erin Vidic, MA SeniorMedicalWriter,PatientInformation Susan Kidney SeniorGraphicDesignSpecialist 子宫肿瘤 NCCN Guidelines® 2023 年第 1 版由以下 NCCN 专家组成员编制： Nadeem R.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "Abu-Rustum, MD/Chair MemorialSloanKeteringCancerCenter Catheryn M.Yashar, MD/Vice Chair UCSanDiegoMoresCancerCenter \\*Rebecca Arend, MD O'NealComprehensiveCancerCenteratUAB \\*Emma Barber, MD RobertH.LurieComprehensiveCancer CenterofNorthwesternUniversity Kristin Bradley, MD UniversityofWisconsin CarboneCancerCenter Rebecca Brooks, MD UCDavisComprehensiveCancerCenter \\*Susana M.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "Campos, MD, MPH, MS Dana-Farber/BrighamandWomen’s CancerCenter Junzo Chino, MD DukeCancerInstitute Hye Sook Chon, MD MofitCancerCenter Christina Chu, MDFoxChaseCancerCenter Marta Ann Crispens, MD Vanderbilt-IngramCancerCenter Shari Damast, MD YaleCancerCenter/SmilowCancerHospital Christine M.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "Fisher, MD, MPH UniversityofColoradoCancerCenter Peter Frederick, MD RoswelParkComprehensiveCancerInstitute David K.Gaffney, MD, PhD HuntsmanCancerInstitute atheUniversityofUtah Robert Giuntoli II, MD AbramsonCancerCenter atheUniversityofPensylvania Ernest Han, MD, PhD CityofHopeNationalMedicalCenter Jordan Holmes, MD, MPH IndianaUniversityMelvinandBrenSimon ComprehensiveCancerCenter Brooke E.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "Howitt, MD StanfordCancerInstitute Jayanthi Lea, MD UTSouthwesternSim ons ComprehensiveCancerCenter \\*Andrea Mariani, MD MayoClinicComprehensiveCancerCenter David Mutch, MD SitemanCancerCenteratBarnesJewishHospitalandWashington UniversityScholofMedicine Christa Nagel, MD TheOhioStateUniversityComprehensive CancerCenter-JamesCancerHospital andSoloveResearchInstitute Larissa Nekhlyudov, MD, MPH Dana-Farber/BrighamandWomen’s CancerCenter Mirna Podoll, MD Vanderbilt-IngramCancerCenter Ritu Salani, MD, MBA UCLAJonson ComprehensiveCancerCenter \\*John Schorge, MD St.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "JudeChildren'sResearchHospital/ TheUniversityofTenese HealthScienceCenter \\*Scott Schuetze, MD, PhD UniversityofMichiganRogelCancerCenter Jean Siedel, DO, MS UniversityofMichiganRogelCancerCenter Rachel Sisodia, MD MasachusetsGeneralHospital CancerCenter Pamela Soliman, MD, MPH TheUniversityofTexas MDAndersonCancerCenter Stefanie Ueda, MD UCSFHelenDilerFamily ComprehensiveCancerCenter Renata Urban, MD FredHutchinsonCancerResearchCenter/ SeatleCancerCareAliance Stephanie L.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "Wethington, MD, MSc TheSidneyKim elComprehensive CancerCenteratJohnsHopkins \\*Emily Wyse PatientAdvocate Kristine Zanotti, MD CaseComprehensiveCancerCenter/ UniversityHospitalsSeidmanCancer CenterandClevelandClinicTausig CancerInstitute # NCCN 工作人员 Nicole McMillian, MS SeniorGuidelinesCordinator Shaili Aggarwal, PhD OncologyScientist/MedicalWriter \\* 审核本患者指南。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "关于公开性原则，请访问 NCCN.org/disclosures。# NCCN 癌症中心 Abramson Cancer Center at the University of Pennsylvania Philadelphia,Pensylvania 80.789.736•penmedicine.org/cancer Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute Cleveland,Ohio 80.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "641.242•UHSeidmanCancerCenter uhospitals.org/services/cancer-services 86.23.810•CTausigCancerInstitute my.clevelandclinic.org/departments/cancer 216.84.8797•CaseC case.edu/cancer City of Hope National Medical Center Duarte,California 80.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "826.4673•cityofhope.org Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center Boston,Masachusets 617.732.50•youhaveus.org 617.726.5130 masgeneral.org/cancer-center Duke Cancer Institute Durham,NorthCarolina 88.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "275.3853•dukecancerinstitute.org Fox Chase Cancer Center Philadelphia,Pensylvania 88.369.2427•foxchase.org Fred & Pamela Buffett Cancer Center Omaha,Nebraska 402.59.560•unmc.edu/cancercenter Fred Hutchinson Cancer Center Seatle,Washington 206.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "67.500•fredhutch.org Huntsman Cancer Institute at the University of Utah SaltLakeCity,Utah 80.824.2073•huntsmancancer.org Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis,Indiana 88.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "60.482•ww.cancer.iu.edu 患者 NCCN Guidelines子宫癌，2023 Mayo Clinic Comprehensive Cancer Center Phoenix/Scotsdale,Arizona Jacksonvile,Florida Rochester,Minesota 480.301.800•Arizona 904.953.0853•Florida 507.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "538.3270•Minesota mayoclinic.org/cancercenter Memorial Sloan Kettering Cancer Center NewYork,NewYork 80.525.225•mskc.org Moffitt Cancer Center Tampa,Florida 88.63.348•mofit.org O’Neal Comprehensive Cancer Center at UAB Birmingham,Alabama 80.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "82.093•uab.edu/onealcancercenter Robert H.Lurie Comprehensive Cancer Center of Northwestern University Chicago,Ilinois 86.587.432•cancer.northwestern.edu Roswell Park Comprehensive Cancer Center Bufalo,NewYork 87.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "275.724•roswelpark.org Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine St.Louis,Misouri 80.60.3606•siteman.wustl.edu St.Jude Children’s Research Hospital/The University of Tennessee Health Science Center Memphis,Tenese 86.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "278.583•stjude.org 901.48.50•uthsc.edu Stanford Cancer Institute Stanford,California 87.68.7535•cancer.stanford.edu The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute Columbus,Ohio 80.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "293.506•cancer.osu.edu The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore,Maryland 410.95.8964 ww.hopkinskim elcancercenter.org The University of Texas MD Anderson Cancer Center Houston,Texas 84.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "269.592•mdanderson.org UC Davis Comprehensive Cancer Center Sacramento,California 916.734.5959•80.70.9261 health.ucdavis.edu/cancer UC San Diego Moores Cancer Center LaJola,California 858.82.610•cancer.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "ucsd.edu UCLA Jonsson Comprehensive Cancer Center LosAngeles,California 310.825.5268•cancer.ucla.edu UCSF Helen Diller Family Comprehensive Cancer Center SanFrancisco,California 80.689.8273•cancer.ucsf.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "edu University of Colorado Cancer Center Aurora,Colorado 720.848.030•coloradocancercenter.org University of Michigan Rogel Cancer Center AnArbor,Michigan 80.865.125•rogelcancercenter.org University of Wisconsin Carbone Cancer Center Madison,Wisconsin 608.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "265.170•uwhealth.org/cancer UT Southwestern Simmons Comprehensive Cancer Center Dalas,Texas 214.648.311•utsouthwestern.edu/ sim ons Vanderbilt-Ingram Cancer Center Nashvile,Tenese 87.936.842•vic.org Yale Cancer Center/ Smilow Cancer Hospital NewHaven,Conecticut 85.",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "4.SMILOW•yalecancercenter.org # 索引 腺肉瘤 8, 23, 46, 48–49, 52, 55 ALK重排 50, 53 生物标志物 14, 26, 41–43, 47, 50, 52–53, 55 CA-125 37, 40 癌肉瘤 7–9, 37–39, 42, 44 透明细胞癌 7–9, 37–38, 44 临床试验 27–29, 41, 43, 52–53 子宫内膜活检 11, 15, 33 子宫内膜间质肉瘤 (ESS) 8, 23, 46, 48–49, 52, 55 家族史 14–15, 32 保留生育能力疗法 17, 32–33, 37, 44 基因检测 14–15, 41 HER2 14, 37, 39, 42 激素受体检测 14–15, 41, 46, 54 激素替代疗法 (HRT) 26, 58 免疫治疗 26, 28, 42–43, 54 炎性肌纤维母细胞瘤 (IMT) 8, 46, 49–50, 53 林奇综合征 7,14–15, 32, 35, 41 错配修复 (MMR) 14–15, 41, 43 NTRK基因融合 41, 43, 50, 53 根治性子宫切除术 17, 35 前哨淋巴结活检 18 浆液性癌 7–9, 37–39, 42, 44 性健康 25, 59 立体定向放疗 (SBRT) 25, 35, 42 立体定向放射外科 (SRS) 25 支持治疗 43, 53 生存状况 57–61 肿瘤突变负荷 (TMB) 41, 43, 53–54 未分化子宫肉瘤 (UUS) 8, 46, 49 子宫平滑肌肉瘤 (uLMS) 8, 23, 46, 49, 50, 54–55 # 子宫癌子宫内膜癌子宫肉瘤 要资助患者 NCCN Guidelines，请访问 NCCNFoundation.org/Donate 本患者 NCCN Guidelines 的语言翻译由 Eisai, Inc 资助。",
    "source": "子宫癌-子宫内膜癌-子宫息肉",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫癌-子宫内膜癌-子宫息肉/子宫癌-子宫内膜癌-子宫息肉.md"
  },
  {
    "text": "世界卫生组织（WHO）指南子宫颈癌前病变筛查和管理 ![](images/016b12adac828985fb50706c68d48be11e5ff529871c1110c7faf56839f260e8.jpg) # 世界卫生组织（WHO)指南：子宫颈癌前病变筛查和管理 # 目录 缩略词 >指南制定概述 vi“即筛即治”策略推荐摘要 vii 目标人群 2 目的 2 # 2.方法 4 指南制定小组 4 问题阐述和结果确定 4 证据合成和资料准备 5 健康结果建模 6 指南推荐方案的制定 7 指南评价及审批流程 8 # 3.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "推荐方案 9 适用于所有“即筛即治”策略的重要注意事项 9 “即筛即治”推荐方案 10 # 4.研究不足与思考 16 5.指南应用 18 指南发布 18 指南评估 18 指南更新 19 参考文献 20 # 附件 附件1.“即筛即治”策略决策流程图 22 附件2.“即筛即治”策略流程图（HIV 阴性或 HIV 状态未知） 23通过 $\\mathsf { H P V }$ 检测进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "23通过 $\\mathsf { H P V }$ 检测 $+ \\mathsf { V } | \\mathsf { A }$ 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。24通过VIA 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。25通过 $\\mathsf { H P V }$ 检测 $^ +$ 阴道镜检查（有或无活检）进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "26通过细胞学检查 $^ +$ 阴道镜检查（有或无活检），并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。27 附件3．“即筛即治”策略流程图（HIV阳性或感染高发地区 HIV 状态未知的 女患者) 28通过 $\\mathsf { H P V }$ 检测进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。28通过 $\\mathsf { H P V }$ 检测 $+ \\mathsf { V } | \\mathsf { A }$ 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "29通过VIA 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。30通过 $\\mathsf { H P V }$ 检测 $^ +$ 阴道镜检查（有或无活检）进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。31通过细胞学检查 $^ +$ 阴道镜检查（有或无活检）进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。32 附件 4.策略证据搜索 33 附件5.PRISMA 流程图，用于纳入和排除研究，进行证据评价 35 # 缩略词 ASCUS 意义不明的非典型性鳞状细胞 CIN 宫颈上皮内瘤变 CKC 冷刀锥切术 ERG 外部评价小组 FICA 弗兰德斯国际合作署 GAVI Alliance 前全球疫苗免疫联盟 GDG 指南制定小组 GRADE 推荐、评估、制订与评价的分级体系 HPV 人乳头瘤病毒 IARC 国际癌症研究机构 INCa 法国国家癌症研究所 LEEP 环形电切术（也称为LLETZ） LLETZ 子宫颈移行带大环切除术（也称为LEEP） MG 方法小组 NCI 美国癌症研究所 NIH 美国国立卫生研究院 PAHO 泛美健康组织 Pap test 巴氏试验（基于细胞学试验的子宫颈癌筛查方法） PICO 研究对象、干预措施、对照类型及研究结局（循证医学证据） PRISMA 系统综述和荟萃分析优先报告的条目 QUADAS 诊断准确性研究质量评价 VIA 醋酸着色肉眼观察 WHO 世界卫生组织 # 指南制定概述 宫颈上皮内瘤变(CIN)是一种癌前病变，根据具体情况可分为三个阶段，分别是CIN1、CIN2或CIN3。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "如果不及时治疗，CIN2或CIN3(亦统称为 $\\mathsf { C l N } 2 +$ 河能会进一步发展为子宫颈癌。与以往通过细胞学检查、阴道镜检查、活检和组织病理学检查的常规流程进行CIN筛查和管理不同，另一种“即筛即治”管理模式，即针对初筛结果阳性的人群，及时有效地进行干预处理。该模式中初筛可采用的检测方法有人乳头瘤病毒 (HPV)检测、醋酸染色肉眼观察(VIA)以及细胞学检查（巴氏试验)。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "干预处理方法包括冷冻疗法、子宫颈移行带大环切除术(LEEP/LLETZ)和冷刀锥切术（CKC）。在已有世界卫生组织指南《使用冷冻疗法治疗宫颈上皮内瘤变》（2011年发布）和《2-3度宫颈上皮内瘤变和原位腺癌治疗》（与现有指南同时发布）的基础上，本指南针对各种“即筛即治”管理模式进行评估推荐，帮助卫生健康部门相关的政策制定者，管理人员、项目负责人和其他业内人士，结合不同国家和区域情况，正确合理的选择适宜的宫颈癌筛查管理策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "对于已经开展子宫颈癌筛查项目的国家，本指南提供的推荐策略可帮助决策者决定是选择根据第一步初筛结果继而立即采用不同干预处理方法的策略，还是选择通过一系列常规流程检测后再选择必须的治疗方案？对于目前尚未开展子宫颈癌筛查项目的国家，本指南可帮助决策者决定采用何种筛查和管理模式。除推荐策略方法之外，附件2还提供了相应策略的流程图，帮助项目负责人根据国家或地区具体情况选择最合适的筛查管理模式。对于每一种策略，本指南都提供了相应的“即筛即治”流程图，请参见附件3（特别是HIV阴性或HIV状态未知的女患者）和附件 4（针对 HIV 阳性或感染高发地区 HIV 状态未知的女患者)。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "本指南根据第2章所述《世界卫生组织指南制定手册》制定，指南制定小组(GDG)成员包括子宫颈癌防治方面的专家学者、临床医生、研究人员以及健康项目负责人和方法学专家。制定过程中，所有的利益冲突均按照世界卫生组织准则解决。在世界卫生组织的合作中心，一支独立的科学家团队对所有筛查方法的准确性和不同CIN治疗方法的效果进行系统性评价（请参见附件5-7），并将评价结果用于模拟和比较针对HIV状态未知、HIV阳性和HIV阴性女患者的不同“即筛即治”策略，最终结果根据GRADE（推荐、评估、制订与评价的分级体系）进行评估，以证据概要表形式报送指南制定小组。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "每一项推荐的 GRADE循证医学证据概要表和证据－建议表均可在线获得（补充材料：A、B节）。本指南针对子宫颈癌的“即筛即治”策略提供了9项推荐筛查管理模式，摘要请参见下一页,完整建议（带备注和证据摘要）请参见本指南第3章。尽管评估“即筛即治”策略的最佳证据都来自随机对照试验，但鲜有随机对照试验来评估报道这些策略中患者重要预后情况。因此，未来研究焦点包括各种采用有序的“即筛即治”策略（例如HPV检测后采用VIA进行分流管理）；针对HIV阳性女患者的“即筛即治”策略；以及“即筛即治”策略后进行患者重要的预后评估。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "# “即筛即治” 策略推荐摘要 这些推荐适用于所有女性患者，不受HIV状态约束，对于已感染HIV的女患者，本指南也提供了特殊建议。专家小组反对将CKC应用于“即筛即治”策略。因此，下述所有策略中建议采用冷冻疗法，患者不适用冷冻疗法时建议采用LEEP治疗。# 专家小组建议： 采用 HPV 检测进行宫颈癌初筛，优于VIA 初筛。但在资源有限地区，如用HPV 检测难以开展，可考虑采用VIA作为初筛方法。采用HPV检测进行宫颈癌初筛，优于细胞学 $^ +$ 阴道镜检查（伴或不伴组织活检）做初筛。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "如某些地区已有完善且准确的细胞学 $^ +$ 阴道镜检查初筛策略，那么HPV检测或细胞学 $^ +$ 阴道镜检查均可作为宫颈癌初筛选择。采用VIA进行宫颈癌初筛，优于细胞学 $^ +$ 阴道镜检查（伴或不伴组织活检）做初筛。若某地区VIA和细胞学 $^ +$ 阴道镜检查均可选择时，即可参考此项推荐。采用HPV检测进行宫颈癌初筛，优于HPV检测 $^ +$ 阴道镜检查（伴或不伴组织活检）做初筛。采用 HPV 检测或 HPV 检测 $+ \\mathsf { V I A }$ 进行宫颈癌初筛皆可。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "采用HPV检测 $+ V I A$ 进行宫颈癌初筛，优于VIA 初筛。采用HPV检测 $+ V I A$ 进行宫颈癌初筛，优于细胞学 $^ +$ 阴道镜检查(伴或不伴组织活检)做初筛。采用 HPV检测 $+ V I A$ 进行宫颈癌初筛，优于 HPV检测 $^ +$ 阴道镜检查（伴或不伴组织活检）做初筛。如下图所示，本指南的制定决策流程图可帮助项目负责人根据具体情况选择最佳策略（请参见附件 $2 1 0$ 附件3（适用于 HIV阴性或 HIV状态未知的女患者）和附件4（适用于 HIV阳性或感染高发地区HIV 状态未知的女患者）的流程图为每一种策略都提供了详细信息。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "![](images/e6678cf6214168c044a7d4efd02ce36550820e8b78c89faf7463082f90b0f588.jpg) 项目制定决策流程图 注意：每个浅粉色气泡框都代表附件3（适用于HIV阴性或状态未知的女患者）或附件4（适用于HIV阳性或感染高发地区HIV状态未知的女患者）中的一个推荐策略。# 1.简介 宫颈上皮内瘤样病变（CIN）是一种癌前病变，根据具体情况可分为三个阶段，分别是CIN1、CIN2或 $\\mathsf { C l N } 3 ^ { 2 }$ 。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "如果不及时治疗，CIN2或CIN3（亦统称为 $\\mathsf { C l N } 2 +$ ）可能会进一步发展为子宫颈癌。据估计，每年大约有 $1 - 2 \\%$ 的女性患有 $\\mathsf { C l N } 2 +$ ，而据报道这个数字在HIV阳性女患者中更高，达到了 $10 \\%$ (1-5)。目前，传统流程是运用细胞学检查（巴氏试验）对妇女进行筛查，当筛查结果为阳性时，可依据后续阴道镜检查和活检结果进行CIN诊断，且只有当 $\\mathsf { C l N } 2 +$ 获得组织病理学证实后才能进行治疗。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "这一传统筛查方法需要训练有素的医护人员和大量实验室设备。但是，在低收入和中等收入国家，由于通过细胞学检查进行筛查的成本较高，因此筛查覆盖率非常低，亟需新的筛查方法。此外，在许多国家，针对细胞学阳性结果进行阴道镜检查和活检，所需要的资源和医护人员都极为匮乏。基于细胞学检查进行筛查的其他瓶颈还包括：需要到较远的医疗机构进行诊断和治疗，以及细胞学检查结果出来之前需要长时间等待。解决上述问题的最好方法是“即筛即治”，即基于筛查结果而不是组织学证实的 $\\mathsf { C l N } 2 +$ 诊断得出治疗决策，筛查后很快就可以治疗一一理想情况下，筛查结果呈阳性就可以立即开始治疗。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "子宫颈癌“即筛即治”项目的目的是降低子宫颈癌发病率和死亡率，同时减少其他不良影响。这一项目必须包括筛查检测方法，筛查策略（即检测顺序）和适当的CIN治疗，以及为患者治疗浸润性子宫颈癌提供转诊服务。目前已得到广泛应用的筛查检测包括人乳头瘤病毒（HPV)检测、细胞学检查（巴氏试验）以及醋酸着色肉眼观察VIA)。这些检测既可以单独进行，也可以按一定顺序依次进行。单独检测时，检测结果为阳性则表明需要进行治疗。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "按顺序检测时，第一次检测结果为阳性的患者需要接受另一检测，只有第二次试验结果为阳性的患者才需要接受治疗。如果第一次检测结果为阳性而第二次结果为阴性，则需对患者进行随访。治疗方法包括冷冻疗法、子宫颈移行区大环切除术(LEEP/LLETZ)和冷刀锥切术 (CKC)。本指南旨在为“即筛即治”项目提供推荐策略，以现有的世界卫生组织指南《使用冷冻疗法治疗宫颈上皮内瘤变》（2011年发布）和《2-3度宫颈上皮内瘤变和原位腺癌治疗》（与现有指南同时发布）为基础。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在指南制定过程中，指南制定小组(GDG)考虑到目前一些可以提供“即筛即治”项目的国家可能还不确定应使用何种策略，因此对各种“即筛即治”策略的利弊进行了详细的比较。对于已经启动子宫颈癌防治项目的国家，本指南可以帮助决策者可帮助决策者决定是选择根据第一步初筛结果继而立即采用不同干预处理方法的策略，还是选择通过一系列常规流程检测后试验再选择必须的治疗方案？对于目前尚未设立子宫颈癌防治项目的国家，本指南可帮助决策者决定采用采用何种筛查和管理方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "此外，附件2还提供了一张决策流程图，帮助项目负责人员根据国家或地区具体情况选择最合适的策略。最新版《子宫颈癌综合防治：基本实践指南（C4-GEP)(10)》还包括适用于各种筛查检测和管理的建议与背景信息。C4-GEP最初由世界卫生组织(WHO）于2006年发布，用于协助临床医师和项目管理人员诊断和治疗CIN，为子宫颈癌防控提供支持。2009年，世界卫生组织承诺对C4-GEP进行必要的更新，增加一些新推荐方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "因此，制定了《使用冷冻疗法治疗CIN的新证据》（新指南于2011年制定完成[7]）；《组织学结果为 $\\mathsf { C l N } 2 +$ 的治疗》（随现在新版指南发布[8]);《宫颈癌前病变的筛查和管理指南》（本指南主题）。此外，在制定各项筛查管理策略推荐方案时，本指南还考虑到了对筛查结果阳性或阴性女患者进行治疗或不治疗的预后和追踪。查检测的准确性由其灵敏度和特异性确定本指南中的推荐方案均基于此来制定，但不能通过灵敏度和特异性来确定筛查管理的预后和追踪随访策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "因此，在制定“即筛即治”策略时，必须考虑筛查管理的预后情况（筛查呈阳性时）或不治疗的追踪随访（筛查呈阴性时），包括子宫颈癌发病率和死亡率、$\\mathsf { C l N } 2 +$ 复发率、治疗后的副作用（和过度治疗）以及医疗资源的合理利用。所以，本指南中的推荐方案是结合了每种筛查方法的准确性和后续管理方案利弊因素分析来共同制定的。# 目标人群 本指南旨在帮助卫生健康部门相关的政策制定者，管理人员、项目负责人和其他业内人士，结合不同国家和区域情况，正确合理的选择适宜的宫颈癌筛查管理策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "生殖保健项目工作人员，尤其是性传播感染疾病(STI，例如人类免疫缺陷病毒／艾滋病）预防和计划生育项目工作人员，以及社区水平和初级卫生保健工作人员也应参考这些指南，了解指南的制定过程以及选择并实施具有循证医学证据的子宫颈癌预防策略的重要性。# 目的 本指南为子宫颈癌“即筛即治”策略提供建议（第3章），此外，还提出了一个决策流程图（附件2）用于选择最佳“即筛即治”策略（附件2），并为所有策略都提供了流程图，包括专门为HIV阴性或HIV状态未知的女患者提供的流程图(附件3);HIV阳性或HIV高感染区内HIV状态未知的女性提供的流程图（附件4）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "本指南还介绍了世界卫生组织制定建议的方法（第2章，以及附件5-7)，并提供了GRADE证据概要表°和证据－建议表4（可在线获得：补充材料A和B节）。本指南还为C4-GEP（10）中的实践信息提供了科学的背景知识和依据。# 2.方法 遵循《世界卫生组织指南制定手册(11，12)》(WHO handbook for guideline development (11,12))制定指南。# 指南制定小组 WHO成立了一个由JoannaCain领导，共拥有17名成员的指南制定小组(GDG)，负责制定用于子宫颈癌防治的“即筛即治”策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "该小组在整个指南制定过程中提供了专业的临床指导和支持。同时，WHO还选择了33位专业人士组成外部评价小组(ERG)，包括拥有丰富的宫颈上皮内瘤变筛查和管理经验的医护人员、病理学家、子宫颈癌预防和治疗研究人员、项目负责人、健康教育工作者、流行病学家、公共卫生官员、护士和方法学家。此外，来自麦克马斯特大学MacGRADE中心（WHO合作中心）的一个方法小组(MG)也在数据综合以及指南制定过程中提供了专业的意见。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "# 问题阐述和结果确定 为了将新证据纳入指南，2011年2月，指南制定小组(GDG)召开会议对本指南“即筛即治”策略章节中需要解决的在问题和结果确定进行了讨论。GDG提出了15个待选问题，为宫颈原位癌筛查和治疗策略的证据评价提供指导。方法小组(MG）使用SurveyMonkey对GDG成员进行了在线匿名调查，以确定问题优先级，决定哪些问题和临床相关并在实践中使用。GDG17个成员中有14名成员参与了调查，在15个问题中确定了7个问题，是关于标准“即筛即治”策略与未广泛应用的策略（例如HPV试验 $^ +$ 细胞学检查)对比有关，因此排除了这7个问题，在剩余8个问题的基础上制定筛查策略（请参见Box1）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在此次会议上，GDG制定了为“即筛即治”策略制定决策和建议时应当考虑的结果列表。这些结果最早在编制世界卫生组织指南《使用冷冻疗法治疗宫颈上皮内瘤变(7)》就已确定。会议之后，MG使用SurveyMonkey对GDG 和ERG小组成员进行了在线调查，确定了关键结果并对结果进行排序。两个小组50个成员中30名成员参与 # Box1：用于子宫颈癌前病变筛查的问题（按优先顺序排列） 1．筛查中是否应该进行HPV检测或VIA？",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "2.筛查中是否应该进行HPV检测，或细胞学检查 $^ +$ 阴道镜检查（有或无活检）？3.筛查中是否应该进行VIA，或细胞学检查 $^ +$ 阴道镜检查（有或无活检）？4.筛查中是否应该进行HPV检测，或HPV检测 $^ +$ 阴道镜检查(有或无活检)?5.筛查中是否应该进行HPV检测 $+ \\mathsf { V I A }$ ，或单独进行HPV检测？6.筛查中是否应该进行HPV检测 $+ \\mathsf { V I A }$ ，或单独进行VIA？",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "7.筛查中是否应该进行HPV检测 $+ \\mathsf { V I A }$ ，或细胞学检查 $^ +$ 阴道镜检查（有或无活检）?8．筛查中是否应该进行HPV检测 $+ V I A$ ，或HPV检测 $^ +$ 阴道镜检查（有或无活检）？了调查，根据对决策的重要性，对结果进行了排序（分为7级，1为完全不重要，7为至关重要）。最终，根据计算，平均重要性在4或以上的结果应该纳入证据评价，并在制定建议时加以考虑（请参见Box2） 女后续追踪研究，这些恰恰对于子宫颈癌前病变筛查非常重要。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "因此，被指南在制定“即筛即治”策略时不是单以随机对照试验的证据为基础。而是结合了筛查检测方法的准确性以及各种CIN治疗方案的效果预后模型来共同完成的。# 证据合成和资料准备 一个“即筛即治”策略由两部分组成：筛查检测和后续的CIN治疗。制定“即筛即治”建议的最佳途径是随机对照试验，将妇女随机分成两组，分别依据“即筛即治”策略A和“即筛即治”策略B进行检测，并对所有妇女的健康结果进行评估和报告（包括那些筛查结果呈假阴性且从未接受治疗的女患者）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "但是目前为止鲜有此类研究，且大多数研究都没有将筛查策略和治疗以及治疗预后联系起来。相反，已进行一系列用于CIN诊断的检测准确性研究（但没有对治疗进行研究）和一些仅对筛查结果呈阳性的女患者治疗之后的预后结果的研究。但目前还没有针对筛查结果呈阴性或假阴性的妇女的随访结果进行检测和评估，以及针对筛查后接受治疗或未接受治疗的妇 # Box2：对制定建议而言非常重要的“即筛即治” 策略的健康结果（按重要性顺序） 1．子宫颈癌死亡率 2.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "子宫颈癌发病率 3．检测到 CIN2、CIN3 4.主要的感染（需要入院治疗或使用抗生 素，例如盆腔炎) 5．产妇出血 6．早产 7.生育率 8．性传播感染(STI)的确定（受益） 9．轻微感染（仅需要门诊治疗） MG搜索了截止到2012年2月的MEDLINE和EMBASE在线数据库中的筛查策略，这些策略比较了HPV检测与VIA试验，或比较了VIA试验和细胞学检查；单独进行了一项搜索以更新CochraneReview，这项报告截止到2012年11月一直在对HPV检测与细胞学检查进行比较；进行了另外一项调查，调查了截止2012年9月的阴道镜检查信息（搜索策略请参见附件5）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "MG将收集到的CIN治疗证据用于制定世界卫生组织指南《宫颈上皮内瘤变2-3和原位腺癌治疗》。搜索没有限制语言和研究设计，以避免遗漏这一领域里的重要研究或以前发表的系统性评价。MG还审查了相关研究的参考文献列表，并联系了WHO GDG小组以便获得其它参考文献°。MG中至少有两名成员独立筛选了相关文献的标题、摘要和全文，并由第三方审查员解决分歧问题。对检测方法的准确性研究，MG则以较低偏倚风险进行观察研究。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "例如，研究中的所有妇女必须接受两种筛查测试，并且所有测试结果呈阳性或阴性（或者测试结果呈阴性的妇女中随机抽取 $10 \\%$ ）的妇女都必须接受“金标准”检测进行确诊。研究还必须包含18岁以上的非怀孕女性，并且要求她们之前没有接受过CIN治疗一既可以是HIV阳性或阴性，也可以是HIV状态未知。依据系统综述和荟萃分析优先报告的条目(PRISMA)列表制定实验流程，以包括或排除某些研究（附件6）。诊断试验准确性评价中的所有研究列表请参见附件7。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "MG两名成员使用一个预先测试的数据摘要表，对患者特征、检测设置和准确度进行数据汇总，同时还使用QUADAS工具（QUalityAssessment for Diagnostic Accuracy Studies ,诊断准确性研究质量评价）收集相关数据用于研究质量评价(13)。我们使用Stata12数据分析和统计软件汇总了所有的检测准确性数据。MG研发了一套数学模型，用以计算对于HIV状态未知或阳性女患者，每一项“即筛即治”策略相对于其他策略的利弊。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "该模型全面考虑了$\\mathsf { C l N } 2 +$ 患病率、疾病自然发展、检测方法准确性以及治疗预后效果和并发症等数据（请参见附件7，了解该模型采用的参考文献）。对于HIV阴性或HIV状态未知和HIV阳性（可在线获得：补充材料A和B节）以及不同年龄段的女性，证据概要表中详细说明了绝对预后评估信息和模型假设概要。MG两名成员均使用GRADE方法（14、15）评估证据质量，并使用GRADE证据概要表对证据及其质量进行报告。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "证据概要表中针对每一个建议的检测方法准确性都提供了筛查检测确性证据（请参见补充材料A和B节；建议参考2.1节）证据概要表中也还提供了源自模型（例如一项“即筛即治”策略的结果）的证据（请参见补充材料A和B节；针对每一年龄段的建议请参见2.2和2.3节）。证据质量或疗效评估的可靠性则依据GRADE标准进行评价，分为高、中、低 或非常低。我们也为每一推荐方案专门制作了表格（证据一建议表）以帮助作出决策。：这些表格包含了证据摘要（利弊利害）证据质量评估、患者价值观和偏好以及任何资源和可行性方面的提示（补充材料：A和B节） # 健康结果建模 过于精确的检测方法并不一定适用于临床筛查。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "向患者推荐一项筛查检测时需要依据该检测对患者后续重要健康预后(PIO)的影响来进行判断。决策分析是一项有力的工具，在仅已知中间结果的情况下，例如检测方法灵敏性和特异性，要基于能否对患者祈祷长期的保护作用来判断。当建议患者进行一项诊断或筛查检测时，一个专门小组会评估此项检测的后续管理措施，例如干预假阳性(FP)和假阴性(FN)的健康风险应该与干预真阴性 (TN)和真阳性(TP)的健康效益相比较。我们使用TreeAgePro2012软件建立了一个数学模型，在设定的检测准确性评估数据和CIN 患病率前提下，通过该模型为每个筛查检测（VIA、HPV及细胞学检查）计算TP、TN、FP和FN的比例。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "然后，我们基于对这些患者的管理方案，以及不同治疗方法（冷冻疗法、CKC和LEEP）的疗效和潜在并发症的综合数据，计算了重要健康结果的概率，以帮助医师进行决策（参见Box2）。为了对健康预后进行全面的计算评估，我们为采取相同筛查检测和治疗方法的4组（TP、TN、FP、FN）患者分别提供了某一健康结果的概率数据。我们的假设为先验假设，在线补充材料A和B节中包含了这些假设的概述（在每一个GRADE证据表下方，这些表格列举了不同“即筛即治“策略后患者的重要健康结果）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "我们也为基于HIV状态（HIV阳性与HIV状态未知比较）和不同年龄段的灵敏度分析进行了先验性假定。# 指南推荐方案的制定 在2012年4月26-28日，GDG、ERG和MG召开会议，讨论方案的制定。GDG和MG各自派出一个成员主持会议，还有来自世界各地的公共卫生和医疗学科专家出席了会议。为了扩展GDG 的地理代表性，在会议期间ERG将参与建议制定过程。MG成员展示了包含利证据、价值观和偏好、资源和可行性的证据概要表和证据一建议表。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在加入对患者价值观和偏好的因素之后，GDG同意将得到的证据应用于所有的方案当中(16-18)。：定性研究的证据显示女患者可能会对筛查检测心怀恐惧，对阴道镜检查活检抱有疑虑，后续管理治疗对她们而言也是一个负担。不过，女患者一旦决定进行筛查，便能够立即接受筛查检测和即时处理治疗。系统性评价的证据表明，筛查结果为阳性的女患者具有更为频繁的CIN1筛查和积极治疗倾向。此外，对照试验的证据显示，女患者们认为冷冻疗法和LEEP可以接受，对“即筛即治”的治疗也十分满意（19) 世界卫生组织近来研发了一套《子宫颈癌防控成本核算工具》（WHO cervical cancer preventionandcontrolcosting tool）（20）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "该工具包含两个模块：一个模块负责HPV疫苗接种成本，另一个负责即筛即治流程成本。这一工具的目的主要是为帮助项目负责人制定预算方案。为了研发这一工具，世界卫生组织从多个国家收集了每种干预方法的成本，并专门定制了计算表。这一工具加上ERG 成员的经验，对于探讨针对每种治疗策略的资源要求十分有益。指南推荐方案由GDG和ERG共同制定，他们从整体角度权衡了“即筛即治”策略可能存在的正面和负面结果，包括重要健康结果、价值观和偏好、资源和可行性，也涵盖了相关信息的确定性。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "专家小组成员基于匿名投票，做出了相关决定。讨论结果收录在每一个建议的证据一建议表中，详细信息请参见在线补充材料A和B节。GDG和ERG还就关键研究空白达成了共识。所有的相关讨论和决定都在2012年4月达成，期间未发生重大分歧。根据世界卫生组织指南制定手册（11，12）要求，建议分为“强烈推荐”或“有条件推荐建议”。凡用辞为“我们推荐”的内容均为“强烈推荐”，用辞为“我们建议”的则为“有条件推荐安”。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "“强烈推荐”表示专家小组十分确定该策略所产生的期望结果优于其他备选策略，而“有条件推荐”则指专家小组不确定该策略是否优于其他备选策略。本指南中介绍了多种“有条件推荐”，具体信息请参见表1。# 指南评价及审批流程 世界卫生组织用于子宫颈癌防治的“即筛即治”策略在制定前经历了以下同行评价： ■ 指南制定过程中产生的问题会在世界卫生组织指导小组中传阅，然后指导小组与GDG讨论。当GDG与WHO指导小组达成共识后，这些问题会提交给ERG。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "1系统评价草案会在GDG中传阅，同时在EGR会议中进行讨论（除了GDG和MG之外，欧洲指南制定小组和世界卫生组织指导小组也参加此次会议）。该会议将讨论已经确定的证据和未确定的证据概要草案。世界卫生组织指导小组与GDG将定期举行讨论会和电话会议，以讨论来自文献评价和模型的数据和包含在模型及结果中的预估参数。在世界卫生组织定稿之前，带有建议的最终版指南将在GDG成员中传阅并进行评价。表1：关于强烈建议和有条件建议的解释 <html><body><table><tr><td>影响</td><td>强烈推荐表述为：我们推荐</td><td>有条件推荐表述为：我们建议</td></tr><tr><td>患者</td><td>该情况下绝大多数患者希望采纳推荐方 案，而只有一小部分患者不会。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "不需要正式的决策辅助，患者就可以做 出符合其价值观和偏好的决定。</td><td>该情况下大多数患者希望采用有条件推 荐方案，而很多患者则相反。</td></tr><tr><td>临床医师</td><td>大多数医师应该接受这种干预。是否遵 守指南中的推荐应该被视为一个质量标 准或绩效指标。</td><td>临床医师应该认识到对每个患者采取不 同的建议，而且还必须帮助患者制定与 其价值观和偏好一致的决策。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "这种情况 下，患者需要借助决策辅助来做出决定。</td></tr><tr><td>决策者</td><td>大多数情况下指南中的强烈推荐可以确 立为一项政策。</td><td>决策需要进行大量的争论及多种利益相 关者的介入。</td></tr></table></body></html> # 3.推荐方案 为辅助项目管理人员制定方案，选择最合适的“即筛即治”策略，本指南提供了一个决策流程图或算法（请参见附件2）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "一旦选择了合适的策略，应遵守该策略的流程图一一请参见附件3（HIV阴性或HIV状态未知的女患者）和附件4（HIV阳性或感染高发地区HIV状态未知的女患者）算法和流程图基于本章中的推荐方案制定。# 适用于所有 “即筛即治” 策略的重要注意事项 # 目标人群 本指南所述建议适用于30岁（推荐的年龄）及以上的女性一这一年龄范围的女性罹患子宫颈癌的风险较高。但是，不同年龄段的期望结果不同，并且与她们的 $\\mathsf { C l N } 2 +$ 的基线风险有关。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "建议对30-49岁之间的女性优先进行筛选，而不是增加筛选次数，甚至一生只筛选一次更佳。筛选频率应根据经济情况、基础结构和其他资源酌情确定。对于HIV阳性或感染高发地区HIV状态未知的女性来说，应注意以下事项：虽然有关HIV阳性女患者筛查和治疗宫颈癌的证据质量比HIV阴性或HIV状态未知的女患者低，但是子宫颈癌筛查仍应在性行为活跃的女性群体中进行，尤其是女性确诊是HIV阳性时。补充材料：A节（HIV阴性或HIV状态未知）和B节（HIV阳性或感染高发地区HIV状态未知）为每一项推荐方案都提供了证据和依据（该材料可在线访问) # 筛查结果注意事项 建议包括基于三种筛查结果的策略：HPV检测（检测阈值 $\\geq 1 .",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "0 \\ p g / \\mathsf { m l } )$ ，细胞学检查（阳性阈值${ \\mathsf { A S C U S + } }$ ，意义不明的非典型性鳞状细胞）和VIA试验。VIA试验适用于移行区可见的妇女（通常是年龄小于50岁的女性），这是因为一旦进入更年期，多数癌前病变发生的移行区经常会退回到子宫颈管中而不可见。# 治疗注意事项 在所有的“即筛即治”建议中，对于筛查结果呈阳性并适合冷冻疗法的女患者来说，冷冻疗法是第一选择。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "不适用冷冻疗法的女患者可选择LEEP疗法。女患者是否适用冷冻疗法应根据C4-GEP(10)中的指南确定：如果整个病变和鳞柱交界部可见且病变没有覆盖子宫颈外口 $7 5 \\%$ 以上，则筛查结果呈阳性的女患者适用冷冻治疗。如果病变超出了冷冻探针范围或进入子宫颈管内，则不适用冷冻疗法，应采用LEEP疗法。治疗前，使用任何一种检测方法（尤其是HPV检测）进行筛查，结果呈阳性的女患者应进行VIA试验以确定是否适用冷冻疗法，排除大病变或疑似宫颈癌一VIA试验应由训练有素的医护人员进行。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "请注意使用VIA试验确定治疗方案适用性（如选择冷冻疗法还是LEEP疗法）的建议(a)，与使用VIA试验进行筛查后确定妇女是否进行后续治疗的建议 (b)，两者之间是有区别的。a.在采用HPV检测的“即筛即治”策略中，HPV阴性女患者将不会接受治疗，HPV阳性女患者将全部接受治疗，VIA试验通常用于确定患者接受冷冻疗法还是LEEP疗法。b．在 HPV检测 $+ V I A$ 试验策略中，HPV阴性女患者将不会接受治疗，而HPV阳性女患者将全部接受VIA试验，以确定治疗方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "HPV和VIA试验结果都呈阳性的女患者将全部接受治疗，而HPV试验结果为阳性，VIA试验结果为阴性的女患者将不会接受治疗。# 筛查间隔及随访 下文列举了最佳筛查间隔，关于全部“即筛即治”策略的筛查间隔时间请参见附件3和4。VIA试验或细胞学检查（子宫颈抹片检查）结果为阴性的女性筛查间隔时间应为每3至5年，HPV检测结果阴性的女性的筛查间隔时间为至少5年。对于已接受治疗的女性，可于一年后进行随访复，以确保治疗的有效性。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "对于HIV阴性或HIV状态未知的女性，请参考附件3的流程图，了解所有策略的流程图。HIV阳性或HIV感染高发区内HIV状态未知的女性如果筛查结果为阴性，则重新筛查的间隔时间应为3年。对于已接受治疗的女性，可于一年后进行随访复查，以确保治疗的有效性。对于HIV阳性或HIV感染高发区内HIV状态未知的女性，请参考附录4的流程图，了解所有策略的流程图。# “即筛即治' 推荐方案 # 建议1.在“即筛即治”策略中，专家小组不建议采用CKC治疗（强烈建议，证据） 备注：专家小组所考虑的不建议CKC治疗的“即筛即治”策略包括HPV检测、VIA试验，或HPV检测 $+ V I A$ 试验筛查。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "尽管在所有“即筛即治”策略中使用CKC治疗的好处与冷冻疗法或LEEP相似，但CKC治疗的副作用更大。本项建议适用于任何HIV状态的女性。请参见补充材料：A和B节。证据概要：联合观察性研究中的低质量证据显示，使用冷刀锥切术（CKC）进行治疗后的宫颈上皮内瘤样病变（CIN）复发率比使用冷冻治疗或环形电切术（LEEP）低 $3 \\%$ 。但两种情况下宫颈癌发生率及相关的死亡率则相差不大，仅 $0 .0 8 \\%$ o与此形成鲜明对比的是，两种情况下导致需要住院或进行输血治疗的大出血的可能性差别很大（在大多数“即筛即治”的治疗策略下，使用CKC治疗的大出血发生率为 $1 / 1 0 0 0$ ，而冷冻疗法或LEEP则为1/10000），且使用CKC治疗后早产的风险也高于冷冻疗法或LEEP法（风险率3.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "41比2.00）。对所有女性患者而言，无论她们是否被正确归类为 $\\mathsf { C l N } 2 +$ 型病变，或是无需治疗但接受了治疗的假阳性患者，上述并发症风险差异都适用，并且这些差异与在对HIV阳性女患者群体进行同样研究得到的利弊关系结果类似。推荐方案2.在资源允许的条件下，专家小组更建议使用HPV检测初筛和冷冻疗法（冷冻疗法不适用时可采用LEEP疗法）治疗，而不是使用VIA试验初筛和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗方案（有条件建议，证据） 7/10000）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "两者在如大出血或感染一类并发症方面的差异很小或没有（例如VIA策略中概率低于1/100000）。这些差异与在对HIV阳性女患者群体进行同样研究得到的利害关系结果类似。但在资源有限而无法进行HPV检测的情况下，专家小组还是建议使用VIA试验初筛和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗，而不是使用HPV检测初筛和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）的治疗方案（有条件建议，证据） 备注：采用HPV检测或VIA试验初筛的“即筛即治”策略与无筛查策略相比，利均大于弊。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "但HPV检测用于初筛在降低癌症发病率和死亡率方面比VIA试验效果更佳。，因此，在资源充足、经济和医疗条件允许的前提下，专家推荐尽可能采用HPV检测进行宫颈癌初筛而非VIA试验。本建议适用于任何HIV状态的女性。请参见补充材料：A和B节。建议3.专家小组推荐使用HPV检测初筛和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗，而非使用细胞学检查 $^ +$ 阴道镜检查（有或无活检）和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗（有条件推荐，证据）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "备注：HPV检测进行宫颈癌初筛在降低癌症发病率及死亡率方面，略优于使用细胞学检查 $^ +$ 阴道镜检查。尽管可能存在对HPV高发群体过度治疗导致更多伤害，且HPV检测作为初筛检出的癌症比例更低，但细胞学检查的质控、培训和等待时间都使其资源需求极大一一额外的阴道镜检查还需要二次预约。不过，某些国家已经通过细胞学检查（截断值为ASCUS或更高的女性） $^ +$ 阴道镜检查建立起高质量的筛查策略，在这种情况下，HPV检测或细胞学 $^ +$ 阴道镜检查均可使用。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "请参见补充材料：A和B节。证据概要：低质量或极低质量证据显示，使用包含HPV检测的“即筛即治”策略筛查后治疗的 $\\mathsf { C l N } 2 +$ 复发率（低于3/1000）宫颈癌发病率（低于1/10000）和死亡率（低于6/100000）均低于使用VIA筛查后的治疗策略，这些差别可能是由于HPV检测初筛策略与VIA试验策略相比，$\\mathsf { C l N } 2 +$ 误诊病例更少（即更少的假阴性结果)两者在过度治疗方面差异相对较小（每1000000位妇女中，HPV试验有157,000名患者为过度处理，VIA试验则为127,000名）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "另外，采用VIA试验初筛查得到的癌症患病数略高（高于证据概要：由于在细胞学检查 $^ +$ 阴道镜检查和HPV检测初筛的诊断准确性方面还没有相关的比较研究，因此只能综合细胞学检查和阴道镜检查的诊断数据，以计算系列试验的效果，得到较低质量的证据。对于细胞学检查 $^ +$ 阴道镜检查（有或无活检）策略，我们分为两种情况进行数据分析： (1)细胞学检查结果为阳性的女性接受阴道镜检查,即基于阴道镜检查结果确定治疗方案；(2)细胞学检查结果为阳性的女性接受阴道镜检查，阴道镜检查结果为阳性的女性接受活检，即基于活检结果确定治疗方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "有证据显示采用HPV检测初筛策略的 $\\mathsf { C l N } 2 +$ 复发率（低于3/1000）宫颈癌发病率（低于1/10000）和死亡率（低于6/100000）均低于细胞学检查 $^ +$ 阴道镜检查策略。这些差别可能是由于HPV检测初筛策略的 $\\mathsf { C l N } 2 +$ 误诊病例更少（即更少的假阴性结果）。不过，当采用HPV检测时，过度治疗的情况会略高于使用细胞学检查 $^ +$ 阴道镜检查（不含活检时高于7/100，含活检时高于10/100），这可能会导致HPV检测初筛策略略高的并发症概率，而使用细胞学检查 $^ +$ 阴道镜检查策略则会在第一次筛查时测出更多的癌症（多于 $1 / 1 0 0 0 \\mathrm { ~ ‰ ~ }$ 建议4.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "专家小组建议采用VIA筛查初筛和冷冻治疗的策略（冷冻疗法不可用时可采用LEEP疗法），而不是使用细胞学检查 $^ +$ 阴道镜检查（有或无活检）和冷冻治疗（冷冻疗法不可用时可采用LEEP疗法）。（强烈建议，证据） 备注：这两种“即筛即治”策略的利弊相似，但有证据显示细胞学检查 $^ +$ 阴道镜检查（有组织活检）的伤害较小。尽管使用VIA试验可能存在过度治疗的问题，且第一次筛查时检出的癌症患者更少，但细胞学检查 $^ +$ 阴道镜检查（有或无活检）策略的质控、培训、等待时间和二次预约都使其资源需求极大。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "建议使用VIA试验初筛而非细胞学检查 $^ +$ 阴道镜检查既适用于正考虑在两种策略中进行选择的国家，也适合已兼有两种策略的国家。证据概要：由于在细胞学检查 $^ +$ 阴道镜检查和VIA试验初筛的诊断准确性方面还没有相关的比较研究，因此只能综合细胞学检查和阴道镜检查的诊断数据，以评估系列试验的效果，得到较低质量的证据。对于细胞学检查 $^ +$ 阴道镜检查（有或无活检）策略，我们分为两种情况进行数据分析： (1)细胞学检查结果为阳性的女性接受阴道镜检查，即基于阴道镜检查结果确定治疗方案；(2)细胞学检查结果为阳性的女性接受阴道镜检查，阴道镜检查结果为阳性的女性接受活检，即基于活检结果确定治疗方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "有证据显示采用上述两种策略的 $\\mathsf { C l N } 2 +$ 复发率、子宫颈癌发病率和死亡率差别不大，甚至没有差异。不过，当采用VIA试验初筛时，过度治疗的情况会略高于使用细胞学检查 $^ +$ 阴道镜检查（不含活检时高于11/100，含活检时高于18/100），这可能会导致HIV试验初筛策略略高的伤害，而使用细胞学检查 $^ +$ 阴道镜检查策略则会在第一次筛查时测出更多的癌症（多于2/1000）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "建议5.专家小组更建议使用单独HPV检测初筛和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗方案，而非使用HPV检测 $^ +$ 阴道镜检查（有或无活检）和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）治疗方案。（条件性建议，④○证据） 备注：这两种策略对于降低癌症发病率和相关死亡率的作用与无筛查策略相比，利皆大于弊成本也显著降低，且利弊相似。虽然阴道镜检查（有或无活检）降低了过度治疗情况以及随之而来的伤害，但由于需要更多的医师培训、质量控制和等待时间，以及可能需要对更多的女性进行随访，该策略的资源需求更高。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "对于没有确立筛查策略的国家，不建议使用HPV检测初筛 $^ +$ 阴道镜检查策略。本建议适用于任何HIV状态的女性。请参见补充材料：A和B节。证据概要：由于在HPV检测 $^ +$ 阴道镜检查的诊断准确性方面还没有相关的研究，因此只能综合HPV检测和阴道镜检查的诊断数据，以评估系列检测的效果，得到较低质量的证据。对于HPV检测 $^ +$ 阴道镜检查（有或无活检）策略，我们分为两种情况进行数据分析：(1)HPV检测结果为阳性的女性接受阴道镜检查，即基于阴道镜检查结果确定治疗方案；(2)HPV检测结果为阳性的女性接受阴道镜检查，阴道镜检查结果为阳性的女性接受活检，即基于活检结果确定治疗方案。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "有证据显示采用上述两种策略的 $\\mathsf { C l N } 2 +$ 复发率、子宫颈癌发病率和死亡率差别不大，甚至没有差异。不过，当采用单独HPV检测初筛时，过度治疗的情况会略高于使用HPV检测 $^ +$ 阴道镜检查（不含活检时高于5/100，含活检时高于12/100），这可能会导致HIV检测策略略高的伤害，而使用HPV检测 $^ +$ 阴道镜检查策略则会在第一次筛查时测出更多的癌症（大于1/1000）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "建议6.专家小组建议使用HPV检测 $+ v \\vert A$ 试验和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）的策略，同时也建议使用单独HPV检测和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）策略（有条件建议， $\\circledast$ 证据） 备注：在降低癌症发病率和相关死亡率方面，使用单一的HPV检测要比使用HPV检测 $+ V I A$ 试验策略更有效，这一点在HIV阳性女患者身上更为显著。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "然而，采用单一HPV检测的“即筛即治”策略很容易导致过度治疗，进而导致更大的伤害。而HPV检测 $+ V I A$ 试验策略的效果仍存在一些不确定性，且HPV检测结果呈阳性时，VIA试验的作用也不确定，缺乏直接证据。此外，对HPV检测结果呈阳性的女患者进行后续VIA试验也需要更多的资源支持：进行二次随访执行VIA试验；需要对医师进行更多的培训工作。基于上述原因，建议医师视具体情况选择HPV检测 $+ V I A$ 试验或单独使用HPV检测，但对于HIV阳性女性患者而言，单独使用HPV检测的优势明显大于劣势。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "请参见补充材料：A和B节。证据概要：由于在HPV检测 $+ V I A$ 试验的诊断准确性方面还没有相关的研究，因此只能综合HPV检测和VIA试验的诊断数据，以评估系列试验的效果，得到较低质量的证据。有证据显示HPV 检测 $+ V I A$ 试验策略的 $\\mathsf { C l N } 2 +$ 复发率（大于4/1000）、子宫颈癌发病率（大于1/10000）和死亡率（大于7/100000）略高。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "这一差别可能源自于HPV检测 $+ V I A$ 试验策略相比单独的HPV检测策略， $\\mathsf { C l N } 2 +$ 误诊率更高（大于6/1000）。当采用HPV检测 $+ V I A$ 试验策略时，第一次筛查时检出癌症数量略高（大于7/10000），而且由于该策略的假阳性率更低，所以过度治疗的比例也可能降低（低于1/10），进而对资源的需求也就更少，并发症也会相应降低。在对HIV阳性女患者进行相同研究时，这些结果更加明显，利害关系的差异更大。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "关于HIV阳性女患者的证据显示，与单一的HPV检测策略相比，采用HPV检测 $+ V I A$ 试验策略的HIV阳性女患者的 $\\mathsf { C l N } 2 +$ 复发率（大于22/1000）、子宫颈癌发病率（大于17/10000）以及死亡率（大于12/10000）更高。但是，使用HPV检测 $+ V I A$ 试验策略时，过度治疗的比例也有所降低（低于1/10），进而进行必要治疗的资源需求也就更少，并发症也会相应降低。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "建议7.专家小组建议使用HPV检测 $+ v \\vert A$ 试验和冷冻治疗（冷冻疗法不可用时可采用LEEP疗法）策略，而不是VIA试验和冷冻治疗（冷冻疗法不可用时可采用LEEP疗法）策略。（有条件建议，证据） 备注：HPV检测 $+ V I A$ 试验策略和单一的VIA试验策略在降低癌症和相关死亡率方面的作用都超过了可能造成的伤害。但是，单一VIA试验策略在第一次筛查时可以检测出更多的癌症，因此由于过度治疗可能造成的伤害也略高。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "由于系列试验（指HPV检测 $+ V I A$ 试验）相对于单一VIA试验的成本问题尚不确定，因此本建议是有条件建议。本建议适用于任何HIV状态的女性。请参见补充材料：A和B节。证据概要：由于在HPV检测 $+ V I A$ 试验的诊断准确性方面还没有相关的研究，因此只能综合HPV检测和VIA试验的诊断数据，以评估系列试验的效果，得到较低质量的证据。有证据显示HPV检测 $+ V I A$ 试验策略和单一的VIA试验策略在$\\mathsf { C l N } 2 +$ 复发率、癌症发病率和相关死亡率方面差异极小，甚至没有差异，原因可能是这两种策略的 $\\mathsf { C l N } 2 +$ 误诊率都相对较低。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "尽管单一VIA试验策略第一次筛查时检测出的癌症数量略高（大于7/10000），但由于假阳性概率很高，所以过度治疗的概率也更大（大于1/10），进而导致更高的并发症概率，产生更高的资源需求。这些差异与在对HIV阳性女患者群体进行同样研究得到的利害关系结果类似。建议8.专家小组建议使用HPV检测 $+ v \\vert A$ 试验和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）策略，而不是细胞学检查 $^ +$ 阴道镜检查（有或无活检）和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "（有条件建议， $\\circledast$ 证据） 备注：上述两种“即筛即治”策略的优势相似，但由于质量控制、培训和等待时间等原因，细胞学检查需要更多的资源，阴道镜检查也需要进行二次随访。本建议适用于任何HIV状态的女性。请参见补充材料：A和B节。证据概要：由于在细胞学检查 $^ +$ 阴道镜检查和HPV检测 $+ V I A$ 试验策略的诊断准确性方面还没有相关的比较研究，因此只能综合诊断数据，以评估系列试验的效果，得到较低质量的证据。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "对于细胞学检查 $^ +$ 阴道镜检查（有或无活检）策略，我们分为两种情况进行数据分析：(1)细胞学检查结果为阳性的女性接受阴道镜检查，即基于阴道镜检查结果确定治疗方案； (2)细胞学检查结果为阳性的女性接受阴道镜检查，阴道镜检查结果为阳性的女性接受活检，即基于活检结果确定治疗方案。有证据显示采用上述两种策略的 $\\mathsf { C l N } 2 +$ 复发率、子宫颈癌发病率和死亡率差别不大，甚至没有差异。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "此外，两种策略在过度治疗方面也相差无几。但是，细胞学检查 $^ +$ 阴道镜检查策略在第一次筛查时检测出的癌症数量略高（大于2/1000 )。建议9.专家小组建议使用HPV检测 $+ v \\vert A$ 试验和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）策略，而不是HPV检测 $^ +$ 阴道镜检查和冷冻疗法（冷冻疗法不可用时可采用LEEP疗法）策略。（有条件建议， $\\circledast$ 证据） 备注：HPV检测 $^ +$ 阴道镜检查策略（有或无活检）在降低癌症和相关死亡率方面的作用和HPV检测 $+ V I A$ 试验策略相比略高。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "尽管专家小组确定两种策略的优势都大于所造成的伤害和成本，但是两种策略之间的成本差异尚无定论。此外，阴道镜检查需要更多的医师培训、质量控制和等待时间，以及可能需要对更多的女性进行随访。与此同时，女患者是否会感受到VIA试验和阴道镜检查之间的差异也不确定，但是女患者不大会接受在阴道镜检查中进行活检。本建议适用于任何HIV状态的女性。请参见补充材料：A和B节。证据概要：由于对两种筛查策略的诊断准确性还没有相关的研究，因此只能综合诊断数据，以评估系列试验的效果，得到较低质量的证据。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "对于HPV检测 $^ +$ 阴道镜检查（有或无活检）策略，我们分为两种情况进行数据分析：(1)HPV检测结果为阳性的女性接受阴道镜检查，即基于阴道镜检查结果确定治疗方案； $( 2 ) { \\mathsf { H P V } }$ 检测结果为阳性的女性接受阴道镜检查，阴道镜检查结果为阳性的女性接受活检，即基于活检结果确定治疗方案。有证据显示与HPV检测 $+ V I A$ 试验策略相比,HPV 检测 $^ +$ 阴道镜检查的 $\\mathsf { C l N } 2 +$ 复发率（无活检时低于 $3 / 1 0 0 0$ ，有活检时低于4/1000）、子宫颈癌发病率（有／无活检时均低于1/10000）和死亡率（有／无活检时均低于6/10000）更低。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "这些差别可能是由于HPV试验检测 $^ +$ 阴道镜检查策略的 $\\mathsf { C l N } 2 +$ 误诊病例更少（例即更少的假阴性结果 $) _ { \\circ }$ 不过，当采用HPV检测 $^ +$ 阴道镜检查策略时，过度治疗的情况会略高于使用HPV检测 $+ V I A$ 试验策略（大于7/100）。两种策略在第一次筛查时检测出的癌症数量相差无几，几乎没有差异。# 4.研究不足与思考 评价“即筛即治”策略效果的最佳证据来自于随机对照试验：试验中，女性随机接受一种或另外一种“即筛即治”策略，然后追踪所有接受筛查的女性，检测重要指标的变化，例如CIN复发率、子宫颈癌发病率以及并发症等。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "但是，我们基本找不到符合要求的随机对照试验以评价“即筛即治”策略效果，以及患者的健康结果。此外，由GDG确认的可用于评价“即筛即治”策略效果的临床研究也是少之又少（例如HPV检测 $+ V I A$ 试验）。事实上，无论是随机对照试验还是其他试验，很少有研究可以评价联合检测，例如HPV检测 $+ V I A$ 试验。另外，也鲜有研究通过随机对照试验来评价联合检测的准确性，或评价HIV阳性或HIV阳性高危女性的治疗效果。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在卫生系统尚不健全、资源有限或质量控制不达标的地区，细胞学检查的应用还存在一些问题。一直以来，为了确保获得准确、可重复的细胞学检查结果，需要投入很大的人力及经济资源；由于细胞检查后不能立即得到结果，因此很可能无法对大量患者进行后续随访，从而削弱细胞学检查的优势。因此，在中低收入地区实施细胞学检测项目是比较困难的。与其他筛查策略相比，细胞学检查 $^ +$ 阴道镜检查（有或无活检）策略在子宫颈癌防控上的优势没有在本指南中列出。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "其它筛查测试如细胞学检查之前的HPV检测也没有在证据评价中述及，也没有根据建议进行类似研究。虽然以HPV检测联合细胞学检查为重要内容的“即筛即治”策略对该领域的工作者具有重大潜在价值，但是专家小组认为这一策略的价值并不能让它列入指南制定过程中需要解决的PICO问题列表（人群、干预、比较、结果）。这在很大程度上是因为专家小组认为细胞学检查与项目指南的关系，与HPV试验、VIA试验和冷冻疗法相比并不密切。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "另外，专家小组也已经达成共识：细胞学检查会影响试验和治疗之间的衔接。因此，本指南没有包括基于HPV检测 $^ +$ 细胞学检查的证据和建议。一旦有研究可以实现更为严密的比较，例如HPV检测/细胞学检查与HPV检测/VIA试验策略（反之亦然），那么这可能会成为下一步GRADE分析的重点，进而得出基于循证医学证据的推荐方案。这些推荐方案对利用VIA试验确定使用冰冻疗法还是LEEP疗法和利用VIA试验确定是否进行治疗进行了区分（请参见第3章解释，“治疗注意事项”副标题下）。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "当HPV状态呈阳性时，只有VIA结果呈阳性的女性才可以进行治疗。但是，很少有研究会评价系列筛查试验的整体诊断准确性，或评估患者的重要健康结果。另外当采用VIA方法确定是否适用冷冻疗法时，也没有研究对患者的健康结果进行比较。GDG还介绍了采用阴道镜检查与“阴道镜影像$^ +$ 活检”之间的区别。对于前者，只对阴道镜检查结果呈阳性，能看到病变的女患者进行治疗。但是对于后者，阴道镜检查结果呈阳性的女患者还要接受活检，活检结果呈阳性才可以治疗，因此本质上而言不属于“即筛即治”策略。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在随机对照试验中，没对系列试验进行评估或比较，诊断准确性观察研究也没有得出可用证据。因此目前只用模拟方法来确定不进行活检时是否仍会产生类似结果，节约资源。由于对“即筛即治”策略的评估缺乏足够的随机对照试验结果，MG引I入了一个模型并因此需要疾病基础风险和自然病史的相关数据。但是，以前完全没有不同年龄段女性及HIV呈阳性的女性患者的 $\\mathsf { C l N } 2 +$ 的自然发展与消退数据，因此在规避道德方面问题的同时，仍然需要长期跟踪调查女性进行研究。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "在实际操作上，确定筛查起止时间、筛查频率非常困难，关于特定年龄段（25-35岁、50岁以上）的女性，以及治疗后的最佳随访时间，有许多疑问需要解答。然而，本手册仍然通过情景建模提出了相关推荐方案，包括筛查年龄段、筛查频率，多长的随访期对宫颈癌的死亡率影响最大。最后，GDG确定了“即筛即治”策略的健康预后结果，并确定了各种健康预后结果的优先级，以为决策提供重要辅助。对于很多健康预后结果来说，只有低质量或极低质量甚至间接证据。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "GDG特别将有关生育和生殖的健康预后结果作为很多女患者关心的重点问题，另外一个问题是HIV传染，但是很少有研究会评估这个结果。GDG也确定了筛查的其他优势，例如性传播感染检测或子宫颈癌检测等一一取决于采用的筛查试验（例如HPV检测或VIA试验）。但是，到目前为止研究并没有对这些优势进行评估。# 5.指南应用 # 指南发布 请访问世界卫生组织文库数据库，或点击世界卫生组织网站“性与生殖健康”和电子评论杂志“世界卫生组织生殖健康文库(RHL)”7中的链接获得指南。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "本指南也将在UNDP（联合国开发计划署）／UNFPA（联合国人口活动基金）／UNICEF（联合国儿童基金会）WHO（世界卫生组织）和世界银行人类生殖（HRP）研究、发展和研究培训特别规划署的WHO生殖健康研究的进展°上发布—WHO生殖健康研究的进展拥有超过2000名订阅用户和众多合作机构。许多机构也将在他们的新闻通讯中发布各种讯息。该指南将以出版物形式分发给世界卫生组织出版物订阅用户，或通过WHO邮件列表免费发放给国家健康主管、卫生部长或健康总干事、WHO出版物文库、WHO代表／联络官、WHO／HQ文库、WHO地区办公室和非现场办公室文库；其他免费收件人，包括国家性与生殖健康主管部门、癌症防控项目、国家生殖健康研究中心和WHO合作中心；位于WHO总部、地区和国家办公室及其他地方的工作人员；相关的非政府组织；关注癌症防控和/或性健康和生殖健康的医学会；科学期刊（包括一般医学期刊和性与生殖健康或癌症专业杂志）；国际组织和捐赠者以及潜在的捐赠者；潜在的出版物译本出版商；以及为该文件编写作出贡献的所有人。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "我们接受关于指南介绍与讨论的会议邀请。我们已经计划在美洲和非洲举行地区会议，为参与2013年国家项目规划的众多利益相关者提供新的推荐策略。其他地区会议将在2014年举行。如果地区办公室提出要求，我们将支持相关国家依据其国情改编指南并且将这些材料与现行国家指南相整合。改编将通过组织地区、亚地区和国家级工作组对每条建议进行讨论，使指南符合所在国家流行病学、文化和社会经济背景。最初，该指南将只提供英文版本，翻译版本将视获得的资金情况酌情推出。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "我们鼓励由第三方将该指南翻译成非联合国语言并进行出版。# 指南评估 本指南在WHO网站（总部和区域网站）的下载量将被视为用户对指南的兴趣指标。我们正与WHO地区办公室合作监控由相关国家提出的关于指南使用的技术协助请求。为此，国内将组织利益相关者会议，并记录建议的清晰度、可行性和有效性反馈。我们还会与各地区办公室一起密切关注有多少国家基于本指南推荐的筛查管理方法来改进其“即筛即治”策略。# 指南更新 GDG将继续与WHO以一种特殊的方式开展合作，从而使研究空白可以得到解决。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "此外，我们还将追踪新出版的“即筛即治”策略的证据，以 便快速进行更新。我们预计指南出版约五年后将获得足够的新证据以更新现有建议推荐方案，并可能加入新的建议。# 参考文献 1.Arbyn M et al.Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine, 2012, 30 Suppl 5: F88-99.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "2.De Vuyst H et al.Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya.British Journal of Cancer, 2012, 107(9):1624-1630.3.Denny L et al.Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Obstetrics & Gynecology, 2008, 111(6):1380-1387.4.Joshi S et al.Screening of cervical neoplasia in HIV-infected women in India.AIDS, 2013, 27(4):607-615.5.Zhang HY et al.HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Asian Pacific Journal of Cancer Prevention, 2012, 13(1):91-96.6.Santesso N et al.; World Health Organization Steering Committee for Recommendations on Use of Cryotherapy for Cervical Cancer Prevention.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "World Health Organization Guidelines: use of cryotherapy for cervical intraepithelial neoplasia.International Journal of Gynecology & Obstetrics, 2012, 118(2):97-102.7.WHO guidelines: use of cryotherapy for cervical intraepithelial neoplasia.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Geneva, World Health Organization, Department of Reproductive Health and Research, 2011 (http://www.who.int/ reproductivehealth/publications/cancers/9789241502856/en/, accessed 24 October 2013).8.WHO guidelines for treatment of cervical intraepithelial neoplasia 2-3 and glandular adenocarcinoma in situ: Cryotherapy, large loop excision of the transformation zone (LEEP/ LLETZ), and cold knife conization.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Geneva, World Health Organization (in process).9.Sellors JW, Sankaranarayanan R.Colposcopy and treatment of cervical intraepithelial neoplasia: a beginner's manual.France, International Agency for Research on Cancer, World Health Organization, 2003 (http://screening.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "iarc.fr/doc/Colposcopymanual.pdf, accessed 24 October 2013).10.Comprehensive cervical cancer control: a guide to essential practice (C4-GEP).Geneva, World Health Organization, Department of Reproductive Health and Research and Department of Chronic Diseases and Health Promotion, 2006 (http://www.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "who.int/reproductivehealth/ publications/cancers/9241547006/en/, accessed 20 August 2013).11.WHO handbook for guideline development.Geneva, World Health Organization, 2010 (http:// www.who.int/hiv/topics/mtct/grc_handbook_mar2010_1.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "pdf, accessed 6 August 2013).12.WHO handbook for guideline development.Geneva, World Health Organization, 2012 (http:/ apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf, accessed 6 August 2013).",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "13.Higgins JPT, Green S, eds.Cochrane handbook for systematic reviews of interventions Version 5.1.0.The Cochrane Collaboration, updated March 2011 (www.cochrane-handbook.org, accessed 6 August 2013).14.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Guyatt GH et al.; GRADE Working Group.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.BMJ, 2008, 336:924-926.15.Schunemann HJ et al.; GRADE Working Group.Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "BMJ, 2008, 336:1106-1110.16.Bradley J et al.Women's perspectives on cervical screening and treatment in developing countries: experiences with new technologies and service delivery strategies.Women and Health, 2006, 43(3):103-121.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "17.Melnikow J et al.Management of the low-grade abnormal Pap smear: what are women's preferences?Journal of Family Practice, 2002, 51(10):849-855.18.Frederiksen ME, Lynge E, Rebolj M.What women want.Women's preferences for the management of low-grade abnormal cervical screening tests: a systematic review.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "BJOG: An International Journal of Obstetrics and Gynaecology, 2012, 119(1):7-19.19.Chirenje ZM et al.A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "Journal of Obstetrics and Gynaecology, 2001, 21(6):617-621.20.WHO cervical cancer prevention and control costing tool (C4P).Geneva, World Health Organization, 2012 (http://www.who.int/nuvi/hpv/cervical_cancer_costing_tool/en/index.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "html, accessed 24 October 2013).# 附件1.“即筛即治” 策略决策流程图 这个决策流程图提供了一个决策树，可以在选择“即筛即治”策略时提供快速参考。项目管理人员和决策者可以从顶部开始，回答相应的问题，以确定各项“即筛即治”策略最适合哪些地区。决策流程图突出了与资源相关的选择，其中包括成本、人员和培训。然而，项目负责人员还需要考虑其他因素，例如在涉及多项筛查测试策略中无法随访的女性数量。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "请参阅本指南第3章中的“即筛即治”策略建议以获取所推荐的策略更详细信息，以及在选择策略时需要考虑的具体因素。关于每个“即筛即治”策略（例如HPV检测 $+ V I A$ 试验）的详细流程信息，请参见附件3流程图（HIV阴性或HIV状态未知的女患者）和附件 4流程图（HIV阳性或感染高发地区 HIV状态未知的女患者）。![](images/d3ccadb5dd94f70abbf9e0996ed2398d029423d8037adc7d1acc12832e3d2887.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "jpg) 备注：每个浅粉色气泡框对应附件3（HIV阴性或HIV状态未知的女患者）或附件4（HIV阳性或感染高发地区HIV状态未知的女患者）中的一种策略。# 附件2.“即筛即治”策略流程图（HIV阴性或HIV状态未知） 以下流程图介绍了每个可用的“即筛即治”策略的实施步骤，但没有说明哪些策略是首选。请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及附件2中的决策流程。请参见每一项建议的证据-建议表，了解指南制定专家小组制定建议时考虑因素的详细信息（补充材料：A和B节） # 通过HPV检测进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "当 HPV 检测结果呈阳性时提供治疗。采用该策略时，可通过VIA 试验确定是否适用于冷冻疗法。![](images/0792d3608b377c020b33d98cbd8dbb3df2c489baa2870310b9f060ff70c591d5.jpg) # 通过HPV检测 $+ V I A$ 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。当 HPV 检测结果呈阳性时，进行VIA试验以确定是否需要提供治疗。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "只有当 HPV 检测和VIA 试验结果都呈阳性时才进行治疗。![](images/16534747ff0fb51fe69316e22bb50a19aa2e51fab2b10b4c322df58d1b0aa064.jpg) 注意：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。通过VIA试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。![](images/0cbcc7444a24d431e1aeabaf4b609051ca514c4e6d442a43c3b3b4dcfbe1e850.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。通过HPV检测 $^ +$ 阴道镜检查（有或无活检）「进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。![](images/082e11f4b87f25fc4345f87635a3e87f9876d5d62be18e8ab1123d9a757e4078.jpg) 通过细胞学检查 $^ +$ 阴道镜检查（有或无活检）’，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "![](images/6a203320daa5d4f69ec2e60ead2319adea74e52c952707c35a92bd9d71fd5e9e.jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。# 附件3．“即筛即治 策略流程图（HIV阳性或感染高发地区HIV状态未知的女患者） 以下流程图介绍了每个可用的“即筛即治”策略的实施步骤，但没有说明哪些策略是首选。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及附件2中的决策流程。请参见每一项建议的证据-建议表，了解指南制定专家小组制定建议时考虑因素的详细信息（补充材料：A和B节）。# 通过HPV检测进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。当 HPV 检测结果呈阳性时提供治疗。采用该策略时，可通过VIA 试验确定是否适用于冷冻疗法。![](images/4732f8dbc28aeb4e44619048d5cf2ab700eeaf88cba07c91fb8b2313fd35f861.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。通过HPV检测 $+ V I A$ 试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP.当 HPV 检测结果呈阳性时，进行VIA试验以确定是否需要提供治疗。只有当 HPV 检测和VIA 试验结果都呈阳性时才进行治疗。![](images/2032737b27f61ecaa94d4db086de0de95e7e2001510ed5bac17ad26bcc3a056b.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。通过VIA试验进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。![](images/0a5003cbba171c7c59cd661342ebe3ad143227ca6c7b91c90f7d2d682b5d471c.jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "通过 HPV 检测 $^ +$ 阴道镜检查（有或无活检）’进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。![](images/b91bad1d534d7d13a35dcb2a464294a4db48d6b34122f3dc5dd033473ff24350.jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。通过细胞学检查 $^ +$ 阴道镜检查（有或无活检）「进行筛查，并采用冷冻疗法治疗，或冷冻疗法不可用时采用LEEP。",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "![](images/2d8c9f29dda5b3d2c49f7f3eafd83e1b9420becb2d251f9e55b2bc92d2bd43b7.jpg) 备注：请参阅本指南第3章“即筛即治”策略建议了解推荐的策略，以及选择策略时应考虑的注意事项。# 附件4.策略证据搜索 HPV（人乳头瘤病毒）检测、VIA（醋酸着色肉眼观察）试验、巴氏试验（细胞学检查）和阴道镜检查的诊断准确性 # VIA试验相对于其他试验： # 在OVIDMEDLINE数据库中检索（截至2012年1月） 1 宫颈上皮内瘤变/ 2 宫颈非典型增生/ 3 宫颈肿瘤/ 4 (（\\*癌前病变或癌前＊或肿瘤转移＊或增生或病变＊或癌前病变＊或原代肿瘤＊或＊癌症或肿瘤\\*） adj3 宫颈\\*）tw.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "5 （ cin或cin $2 ^ { \\star }$ 或 $\\sin 3 ^ { \\star }$ 或cin1）tw.6 1或2或3或4或5 7 醋酸/或醋酸.tw.8 （VIA和肉眼观察）tw.9 （肉眼检查）tw.10 AAT.tw.11 或/7-10 12 HPV.tw.13 （乳头状瘤或（乳头瘤病毒））tw.14 EXP乳头瘤病毒科/ 15 （或/12-14）和（＊试验或检测\\*）tw.16 阴道涂片/ 17 （巴氏\\*adj（\\*涂片或试验\\*））tw.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "18 细胞学\\*tw.19 或/16-18 20 11和15 21 11和19 22 15和19 23 15或20或21或22 24 6和23 25 灵敏度：mp.26 预测值：mp.27 准确性：tw.28 筛查：tw.29 大规模筛查/ 30 诊断比值比 \\*tw.31 似然比\\*.tw.32 （受试者工作特性或受试者工作特性或受试者工作特性或受试者工作特性或 ROC或ROC 曲线）tw.33 （阳性\\*adj3 结果\\*）tw.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "34 或/25-33 35 24和34 # 在荷兰医学文摘数据库、麦克兰图书馆和LILACS中进行搜索 OVIDMEDLINE检索词被改编为适合每个数据库的主题词 # 阴道镜检查： # 在OVIDMEDLINE数据库和荷兰医学文摘数据库中搜索（截至2012年1月） 1 exp 子宫颈疾病/di 2 宫颈上皮内瘤变/ 3 宫宫颈非典型增生/ 4 宫颈肿瘤/ 5 (（＊癌前病变或癌前＊或肿瘤转移＊或增生或病变＊或癌前病变＊或原代肿瘤＊或\\*癌或恶性肿瘤＊） adj3宫颈\\*）tw.",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "6 （CIN或CIN2\\*或CIN3\\*或CIN1）tw.7 或/1-6 8 （阴道镜检查和（敏感性或特异性受试者工作特性或受试者工作特性或受试者工作特性或受试者工 作特性或ROC，或ROC曲线或预测值或似然比或精确度＊或诊断法或诊断））.tw.9 7和8 # 附件5.PRISMA流程图，用于纳入和排除研究，进行证据评价 HPV（人乳头瘤病毒）检测、VIA（醋酸着色肉眼观察）试验、巴氏试验（细胞学检查）和阴道镜检查的诊断准确性 ![](images/efab43ae402207b390f7a4c8c7832268b0288e73824b5c870289f582775f3486.jpg)",
    "source": "子宫颈癌前病变筛查和管理-WHO指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/子宫颈癌前病变筛查和管理-WHO指南/子宫颈癌前病变筛查和管理-WHO指南.md"
  },
  {
    "text": "![](images/0ad8915a8c9e6235f0daabc213dd04e9296d4c27428f713b9072ce6c55046c8f.jpg) # 宫颈癌患者指南 研究 · 宣传 · 推广 · 教育 ![](images/69bb234752d0b2e0c6f3ed0385651fde47695bdfc86173b54fad5e7b94f3b78c.jpg) # 引言 您和您的家属已经知道了宫颈癌诊断结果 在诊断时，您收到的信息量可能会让您感到不知所措。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "一刹那，您可能会觉得有许多未回答的问题，要做的决定，以及有太多的信息需要了解。在讨论您的诊断和治疗时，让朋友和家属陪着您可能会好些。在整个治疗过程中，专业的医护团队将配合您和您的家属。团队中每个人都有重要的分工，但团队中最重要的成员是您自己。为了在治疗过程中发挥积极作用，您应该尽可能多地了解宫颈癌。这本小册子将带您了解有关宫颈癌的基本知识。它将向您介绍谁可能会加入您的治疗团队。此外，它还将确定宫颈癌不同类型的治疗方法。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "希望这些信息能帮助您做好准备，与您的治疗团队对接，并对您的治疗计划感到更有把握。![](images/132c0fae852e5f8d9aafef64cf69bc0f4bb5b65d38c0b7540f71713183af8568.jpg) # 宫颈癌： 概述 当身体某个部位的细胞异常生长时就会发生癌症。宫颈癌是一种原发于子宫颈的癌症，子宫颈是子宫的一部分，开口于阴道。作为子宫的一部分，当子宫颈扩张，开口完全打开时，婴儿可顺式通过产道。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "正常的子宫颈有两种主要类型的细胞：鳞状（或平状）细胞，保护宫颈的外部，和腺体细胞，主要在宫颈内部，产生排卵时常见的液体和粘液。宫颈癌是由宫颈中这两种细胞类型的异常变化引起的，它是唯一可以通过定期筛查和预防性接种来预防的妇科癌症。# 预防、筛查、早期发现 几乎所有的宫颈癌都是由持续感染高危型人类乳突病毒（HPV）引起的。HPV 疫苗是一种预防癌症的疫苗，可以预防许多与 HPV 有关的癌症，包括宫颈癌。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "男孩和女孩最好在 11-12 岁性行为活跃之前接种疫苗，可以最大限度地预防癌前病变和癌症的发生。建议所有 9-26 岁的年轻人都接种 HPV 疫苗来预防癌症。HPV疫苗适用于 45 岁以下的男性和女性接种。即使接种了疫苗，定期的巴氏涂片检查和 HPV 检测也是预防宫颈癌或及早发现宫颈癌并获得最佳治疗的重要方法。异常检测后的随访和了解您的结果是您对自己负责的一个重要方式。# 症状 宫颈癌前期病变通常没有症状。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "因此一定要做巴氏和/或 HPV 检测。患者可能没有任何症状，直到细胞癌变并侵入宫颈或其他盆腔器官的最深处。# 这些症状包括： 阴道分泌物 异常阴道出血 阴道异味 • 疼痛 这些症状可能是由癌症或其他健康问题引起的。如果女性有任何这些症状，一定要去看医生，这一点很重要。宫颈癌患者年龄通常在 30 至 55 岁，但切记，任何长期未接受筛查或宫颈有症状的女性也可能发展成宫颈癌。要确保您的检测是最新的，并鼓励其他人也这样做。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "# 医疗评估 当女性出现相关症状时，应进行盆腔检查，包括直肠阴道检查，并进行全身体检。如果检查结果异常，可能会建议女性接受额外的检查，如更具体的 HPV检查、阴道镜检查（通过放大镜观察宫颈），以及根据阴道镜检查的结果进行活检。如果怀疑或诊断出宫颈癌，首先一定要咨询妇科肿瘤专家了解治疗。想要了解您所在地区的妇科肿瘤专家，请登录妇女癌症基金会网站 (foundationforwomenscancer.org),输入您的邮政编码。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "![](images/aae497ae4dc5b2dd71f423b5825776e6ecd41e9ddffc7b6415d7ce8aa962f685.jpg) ![](images/b71a5122e6977891f641b8d620a9e65faaf8d0d9cbce94ca6db6a4e85b2bdc6f.jpg) # 配合您的治疗团队 在您的治疗过程中，您将会接触到许多医护人员。他们都是您的治疗团队成员。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "他们相互合作，为您提供所需的特殊护理。您的治疗团队可能包括以下一些专业医护人员： 妇科肿瘤医生，是拥有医师资格，且在美国妇产科委员会批准的研究项目中接受过三到四年妇科癌症治疗专门培训的妇产科医生。妇科肿瘤医生，负责管理您从诊断到完成治疗期间的治疗工作。# 为您治疗的医生还可能包括： 医学肿瘤医师，专业使用药物疗法（化疗）来治疗癌症。放射肿瘤医师，专业使用放射疗法来治疗癌症。肿瘤科护士，专门提供癌症护理。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "肿瘤科护士可以在护理的各个方面配合您，从帮助您了解您的诊断和治疗到提供情感和社会支持。在咨询和实际援助、社区支持计划、家庭护理、交通、医疗援助、保险和权利计划方面受过专业培训的社会工作者。尤其是在您刚被诊断出来， 不确定下一步该怎么做的时候，他们都会挺身而出。患者导航员，他们对患者进行疾病教育，并在整个癌症治疗过程中充当患者和其照顾者的代言人。营养师或注册营养师，他们帮助您保持或开始养成健康的饮食习惯。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "而这在康复过程中很重要。这些专业人士可以帮助您克服治疗的潜在副作用，如食欲不佳、恶心或口腔溃疡。需要注意的是，自然疗法和补充剂只能在自然疗法医生的指导下与妇科肿瘤医生的协商后服用。# 与您的治疗团队沟通 应该得到您的治疗团队的专业建议和治疗。一定要与您的团队成员敞开谈论您的担忧。让他们知道什么对您来说是重要的。如果您自己沟通不便，这些提示可能会有所帮助： 在就诊前列一个问题清单。先问最重要的问题。• 做笔记或询问是否可以记录科室就诊和电话沟通内容。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "• 如果您有不明白的地方，请治疗团队成员用不同的方式再解释一遍。• 如果可能的话，当您与治疗团队成员见面讨论检测结果和治疗方案时，请带一名陪诊人员。当诊断出宫颈癌时，确定癌症是否已经扩散至关重要。您的治疗团队可能会做更多的检测来确定这一点。此外，在手术过程中可以进行特定的程序来确定疾病的程度。这个过程被称为分期。分期有助于确定您的癌症的确切程度以及适合您的最佳治疗方案。癌症分期可划分为 I 期、II 期、III 期或IV 期，如下页所示。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "如果您能够进行手术，手术的结果可能有助于确定分期。如果因为肿瘤的大小或位置而没有计划进行手术，可以通过 CT、PET-CT 或MRI 等放射检查来确定分期。癌症分期将帮助您的团队决定采取适合您的最佳治疗方案。还会对癌症进行分级。癌症等级指的是细胞在显微镜下显示的异常程度。低级别肿瘤，也被称为 1 级，其特征类似于正常的宫颈细胞。相比之下，在高级别肿瘤（3 级）中，显微镜下的外观与正常情况有很大的变化。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "一旦被诊断为宫颈癌，您的医疗团队可能会建议进行影像学检查（放射学检查），如 MRI、CAT（CT）扫描或PET 扫描，以帮助确定癌症的确切位置并设计最佳方案。重要的是，您的手术要由在治疗女性生殖系统癌症方面受过专门培训的妇科肿瘤医生来做。研究表明，治疗中心患者容量越高，经其妇科肿瘤专家治疗后，患者的预后改善越好。# 癌症分期 # 宫颈癌分期 # I 期 只在宫颈中发现这种癌症。# IV 期 癌症已经扩散到盆腔内或盆腔外的其他身体部位。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "膀胱、直肠、腹部、肝脏、肠道或肺部可见癌细胞。癌症已经从子宫颈扩散到阴道上部或子宫周围的组织， ![](images/21c47cb6b9f944c4c2dd9b1403c032bb36e5aef091044c46ef5798795181830c.jpg) # II 期 癌症已扩散到阴道下部或盆壁。它可能会阻碍尿液流向膀胱。在盆腔的淋巴结中也可能发现癌细胞。但没有扩散到盆壁。（盆壁是指排列在盆腔内侧的肌肉和结缔组织。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "）在盆腔的淋巴结中也可能发现癌细胞。# III 期 ![](images/5278863ca5635ea56315cfe956b738e3b9fe68b2dfda0381ff488c63a871a198.jpg) ![](images/5011543840e571b86994de078e3c8f9c66f5789ecfe1075bb334c8df24e0b7bc.jpg) # 治疗类型和副作用 宫颈癌的治疗手段包括手术、放疗和/或化疗。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "根据一系列因素，您的治疗团队可能建议使用综合疗法来治疗您的癌症。# 了解治疗的目标 当您开始接受治疗时，请确保您明白会发生什么。该治疗是为了治愈吗？治愈的机会有多大？治愈的机会有多大？使我活得更好或更长久？非常重要的是，一定要了解治疗的真相——以及副作用、费用等潜在成本——这样您才能为自己和想要的生活做出最好的决定。宫颈癌的治疗有副作用。多数副作用可以得到控制或最小化。常见的副作用可能会影响肠道或膀胱功能、性功能或生育能力，所以您一定要优先考虑从治疗团队处获得所需信息。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "在开始治疗之前，重要的是了解可能的副作用，并与您的治疗团队成员讨论您的感受或担忧。他们可以让您做好准备，告诉您出现哪些副作用时应立即向他们报告。他们还可以帮助您找到控制副作用的方法。# 手术 手术是早期宫颈癌最常见的治疗方法，尽管也可以使用放射线，而且通常效果等同。可以进行几种类型的手术，但您最终的选择将取决于您的妇科肿瘤医生考虑的几个因素，特别是您的癌症的分期和大小，以及您的年龄、一般健康状况和保留生育能力的选择。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "# 宫颈锥切术 锥切是指通过手术只切除子宫颈的癌变部分（或在许多病例中切除的是癌前病变部分）。锥切术只适用于最早期的癌症，即那些微小的癌症。这是患有非常小的癌症并希望保留生育能力的女性的首选治疗方法。# 简单的子宫切除术 在简单的腹部子宫切除术中，子宫和宫颈通过腹部的一个切口被切除。在不太常见的阴道子宫切除术中，这些器官通过阴道被切除。这些类型的子宫切除术适合于对那些不希望保留子宫的最早期癌症患者。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "# 根治性子宫颈切除术 在这种手术中，您的子宫颈和周围组织被切除，但子宫上部被保留下来，以便将来妊娠。这种手术只适用于经过仔细筛选的女性，并取决于多种因素，如年龄、生育能力、肿瘤大小、影像学结果或肿瘤类型。# 根治性子宫切除术 这是一种更复杂的手术，用于切除子宫/宫颈和其他组织。这种手术通常是通过一个开放的腹部切口进行的。根治一词意味着要切除子宫和子宫与盆壁之间的额外组织，以及部分阴道上部。虽然有很多方法能够进行这类手术，比如开腹（腹部）或微创（腹腔镜或机器人），但较新的数据表明，传统腹部切口的效果可能更好。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "虽然在某些临床情况下存在一些争议，但重要的是要了解您的手术入路，并与您的外科医生讨论风险、益处和期望。# 淋巴结评估 在这些手术中，会切除盆腔内的淋巴结进行检查，以确定癌症是否已经扩散。完整的淋巴结清扫术（盆腔淋巴结切除术）是指沿血管切除标准区域内的淋巴结。使用染色技术定位并只切除选定的淋巴结，这被称为前哨淋巴结定位，可以最大限度地减少淋巴结切除的副作用，如淋巴水肿（腿部肿胀）。![](images/90f483e4b97951f622f7d8cbf9ea425b65d8515de271ee67efbf056ca7f1bfe6.",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "jpg) ![](images/d8476605761971b3e0673aa3ea324e265829496ce48280f842e8e23364a40872.jpg) # 切除输卵管和卵巢 在一些病例中，必须切除两个卵巢和两个输卵管，这种手术被称为双侧输卵管卵巢切除术。但通常对于年轻的女性来说，卵巢可能不动。向您的外科医生了解卵巢切除的风险和益处是了解您的手术方案的重要部分。# 手术的副作用 术后常见疼痛和不适。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "疼痛可以用药物控制。如果您的疼痛超过了轻度，请告诉您的治疗团队。# 其他早期副作用 # （术后数天至数周）： 切口周围腹部酸痛恶心或食欲下降排尿困难，因此可能需要在膀胱内留置几天至几周的 Foley 导尿管 • 痉挛和胀痛 • 少量分泌物或出血 • 疲乏 # 后期副作用 排尿困难 便秘 阴道缩短 （取决于手术的程度） 在您手术时可能会采取一些措施，以尽量减少这些副作用（如在您的膀胱内放置一根临时引流管）。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "做了子宫切除术的女性将停经，且不再有生育能力。如果保留卵巢，激素水平将保持不变，如果切除卵巢，激素水平可能下降到绝经水平。如果卵巢被切除，通常可以选择激素疗法来治疗更年期症状。# 放射治疗 放射治疗（也叫放疗）是使用高能量的辐射来杀死癌细胞或阻止其生长。放射治疗是治疗早期宫颈癌的有效手段。然而，在早期宫颈癌中，它更多地是作为术后的额外治疗，用于癌症复发风险最高的患者（例如当肿瘤可能已经扩散到宫颈之外）。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "放疗和化疗最常用于治疗较大或较晚期的癌症，因为那时它比手术更有效。将根据您的分期检测、检查和手术（如果在您评估时根据检查结果进行了手术）的信息来确定您是否需要进行放射治疗。有两种类型的放射疗法可用于治疗宫颈癌。宫颈癌的放射治疗最常与化疗联合进行。外部放射治疗是使用一台机器，将辐射指向身体的一个精确区域。该疗法通常每天进行一次，从周一到周五，持续约六周。在治疗过程中，放射线不会造成伤害，每天只需要几分钟的时间。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "您可以在诊所、医院或放射肿瘤科科室接受治疗，通常都是当日来当日回。内部放射治疗（也称为近距离放射治疗）包括在阴道内或宫颈附近放置一个含有放射性物质的小胶囊。这种手术有时可以在门诊进行，其他时候需要住院一晚或两晚。可服用药物来缓解这些手术带来的不适。在放射性胶囊置入期间，您的家属只允许陪您一小会儿，不过在您回家前，就会取出放射性胶囊。# 放射治疗的副作用 放射治疗的副作用取决于使用的剂量和接受治疗的身体部位。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "宫颈癌患者的常见副作用如下。# 早期副作用 （发生在治疗期间）： 治疗部位皮肤干燥、发红 疲乏 贫血 腹泻和恶心 排尿时的不适感 这些副作用大多是暂时的。不是每个人都会经历所有这些副作用。一定要与您的治疗团队成员讨论您所经历的任何副作用。他们可以帮您找一些控制副作用的办法。# 后期副作用： 阴道变窄，不再润滑尿频（放射性膀胱炎）• 腹泻（放射性结肠炎）过早或突然绝经（如果卵巢停止工作）皮肤增厚和刺激盆腔疼痛淋巴水肿（腿部肿胀） 一定要与您的医疗保健团队讨论，您可以做什么来减少辐射带来的长期副作用的风险。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "一些长期的并发症，例如阴道变窄，一旦严重，预防比治疗更好。![](images/276a40f6e5963035b6da87c2bbedbe586e416cd459837d25d8dbdf08865d5616.jpg) # 化疗 化疗是使用药物来杀死癌细胞。宫颈癌化疗通常是通过静脉注射（注入静脉）进行的。您可以在医生办公室或门诊部接受治疗。这些药物通过血液到达身体的各个部位。这就是为什么化疗可以有效地治疗已经扩散到宫颈以外的宫颈癌。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "然而，杀死癌细胞的药物也可能损害健康细胞。为了限制对健康细胞的损害，化疗通常是分周期进行的。化疗期与休息期交替进行，休息期间不进行化疗。通常也会发生副作用，但可以控制。免疫疗法，包括通过静脉注射的药物，可能是治疗复发性宫颈癌的另一种手段。# 化疗的副作用 副作用因使用的化疗药物类型和使用的药物数量而异。此外，化疗可用于初始治疗或在癌症复发时使用。每个人对化疗的反应不同。有些人的副作用可能很少，而有些人则会有几种副作用。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "大多数副作用是暂时的。了解您将接受哪种特定的化疗手段以及特定的副作用是很重要的。化疗的一般副作用可能包括： 恶心或呕吐 食欲不振 口疮 感染机会升高 易出血或瘀伤 脱发 疲乏 便秘 # 参加临床试验的重要性 目前有许多正在进行的临床试验，研究治疗宫颈癌的新方法和更好的方法。因为被诊断为妇科癌症的女性愿意参加先前的临床试验，所以得出了目前许多可行的治疗方案。临床试验旨在检测一些最新和最有希望的宫颈癌治疗方案。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "妇女癌基金会与 NRG肿瘤学（原妇科肿瘤学小组）以及其他机构合作，提供有关当前临床试验的信息。其中，NRC 肿瘤学是唯一一个专门从事妇科癌症临床试验的国家癌症研究所合作小组的一部分。所有患者，无论其种族、民族、语言、社会经济地位或年龄，都有可能符合试验条件，参加的人越多，试验效果会越好。欲了解更多关于可供注册的临床试验的信息，请访问 www.clinicaltrials.gov。![](images/294b1868680ab2dfe7e992f4f5bd3aa218769ba0ca37521d62800fb6979d2727.",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "jpg) # 癌症治疗与生活 被诊断为妇科癌症并接受癌症治疗的经历可能会改变您对自己身体的感觉，并将在许多方面影响您的生活。您可能会经历许多或相对较少的副作用。了解可能的治疗效果可能有助于您预测副作用并计划应对方法。# 疲乏 无论医生开出什么样的治疗方案，您都可能会经历疲乏、频繁就医，以及感觉不够好而无法顾及家务的情况。您将需要依靠家属和朋友帮您做您平常做的一些事情。您可能会考虑雇人帮忙做家务，直到您感觉自己足够良好，可以重新自己打理。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "如果您知道家里无人帮忙，应尽早与您的医疗团队坦诚沟通，以便探讨其他方案。饮食一定要有营养，如果需要的话，一定要请求帮助，在家里保持健康的饮食和零食选择。治疗疲乏方面，务必检查您的血细胞计数，以排除贫血可能。也可以服用缓解疲乏的药物。# 面对世界 癌症的影响和癌症治疗可能会改变您的样貌。您可能会出现疲乏、脸色苍白、行动迟缓，还可能不得不面对暂时的脱发。您可能会因为这些变化而感到难为情。这时，您可以想象一下，如果您有一个朋友或姐妹看起来跟您一样，您会有什么感受，这可能会对您有所帮助。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "记住，许多人在注意到这些变化时，是在爱您而不是在评判您。# 工作便利 在治疗的头一两个月，您可能需要离开工作岗位较长一段时间。与您的单位主管和您的医疗护理团队讨论，制定一个现实的缺勤和重返工作岗位的计划。记得告诉您的单位主管，任何计划都需要灵活制定，因为您的需求可能随着治疗的进展而改变。《家庭医疗休假法》（FMLA）为因健康原因必须离开工作的员工和家庭成员提供了某些保护。# 家庭、友谊和乐趣 无论您接受哪种类型的治疗，您都可能会经历副作用，而这些副作用可能影响您与朋友和家属一起参加社交活动。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "如果有特殊事件发生，如婚礼或毕业典礼，请先行与您的医疗保健团队沟通。您的治疗时间可能会作出调整，以使您在这些特殊的日子里尽可能地感觉良好。制定喜欢的活动计划时，千万不要犹豫不决。有时候，可能会因无奈而取消计划，也可能提前离开活动，但是美好的时光会帮助您在艰难的日子里找到生的希望。年幼的孩子往往很难理解您所经历的事情。疏导人员可以帮助您回答问题并帮助您的孩子应对您的变化。请家属和朋友帮助您维持孩子的正常生活也是一个好主意。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "# 开车 对许多人来说，开车是成人生活中几乎不可缺少的一部分。如果您正在服用会导致嗜睡的药物，如麻醉性止痛药和一些恶心药物，请勿开车。大多数患者可以在手术后几周内恢复开车，且通常患者在化疗和放疗期间大部分时间都是可以开车的。一定要向您的医疗保健团队询问有关开车的问题。![](images/2d276530c82c151be5e14136a83e5da39b89f6e73b59a95348694e9ef8639e20.",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "jpg) # 锻炼身体 在治疗过程中，您可能发现，即使是去卧室，那几阶楼梯对您来说都是挑战，哪怕您在成年后都在努力运动保持身材。不得不减少或中断健身活动令人沮丧，但也是正常的。如果您做过手术，请咨询医生关于锻炼的具体指导。在化疗或放疗期间，根据您的感觉来调整锻炼计划。应避免过度劳累或脱水。在结束癌症治疗后的几周和几个月内，您可以恢复到以前的体能水平。![](images/a4d414c3c842db7eee3c4cd2d00730b2127406c11981405736fbd272401bd179.",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "jpg) # 性行为和亲密关系 一些治疗宫颈癌的方法可能会引起副作用，可能会改变您对自己身体的感觉，或使您难以享受亲密关系或性关系。您会经历哪些副作用取决于您的治疗过程。可能会有副作用，也可能完全没有副作用。了解可能的副作用有助于您预测副作用并学习如何应对。# 可能的副作用包括： 脱发。作为化疗的常见副作用，脱发通常是暂时的。但也是难以接受的。如果您出现脱发，您可以选择戴上漂亮的假发、围巾或其他头饰。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "阴道变化。某些形式的治疗，如子宫切除术和放射治疗，可能导致阴道干燥、缩短和变窄。这些变化会让性行为变得不舒服。使用非处方的阴道润滑剂可以让您感到更舒适。您的治疗团队也可能会建议使用阴道扩张器。性欲减退。在癌症治疗期间，您所经历的压力和疲乏可能导致您在一段时间内失去性欲。# 应对技巧 与您的治疗团队沟通。他们可以根据您的个人情况提出相应建议，所以一定要对她们坦承。您可能想问： 我的治疗将如何影响我的性生活？",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "这些影响是暂时的吗？是否有其他治疗方案可以减轻这些影响？• 关于我该如何处理治疗对我性生活的影响，您有什么建议？向您的医疗团队报告您的症状，并寻求性功能方面的治疗。不要害怕向您的医疗护理团队提及您对性功能的任何担忧。性生活对许多患者来说是生活质量的重要组成部分，即使您的癌症得到了控制，也不应该被忽视。针对盆底和性功能的物理治疗，包括夫妇性治疗，以及包括激素和非激素的药物治疗，都可以帮助缓解症状。与您的伴侣进行沟通。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "癌症会给伴侣双方都带来压力。谈论癌症对您伴侣关系中的性和情感影响可能有些困难。但是，如果您谈论这些困难，可能会发现反而更容易解决。准备好分享您自己的感受，并倾听您的伴侣说什么。将您的注意力转移到亲密关系上。性交只是亲密关系的一个部分。您会发现，抚摸、亲吻和拥抱同样能让人感到充实。对自己要有耐心。要理解恢复性关系需要时间。您的治疗团队会告诉您治疗后能否性生活，以及需要多久才能开始性生活。可能在您情感上做好准备之前，需要很久。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "给自己留足时间。心态放开。对改善性生活的方法放开心态，保持幽默，可能有助于您和您的伴侣找到最适合你们的方法。# 为您带来希望的信息 在您经历癌症治疗时，对自己要有耐心。要理解恢复到完整的生活需要时间。如果您的治疗团队知道您的困扰，他们可以指导您解决即将面临的困难。敞开心扉，谈论困扰您的事情。给自己留足时间。培养希望。即使面对癌症，茫然不知所措时，也要靠您自己来掌控自己的反应。希望能帮助您看到生活的积极方面。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "如果您有内在的精神信仰，请联系您的宗教团体，给您额外的支持来面对每天的生活。寻求支持。有许多资源可以帮助您处理因癌症及其治疗而产生的身体、性或情感问题。经过专门培训的疏导人员可以帮助您处理癌症对您生活的影响。支持小组是另一个良好的资源。与您有类似经历的人可聚集在一起，互相分享经验，相互给予建议和情感支持。想要了解您所在地区的支持服务，请咨询您的治疗团队成员，或联系下一页所示资源。请记住，我们是敬业的医疗护理团队，我们时刻与您在一起。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "预先医疗指示是一款实用的工具，可以澄清您的医疗护理愿望。我们鼓励患者和家属都填写一份。这样，您的医疗护理团队就可以根据该指示开展治疗。# 要分享的事实 • 大多数宫颈癌病例是可以预防的。• 在性行为活跃之前为少年儿童接种疫苗可以预防宫颈癌前病变和癌症。• 在建议的时间间隔内定期进行巴氏检查和 HPV 检测对预防宫颈癌同样重要。# 症状 性交后出血 经期间分泌物过多和异常出血 阴道异味 疼痛 这些症状可能是由癌症或其他健康问题引起的。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "如果女性有任何这些症状，一定要去看医生，这一点很重要。大多数女性不会有任何症状，因此接种疫苗和在建议时间内定期进行巴氏检查和 HPV检测，是预防宫颈癌的关键。# 风险因素 • 几乎所有的宫颈癌都是由人类乳突病毒，即 HPV 的持续感染引起的。宫颈癌多发生于 30 至 50 岁女性，但年轻女性也有患病风险。吸烟会削弱免疫系统，进而导致持续的 HPV 感染。# 减少风险 • 按照为您提供治疗服务的医疗机构的建议定期进行巴氏检查和 HPV 检测，了解自己的检查结果，并询问后续方案。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "接种 HPV 疫苗，并向其他人包括青少年推荐 HPV 疫苗，以便将来预防癌症。• HPV 疫苗可以帮助预防由某些高危人乳突病毒（HPV）类型引起的癌前病变和宫颈癌、外阴癌、阴道癌、肛门癌、口咽癌和其他头颈部癌症。男孩和女孩应该在青春期前或 9-26 岁之间接种疫苗。HPV 疫苗适用于 45 岁以下的男性和女性接种。如果您的检查结果是宫颈癌前病变或癌症阳性，请寻求妇科肿瘤医生进行治疗。# 您可以提供哪些帮助 提高大众对妇科癌症的认识。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "在线为妇女癌症基金会捐款。个人或与基金会合作举办筹款活动。通过您的雇主向基金会提供等额捐赠。向基金会捐赠股票或证券。向基金会指定一份有计划的捐赠 妇女癌症基金会为患者、组织工作者和公众提供许多资源，包括美国各地的幸存者课程、网络研讨会和在线教育系列课程。如要捐赠或了解更多信息，请给基金会发电子邮件至 info@foundationforwomenscancer.org或致电 312.578.1439。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "捐赠和了解更多 foundationforwomenscancer.org 妇女癌症基金会（The Foundation for Women’s Cancer，FWC）是一个按照美国第 501(c)3 条规定成立的非营利组织，致力于支持妇科癌症的研究、教育和提高公众意识。foundationforwomencancer.org info@foundationforwomenscancer.org 电话：312.578.1439 传真：312.235.4059 妇女癌症基金会地址：230 W.Monroe, Suite 710Chicago, IL 60606–4703 FWC 是妇科肿瘤协会的官方基金会。本手册的印刷得到了卫材、葛兰素史克、默克和 Seagen/Genmab 的慷慨教育赞助。赞助不包括编辑方面的投入。内容由妇女癌症基金会（FWC）开发。",
    "source": "宫颈癌患者指南",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌患者指南/宫颈癌患者指南.md"
  },
  {
    "text": "# 第三章 # 浸润性宫颈癌简介 <html><body><table><tr><td>临床前浸润性宫颈癌是指有很小间质浸润的早期癌，常无症状或临床体征。</td></tr><tr><td>·随着间质浸润的进展，病变的临床表现变得明显，在以阴道窥器检查时可见多种肿瘤形态。</td></tr><tr><td>·组织学上，90%~95%的浸润性宫颈癌是鳞癌；在大多数发展中国家，只有不到5%的宫颈癌是腺 癌。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "</td></tr><tr><td>、目前最广泛应用的浸润性宫颈癌的分期是基于肿瘤的大小及病变扩散至阴道、宫旁、膀胱、直肠及 远处器官转移的程度。</td></tr><tr><td>，目前临床分期仍是影响浸润性宫颈癌患者生存的惟一最重要的预后因素。</td></tr></table></body></html> 本章论述浸润性宫颈癌的临床特点和诊断。浸润性宫颈癌往往在妇科检查中被发现并通过病理活检组织学检查证实。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "但部分宫颈癌无症状和肉眼异常所见，称为临床前浸润性宫颈癌。因此，阴道镜检查在诊断临床前早期浸润癌中起着重要作用。# 临床特点 患浸润性宫颈癌的妇女常有下列症状：经期间出血、性交出血、月经量过多、白带增多、恶臭白带，反复发作的膀胱炎，尿急或小便困难，后背痛或下腹痛。晚期宫颈癌可因严重贫血出现呼吸困难及尿路阻塞、下肢水肿、血尿、肠梗阻、恶病质等症状。大多数患者在阴道检查可见溃疡型增大的肿物。在很早期的间质浸润阶段，宫颈癌一般无明显症状和临床体征，因此，被称为临床前宫颈浸润癌。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "最早期的浸润癌称之为微小浸润癌：间质浸润深度不超过 $5 \\mathrm { m m }$ ，宽度不超过 $7 \\mathrm { m m }$ 。早期浸润癌表现为小芽状的浸润细胞，突破基底膜并伸向间质(图3.1和图3.2)。以局部淋巴细胞聚集及浸润灶周围基质疏松为表现形式，间质对浸润的反应证据可能是明显的。随着间质浸润的进展，临床病变明显，在阴道检查时常见数种肿瘤形态。很早期的病变可表现为宫颈局部区域粗糙、发红、颗粒感并有接触性出血（图3.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "3)。癌灶呈外生型、内生型或混合型（图3.4至图3.6)。外生型肿瘤往往浅表浸润，庞大的肿瘤突向阴道，呈蘑菇状或增生状、凸出的菜花样，伴息肉状或乳头瘤状突起的肿物。内生型肿瘤可向间质广泛浸润，使宫颈变形，而宫颈表面常无明显的肿物。这些病变可扩张至宫颈管，而宫颈表层鳞状上皮完整，直至肿瘤增至 $5 { \\sim } 6 \\mathrm { c m }$ 直径。其结果是变成增大而不规则的桶状宫颈，伴表面粗糙，乳头瘤状或颗粒状。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "这种肿瘤仍可无症状很长时间。部分外生和内生型肿瘤随间质浸润加深也常表现为溃疡状。所有类型的宫颈癌中，接触性出血及局部坏死是主要临床特点。由于坏死组织合并厌氧菌感染，恶臭白带也很多见。随着浸润的继续进展，肿瘤可直接侵犯阴道、宫旁、盆壁、膀胱和直肠。由于晚期局部肿瘤压迫输尿管引起尿路梗阻以致肾盂积水，最终可引[起肾衰。伴随着局部浸润，区域淋巴结发生转移，腹主动脉旁的淋巴转移通过淋巴结包膜和直接浸润至脊椎和神经根。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "坐骨神经根分枝的直接侵犯或受压引起背部疼痛，而盆腔静脉及淋巴侵犯引起下肢水肿。血行转移至腰椎腰肌可能不发生淋巴结病变。远处转移发生在病变晚期，通常侵犯腹主动脉淋巴结、肺、肝、骨等其他组织。![](images/27de3ee4d10097a24c9e92f12708a2fa106ab9c97931e549a6d1f5ebdf9ba74c.jpg) 图3.1 组织学表现：早期间质浸润（ $\\left.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "\\times 4 0 \\right.$ 1 ![](images/5526636c06f9bd93318a2cdafbe5ef180e63ae81ce42102bc62221e6185205f1.jpg) 图3.2组织学表现：早期间质浸润（ $\\left.\\times 1 0 \\right.$ ![](images/accfb0f173414712412e2502554655cb755c84a016c56fb291b7d76c1df8575c.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "jpg) 图3.3早期浸润宫颈癌 ![](images/c53064bbaccb254a7a8b69c41009bf05d00b6b69a6a3e1d58e6f51cf784faf23.jpg) 图3.4浸润性宫颈癌 ![](images/6f20577e28383f361d3ad16cf22c930da99039d5079bde7758fec23c26c1ae31.jpg) 图3.5浸润性宫颈癌 !",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "[](images/d08deeabfe158f2c7cdba3ac489ec73eda677906482a4a23e22f4bcc5a1cf06f.jpg) 图3.6晚期浸润性宫颈癌，溃疡型 # 显微镜下病理学 在发展中国家大约 $9 0 \\% { \\sim } 9 5 \\%$ 的宫颈浸润癌为鳞癌(图3.7和图 3.8)； $2 \\% \\mathrm { \\sim } 8 \\%$ 是腺癌(图3.9)。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "在显微镜下，大部分鳞癌表现为肿瘤细胞中的间质呈条索样的网状浸润，并且表现为各种各样的肿瘤状态、细胞形态和分化程度。由索状的恶性细胞分开的宫颈间质被淋巴细胞、浆细胞浸润。这些癌细胞可再分为角化型和非角化型。肿瘤细胞可分为：高分化、中分化、低分化三种。约 $5 0 \\% { \\sim } 6 0 \\%$ 的宫颈癌为中分化，其余高分化和低分化各占一半。![](images/8e785cee0748efda0e914fca865a82767757df23e6ab3be85dd4daec64e7328e.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "jpg) 图 3.7组织学—角化型、高分化浸润性鳞状细胞癌（ $\\left( \\times 1 0 \\right)$ 1 ![](images/374e63038e8e4ad20343f975b4a1c5d4055f70b3810fa88094bf1fe7bdc9c469.jpg) 图 3.8组织学—非角化型、浸润性鳞状细胞癌（ $\\cdot \\times 1 0$ ） 角化型鳞状细胞癌是由特征性的旋涡状上皮细胞包含中央角化细胞巢（角化珠）组成（图3.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "7)。细胞核大、染色质颗粒增粗、核深染、除透明角质性的颗粒和细胞质的角化以外，细胞间桥明显。仅可见少量核分裂象。非角化型鳞状细胞癌（图3.8）表现为不规则的、膨大的多边形细胞锯齿状浸润间质，可能有角化不良和细胞间桥。细胞和核的多型性明显，核分裂象多见，无角化珠。其他不常见的鳞状细胞癌类型有：湿疣样鳞癌(又称疣状鳞癌)；乳头状鳞状细胞癌；淋巴上皮瘤样癌、鳞状透明细胞癌。在许多发展中国家，腺癌在宫颈癌中的比例小于 $5 \\%$ ，来源于宫颈管腺上皮。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "最常见的腺癌形式是宫颈管细胞类型，异型的腺体不同形状和大小伴芽状和分支（图3.9)。多数腺癌为中、高分化。腺体成分排列复杂，可见乳头从表面突人管腔，有些细胞含有中量至大量黏蛋白。其他类型腺癌包括：肠型，印戒细胞型腺癌，恶性腺瘤，绒毛腺管状乳头状腺癌，宫内膜样腺癌和乳头浆液性腺癌。宫颈腺鳞癌包括腺癌和鳞癌的成分。无论宫颈鳞癌还是腺癌，发现脉管瘤栓是潜在性侵袭性生长的证据，与区域淋巴结转移的危险性有关。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "偶尔发生的血管浸润是预后不佳的征象，与远处转移或血行转移有关。虽然浸润性宫颈癌的脱落细胞学特征已经被很好地描述，但细胞学并不是诊断浸润性病变的可靠方法。在细胞学涂片中确认病变需要丰富的经验。因为在一张宫颈涂片的碎片细胞及血细胞中仅有数个癌细胞。宫颈腺癌很难由细胞学家识别；只有在其细胞极度异型时才有可能被细胞学家发现。对个别细胞类型的认识更复杂。所以，宫颈浸润癌最终确诊总是要基于组织病理学诊断。肿瘤周围的组织标本对诊断是最好的，因为更可能包含了形态完整的肿瘤组织，而从肿瘤中心取的活检标本，可能有坏死组织，而影响组织学诊断的准确性。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "![](images/543a4b20968c470a9de3bd991b599c412cb2007f2b663f5374a6643fa7e5781c.jpg) 图3.9组织学——高分化浸润性腺癌（ $\\times 2 0$ 1 # 分期 无论制定治疗计划还是估计预后均需详细评估病人的一般状况及确定宫颈癌的临床分期。广泛应用的宫颈癌分期是FIGO 制定的标准，见表3.1。主要根据肿瘤大小及盆腔内浸润范围制定的分期系统。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "通过临床及各种辅助检查评估肿瘤的扩散范围，并将其分为I\\~IⅣ期（表3.1和图3.10)，I期代表了肿瘤局限于宫颈，而V期代表癌已扩散转移至远处器官。表3.1 FIGO分期（见图3.10） <html><body><table><tr><td colspan=\"2\">衣3.1F1G0分期（见图3.10)</td></tr><tr><td colspan=\"2\">I期 癌灶严格局限于子宫颈；扩散至宫体可不考虑。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "IA1和IA2 期的分期是基于切除组织的显微镜下检查诊断，</td></tr><tr><td>这些组织最好是包括全部病变在内的锥切标本。IA期 IAi期 IA2期</td><td>浸润癌仅在显微镜下确认。间质浸润的深度不超过 5.0 mm,宽度不超过 7.0mm。间质浸润深度不超过3.0mm，宽度不超过7.0mm。间质浸润深度大于 3.0 mm，但不超过5 mm，宽度不超过 7 mm。</td></tr><tr><td>IB期 IBi期 IB2期 Ⅱ期</td><td>临床病灶局限于宫颈或临床前期病灶大于IA期。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "所有肉眼所见病灶，即使是表浅浸润，亦属于IB期。临床病灶不大于4.0cm。临床病灶大于4.0cm。</td></tr><tr><td colspan=\"2\"></td></tr><tr><td></td><td>癌灶超出子宫颈，但未扩散至盆壁；癌累及阴道，但未达阴道下1/3</td></tr><tr><td>IIA期</td><td>无明显宫旁浸润，癌累及阴道上2/3。</td></tr><tr><td>Il期</td><td>有明显宫旁浸润，但未达盆壁。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "</td></tr><tr><td colspan=\"2\">Ⅲ期</td></tr><tr><td>除非已知其他原因所致，均列入ⅢI期。</td><td>癌浸润达盆壁。直肠检查肿瘤与盆壁之间没有无癌间隙。肿瘤累及阴道下1/3。凡有肾盂积水或肾无功能者，</td></tr><tr><td>IIIA期 IIIB期</td><td>宫旁浸润未达盆壁，但累及阴道下1/3。癌浸润达盆壁，或肾盂积水，或肾无功能。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "</td></tr><tr><td>IV期</td><td></td></tr><tr><td colspan=\"2\">癌扩散超出真骨盆或临床已侵犯膀胱粘膜和/或直肠粘膜。</td></tr><tr><td>IVA期 癌扩散到邻近器官。IVB期 癌扩散至远处器官。</td><td></td></tr><tr><td colspan=\"2\"></td></tr></table></body></html> FIGO分期采用以下检查方法：阴道的视诊和触诊、直肠指诊、阴道镜、膀胱镜、颈管刮术、宫腔镜、静脉尿路造影、胸部及骨骼X像、淋巴造影、B超，CT、MRI和腹腔镜检查可能提供另外的信息，但这些信息不能用于FIGO临床分期，尽管这些检查可能提供对制定治疗计划有用的信息。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "在很多资源缺乏的医疗单位，窥阴具检查及阴道和直肠指检是决定分期的仅可施行的方法。如有可能，膀胱镜及胸部、骨骼影像学检查及静脉尿路造影可以作为辅助检查方法。无论何时当宫颈癌应常规进行分期，在病历中详细记录并用图描述，而进行分期所做的检查过程也应该详细记录 ![](images/62c20c9fec62a4bc1f8ab372c798590d39938c1756788b605f644c4f2a6068e5.",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "jpg) 图3.10子宫颈癌临床分期示意图 # 治疗及预后 子宫颈癌的标准治疗方法可能包括手术治疗或放疗或二者综合。早期宫颈癌（I期及ⅡA期）采用手术或放疗，一旦病变范围超出宫颈或阴道穹隆或手术无效时，应选择放疗。宫颈癌的放疗常包括体外照射（整个盆腔）和腔内照射（控制疾病中心部分)。局部晚期宫颈癌如IIB 期及Ⅲ期，腔内放疗配合体外照射较单纯体外照射会明显改善局部控制及生存。微小浸润性宫颈癌（IA期）的手术方法有：宫颈锥切或全宫切除或扩大全宫切除。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "而IB和ⅡIA期患者可采用根治性全子宫切除（Wertheim）和盆腔淋巴清扫术，或采用腔内放疗，或体外加腔内放疗。在部分瘤体较小（小于 $2 \\mathrm { c m }$ ）的IB期宫颈癌可行根治性宫颈切除，联合腹腔镜下淋巴结清扫术，从而挽救病人的生育功能。对早期浸润癌（IB期和ⅡA期）而言，放疗和手术的疗效相当。ⅡB及Ⅲ期病人可给予腔内及体外的联合放疗。IⅣ期可采用姑息性体外放疗或和化疗。晚期宫颈癌合并顺铂化疗能改善单纯放疗的效果。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "随机临床试验结果已显示，在放疗同时辅以顺铂为基础的化疗，可明显改善总生存率和无瘤生存期。（Thomas，2000，Green et al.，2001）。放化疗结合对控制局部复发及远期复发均有益。联合治疗使总生存率提高 $1 6 \\%$ 。放化疗同步将成为晚期宫颈癌新的标准化治疗。目前临床分期仍是影响长期生存的惟一最重要的指标；生存率亦随年龄而下降。其他影响生存率的因素包括健康及营养状况。贫血病人对治疗的反应差；同样HIV血清阳性者预后差。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "数个临床和人群研究证实I期宫颈癌的五年生存率高（ $> 7 5 \\%$ ），随分期升高五年生存率快速下降（IV期 $< 1 0 \\%$ >（Delgado et al.; 1990; Fagundes et al.， 1992;Kosary et al., 1994; Gatta et al., 1998; Sankara-narayanan et al.，1998;Denton et al.，2000)。",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  },
  {
    "text": "—组大样本宫颈癌放疗的研究结果显示，常见的远处转移率（最常见的转移部位为腹主动脉旁淋巴结、肺、腹腔、肝、和胃肠道）随分期提高而递增，从IA期的 $3 \\%$ 增加到IV期的 $7 5 \\%$ (Fagundes et al.,1992)，在1 028 名接受根治性手术的患者中，生存率与肿瘤体积相关（Brughardt et al.，1992），肿瘤体积 $< 2 .5 \\mathrm { c m } ^ { 3 }$ 者的五年生存率为 $91 \\%$ ，肿瘤体积$1 0 { \\sim } 5 0 \\mathrm { c m } ^ { 3 }$ 的五年生存率则为 $70 \\%$ 。三年无瘤生存率范围为：I期的肿瘤 ${ \\leqslant } 5 \\mathrm { m m }$ 为 $9 4 .6 \\%$ ；而 $\\geqslant 2 1 \\mathrm { m m }$ 者则为 $5 9 .5 \\%$ （Delgado et al.，1990)。晚期宫颈癌常伴有脉管浸润、盆腔扩散、腹主动脉旁淋巴转移和远处转移。(译者 张 凯)",
    "source": "沁润性宫颈癌简介",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/沁润性宫颈癌简介/沁润性宫颈癌简介.md"
  }
]